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Pathology is the medical science that deals with all aspects of disease, 
but with special reference to the essential nature, the causes, and the devel-
opment of abnormal conditions. In this sense, knowledge of pathology is the 
base of research for the student of medical science and practice. This book 
contains material in general pathology in the context of modern biology and 
physiology. 
To help the reader in understanding and retaining complex and detailed 
information, we have illustrated book by photomicrographs and graphic rep-
resentations of pathologic alterations. Every photograph included in this work 
illustrates an important morphologic entity. 
In this book, we tried to represent the classical morphologic descrip-
tions of disease and contemporary scientific concepts that serves to join tradi-
tional pathology with the modern revolution in biology. 









PATHOLOGICAL ANATOMY – is a part of pathology (“pathos”-disease), study-
ing the different aspects of disease. Pathological anatomy studies structural (ma-
terial) bases of diseases. This study serves as to theory of medicine, as to clinical 
practice. Due to this pathological anatomy is a scientific-applied subject. 
Theoretical, scientific value of pathological anatomy is revealed in 
study of common natural laws of cell pathology development, pathological 
processes and disease (i.m. human general pathology). Human general pa-
thology (pathology of cells and morphology of common pathological pro-
cesses) is a content of general pathological anatomy course. 
Clinical value of pathological anatomy is the study of structural bases 
of human disease, specific features of each disease or creation of patient 
anatomy (clinical anatomy). It is a content of special pathology. 
The study of general and special pathology are correlated because of 
common pathological processes are the contents as to syndromes, as of hu-
man disease. The study of syndromes and disease structural bases is connect-
ed with their clinical features. So, clinical-anatomical direction is characteris-
tic feature of modern pathological anatomy. 
Disease is considered to be the human organism vital functions dis-
turbances. And structural and functional changes in disease are correlated. 
Functional changes without the structural changes are absent. This is the base 
of one of the pathological anatomy principle – entirety and correlation of 
structure and function. 
The study of pathological processes and disease includes: 
• the causes of their appearance (etiology), 
• mechanisms of development (pathogenesis), 
• morphological bases of this mechanisms (morphogenesis), 




• death and the mechanisms of death (tanatogenesis). 
One of the tasks of PA is the elaboration of study about the diagnose. 
PA pays attention on variability of diseases (pathomorphosis) and dis-
eases, the cause of which is a doctor activity (pathology of therapy). 
Pathomorphosis reflects: 
1. changes in the morbidity and mortality structure, 
2. Changes of the clinico-morphological features of disease due to use 
of medicines (therapeutic pathomorphosis). 
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OBJECTS, METHODS AND LEVELS OF PATHOLOGICAL 
ANATOMY INVESTIGATION 
Pathological anatomy takes material for investigation from autopsy, 
surgical operations, biopsy and experimental investigations. 
Autopsy (greece: “autopsia” – to see by proper eyes) gives infor-
mation about as severe changes, causing the patients death, as initial one, 
which are revealed microscopically (more frequently). Due to this the study 
of many diseases stages is possible. Organs and tissues taken at autopsy are 
studied as macroscopically as microscopically with use of light microscopic 
methods. 
Autopsy determines the causes of patient death, peculiarities of dis-
ease course, effectiveness of medicine therapy, diagnostic methods, and 
makes up the statistics of mortality. 
Biopsy (“bios” – life, “opsis” – vision) is diagnostic vital investiga-
tion of tissue. Biopsy is performed at all medical departments to prove or to 
determine clinical diagnose, to receive the information about the course of 
disease, its character and prognosis, expediency of use and effectiveness of 
therapy, and gives the information about possible negative effects of drugs. 
Biopsy gives the possibility to study initial changes of cells and tis-
sues by electron microscopy, histochemical, histoimmunochemical and en-
zymological methods, to study those initial changes of disease the clinical 
manifestations of which are absent due to development of compensatory-
adaptive processes. 
The modern pathological anatomy methods give the functional valua-
tion of changed structures due to disease, to receive the information about 
essence and pathogenesis of pathological process, as about degree of com-
pensation of disturbed functions. 
So, biopsy material is one of the main object of investigation as for 
practical, as for theoretical pathological anatomy. 
Experiment is very important to clear pathogenesis and morphogene-
sis of disease. To make up the adequate model of human disease is very dif-
ficult, but the patterns of many diseases have been formed. They help to un-
derstand deeply the pathogenesis and morphogenesis of diseases. The ex-
perimental patterns give possibility to study the action of some drugs, to 
make up the methods of surgical operations. So, modern pathological anat-
omy is clinical pathology. 
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The study of structural bases of disease is performed at different lev-
els: organism, systemic, organ, tissue, cellular, subcellular, molecular. 
Organism level allows to see the disease of entire organism, its dif-
ferent manifestations and correlation of organs and systems. 
Systemic level – the level of study of any system of organs and tis-
sues, combined by common functions (for example: system of connective 
tissue, system of blood, digestive system). 
Organ level allows revealing the changes of organs, which are distin-
guished macroscopically or sometimes only with use of microscopic meth-
ods. 
Tissue and cellular levels – the levels of study of changed tissues, 
cells and intercellular mater with use of microscopic methods. 
Sub cellular level – allows to observe using electron microscopic the 
changes of ultra structures of cells and intercellular matter, which are the 
primary morphological features of disease. 
Molecular level – disease study is possible due to use of some com-
plex methods (electron microscopic, cytochemical and other). 
So, deep morphological investigation of disease requires the all mod-
ern methods. The tasks of pathological anatomy today determine its particu-
lar place among the medical subjects. Simultaneously pathological anatomy 
is the theory of medicine defined the material base of disease and clinical 
morphology to determine the diagnose. 
Pathological anatomy is based on the principles: 
1. Structure and functions. 
2. Clinico-anatomical. 
The first one allows to determine correlation between pathological 
anatomy and other theoretical subjects (anatomy, histology, physiology, bi-
ochemistry) and to study the bases of pathology. The second principle – 
clinico-anatomical direction – proves the necessity of pathological anatomy 
data for other clinical subjects and doctor’s practice. 
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MORPHOLOGY OF CELL INJURY 
Depending upon the severity of cell injury degree of damage and re-
sidual effects on cell and tissues are variable. In general, morphologic 
changes in various forms of cell injury can be classified as shown in Table 1 
and are discussed below. 
 
Table 1. Classification of morphologic forms of cell injury 
 
№ Mechanism of cell injury Nomenclature  
1 Reversible cell injury Retrogressive changes (older term: 
degeneration) 
2 Irreversible cell injury Cell death (necrosis) 
3 Programmed cell death Apoptosis 
4 Residual effects of cell injury Subcellular alteration 
5 Deranged cell metabolism 
(dystrophy) 
Intracellular accumulation of lipid, 
protein, carbohydrate 
6 After-effects of necrosis Gangrene, pathologic calcification 
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MORPHOLOGY OF SUB-CELLULAR ALTERATIONS IN CELL 
INJURY 
Certain morphologically distinct alterations at subcellular level are 
noticeable in both acute and chronic forms of cell injury. These occur at the 
level of cytoskeleton, lysosomes, endoplasmic reticulum and mitochondria: 
1. CYTOSKELETAL CHANGES. Components of cytoskeleton 
may show the following morphologic abnormalities: 
i) Defective microtubules: 
• In Chediak-Higashi syndrome characterised by poor phagocytic 
activity of neutrophils 
• Poor sperm motility causing sterility 
• Immotile cilia syndrome (Kartagener's syndrome) characterised 
by immotile cilia of respiratory tract and consequent chronic infection due to 
defective clearance of inhaled bacteria 
• Defects in leucocyte function of phagocytes such as migration and 
chemotaxis  
ii) Defective microfilaments: 
• In myopathies 
• Muscular dystrophies 
iii) Accumulation of intermediate filaments: Various classes of 
intermediate filaments (cytokeratin, desmin, vimentin, glial fibrillary acidic 
protein, and neurofilament) may accumulate in the cytosol. For example: 
• Mallory's body or alcoholic hyaline as intracytoplasmic eosino-
philic inclusion seen in alcoholic liver disease which is collection of cy-
tokeratin intermediate disease which is collection of cytokeratin intermedi-
ate filaments. 
• Neurofibrillary tangles, neurities and senile plaques in Alzheimer's 
disease are composed of neurofilaments and paired helical filaments. 
2. LYSOSOMAL CHANGES. Lysosomes contain powerful hy-
drolytic enzymes. Heterophagy and autophagy are the two ways by 
which lysosomes show morphologic changes of phagocytic function. 
i) Heterophagy. Phagocytosis (cell eating) and pinocytosis (cell 
drinking) are the two forms by which material from outside is taken up by 
the lysosomes of cells such as polymorphs and macrophages to form 
phagolysosomes. This is termed heterophagy. Microbial agents and foreign 
particulate material are eliminated by this mechanism. 
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ii) Autophagy. This is the process by which worn out intracellular 
organelles and other cytoplasmic material form autophagic vacuole that 
fuses with lysosome to form autophagolysosome. 
iii) Indigestible material. Some indigestible exogenous particles 
such as carbon or endogenous substances such as lipofuscin may persist in 
the lysosomes of the cells for a long time as residual bodies. 
iv) Storage diseases. As discussed in Chapter 9, a group of lysoso-
mal storage diseases due to hereditary deficiency of enzymes may result 
in abnormal collection of metabolites in the lysosomes of cells. 
3. S.E.R. HYPERTROPHY. Hypertrophy of smooth endoplasmic 
reticulum of liver cells as an adaptive change may occur in response to 
prolonged use of barbiturates. 
4. MITOCHONDRIAL CHANGES. Mitochondrial injury plays an 
important role in cell injury. Morphologic changes of cell injury in mito-
chondria may be seen in the following conditions: 
i) Megamitochondria. Megamitochondria consisting of unusually big 
mitochondria are seen in alcoholic liver disease and nutritional deficiency 
conditions. 
ii) Alterations in the number of mitochondria may occur. Their num-
ber increases in hypertrophy and decreases in atrophy. 
iii) Oncocytoma in the salivary glands, thyroid and kidneys consists 
of tumour cells having very large mitochondria. 
iv) Myopathies having defect in mitochondria have abnormal cristae. 
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DYSTROPHY 
Dystrophy – is a pathological process resulting from cells and tissues 
metabolism disturbances and accompanying with the structural damage. 
The causes of dystrophy are: 
- disturbances of cell auto regulation 
- dysfunction organism transport systems (blood, lymph) 
- disturbances of neurohumoral regulation of metabolism 
They consider this factor to cause cells enzymes disturbances. Due to 
this we may say that all dystrophy are enzymopathia. 
There are 4 mechanisms of dystrophy development: 
1. Infiltration – superfluous entering of the metabolism products 
from the blood and lymph into cells and intercellular matter and accumula-
tion there. For example: infiltration by glucose of the kidney tubulus epithe-
lium in diabetes. 
2. Decomposition – disintegration of cells structures and intercellular 
matter with accumulation of its products in the cells. 
3. Abnormal synthesis – synthesis and accumulation in cells unusual 
substances, witch don’t occur there in norm. For example: synthesis of glu-
cose in diabetes; synthesis of amyloid. 
4. Transformation – formation of one kind metabolism products in-
stead of another one from common products. For example: synthesis of pro-
teins from the lipids and carbohydrates. 
 
Classification: 









3. According to genetic factor influence: 
- congenital (primary), 
- acquired (secondary), 
4. According to spreading: 
- local, 
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- general (total). 
PARENCHYMATOUS DYSTROPHIES 
Parenchymatous dystrophies develop when  changes occur mainly in 
organ parenchyma (in cells). Intracellular accumulation of substances in 
abnormal amounts can occur within the cytoplasm (especially lysosomes) or 
nucleus of the cell. This phenomenon was previously referred to as infiltra-
tion, implying thereby that something unusual has infiltrated the cell from 
outside which is not always the case. Intracellular accumulation of the 
substance in mild degree causes reversible cell injury while more severe 
damage results in irreversible cell injury. Such abnormal intracellular accu-
mulations can be divided into 3 groups: 
i) Accumulation of constituents of normal cell metabolism produced in 
excess e.g. accumulations of lipids (fatty change, cholesterol deposits), 
proteins and carbohydrates. 
ii) Accumulation of abnormal substances produced as a result of ab-
normal metabolism due to lack of some enzymes e.g. storage diseases or 
inborn errors of metabolism. 
iii) Accumulation of pigments e.g. endogenous pigments under special 
circumstances, and exogenous pigments due to lack of enzymatic mecha-
nisms to degrade the substances or transport them to other sites. 
 
According to the metabolism type disturbances parenchymatous dys-
trophies are subdivided into protein, lipid and carbohydrate. 
Parenchymatous protein dystrophies. Pathologic accumulation of 
proteins in the cytoplasm of cells may occur in the following conditions. 
1. In proteinuria, there is excessive renal tubular reabsorption of 
proteins by the proximal tubular epithelial cells which show pink hyaline 
droplets in their cytoplasm. The change is reversible so that with control 
of proteinuria the protein droplets disappear. 
2. The cytoplasm of actively functioning plasma cells shows pink 
hyaline inclusions called Russell`s bodies representing synthesized im-
munoglobulins. 
3. In α1-antitrypsin deficiency, the cytoplasm of hepatocytes shows 
eosinophilic globular deposits of a mutant protein. 
4. Mallory`s body or alcoholic hyaline in the hepatocytes is intra-
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Fig. 1. Alcoholic hyaline in hepatocytes. H and E 
stained section, x 400. 
 
cellular accumulation of intermediate filaments of cytokeratin and appear 
as amorphous pink masses. 




Hyaline-drop dystrophy. The protein droplets (like hyaline) appear in 
cytoplasm. The word “hyaline” means glassy (hyalos = glass). Hyaline is a 
descriptive histologic term for glassy, homogeneous, eosinophilic appear-
ance of material in haematoxylin and eosin-stained sections and does not 
refer to any specific substance. Hyaline change is associated with heteroge-
neous pathologic conditions and may be intracellular or extracellular. 
Intracellular hyaline is mainly seen in epithelial cells. This dystrophy 
occurs in kidneys, liver, rarely in myocardium and voluntary muscle. For 
example: 
1. Hyaline droplets in 
the proximal tubular epithe-
lial cells in cases of exces-
sive reabsorption of plasma 
proteins. 
2. Hyaline degeneration 
of voluntary muscle, also 
called Zenker's degenera-
tion, occurs in rectus ab-
dominalis muscle in ty-
phoid fever. The muscle 
loses its fibrillar staining 
and becomes glassy and 
hyaline. 
3. In alcoholic liver cell injury. 
4. Nuclear or cytoplasmic hyaline inclusions seen in some viral infec-
tions. 
5. Russell's bodies representing excessive immunoglobulins in the 
rough endoplasmic reticulum of the plasma cells. 
This form of dystrophy is irreversible. The function of organ is dis-
turbed. Coagulative focal or total cellular necrosis develops. 
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Hydropic (vacuolar, balloon) dystrophy is characterized by the ap-
pearance of vacuoles with cytoplasmatic fluid in the cells.  
This is the most common and earliest form of cell injury from almost 
all causes. Other synonyms of cellular swelling used in the past are cloudy 
swelling (for gross appearance of the affected organ), hydropic change (ac-
cumulation of water within the cell), and vacuolar degeneration (due to cy-
toplasmic vacuolation). 
The common causes of cellular swelling include: bacterial toxins, 
chemicals, poisons, burns, high fever, intravenous administration of hyper-
tonic glucose or saline etc. 
Cloudy swelling results from impaired regulation of cellular volume, 
especially for sodium. This regulation operates on 3 levels: at the plasma 
membrane itself, at the sodium pump on the plasma membrane, and at the 
supply of ATP. Injurious agent may interfere with these regulatory mecha-
nisms and result in accumulation of sodium in the cell which, in turn, leads 
to inflow of water to maintain iso-osmotic conditions and hence cellular 
swelling occurs. 
Grossly, the affected organ such as kidney, liver or heart muscle is 
enlarged due to swelling. The cut surface bulges outwards and is slightly 
opaque. Microscopically, it is characterised by the following features: 
1. The cells are swollen and the microvasculature compressed. The 
cellular swelling is due to increased influx of sodium and extracellular wa-
ter into the cell and escape of potassium. 
2. Small clear vacuoles are seen in the cells and hence the term vacu-
olar degeneration. These vacuoles represent distended cisternae of the en-
doplasmic reticulum. 
3. Ultrastructural changes in hydropic swelling include the following: 
i) Dilatation of endoplasmic reticulum, 
ii) Detachment of polysomes from the surface of RER, 
iii) Mitochondrial swelling, 
iv) Blebs on the plasma membrane, 
v) Loss of fibrillarity of nucleolus. 
It may be mentioned here the hydropic swelling is entirely reversible 
if the injurious agent is removed. 
This kind of dystrophy occurs in epidermis (in smallpox), in kidney 
(tubular necrosis), in adrenal glands cortex, in hepatocytes and in nervous 
cells. At the late stages the cells look like balloons, and after that rupture of 
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cytoplasm happens. This form of dystrophy is irreversible and results in cell 
death (focal or total colliquative cellular necrosis). 
 
Keratin dystrophy. It is increased formation of keratin matter in ke-
ratinized epithelium (hy-
perkeratosis, ichtiosis) or 
keratin matter formation in 
epithelium, in witch in 
norm it is absent (leu-
koplakia) or keratinization 
in epithelial tumors (patho-
logical formation of keratin 





Parenchymatous fatty (lipid) dystrophy 
Fatty change, steatosis or fatty metamorphosis is the intracellular ac-
cumulation of neutral fat within parenchymal cells. It includes the older, now 
abandoned, terms of fatty degeneration and fatty infiltration because fatty 
change neither necessarily involves degeneration nor infiltration. The deposit 
is in the cytosol and represents an absolute increase in the intracellular lipids. It 
is especially common in the liver but may occur in other non-fatty tissues like 
the heart, kidneys, skeletal muscle and other organs. 
One of the main cause of fatty (lipid) dystrophy is the oxygen insuffi-
ciency (hypoxia), resulting from cardiovascular diseases, anemia, diseases 
the lung. Another cause is intoxication. 
Heart. In the myocardiocytes lipids appear, then they force out cyto-
plasm. If this dystrophic process is not severe, externally organ doesn’t 
change. In severe process the organ will be flabby, with increased sizes and 
in dissection of yellowish color. In endocardium yellow-white striation is 
visible, particularly in papillary muscles. 
Liver. Liver is the most common site for accumulation of fat because 
it plays central role in fat metabolism. Depending upon the cause and 
Fig. 2. “Squamous perls” (а) in squamouscellular 
carcinoma. H and E stained section, x 200. 
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amount of accumulation, fatty change may be mild and reversible, or severe 
producing irreversible cell injury and cell death. 
The most common causes of fatty liver include the following: 




v) diabetes mellitus; 
vi) chronic illnesses (e.g. tuberculosis); 
vii) late pregnancy; 
viii) hypoxia (e.g. anaemia, cardiac failure); 
ix) hepatotoxins (e.g. carbon tetrachloride, chloroform ether, aflatox-
ins and other poisons); 
x) certain drugs (e.g. administration of oestrogen, steroids, tetra-
cycline etc); and 
Fig. 3. Fatty (lipid) dystrophy of the liver (a – grossly, 




xi) Reye's syndrome. 
Pathogenesis of fatty liver depends upon the stage at which the indi-
vidual etiologic agent acts in the normal fat transport and metabolism 
Normally, lipids are derived from 2 sources: 
• From diet as chylomicrons (containing triglycerides and phospho-
lipids) and as free fatty acids; and 
• From adipose tissue as free fatty acids. 
Free fatty acids from either of these sources enter the liver cell. 
Normally, a small part of fatty acids is synthesised from acetate in the liver 
cells. Most of fatty acid is esterified to triglycerides by the action of a-
glycerophosphate and only a small part is changed into cholesterol, phos-
pholipids and ketone bodies. Intra-celluar triglycerides require lipid accep-
tor protein' to form lipoprotein, the form in which lipids are normally ex-
creted from the liver cells. 
Intracellular accumulation of triglycerides leading to fatty liver can 
occur due to defect at one or more of the following 6 steps in the normal fat 
metabolism:  
1. Increased entry of free fatty acids into the liver. 
2. Increased synthesis of fatty acids by the liver. 
3. Decreased conversion of fatty acids into ketone bodies resulting in 
increased esterification of fatty acids to triglycerides. 
4. Increased α-glycerophosphate causing increased esterification of 
fatty acids to triglycerides. 
5. Decreased synthesis of 'lipid acceptor protein' resulting in de-
creased formation of lipoprotein from triglycerides.  
6. Block in the excretion of lipoprotein from the liver into plasma. 
In most cases of fatty liver, one of the above mechanisms is operat-
ing. But in the case of liver cell injury by chronic alcoholism, many fac-
tors are implicated viz.: 
• increased lipolysis, 
• increased free fatty acid synthesis, 
• decreased triglyceride utilisation, 
• decreased fatty acid oxidation to ketone bodies, and 
• block in lipoprotein excretion. 
Even a severe form of liver cell dysfunction may be reversible. For 
example, an alcoholic who has not developed progressive fibrosis in the 
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form of cirrhosis, the enlarged fatty liver may return to normal if the per-
son becomes teetotaler. 
Grossly, the fatty liver is enlarged with a tense, glistening capsule 
and rounded margins. The cut surface bulges slightly and is pale-yellow 
to yellow and is greasy to touch. 
Microscopically, there are numerous lipid vacuoles in the cytoplasm 
of hepatocytes. The vacuoles are initially small and are present around the 
nucleus (microvesicular). But with progression of the process, the vacu-
oles become large pushing the nucleus to the periphery of the cells 
(macrovesicular). At times, the hepatocytes laden with large lipid vacu-
oles may rupture and lipid vacuoles coalesce to form fatty cysts. Infte-
quently, lipogranulomas may appear consisting of collections of lympho-
cytes, macrophages, and some multinucleated giant cells. Fat in the tissue 
can be demonstrated by frozen section followed by fat stains such as Sudan 
dyes (Sudan III, IV, Sudan black), oil red O and osmic acid. 
Kidney. More frequently epithelium is affected. Kidneys are en-
larged, swelling, friable. 
Cholesterol. Intracellular deposits of cholesterol and its esters in 
macrophages may occur when there is hypercholesterolaemia. This turns 
macrophages into foam cells. The examples are: 
1. Fibrofatty plaques of aterosclerosis 
2. Clusters of foam cells in tumour-like masses called xanthomas 
and xanthelasma. 
 
Parenchymatous carbohydrate dystrophies 
They are connected with the glycogen and glycoprotein metabolism 
disturbances. Conditions associated with excessive accumulation of intra-
cellular glycogen are as under: 
1. In diabetes mellitus, when absolute or relative insulin insufficient-
ly take place, there is intracellular accumulation of glycogen in different 
tissues because normal cellular uptake of glucose is impaired. The metabo-
lism of glucose with glycogen formation is disturbed. Hyperglykemia, gluco-
suria result from this. Glycogen deposits in diabetes mellitus are seen in epi-
thelium of distal portion of proximal convoluted tubule and descending loop of 
Henle, in the hepatocytes, in beta cells of pancreatic islets, and in cardiac mus-
cle cells. Deposits of glycogen produce clear vacuoles in the cytoplasm of the 
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affected cells. Bests carmine and periodic acid-Schiff (PAS) staining may be 
employed to confirm the presence of glycogen in the cells. 
2. In glycogen storage diseases or glycogenosis, there is defective 
metabolism of glycogen due to genetic disorders. 
In glycoprotein metabolism disturbances the cells accumulate mucins 
and mucous like substances. It occurs in inflammatory processes in mucous 
coats. The number of mucous, producing by mucous cells, increases; mucous 
changes it physic-chemical properties. It may cause the occlusion of the bron-
chi lumen, gland ducts. Sometime mucous like colloid substances are pro-
duced (colloid strum). Hystochemical staning reveals the glycoproteins. 
 
STORAGE DISEASES 
There are a lot of diseases, which are due to hereditary factors and are 
connected with metabolism disturbance. These diseases are called storage 
diseases or enzymopathy. 
A few general comments should be made about all storage diseases: 
• All the storage diseases occur as a result of autosomal recessive, or 
sex-(X-) linked recessive genetic transmissions. 
• Most of the storage diseases are lysosomal storage diseases. Out of 
the glycogen storage diseases, only type II (Pompe's disease) is due to lyso-
somal enzyme deficiency. 
According to the type of metabolism disturbance storage diseases 




The type of proteinoses, lipidosis and glycogenoses depends on the 
defect in the enzyme. The most frequent lipidoses are Gaucher's disease, 
Niemann-Pick disease. 
Gaucher's disease 
This is an autosomal recessive disorder in which there is a deficiency of 
lysosomal enzyme, glucocerebrosidase, which normally cleaves glucose from 
ceramide. This results in lysosomal accumulation of glucocerebroside 
(ceramide-glucose) in phagocytes of the body and sometimes in the neurons. 
The main sources of glucocerebroside in phagocytic cells of the body and 
sometimes in the neurons are the membrane glycolipids of old leukocytes and 
erythrocytes, while the deposits in the neurons consist of gangliosides. 
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Clinically, there are 3 types of Gaucher's disease: 
1. Type 1 or classic form is the adult form of the disease in which 
there is storage of glycocerebrosides in the phagocytes of the body, princi-
pally involving the spleen, liver, bone marrow and lymph nodes. This is the 
most common type comprising 80% of all cases of Gaucher's disease. 
2. Type II is the infantile form in which there is progressive involve-
ment of the central nervous system. 
3. Type III is the juvenile form of the disease having features in between 
type I and type II, i.e. they have systemic involvement like in type I and pro-
gressive involvement of the central nervous system (CNS) as in type II. 
Morphology 
• In addition to involvement of different organs and systems (spleno-
megaly, hepatomegaly, lymphadenopathy, bone marrow and cerebral in-
volvement), a few other features include pancytopenia, or thrombocytope-
nia secondary to hypersplenism, bone pains and pathological fractures. 
• Microscopically, large number of characteristically distended and 
enlarged macrophages called Gaucher cells are found in the spleen, liver, 
bone marrow and lymph nodes, and in the case of neuronal involvement, in 
the Virchow-Robin space. The cytoplasm of these cells is abundant, granu-
lar and fibrillar resembling crumpled tissue paper. They have mostly a sin-
gle nucleus but occasionally may have two or three nuclei. These cells often 
show erythrophagocytosis and are rich in acid phosphatase. 
Niemann-pick disease 
• This is also an autosomal recessive disorder characterized by accu-
mulation of sphingomyelin and cholesterol. 
• The majority of the cases (about 80%) have deficiency of sphingo-
myelinase, which is required for cleavage of sphingomyelin, while a few 
cases probably result from deficiency of an activator protein. 
• The condition presents in infancy and is characterized by hepato-
splenomegaly, lymphadenopathy and physical and mental underdevelop-
ment. 
• About a quarter of patients present with familial amaurotic idiocy 
with characteristic cherry-red spots in the macula of the retina. 
• The storage of sphingomyelin and cholesterol occurs within the ly-
sosomes, particularly in the cells of mononuclear phagocyte system. 
• The cells of Niemann-Pick disease are somewhat smaller than Gau-
cher cells and their cytoplasm is not wrinkled but is foamy and vacuolated 
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which stains positively with fat stains. These cells are located in the spleen, 
liver, lymph nodes, bone marrow, lungs, intestine and brain. 
 
The most frequent glycogen storage diseases or glycogenoses are 
Pompe's disease, Mc Ardle's disease and Gierke disease. There is a defec-
tive metabolism of glycogen due to genetic disorders. 
Pompe's Disease -  is also an autosomal recessive disorder due to de-
ficiency of a lysosomal enzyme, acid mahase. Its deficiency results in ac-
cumulation of glycogen in many tissues, most often in the heart and skeletal 
muscles leading to cardio-megaly and hypotonia. 
Mc Ardle's Disease -the condition occurs due to deficiency of muscle 
phosphorylase resulting in accumulation of glycogen in the muscle (defi-
ciency of liver phosphorylase). The disease is common in 2nd – 4th decades 
of life and is characterized by painful muscle cramps, especially after exer-
cise, and detection of myoglobinuria in half of the cases. 
Gierke Disease - is inherited as autosomal recessive disorder due to 
deficiency of enzyme glucose-6-phosphatase. In the absence of glucose-6-
phosphatase, excess of normal type of glycogen accumulates in the liver 
and also results in hypoglycemia due to reduced formation of free glucose 
from glycogen. As a result, fat is metabolized for energy requirement lead-
ing to hyperlipoproteinemia and ketosis. Other change due to deranged glu-
cose metabolism is hyperuricemia. The disease manifests clinically in in-
fancy with failure to grow and stunted growth. Most prominent feature is 
enormous hepatomegaly with intracytoplasmic and intranuclear paren-
chymatous glycogen. The kidneys are also enlarged and show intracyto-
plasmic glycogen in tubular epithelial cells. Other features include gout, 
skin xanthomas and bleeding tendencies due to platelet dysfunction. 
The outcome of storage diseases is unfavorable because of its insuffi-
ciency of the respective organ. 
MESENCHIMAL DYSTROPHIES 
It is pathological process which damages the strome of organs and 
blood vessels walls. Accordind to the metabolism type disturbances mesen-
chimal dystrophies are subdivided into protein, lipid and carbohydrate. 
Protein mesenchimal dystrophies include mucoid swelling, fibrinoid 
swelling, hyalinosis and amyloidosis. First 3 forms are the stages of connec-
tive tissue damage. The base of this process is the entering of blood plasma 
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components through vessels wall and accumulation of them in intercellular 
matter. 
Mucoid swelling is reversible damage of connective tissue. The gly-
coproteins, glycoproteins, glucosaminoglycans and blood plasma proteins 
are accumulated in intercellular mater; a volume of fluid increases too. For 
this kind of dystrophy metachromasia is characteristic histological sign. It 
means the ability to give unordinary colour during staining. Microsigns are 
swelling of collagen fibers, increasing of their sizes. Macroscopic signs are 
almost absent. This process is reversible and in case of pathogen factor re-
moving the structure of tissue restores. If pathogen factor action continues, 
the fibrinoid swelling develops. 
Fibrinoid swelling – more deep and irreversible damage of connec-
tive tissue, accompaning with the fibrinoid formation. This is complex sub-
stance, which consists of fibrin, blood plasma proteins, products of collagen 
fibers destruction, nucleoproteins. The collagen fibers lose their structure. 
Metachromazia is not observed. Fibrinoid swelling may be generalized (in 
systemic diseases of the connective tissue) and localized (in chronic in-
flammation). The final stage of this process is fibrinoid necrosis, sclerosis 
or hyalinosis. Externally organs are almost not changed. 
Hyalinosis (extracellular hyaline, hyaline degeneration) is seen in 
connective tissues. Hyaline is pathological close (dense) substance like hya-
line cartilage, covering articular surfaces. It consists of fibrillar proteins: fi-
brin, blood plasma proteins, immunoglobulins, and lipids. 
There are 2 types of hyalinosis: hyalinosis of vessels and hyalinosis 
of connective tissue. 
i) Hyalinosis of vessels damage mainly small arteries and arterioles. 
Due to accumulation of hyaline in the wall blood vessels look like dense tu-
bules (“glass tubes”) with narrowing lumen. It results in blood supply dis-
turbances in tissues and organs. 
There are 3 kinds of vascular hyaline according to its nature: 
1. Simple – contains the plasma proteins (occurs in arterial hyperten-
sion). 
2. Lipohyaline – contains lipids (occurs in diabetes). 
3. Complex – contains immune components, fibrin, and damaged 
structures of the vascular wall (in diseases of immune system). 
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ii) Hyalinosis of connective tissue follows to fibrinoid swelling and is 
accompanied with the fibres structures destruction. Such changes occur in 
rheumatic disease, in the bottom of chronic stomach ulcer, in old scars. 
Some examples of extracellular hyaline changes are: 
1. Hyaline degeneration in the uterus leiomyomas. 
2. Hyalinized old scar of fibrocollagenous tissues. 
3. Hyaline arteriolosclerosis is renal vessels in hypertension and dia-
betes mellitus. 
4. Hyalinized glomeruli in chronic glomerulonephritis. 
5. Corpora amylacea are rounded masses of concentric hyaline lami-
nae seen in the prostate, brain and spinal cord in the elderly persons, and in 
old infarcts of the lung. 
Amyloidosis is a kind of mesenchimal protein dystrophy. Amyloid is 
a hyaline glycoprotein material with a microfibril structure that stains under 
Congo red dye. It is stored systemically or locally in the extracellular space, 
giving the respective tissue a glassy, wax-like appearance. 
Amyloidoses represent a group of disorders of varying etiology that 
involve the deposit of amyloid in tissue. The following forms are differenti-
ated according to the site: 
– Systemic amyloidoses involve amyloid deposits in several organs 
and/or tissues. 
– Localized amyloidoses involve amyloid deposits in one organ 
and/or tissue. 
Structure of Amyloid 
These components are common to all types of amyloid: 
– Fibril protein with a B-pleated structure (B-pleated fibrils). This 
protein varies with the underlying disease and its name is used to identify 
the respective type of amyloid. 
– Amyloid P component arises from SAP (serum amyloid P compo-
nent, which is physiologic serum protein, a component of the glomerular 
basement membrane). 
– Heparan sulfate proteoglycanes are proteoglycanes of the basement 
membrane type. 
All components have antigenic properties. 
Substances used for detecting amyloid: 
– Lugol’s solution normally detects starches (hence the name “amyloid”). 
– Amyloid is positive under Congo red. 
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– Amyloid shows green birefringence under polarized light. 
The reasons of amyloidosis development are unknown. Theories of 
amyloifosis are: 
1. The immunological theory (amyloidosis is the result of antibody-
antigen interaction). 
2. The theory of cellular local synthesis (amyloid is produced by 
mesenchyma descended cells). 
3. The mutational theory (the synthesis of amyloid is the result of 
genes cell mutation which produce amyloid). 
Amyloid can store along reticular fibers (perireticular amyloidosis 
with involvement of spleen, kidneys, liver, intestine, adrenal glands, an intima 
of small and medium calibre vessels) and along collagenic fibers (pericolla-
genous amyloidosis with the lesion of large vessels, myocardium, muscles, 
nerves and skin). Organs affected by amyloidosis are increased in sizes, dense 
in consistence; they have a tallowy appearance on the cut section. 
 
Types of Amyloid 
AL Amyloid, Synonym: light-chain amyloid. 
Pathogenesis: AL amyloid is the derivative of variable parts of the 
immunoglobulin light chains (k chains more often than j chains). An im-
mune stimulus causes proliferation of a plasma cell clone, triggering for-
mation of a monoclonal immunoglobulin with an excess of light chains. The 
result is incomplete lysosomal breakdown of the immunoglobulin light 
chains in the macrophages, which in turn causes formation of k and j light 
chain fragments. These fragments condense to b-clumpy fibrils with a b-
pleated sheet structure. Manifestation as systemic amyloidosis: see primary 
forms of amyloidosis. 
 
AA Amyloid, Synonym: amyloid A. 
Pathogenesis: AA amyloid is the derivative of an HDL apolipopro-
tein (SAA = serum amyloid A precursor protein). In an inflammation, the 
acute-phase proteins are synthesized in the liver during the acute phase. 
These include SAA, which is released into the serum and phagocytized by 
cells of the macrophage system. There, the lysosomes cleave off the amy-
loid-forming fragments. These fragments condense to b-clumpy fibrils with 
a b-pleated sheet structure. 
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Manifestation as systemic amyloidosis: see secondary forms of amy-
loidosis. 
 
AF Amyloid, Synonym: familial amyloid. 
Pathogenesis: AF amyloid is the derivative of transthyretin (the 
transport protein for thyroxin and retinol). A single-point mutation of trans-
thyretin generates amyloid-forming fragments without prior proteolytic 
cleavage. These fragments condense to b-pleated fibrils with a b-clumpy 
sheet structure. 
Manifestation as local amyloidosis: 
– Kidney amyloidosis. 
– Predominant distal polyneuropathies: Amyloid deposits cause nerve 
damage with sensory deficits and weakening of reflexes. 
– Hypertrophic cardiomyopathy: Amyloid deposits between the mus-
cle cells in the myocardium cause fatty hardening of the myocardium. 
 
AE Amyloid, Synonym: endocrine amyloid. 
Pathogenesis: AE amyloid comes from endocrine cells. Endocrine 
cells cause generation of abnormal peptides, which in turn result in incom-
plete proteolytic breakdown with residual amyloid fragments. These frag-
ments condense to b-clumpy fibrils with a b-pleated sheet structure. 
Manifestation as local amyloidosis: 
– Islet amyloidosis: Amyloid deposits in the islets of Langerhans in 
the pancreas displace the endocrine cells (A, B), causing type II diabetes 
mellitus. 
– Calcitonin amyloid: The clumped configuration of cells in a C-cell 
thyroid carcinoma (C1) form clumpy deposits of AE amyloid in the tumor 
stroma (C2) and express calcitonin ( D). 
 
AS Amyloid, Synonym: amyloid of aging. 
Pathogenesis: AS amyloid is produced in abnormally aging brains. 
Mutation of a gene on chromosome 21 (which normally codes for a protein-
ase inhibitor) causes coding of an atypical b-amyloid precursor proteins (b-
APP). These proteins condense to b-clumpy fibrils with a b-pleated sheet 
structure. 
Manifestation as local amyloidosis: 
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– Alzheimer’s disease involves focal Amyloid deposits in the brain 
known as “Amyloid cores” (E, F), some of which are surrounded by dis-
tended nerve endings with an abnormal cytoskeleton. 
– Down’s syndrome (trisomy 21). 
 
Classification of amyloidosis: 
I) by origin: 
• Idiopathic (synonym: atypical, primary) amyloidosis occur in the 
absence of a discernible prior disorder or a discernible etiology. 
This also includes the paramyloidoses. These disorders are character-
ized by generalized deposits of amyloid that occur in the setting of lympho-
plasmacytic neoplasms. Deposition sites especially include mesenchymal 
organs less often affected in classic secondary amyloidosis: the tongue, 
skeletal musculature, and myocardium. The nerves, brain, skin, and lungs 
are affected less frequently. 
• Hereditary amyloidosis. The synthesis of abnormal protein is ge-
netically determined. 
• Acquired amyloidosis (synonym: reactive systemic amyloidosis, 
secondary). Amyloidosis occurs secondary to such diseases as rheumatoid 
arthritis, chronic osteomyelitis, chronic abscess of lung, bronchiectatic dis-
ease, multiple myeloma, tuberculosis. 
• Senile amyloidosis. This form develops in elderly persons; it is 
connected with general disturbances of protein metabolism. 
• Local tumor-like amyloidosis - amyloid accumulates locally in the 
form of node. 
II) by specificity of fibrillar protein; 
III) by extension: 
• Systemic. 
• Localized form. It is limited to a single organ or circumscribed ar-
ea within organs. Some forms of hereditary, senile amyloidosis and local 
tumor-like amyloidosis are referred to this form. Locations and forms in-
clude: 
– Brain: cerebral amyloidosis. 
– Nerves: polyneuropathic amyloidosis.  
– Heart: cardiomyopathic amyloidosis. 
– Lung: respiratory-tract amyloidosis. 
– Kidney: nephropathic amyloidosis. 
– Eye: ocular amyloidosis. 
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– Endocrine system: AE amyloidosis. 




IV) by clinical manifestations: 
• cardiopathic; 






General amyloidosis is characterized by lesion of adrenal glands, 
kidneys, liver, nervous system, heart. Amyloid accumulates in lymphatic 
follicles of the spleen (sago-spleen) or evenly in all pulp (a tallowy spleen). 
Kidneys become dense, tallowy too. Amyloidosis of kidneys leads to a 
chronic renal insufficiency. 
Clinical presentation of amyloidosis: 
AL Amyloidosis 
Fig.4. Kidney amyloidosis (a – grossly, b – microscopically, H and E 






– Carpal tunnel 
syndrome due to amy-
loid deposits in the 
transverse carpal liga-
ment with secondary 
compressive neuropa-
thy of the median 
nerve leading to atro-
phy of the muscles of 
the thenar eminence. 
– Macroglossia 
with swallowing diffi-
culties (dysphagia) due 
to amyloid deposits in 
the tongue. 
– Skin: papillary 
lesions and purpura (punctuate bleeding sites). 
– Joints: Major joints exhibit arthritic symptoms. 
Late symptoms: 
– Heart: Heart failure not responding to treatment, occasionally ac-
companied by conduction disorders due to restrictive cardiomyopathy. Am-
yloid deposits in the myocardium impair its contractility and elasticity, pro-
ducing reactive thickening of the myocardium (hypertrophy) with ventricu-
lar narrowing lacking mechanical efficiency. 
– Liver: Hepatomegaly (enlargement of the liver) due to perisinusoi-
dal amyloid deposits (C, D). This causes atrophy of the hepatic cords with 
strikingly little functional impairment. 
– Small bowel: Amyloid deposits in the submucosa and around the 
arteries cause obstructions, mucosal bleeding, and diarrhea where the au-
tonomous nervous system is involved. 
– Nerves: Peripheral neuropathy, usually associated with sensory def-
icits. 
– Lung: Respiratory insufficiency is present only where there are dif-
fuse amyloid deposits in the alveolar and extraalveolar interstitium (the 
bronchial wall). 
 
Fig. 5. Amyloidosis of the spleen. H and E stained sec-




– Kidney: Amyloid deposits occur in the mesangium and coils of the 
glomeruli (E, F) and/or predominantly in the arterial branches (AA greater 
than 50%; AL 15%; AF 25%). This leads to impaired renal function in the 




– Edemas, occurring primarily in the lower leg in adults and primari-
ly in the eyelids in children. 
– Liver: Hepatomegaly (enlargement of the liver) with negligible 
functional deficiency. 
− Small bowel: Obstructions and mucosal bleeding. 
 
Mesenchymal lipid (fatty) dystrophies result from the disturbances of 
lipids and cholesterol metabolism. Stromal fatty infiltration is quite differ-
ent from fatty change previously described. Stromal fatty infiltration is 
the accumulation of mature adipose cells in the stromal connective tissue 
in contrast to intracellular deposition of fat in the parenchymal cells in 
fatty changes. This condition occurs most often in patients with obesity. 
The two commonly affected organs are the heart and the pancreas. The 
presence of mature adipose cells in the stroma generally does not cause 
any dysfunction. In the heart stromal fatty infiltration is associated with 
increased adipose tissue in the epicardium. 
There are 2 types of General obesity: primary (the cause is unknown) 
and secondary (in diseases of the central nerve and endocrine systems). 
General obesity is classified into 4 forms: symmetric, upper (mainly in the 
regions of head, upper limbs), middle (in the region of abdomen), interior 
(lower limbs). 
There are several types of secondary obesity: 
1. Alimentary (a lot of lipids in food). 
2. Cerebral. 
3. Endocrine (e.g. in Icenko-Kushing syndrome). 
4. Hereditary (eg.in Gierke's disease). 




In hypertrophic type adipose tissue enlarges due to increased volume 
of fatty cells, in hyperplastic – due to increase in their number.  
Depending on the excess of patient’s body weight compared to the 
norm, 4 degrees of obesity are defined: 
1st degree – when 20 - 29% of overweight ; 
2nd degree - when 30 - 49% of overweight; 
3rd degree – when  50 - 99% of overweight ; 
4th degree – when body weight increases up to 100% and more. 
Severe reduction in the amount of neutral fat in the whole organism is 
cachexia. 
Local increasing of fat tissue number is termed lipomatosis and oc-
curs in Dercum's disease when painful fat nodes appear in the subcutaneous 
fat of the lower and upper extremities and trunk. 
The cholesterol metabolism disturbance is the base of atherosclerosis 
with the damage of blood vessel wall internal coat. It causes the narrowing 
of arteries lumen. 
 
Mesenchymal carbohydrate dystrophies result from the glycopro-
teids and glycosaminoglycans metabolism disturbances. When glycopro-
teids metabolism is disturbed, chromotropic substances are released from 
the protein bonds. The products of metabolism are accumulated in the inter-
cellular mater. Collagens are replaced by mucous substance, connective and 
cartilage tissue lose their structure. More frequently this process is connect-
ed with endocrine dysfunctions.  
Connective tissue mucin is associated with: 
• Mucoid or myxoid degeneration in some tumors (myxoma). 
• Neurofibromas, soft tissue sarcomas, etc. 
• Myxomatous change in the dermis in myxedema (mucous edema in 
hypothyreosis). 
• Myxoid change in the synovium in ganglion on a wrist. 
The condition results in colliquative necrosis with formation of cavi-
ties filled with mucus. 
Mucopolysaccharidoses (MPS) 
• Disturbance of glycosaminoglycans (GAG) is due to hereditary fac-
tors as in a storage disease. 
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• It is characterized by the deficiency of specific lysosomal enzyme 
involved in the degradation of mucopolysaccharides or glycosaminogly-
cans. 
• Syndrome of MPS manifests in infancy or early childhood and in-
volves multiple organs and tissues, chiefly connective tissues, liver, spleen, 
bone marrow, lymph nodes, kidneys, heart and brain. 
• The mucopolysaccarides accumulate in mononuclear phagocytic 
cells, endothelial cells, smooth muscle cells and fibroblasts. The material is 
finely granular and PAS-positive by light microscopy. 
• By electron microscopy, it appears in the swollen lysosomes and 
can be identified biochemically as mucopolysaccharide.  
• The most frequent of them are Pfaundler-Hurler disease, or gargoy-
lism. Its cause is congenital defect of the enzyme determined GAG metabo-
lism. This disease is characterized by irregular skeleton growth, “massive” 
skull, heart defects, inguinal and umbilical hernias, hepato- and splenomeg-
aly, keratoleukoma (retina opacity). 
MIXED DYSTROPHIES 
It is pathological process which effects stroma and parenchyma. This 
kind of dystrophy includes the metabolism disturbances of nucleoproteins, 
lipoproteins, mineral substances, chromoproteins (pigments). 
 
PIGMENTS are coloured substances present in most living beings in-
cluding humans. There are 2 broad categories of pigments: endogenous and 
exogenous. 
A. Endogenous pigments (chromoproteins) are either  normal constit-
uents of cells or accumulate under special circumstances e.g melanin, 
ochronosis, haemoprotein-derived pigments and lipofuscin. 
B. Exogenous pigments are those which are introduced into the body 
from outside such as by inhalation, ingestion or inoculation. 
A. ENDOGENOUS PIGMENTS 
According to the pigment structure endogenous pigments are classi-
fied into: 
1. Proteinogenic (tyrosinogenic) pigments. 
2. Haemoprotein-derived (haemoglobinogenic) pigments. 
3. Lipidogenic (lipid) pigments. 
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PROTEINOGENIC (TYROSINOGENIC) PIGMENTS 
MELANIN is the proteinogenic brown-black pigment normally pre-
sent in the hair, skin, choroid of the eye, meninges and adrenal medulla. It is 
synthesised in the melanocytes and dendritic cells, both of which are pre-
sent in the basal cells of the epidermis and is stored in the form of cyto-
plasmic granules in the phagocytic cells called the melanophorocyte, pre-
sent in the underlying dermis. Melanocytes possess the enzyme tyrosinase 
necessary for synthesis of melanin from tyrosine. However, sometimes 
tyrosinase is present but is not active and hence no melanin pigment is visi-
ble. In such cases, the presence of tyrosinase can be detected by incubation 
of tissue section in the solution of dihydroxy phenyl alanine (DOPA). If 
the enzyme presents, dark pigment is identified in pigment cells. This test is 
called as DOPA reaction and is particularly useful in differentiating 
amelanotic melanoma from other anaplastic tumours. Various disorders of 
melanin pigmentation cause generalised and localised hyperpigmenta-
tion and hypopigmentation. 
Generalised hyperpigmentation: 
a) In Addison's disease, there is generalised hyperpigmentation 
of the skin, especially in areas exposed to light, and of buccal mucosa. 
b) Chloasma observed during pregnancy is the hyperpigmentation 
on the skin of face, nipples, and genitalia and occurs under the influence of 
oestrogen. A similar appearance may be observed in women taking oral 
contraceptives. 
c) In chronic arsenical poisoning, there is characteristic rain-drop 
pigmentation of the skin. 
Focal hyperpigmentation: 
a) Cafe-au-lait spots are pigmented patches seen in neurofibromato-
sis and Albright's syndrome. 
b) Peutz-Jeghers' syndrome is characterized by focal perioral pigmen-
tation. 
c) Melanosis coli is pigmentation of the mucosa of the colon. 
d) Melanotic tumours, both benign such as pigmented naevi, and ma-
lignant such as melanoma, are associated with increased melanogenesis. 
e) Lentigo is a pre-malignant condition in which there is focal hyper-
pigmentation on the skin of hands, face, neck, and arms. 
Generalised hypopigmentation: albinism is an extreme degree of 
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generalized hypopigmentation in which tyrosinase activity of the melano-
cytes is genetically defective and no melanin is formed. Albinos have blond 
hair, poor vision and severe photophobia. They are highly sensitive to sun-
light. Chronic sun exposure may lead to precancerous lesions and squa-
mous and basal cell cancers of the skin in such individuals. 
Localised hypopigmentation: 
a) Leucoderma is a form of partial albinism and is an inherited disorder. 
b) Vitiligo is local hypopigmentation of the skin and is more common. 
It may have familial tendency. 
c) Acquired focal hypopigmentation can result from various causes 
such as leprosy, healing of wounds, DLE, radiation dermatitis etc. 
 
ADRENOCHROME is a pigment of dark brown color. It is situated in 
a form of small kernels in the cells of adrenal glands medullar. It can be 
found in pheochromocytoma. 
THE PIGMENT OF ENTEROCHROMAFFIN CELLS GRANULES is a 
tryptophan derivative. The excessive amounts of this pigment are found in 
tumors of enterochromaffin cells which are called carcinoid tumors. 
OCHRONOSIS 
Ochronosis is an autosomal recessive disorder in which there is defi-
ciency of an oxidase enzyme required for breakdown of homogentisic acid 
which then accumulates in the tissues and is excreted in the urine. The 
pigment is melanin-like and is deposited both intra-cellularly and inter-
cellularly. Most commonly affected tissues are the cartilages, capsules of 
joints, ligaments and tendons. In almost all the cases, alkaptonuria is 
present in which homogentisic acid is excreted by the kidneys. The urine 
of these patients, if allowed to stand for some hours in air, turns black due 
to oxidation of homogentisic acid. 
HAEMOPROTEIN-DERIVED PIGMENTS 
Haemoproteins are the most important endogenous pigments derived 
from haemoglobin, cytochromes and their breakdown products. For an 
understanding of disorders of haemoproteins, it is essential to have 
knowledge of normal iron metabolism and its transport. In disordered iron 
metabolism and transport, haemoprotein-derived pigments accumulate 
in the body. These pigments are haemosiderin, haematin, bilirubin, and 
porphyrins. 
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Hemoprotein-derived pigments include normal (feritin, haemosyder-
in, bilirubin) and pathological (haematoidin, haematin, porphirin). 
• Ferritin is iron complexed to apoferritin and can be identified by 
electron microscopy. It is located in liver, spleen, bone marrow and lymph 
nodes. There are two forms of ferritin: inactive and active (formed due to 
lack of oxygen, characterized by vasoparalytic and hypotensive actions). 
Active ferritin is adrenalin antagonist). The pathological condition charac-
terized by increasing of ferritin level in blood and tissues is haemosiderosis. 
Ferritinaemia is a cause of shock irreversibility. 
• Haemosiderin, which is formed by aggregates of ferritin and is 
identifiable by light microscopy as golden- yellow to brown, granular 
pigment, especially within the mononuclear phagocytes of the bone mar-
row, spleen and liver where breakdown of senescent red cells takes place. 
Haemosiderin is ferric iron that can be demonstrated by Prussian blue re-
action. In this reaction, colourless potassium ferrocyanide reacts with 
ferric ions of haemosiderin to form deep blue ferric-ferrocyanide 
Excessive storage of haemosiderin occurs in situations when 
there is increased breakdown of red cells, or systemic overload of iron 
due to primary (idiopathic, hereditary) haemochromatosis, and secondary 
(acquired) causes such as in thalassaemia, sideroblastic anaemia, alco-
holic cirrhosis, multiple blood transfusions etc. 
Accordingly, the effects of haemosiderin excess are as under: 
a) Local haemosiderosis. This develops whenever there is haem-
orrhage into the tissues. With lysis of red cells, haemoglobin is liberated 
which is taken up by macrophages where it is degraded and stored as 
haemosiderin. The changing colours of a bruise or a black eye are caused 
by the pigments like biliverdin and bilirubin which are formed during 
transformation of haemoglobin into haemosiderin. Another example of lo-
cal haemosiderosis is brown induration in the lungs as a result of small 
haemorrhages as occur in mitral stenosis and left ventricular failure. Mi-
croscopy reveals the presence of 'heart failure cells' which are haemosider-
in-laden alveolar macrophages. 
b) Generalised haemosiderosis. Systemic overload with iron 




tion of haemosiderin occurs in 
the parenchymal cells of the 
liver, pancreas, kidney, and 
heart. The causes for paren-
chymatous haemosiderosis in-
clude: 
i) excessive intestinal ab-
sorption of iron (e.g. in haemo-
chromatosis); 
ii) increased erythropoiet-
ic activity (e.g. in haemolytic 
anaemia); 
iii) excessive intake of 
dietary iron (e.g. in Bantu's 
disease in black tribals of South 
Africa who conventionally pre-
pare their alcoholic beverages 
in iron pots that serves as a rich 
source of additional dietary 
iron). 
– Reticuloendothelial depo-
sition occurs usually following 
repeated blood transfusions or 
after parenteral iron therapy. 
c) Idiopathic haemo-
chromatosis. This is an auto-
somal dominant disease charac-
terised by excessive absorption 
of iron. It is associated with triad of pigmentary liver cirrhosis, pancreatic 
damage resulting in diabetes mellitus, and skin pigmentation. On the basis of 
the last two features the disease has come to be termed as 'bronze diabetes'. 
 
• Bilirubin is a normal haemoglobin-derived non-iron containing 
pigment which presents in the bile. It is derived from porphyrin ring of the 
haemmoiety of haemoglobin. 
Fig.6. Haemosiderosis of the lungs. H and E 
stained section, x 200. 
 1 – storage of haemosiderin. 
Fig.7 . Haemosiderosis of the lungs. Prussian 
blue reaction. 




Bilirubin is formed in the cells of reticular-endothelial system in 
erythrocytes destruction and enters the blood. This is free or indirect biliru-
bin. It enters the hepatocytes where it is associated with glucuronic acid (di-
rect bilirubin). Then it enters the small intestine, where some of it enter the 
blood, and last portion color the stool and urine (stercobilin and urobilin). 
Normal level of bilirubin in blood is less than 1mg/dl. Excess of bili-
rubin causes an important clinical condition called jaundice. 
Briefly, jaundice appears in one of the following 3 ways: 
a) Prehepatic (or haemolytic), when there is excessive destruc-
tion of red cells. 
b) Posthepatic (or obstructive, or mechanical), which results from 
obstruction to the outflow of 
conjugated bilirubin. 
c) Hepatocellular (or 
hepatic) that results from fail-
ure of hepatocytes to conjugate 
bilirubin and inability of bili-
rubin to pass from the liver to 
intestine. Excessive accumu-
lation of bilirubin pigment can 
be seen in different tissues and 
fluids of the body, especially in 
the hepatocytes, Kupffer cells 
and bile sinusoids. Skin and 
sclerae become distinctly yel-
low. In infants, rise in unconjugated bilirubin may produce toxic brain inju-
ry called kernicterus. 
 
• Haematin is a haemoprotein-derived brown-black pigment contain-
ing haem iron in ferric form. But it differs from haemosiderin because it can-
not be stained by Prussian blue reaction, probably because of formation of 
complex with a protein so that it is unable to react in the stain. Haematin 
pigment is seen most commonly in chronic malaria and in mismatched 
blood transfusions. 
There are three types of haematin: 
Fig.8. «Liver in mechanical jaundice». (he-
matoxylin and eosin staining). 
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− Muriatic haematin is formed in gastric erosions and ulcers as the 
result of interaction between haemoglobin and enzymes with chloric acid of 
gastric juice. 
− Hemomelanin is a brown pigment produced by malarial parasites 
from haemoglobin; it is taken up by monocytes in the blood and subse-
quently deposited in the liver and spleen. 
− Formalin pigment looks like dark brown grains, it can be found in 
the tissues fixed with acid formalin (with pH below 6.0). 
 
• Porphyrins are tetrapyrrols which exist in 3 forms in nature com-
bined with different metals: 
i) haem contains iron; 
ii) chlorophyll contains magnesium; and 
iii) cobalamin contains cobalt. 
Porphyria results from genetic deficiency of one of the enzymes re-
quired for the synthesis of haem so that there is excessive production of 
porphyrins. Often, the genetic deficiency is precipitated by intake of some 
drugs. Porphyrias are broadly of 2 types: erythropoietic and hepatic. 
(a) Erythropoietic porphyrias. These have defective synthesis of 
haem in the erythrocytes. These may be further of 2 subtypes:  
– Congenital type, in which the urine is red due to presence of 
uroporphyrin I and coproporphyrin 1. The skin of these infants is highly 
photosensitive. Bones and skin show red brown discoloration. 
– Erythropoietic protoporphyria, in which there is excess of proto-
porphyrin but no excess of porphyrin in the urine. 
(b) Hepatic porphyrias. These are more common and have a defect in 
synthesis of haem in the liver. Its further subtypes include the following:  
– Acute intermittent porphyria is characterised by acute episodes of 
3 patterns: abdominal, neurological, and psychotic. These patients do not 
have photosensitivity. There is excessive delta aminolaevulinic acid and 
porphobilinogen in the urine. 
– Variegate porphyria is common in the whites of South Africa. 
Photosensitivity occurs and there are acute attacks of colicky ab-
dominal pain and neurological manifestations. 
– Hereditary coproporphyria is quite rare. 
– Porphyria cutanea tarda is the most common of all porphyrias. 
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Porphyrins collect in the liver and small quantity is excreted in the urine. 
Skin lesions are similar to those in variegate porphyria. Most of the pa-
tients have associated haemosiderosis with cirrhosis which may eventually 
develop into hepatocellular carcinoma. 
 
LIPIDOGENIC PIGMENTS 
Lipidogenic pigments include lipofuscin, pigment of vitamin E insuf-
ficiency, ceroid, and lipochrome.  
Lipofuscin (wear and tear pigment) 
Lipofuscin is yellowish-brown intracellular lipid pigment (lipo = 
fat, fuscus = dark). The pigment is often found in atrophied cells of old age 
and hence has the name 'wear and tear pigment'. It is seen in the myocardial 
fibres, hepatocytes, cells of the testes and neurons. The pigment often ac-
cumulates in the central part of the cells around the nuclei. In the heart 
muscle, the change is associated with wasting of the muscle and is com-
monly referred to as “brown atrophy”. Deposition of lipofuscin in neurons is 
seen in senile dementia. However, the pigment may, at times, accumulate 
rapidly in different cells in wasting diseases unrelated to aging. 
Lipofuscin represents the collection of indigestible material in the ly-
sosomes after autophagy and is therefore an example of residual bodies. 
The pigment can be stained by fat stains but differs from other lipids in be-
ing fluorescent and acid-fast. 
By electron microscopy, lipofuscin appears as intra-lysosomal elec-
tron-dense granules in perinuclear location. These granules are composed 
of lipid-protein complexes. 
 
B. EXOGENOUS PIGMENTS 
INHALED PIGMENTS 
The lungs of most individuals, especially of those living in urban areas 
due to atmospheric pollutants and of smokers, show a large number of in-
haled pigmented materials. The most commonly inhaled substances are 
carbon or coal dust; others are silica or stone dust, iron or iron oxide, asbes-
tos and various other organic substances. These substances may produce occu-
pational lung diseases called pneumoconiosis. The pigment particles after inha-
lation are taken up by alveolar macrophages. Some of the pigment-laden mac-
rophages are coughed out via bronchi, while some settle in the interstitial tissue 
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of the lung and in the respiratory bronchioles and pass into lymphatics to be de-
posited in the hilar lymph nodes. Anthracosis (i.e. deposition of cabon particles) 
is seen in almost every adult lung and generally provokes no reaction of tissue 
injury. However, extensive deposition of particulate material over many years 
in coal miners' pneumoconiosis, silicosis, asbestosis, etc. provoke low grade in-
flammation, fibrosis and impaired respiratory function. 
INGESTED PIGMENTS 
Chronic ingestion of certain metals may produce pigmentation. 
The examples are as under: 
i) Argyria is chronic ingestion of silver compounds and results in 
brownish pigmentation in the skin, bowel, and kidney. 
ii) Chronic lead poisoning may produce the characteristic blue lines on 
teeth at the gumline. 
iii) Melanosis coli results from prolonged ingestion of certain cathartics. 
iv) Carotenaemia is yellowish-red coloration of the skin caused by ex-
cessive ingestion of carrots which contain carotene. 
INJECTED PIGMENTS (TATTOOING) 
Pigments like India ink, cinnabar and carbon are introduced into the 
dermis in the process of tattooing where the pigment is taken up by macrophag-
es and lies permanently in the connective tissue. The examples of injected pig-
ments are prolonged use of ointments containing mercury, dirt left accidentally 
in a wound, and tattoing by pricking the skin with dyes.  
DISTURBANCES OF MINERAL METABOLISM.  
PATHOLOGIC CALCIFICATION. 
Deposition of calcium salts in tissues other than osteoid or enamel is 
called pathologic or heterotopic calcification. Three distinct types of patho-
logic calcification are recognised: 
• Dystrophic calcification, which is characterised by deposition of 
calcium salts in dead or degenerated tissues with normal calcium metabo-
lism and normal serum calcium levels. 
• Metastatic calcification, on the other hand, occurs in apparently 
normal tissues and is associated with deranged calcium metabolism and hy-
percalcaemia. 
• Metabolic calcification, main cause of it`s development is an unsta-
bility of buffer systems of the blood and tissue liquid. 
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Etiology and pathogenesis of the three are different but morphologi-
cally the deposits in all resemble normal minerals of the bone. 
Histologically, in routine H and E stained sections, calcium salts ap-
pear as deeply basophilic, irregular and granular clumps. The deposits may 
be intra-cellular, extracellular, or at both locations. Occasionally, heterotop-
ic bone formation (ossification) may occur. Calcium deposits can be con-
firmed by special stains like silver impregnation method of von-Kossa pro-
ducing black colour, and alizarin red S that produces red staining. Patholog-
ic calcification is often accompanied by diffuse or granular deposits of iron 
giving positive Prussian blue reaction. 
 
DYSTROPHIC CALCIFICATION. As apparent from definition, dys-
trophic calcification may occur due to 2 types of causes: 
• Calcification in dead tissue 
• Calcification of degenerated tissue. 
Calcification in dead tissue: 
1. Caseous necrosis in tuberculosis is the most common site for dys-
trophic calcification. Liv-
ing bacilli may be present 
even in calcified tubercu-
lous lesions, lymph nodes, 
lungs, etc. 
2. Liquefaction ne-
crosis in chronic abscesses 
may get calcified. 
3. Fat necrosis fol-
lowing acute pancreatitis 
or traumatic fat necrosis 
in the breast results in 
deposition of calcium 
soaps. 
4. Infarcts may sometimes undergo dystrophic calcification. 
5. Thrombi, especially in the veins, may produce phleboliths. 
6. Haematomas in the vicinity of bones may undergo dystrophic cal-
cification. 
7. Dead parasites like in hydatid cyst, Schistosoma eggs, and cysticerco-
sis are some of the examples showing dystrophic calcification. 
Fig. 9. dystrophic calcification of skeletal muscle in 
Cencer`s necrosis. H and E stained section, x 200. 
 1 - deposition of calcium soaps. 
1 
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8. Calcification in breast cancer detected by mammography. 
9. Congenital toxoplasmosis involving the central nervous system 
visualised by calcification in the infant brain. 
 
Calcification in degenerated tissues: 
1. Dense old scars may undergo hyaline degeneration and subsequent 
calcification. 
2. Atheromas in the aorta and coronaries frequently undergo calcifi-
cation. 
3. Monckeberg's sclerosis shows calcification in the tunica media of 
muscular arteries in elderly people. 
4. Stroma of tumours such as uterine fibroids, breast cancer, thyroid 
adenoma, goitre etc show calcification. Some tumours show characteristic 
spherules of calcification called psammoma bodies or calcospherites such as 
in meningioma, papillary serous cystadenocarcinoma of the ovary and pa-
pillary carcinoma of the thyroid. 
5. Cysts which have been present for a long time may show calcifica-
tion of their walls e.g. epidermal and pilar cysts. 
6. Calcinosis cutis is a condition of unknown cause in which there are 
irregular nodular deposits of calcium salts in the skin and subcutaneous tissue. 
7. Senile degenerative changes may be accompanied by dystrophic 
calcification such as in costal cartilages, tracheal or bronchial cartilages, 
and pineal gland in the brain etc. 
The pathogenesis of dystrophic calcification is not quite clear. A few 
factors like local alteration of pH in the necrotic tissue and release of en-
zymes (e.g. alkaline phosphatase) from necrotic or degenerafed tissue have 
been implicated which favour deposition of calcium salts. More recently, 
however, the process of dystrophic calcification has been likened to the 
formation of normal hydroxyapatite in the bone involving 2 phases: initia-
tion and propagation. 
• Initiation is the phase in which calcium and phosphates begin to ac-
cumulate intracellularly in the mitochondria, or extracellularly in mem-
brane-bound vesicles. 
• Propagation is the phase in which minerals deposited in the initia-
tion phase are propagated to form mineral crystals. 
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METASTATIC CALCIFICATION. Since metastatic calcification occurs in 
normal tissues due to hypercalcaemia, its causes would include one of the 
following two conditions: 
• Excessive mobilisation of calcium from the bone. 
• Excessive absorption of calcium from the gut. 
Excessive mobilisation of calcium from the bone. 
These causes are more common and include the following: 
1. Hyperparathyroidism which may be primary such as due to para-
thyroid adenoma, or secondary such as from parathyroid hyperplasia, chron-
ic renal failure etc. 
2. Bony destructive lesions such as multiple myeloma, metastatic 
carcinoma. 
3. Prolonged immobilisation of a patient results in disuse atrophy of 
the bones and hypercalcaemia. 
Excessive absorption of calcium from the gut. Less often, excess 
calcium may be absorbed from the gut causing hypercalcaemia and meta-
static calcification. These causes are as under: 
1. Hypervitaminosis D results in increased calcium absorption. 
2. Milk-alkali syndrome caused by excessive oral intake of calcium 
in the form of milk and administration of calcium carbonate in the treatment 
of peptic ulcer. 
3. Hypercalcaemia of infancy is another condition in which metastat-
ic calcification may occur. 
Metastatic calcification may occur in any normal tissue of the body 
but affects the following organs more commonly: 
• Kidneys, especially at the basement membrane of tubular epitheli-
um and in the tubular lumina causing nephrocalcinosis. 
• Lungs, especially in the alveolar walls. 
• Stomach, on the acid-secreting fundal glands. 
• Blood vessels, especially on the internal elastic lamina. 
• Cornea is another site affected by metastatic calcification. 
The pathogenesis of metastatic calcification at the above mentioned 
sites is based on the hypothesis that these sites have relatively high (alka-
line) pH which favours the precipitation of the calcium. 
 
METABOLIC CALCIFICATION. The mechanism of metabolic calcification 
development is not clearly understood. The principal value is significanced 
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to instability of the organism buffer systems. Owing to this instability salts 
of calcium are not kept in blood and interstitial fluid. Hereditary sensitivity 
of tissues to calcium has a significant role too. 
 
NUCLEOPROTEINS METABOLISM DISTURBANCES 
Disturbances of nucleoproteins metabolism are characterised by ex-
cessive formation of uric acid and precipitation of its salts in the tissues. 
This process is observed at podagra, urolithiasis and uric acid infarction of 
kidneys. 
The podagra (gout) is characterized by periodic precipitation of sodi-
um salt of uric acid in joints accompanied by a painful attack. An increase 
in uric acid salts content in blood (hyperuricemia) and in urine (hyperuricu-
ria) is found in patients. Salts (are) usually accumulate in synovia and carti-
lages of foots and small joints of hands, talocrural and knee joints, in ten-
dons and articular bags, in the cartilage of auricles. There is necrotizing of 
tissues in which salts precipitate in the form of crystals or amorphous sub-
stances. An inflammatory reaction with appearance of giant cells develops 
around salts depositions and necrotic foci. Podagric tophus develops when 
there is an increase of salt deposition and connective tissue growth in peri-
articular region and adjacent tissue. It arises in auricles and other parts of 
the body leading to the deformation of joints. 
Changes in kidneys. There is accumulation of uric acid and sodium 
salt of uric acid salts in renal tubules and collecting tubes with the obtura-
tion of their lumens and development of secondary inflammatory and 
atrophic changes (gouty kidneys) at podagra.  
The development of podagra is mainly caused by congenital disturb-
ances of metabolism (primary gout), thus the role of dietary habits and over-
use of animal proteins is great. Less often gout is the complication of other 
diseases (secondary gout), such, as nephrocirrhosis, leukaemias, etc. 
Urolithiasis is caused, first of all, by the disturbances of purine me-
tabolism i.e. it can be the manifestation of so-called urine acid diathesis. 
Thus urates are formed in kidneys and urinary tracts. 
Uric acid infarct occurs in newborns of two days old and upward. It 
is manifested by depositions of amorphous substances of sodium salt of uric 
acid and ammonium in renal tubules and collecting tubes. The cause of uric 
acid infarction is intensive metabolism in the first days of newborn life. It 
reflects an adaptative reaction of kidneys to the new conditions of existence. 
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IRREVERSIBLE CELL INJURY (CELL DEATH) 
Cell death is a state of irreversible injury. It may occur in the living 
body as a local or focal change (i.e. necrosis and apoptosis) and the changes 
that follow it (i.e. gangrene and pathologic calcification), or result in end of 
the life (somatic death). These pathologic processes involved in cell death 
are described below. 
NECROSIS 
Necrosis is defined as focal death along with degradation of tissue by 
hydrolytic enzymes liberated by cell. It is invariably accompanied by in-
flammatory reaction. 
Necrosis can be caused by various agents such as hypoxia, chemical 
and physical agents, microbial agents and immunological injury.  





5. Vascular, or ischemic. 
Necrosis may occur due to external or internal factors. 
External factors may be mechanical trauma (physical damage to the 
body which causes cellular breakdown), damage to blood vessels (which 
may disrupt blood supply to associated tissue), and ischemia, thermal ef-
fects (extremely high or low temperature). 
Internal factors causing necrosis include: trophoneurotic disorders; 
injury and paralysis of nerve cells, action of pancreatic enzymes (lipases), 
components of the immune system, such as the complement system; bacte-
rial toxins; activated natural killer cells; and peritoneal macrophages. 
So, according to the mechanism of pathological factor action necrosis 
is classified into direct (produced by mechanical, physical, chemical, and 
toxic factors) and indirect (caused by vascular and neurogenous disturb-
ances). 
Two essential changes bring about irreversible cell injury in necrosis 
– cell digestion by lytic enzymes and denaturation of proteins. These pro-
cesses are morphologically identified by characteristic cytoplasmic and nu-
clear changes in necrotic cell. The cytoplasm appears homogeneous and in-
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tensely eosinophilic. Occasionally, it may show vacuolation or dystrophic 
calcification. The nuclear changes include condensation of nuclear chroma-
tin (pyknosis) which may either undergo dissolution (karyolysis) or frag-
mentation into many granular clumps (karyorrhexis). 
There are 4 stages of necrosis: paranecrosis, necrobyosis, necrosis, 
aytolysis. 
Autolysis (self-digestion) is disintegration of the cell by its own hy-
drolytic enzymes liberated from lysosomes. Autolysis can occur in the liv-
ing body when it is surrounded by inflammatory reaction (vital reaction), or 
may occur as postmortem change in which there is complete absence of sur-
rounding inflammatory response. Autolysis is rapid in some tissues rich in 
hydrolytic enzymes such as in the pancreas, and gastric mucosa; intermedi-
ate in tissues like the heart, liver and kidney; and slow in fibrous tissue. 
Morphologically, autolysis is identified by homogeneous and eosinophilic 
cytoplasm with loss of cellular details and remains of cell as debris. 
 
Morphologically, 6 distinct types of necrosis are identified: coagu-
lative (includes fibrinoid, Cencer`s, caseous subtypes), liquefaction (or col-
liquative), fat, gangrene, ischemic necrosis and sequestration. 
1. Coagulative necrosis 
This is the most common type of necrosis caused by irreversible focal 
injury, mostly from sudden cessation of blood flow (ischaemia), and less 
often from bacterial and chemical agents. It develops in tissues rich with 
the protein. The organs commonly affected are the heart, kidney, and 
spleen. 
Grossly, foci of coagulative necrosis in the early stage are pale, firm, 
and slightly swollen. With progression, they become more yellowish, softer, 
and shrunken.  
Microscopically, the hallmark of coagulative necrosis is the conversion 
of normal cells into their 'tombstones' i.e. outlines of the cells are retained 
so that the cell type can still be recognised but their cytoplasmic and nuclear 
details are lost. The necrosed cells are swollen and appear more eosinophilic 
than the normal, along with nuclear changes described above. This pattern of 
microscopic change results from 2 processes: denaturation of proteins and en-
zymatic digestion of the cell. But cell digestion and liquefaction fail to occur. 
Eventually, the necrosed focus is infiltrated by inflammatory cells and the dead 
cells are phagocytosed leaving granular debris and fragments of cells. 
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Caseous necrosis is found in the centre of foci of tuberculous in-
fections. It combines features of both coagulative and liquefactive ne-
crosis. 
Grossly, foci of caseous necrosis, as the name implies, resemble dry 
curd and are soft, granular and yellowish. This appearance is partly at-
tributed to the histotoxic effects of lipopolysaccharides present in the cap-
sule of the tubercle bacilli, Mycobacterium tuberculosis. 
Microscopically, the necrosed foci are structureless, eosinophilic, 
and contain granular debris. The surrounding tissue shows characteris-
tic granulomatous inflammatory reaction consisting of epithelioid 
cells with interspersed giant cells of Langhans or foreign body type 
and peripheral mantle of lymphocytes. 
 
Fibrinoid necrosis or fibrinoid degeneration is characterised by 
deposition of fibrin-like material which has the staining properties of fibrin. 
It is encountered in various examples of immunologic tissue injury (e.g. in 
immune complex vasculitis, autoimmune disease, Arthus reaction etc), arte-
rioles in hypertension, peptic ulcer etc. 
Microscopically, fibrinoid necrosis is identified by brightly eosino-
philic, hyaline-like deposition in the vessel wall or on the luminal surface 
of a peptic ulcer. Local haemorrhages may occur due to rupture of these 
blood vessels 
 
Cencer’s necrosis occurs in striated muscles of abdomen cavity in 
Enteric fever. 
 
2. Liquefaction (colliquative) necrosis 
Liquefaction or colliquative necrosis occurs commonly due to is-
chaemic injury and bacterial or fungal infections. It occurs due to degrada-
tion of tissue by the action of powerful hydrolytic enzymes and develops in 
tissues rich with the liquid. The common examples are brain infarct and 
abscess cavity. 
Grossly, the affected area is soft with liquefied centre containing ne-
crotic debris. Later, a cyst wall is formed. 
Microscopically, the cystic space contains necrotic cell debris and 
macrophages filled with phagocytosed material. The cyst wall is 
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formed by proliferating capillaries, inflammatory cells, and gliosis 
(proliferating glial cells) in the case of brain and proliferating fibroblasts in 
the case of abscess cavity. 
 
3. Fat necrosis 
Fat necrosis is a special form of cell death occurring at two anatom-
ically different locations but morphologically similar lesions. These are: 
following acute pancreatic necrosis, and traumatic fat necrosis commonly 
in breasts. 
In the case of pancreas, there is liberation of pancreatic lipases from 
injured or inflamed tissue that results in necrosis of the pancreas as well as 
of the fat depots throughout the peritoneal cavity, and sometimes, even af-
fecting the extra-abdominal adipose tissue. 
Fat necrosis in either of the two instances results in hydrolysis of 
neutral fat present in adipose cells into glycerol and free fatty acids. The 
damaged adipose cells assume cloudy appearance when only free fatty acids 
remain behind, after glycerol leaks out. The leaked out free fatty acids, on 
the other hand, complex with calcium to form calcium soaps (saponifica-
tion) discussed later under dystrophic calcification. 
Grossly, fat necrosis appears as yellowish-white and firm deposits. 
Formation of calcium soaps imparts the necrosed foci firmer and chalky 
white appearance. 
Microscopically, the necrosed fat cells have cloudy appearance and 
are surrounded by an inflammatory reaction. Formation of calcium soaps 




Gangrene is a form of necrosis of tissue with superadded putrefac-
tion. The type of necrosis is usually coagulative due to ischaemia (e.g. in 
gangrene of the bowel, gangrene of limb). On the other hand, gangrenous or 
necrotising inflammation is characterised by primarily inflammation pro-
voked by virulent bacteria resulting in massive tissue necrosis. Thus the 
end-result of necrotising inflammation and gangrene is the same but the 
way two are produced is different. The examples of necrotising inflamma-
tion are: gangrene lung, gangrenous appendicitis, and noma (cancrum oris). 
There are 3 main forms of gangrene – dry, wet and gas gangrene. In 
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either type of gangrene, coagulative necrosis undergoes liquefaction by the 
action of putrefactive bacteria. 
 
Dry Gangrene. This form of gangrene begins in the distal part of a 
limb due to ischaemia. The typical example is the dry gangrene in the toes 
and feet of an old patient due to arteriosclerosis. Other causes include 
thromboangiitis obliterans (Buerger's disease), Raynaud's disease, trauma, 
ergot poisoning. It is usually initiated in one of the toes which is farthest 
from the blood supply, containing so little blood that even the invading bac-
teria find it hard to grow in the necrosed tissue. The gangrene spreads slow-
ly upwards until it reaches a point where the blood supply is adequate to 
keep the tissue viable. A line of separation is formed at this point between 
the gangrenous part and the viable part. 
Macroscopically, 
the affected part is dry, 
shrunken and dark black, 
resembling the foot of a 
mummy. It is black due to 
liberation of haemoglobin 
from haemolysed red 
blood cells which is acted 
upon by hydrogen disul-
fide (H2S) produced by 
bacteria resulting in for-
mation of black iron sul-
fide. The line of separa-
tion usually brings about complete separation with eventual falling off of 
the gangrenous tissue if it is not removed surgically. 
Histologically, there is necrosis with smudging of the tissue (see Fig. 
10). The line of separation consists of inflammatory granulation tissue. 
 
Wet Gangrene. This occurs in naturally moist tissues and organs 
such as the mouth, bowel, lung, cervix, vulva etc. Diabetic foot is another 
example of wet gangrene due to high sugar content in the necrosed tissue 
which favours growth of bacteria. Bed sores occurring in a bed-ridden pa-
tient due to pressure on sites like the sacrum, buttocks and heels are the oth-
er important clinical conditions included in wet gangrene. Wet gangrene 
Fig. 10. Dry Gangrene. H and E stained section, x 200. 
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usually develops rapidly due to blockage of venous and less commonly ar-
terial blood flow from thrombosis or embolism. The affected part is stuffed 
with blood which favours the rapid growth of putrefactive bacteria. The tox-
ic products formed by bacteria are absorbed causing systemic manifesta-
tions of septicaemia, and finally death. The spreading wet gangrene lacks 
clear cut line of demarcation and may spread to peritoneal cavity causing 
peritonitis. 
Macroscopically, the affected part is soft, swollen, putrid, rotten and 
dark. The classic example is gangrene of bowel, commonly due to strangu-
lated hernia, volvulus or intussusception. The part is stained dark due to the 
same mechanism as in dry gangrene. 
Histologically, there is coagulative necrosis with stuffing of affected 
part with blood. There is ulceration of the mucosa and intense inflammatory in-
filtration. Lumen of the bowel contains mucus and blood. The line of demarca-
tion between gangrenous segment and viable bowel is generally not clear cut. 
 
Gas Gangrene. Gas gangrene is a special form of wet gangrene 
caused by gas-forming clostridia (gram-positive anaerobic bacteria) which 
gain entry into the tissues through open contaminated wounds, especially in 
the muscles, or as a complication of operation on colon which normally 
contains clostridia. Clostridia produce various toxins which produce necro-
sis and oedema locally and are also absorbed producing profound systemic 
manifestations. 
Grossly, the affected area is swollen, oedematous, painful and crepi-
tant due to accumulation of gas bubbles within the tissues. Subsequently, 
the affected tissue becomes dark black and foul smelling. 
Microscopically, the muscle fibres undergo coagulative necrosis with 
liquefaction. Large number of gram-positive bacilli can be identified. At the 
periphery, a zone of leucocytic infiltration, oedema and congestion are 
found. Capillary and venous thrombi are common. 
 
5. Infarction, or vascular (ischemic) necrosis.  
Infarcts are classified depending upon different features: 
– according to the shape of infarction zone: 
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1. Wedge-shaped 
infarction (in organs with 
the main-line type of vas-
cularization e.g. in 










infarction (in organs with 
disseminated or mixed 











– according to the color of infarction zone: 
1. Pale or anaemic, due to arterial occlusion and are seen in compact or-
gans (e.g. spleen, brain). 
2. Pale with haemorrhagic crown (e.g. heart, kidneys). 
3. Red or haemorrhagic, seen in soft loose tissues and are caused ei-
ther by pulmonary arterial obstruction (e.g. in the lungs) or by arterial or 
venous occlusion (e.g. in the intestines). 
 
– according to their age: 
• recent, or fresh, 
Fig. 11. Wedge-shaped pale infarction of the spleen. 
 




• old, or healed. 
– according to presence or absence of infection: 
• bland, when free of bacterial contamination, 
• septic, when infected. 
 
6. Sequestration develops in bones and is characterized by the ab-
sence of boundary between the necrotic zone and surrounded tissue. 
 
FATE OF NECROSIS  
• Regeneration of tissues – the replacement of the dead tissue with a 
new one. 
• Incapsulation – the formation of the connective tissue capsule 
around necrotic area. 
• Organization – the replacement of the dead tissue with connective 
tissue. 
• Petrification – replacement of the dead tissue and the deposition 
of calcium salts. 
• Ossification – the formation of the bone tissue in the necrotic area. 
• Hyaline change – the appearance of the hyaline-like substance in the 
necrotic area.  
• Suppuration, or purulent fusion of necrotic tissues. 
• Sequestration – formation of sequester. 
• Mutilation – spontaneous tearing away of the dead tissue. 
• Cyst formation. 
 
APOPTOSIS 
Apoptosis is a form of “coordinated and internally programmed cell 
death” which is of significance in a variety of physiologic and pathologic 
conditions (apoptosis is a Greek word meaning “failing off” or “dropping 
off”). The term was first coined in 1972 as distinct from necrosis. 
Morphologic changes: The characteristic morphologic changes in 
apoptosis as seen in histologic and electron microscopic examination are as 
under: 
1. Shrinkage of cell with dense cytoplasm and almost normal orga-
nelles. 
2. Convolutions of the cell membrane with formation of mem-
brane-bound near-spherical bodies called apoptotic bodies containing com-
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pacted organelles. 
3. Chromatin condensation around the periphery of nucleus. 
4. Characteristically, there is no acute inflammatory reaction. 
5. Phagocytosis of apoptotic bodies by macrophages takes place at 
varying speed. There may be swift phagocytosis, or loosely floating apop-
totic cells after losing contact, with each other and basement membrane as 
single cells, or may result in major cell loss in the tissue without significant 
change in the overall tissue structure. 
Histologic examination of tissues stained with H & E shows apopto-
sis involving single cells or small clusters of cells in the background of viable 
cells. The apoptotic cells are round to oval shrunken masses of intensely eo-
sinophilic cytoplasm containing condensed or fragmented nuclear chromatin. 
Unlike necrosis, inflammatory response around apoptosis is absent. 
 
Biochemical changes: Biochemical processes underlying the mor-
phologic changes are as under: 
1. Proteolysis of cytoskeletal proteins. 
2. Protein-protein cross linking. 
3. Fragmentation of nuclear chromatin by activation of nuclease. 
4. Appearance of phosphatidylserine on the outer surface of cell 
membrane. 
5. In some forms of apoptosis, appearance of an adhesive glycopro-
tein thrombospondin on the outer surface of apoptotic bodies. 
6. Appearance of phosphatidylserine and thrombospondin on the 
outer surface of apoptotic cell facilitates early recognition by macrophages 
for phagocytosis prior to appearance of inflammatory cells. 
7. The biochemical mechanism underlying rapid cell shrinkage, 
however, remains unexplained. 
 
Identifying apoptotic cells. Identifying and counting of apoptotic 
cells is possible by following methods: 
1. Staining of chromatin condensation (by haematoxylin, Feulgen, 
or acridine orange). 
2. Flow cytometry to visualise rapid cell shrinkage. 
3. DNA changes detected by in situ techniques or by gel electrophoresis. 
4. Annexin V as marker for apoptotic cell membrane having phos-
phatidylserine on the cell exterior. 
 51 
 
Molecular mechanisms of apoptosis. 
Several physiologic and pathologic processes activate apoptosis in a 
variety of ways. However, in general the following events sum up the se-
quence involved in apoptosis: 
1. Initiators of apoptosis. Stimuli for signalling programmed 
cell death act either at the cell membrane or intracellularly. These include: 
i) Absence of stimuli required for normal cell survival (e.g. absence 
of certain hormones, growth factors, cytokines). 
ii) Activators of programmed cell death (e.g. receptors for TNF). 
iii) Intracellular stimuli include heat, radiation, hypoxia etc. 
2. Regulators of apoptosis. After a cell has been initiated into 
apoptosis by above-mentioned signals, next comes the phase in which cer-
tain proteins convert death signals to the final programmed cell death and 
thus determine the outcome. These regulator proteins include the fol-
lowing: 
i) bcl-2. bcl-2 protein is a human counterpart of ced-9 (cell death) 
gene found in programmed cell death of nematode worm C. elegans. bcl-2 
is located in the outer mitochondrial membrane and may regulate the apop-
totic process by binding to some other related proteins e.g to bax and bad 
for promoting apoptosis, and bcl-XL for inhibiting apoptosis. Another im-
portant bcl-2 binding protein in the cytosol is the pro-apoptotic protease ac-
tivating factor (apaf-1) which is a mammalian counterpart of gene ced-4 of 
nematode. The net effect on the mitochondrial membrane is thus based on 
the pro-apoptotic and anti-apoptotic members of bcl-2 protein family. 
ii) Other apoptotic regulator proteins. Besides bcl-2, other important 
regulator proteins of apoptosis are p53 protein, caspases, bax and certain 
viruses (adenovirus, papillomavirus, hepatitis B virus). 
3. Programmed cell death. The final outcome of apoptotic regulators 
in the programmed cell death involves the following pathways: 
i) Fas receptor activation. Cell surface receptor Fas (CD 95) presents 
on cytotoxic (CD 8 +) T cells. On coming in contact with the target cell, the 
Fas receptor is activated. This leads to activation of caspases and subse-
quent proteolysis. 
ii) Ceramide generation. Due to hydrolysis of phospholipid sphingo-
myelin of the plasma membrane, ceramide is generated. Ceramide is impli-
cated in further mito-chondrial injury. 
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iii) DNA damage. Damage to DNA produced by various agents such 
as ionising radiation, chemotherapeutic agents, activated oxygen species 
lead to apoptosis. DNA damage affects nuclear protein p53 which induces 
the synthesis of cell death promoting protein Bax. 
Phagocytosis. The dead apoptotic cells and their fragments possess 
cell surface receptors which facilitate their identification by adjacent phag-
ocytes. The phagocytosis is unaccompanied by any other inflammatory 
cells. 
 
Apoptosis in biologic processes.  
Apoptosis is responsible for mediating cell death in a wide variety of 
physiologic and pathologic processes as under: 
Physiologic Processes: 
1. Organized cell destruction in sculpting of tissues during develop-
ment of embryo. 
2. Physiologic involution of cells in hormone-dependent tissues e.g. 
endometrial shedding, regression of lactating breast after withdrawal of 
breast feeding. 
3. Normal cell destruction followed by replacement proliferation 
such as in intestinal epithelium. 
4. Involution of the thymus in early age. 
Pathologic Processes: 
1. Cell death in tumours exposed to chemotherapeutic agents. 
2. Cell death by cytotoxic T cells in immune mechanisms such as 
in graft-versus-host disease and rejection reactions. 
3. Cell death in viral infections e.g. formation of Councilman 
bodies in viral hepatitis 
4. Pathologic atrophy of organs and tissues on withdrawal of 
stimuli e.g. prostatic atrophy after orchiectomy, atrophy of kidney or sali-
vary gland on obstruction of ureter or ducts, respectively. 
5. Progressive depletion of CD4+ T cells in the pathogenesis of 
AIDS. 
6. Cell death in response to injurious agents involved in causation 
of necrosis e.g. radiation, hypoxia and mild thermal injury. 
7. In degenerative diseases of CNS e.g. in Alzheimer's disease, 
Parkinson's disease, and chronic infective dementias. 
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GENERAL DEATH.  DEATH SIGNS.  POSTMORTAL CHANGES. 
Death is a biological process of irreversible organism vital activity 
cessation. Death results in the man transformation into the corpse (cadaver). 
Depending on the causes of death there are nature (physiological), 
violent death and the death due to diseases. 
Physiological death comes in elder persons and long-livers due to na-
ture (physiological) wear of the organism. A man lifetime is not limited. 
According to the world data the age of long-livers may be 150 years and 
more.  
Violent death happens from such acts (deliberate in deliberate) as 
murder, suicide, death due to traumas (e.g. street, industrial, home), exi-
dents (e.g. transport catastrophe). Being social-legal categories it is studied 
by forensic medicine and justice institutions. 
The death due to diseases results from incompatibility of the life and 
changes in the organism, caused by pathological (ill) processes. Usually 
death comes slowly and is accompanied by the disappearance of vital func-
tions. But sometimes the death arises suddenly – sudden death. It occurs in 
latent or enough compensated disease, when suddenly mortal complication 
develops (profuse bleeding in aorta rupture, acute myocardium infarction 
due to coronary artery thrombosis, hemorrhagic stroke).  
Depending on development of vital activity reversible and irreversi-
ble changes there are clinical and biological death. Clinical death is charac-
terized by the breath and blood circulation stop. But these changes of organ-
ism activity are reversible during some minutes (the time of brain cortex 
surviving). The base of clinical death is hypoxia state (mainly CNS) due to 
blood circulation stop) and absence of its central regulation. 
Clinical death is predisposed by agonies, which is characterized by 
the uncoordinated activity of homeostatic system in terminal period (ar-
rhythmia, paralyze of sphincters, lung oedema). Due to this agony, continu-
ing from some minutes to some hours, is considered as terminal state result-
ing in clinical death. 
Terminal state (agony, shock, haemorrhage and other) and clinical 
death need the reanimation methods. 
Biological death means irreversible changes of organism vital activi-
ty, onset of autolytic processes. However, in biological death the death of 
cells and tissues don’t occur simultaneously. First the central nervous sys-
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tem dies. In 5-6 min after breath and blood circulation stop the ultra struc-
tural elements of brain and spinal cord parenchymatous cells have been de-
stroyed. In the other organs and tissues (skeen, kidney, heart, lungs and oth-
er) this process continues during hours and sometime days. Common struc-
ture of many organs and tissues, observed microscopically after the death, is 
kept during long time. And only electron microscopy helps to determine de-
struction of the cells ultra structure. Due to this pathologist can assume the 
pathological changes of cadaver organs and tissues using the microscopic 
methods.  
Biological death is accompanied with the appearing of some signs of 
death and post mortal changes: 
• cadaveric cooling, 
• cadaveric rigidity,  
• cadaveric desiccation, 
• blood redistribution, 
• livores mortis (cadaveric spots), 
• putrefaction (cadaveric decay). 
Cadaver cooling (algor mortis) results from the heat producing ces-
sation and equalization of the body and environment temperature. The cool-
ing of cadaver comes slowly in patients with fever before death or with 
spasms in long agonic period. Sometimes (tetanus, poisoning with strych-
nine) during first hours after death the cadaver temperature may increase. 
Cadaver rigidity (rigor mortis) is characterized by the hardening of 
the voluntary and involuntary muscles. It results from disappearance of the 
АТF from the muscles after death and accumulation of the lactase acid 
there. Cadaver rigidity starts usually in 2-5 hours after death and to the end 
of 1st day involves whole musculature. First the muscles of facial expression 
and mystification undergo the rigidity and then the muscles of neck, trunk 
and extremities. Cadaver rigidity continues during 2-3 days and then disap-
pears in the same sequence. Cadaver rigidity is more expressed and early in 
persons with developed musculature and in cases when the death is accom-
panied by the spasms (e.g. tetanus, poisoning with strychnine). Poor cadav-
er rigidity occurs in elder persons and children, in patients died due to sep-
sis, in cachectic patients. In prematurely born fetus cadaver rigidity is ab-
sent. Low temperature of environment makes difficult the cadaver rigidity 
development and prolongs its continuation. High temperature accelerates 
the cadaver rigidity disappearance. 
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Cadaver desiccation arises due to evaporation of moisture from the 
body surface. This process may be local, but may spread and involve whole 
corpse (cadaver mummification). First desiccation involves the skin, eyes-
balls, and mucous coats. It is results in turbidity of cornea, dry brown trian-
gle spots appearance on it. The base of this spots is facing to the cornea, and 
the apex – to eye angle. The mucous coats become dry, hard, of brown col-
our. First of all, dry, yellow-brown, parchment spots appear in the places of 
epidermis damage and maceration of the skin. These spots should be diag-
nosed with the vital burns and grazes. 
Blood redistribution means the fullness of the veins, whereas the ar-
teries become almost empty. In the veins and right chambers of the heart the 
post mortal blood coagulation occurs. The post mortal blood clots have yel-
low or red colour, smooth surface, elastic consistence, they don’t attach to 
the wall. In prolonged death there are a lot of blood clots, in sudden death – 
less number. 
Death resulting from asphyxia doesn’t accompanied by the blood co-
agulation. With time haemolysis comes. 
Cadaver spots (livores mortis) arise due to blood redistribution in the 
corpse. Their location depends on corpse position. In 3-6 hours after death 
the cadaveric (post-mortem) hypostasises appear on the skin of underlying 
body parts due to accumulation of the blood in the veins of these regions. 
They are dark violet and become pale when pressing. The cadaver hyposta-
sises are absent in the regions of body undergoing to compression (sacrum 
region, scapula in the back lying position). They are more expressed in 
death due to diseases resulting in general venous hyperaemia and worse ex-
pressed in cahexia, hypovolemia, and anaemia. 
When postmortal haemolysis of red blood cells comes, the regions of 
cadaver hypostasises are impregnated with the blood plasma, diffusing from 
blood vessels and colouring with haemoglobin. The late cadaver spots ap-
pear – cadaver imbibitions. These spots are red or pink colour and don’t 
disappear when pressing. 
Cadaver decay is accompanied with autolysis and putrefaction. 
Postmortal autolysis arises early and more expressed in the glandular organs 
(liver, pancreas) and stomach, the cells of which are rich with hydrolytic 
enzymes. Self-digestion of pancreas arises very early. Due to activity of 
gastric juices increase the post mortal self-digestion of stomach develops 
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(gastromalacia). Esophagomalacia due to regurgitation and pneumomala-
cia acida due to aspiration of stomach contents are possible. 
Putrefactive bacteria undergo the multiplication in the intestine, 
spread in the organism and cause the general putrefactive processes. Putre-
faction increases postmortal autolysis, resulting in tissues melting and 
change of the colour into green due to destruction of haemoglobin and FeS 
formation. 
Forming due to cadaver decay gases blow out the intestine, enter the 
tissues and organs and give them the foamy shape (palpation reveals crepi-
tating cadaver emphysema). To stop or to prevent the cadaver putrefaction 
the cold freezing chamber and embalming are used. 
 57 
CELLULAR ADAPTATIONS 
The cell responds to injuries that fail to destroy it with either increased 
or decreased function. This response results from changes in its metabolism 
of structural and functional substances and may include cell proliferation. 
This also applies to the term dystrophy, which harkens back to the time be-
fore biochemistry and refers to the development of weakened structures orig-
inally attributed to nutritional deficiencies, and to the term degeneration, re-
ferring to transformation of a tissue into one of lesser quality. 
Adaptive response with increased function (hypertrophy and hy-
perplasia): Hypertrophy results when functional internal cellular structures 
increase, causing the volume of the organ to increase. In hyperplasia, the 
expansion of the organ is also due to an increase in the number of cells. Cel-
lular proliferation in these cases continues to follow the normal pattern of 
cell division and maturation. However, it is not always possible to draw a 
clear histological distinction between this type of proliferation and the au-
tonomous cell growth of a tumour. 
Adaptive response with decreased function (atrophy): This re-
sponse initially manifests itself as atrophy in which a reduction in only the 
structural components of the cells occurs (simple atrophy). Later the total 
number of cells in the organ also decreases (numeric atrophy). The reduc-
tion in the quantity of cells is effected by the programmed death of individ-
ual cells. 
Particular form of physiologic and pathologic adaptations is the 
changing of cells phenotypic differentiation pathway (i.e. metaplasia and 
dysplasia). 
In general, the adaptive responses are reversible on withdrawal of 
stimulus. However, if the irritant stimulus persists for long time, the cell 
may not be able to survive and may either die or progress further (e.g. cell 
death in sustained atrophy, progression of dysplasia into carcinoma-in-situ). 
Thus, the concept of evolution “survival of the fittest” holds true for adapta-
tion as “survival of the adaptable”. 
Various mechanisms which may be involved in adaptive cellular re-
sponses include: 
• Altered cell surface receptor binding 
• Alterations in signal for protein synthesis 
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• Synthesis of new proteins by the target cell such as heat-shock pro-
teins (HSPs). 
Common forms of cellular adaptive responses along with examples 
of physiologic and pathologic adaptations are briefly discussed below. 
 
ATROPHY 
Reduction of the number and size of parenchymal cells of an organ or 
its parts which was once normal is called atrophy (c.f. hypoplasia which is 
the term used for developmentally small size, and aplasia for extreme fail-
ure of development so that only rudimentary tissue is present). 
Atrophy may occur from physiologic or pathologic causes. 
A. Physiologic atrophy. Atrophy is a normal process of aging in some 
tissues which could be due to loss of endocrine stimulation or arteriosclerosis. 
For example: 
i) Atrophy of lymphoid tissue in lymph nodes, appendix and thymus, 
ii) Atrophy of gonads after menopause, 
iii) Atrophy of brain. 
B. Pathologic atrophy. It may be general and local.  
General atrophy is observed  in cachexy (starvation) due to: 
• Oncologic diseases, 
• Chronic infectious diseases, 
• Injury of hypophysis (endocrine cachexia), 
• Injury of hypothalamus (cerebral cachexia). 
In starvation, there is first depletion of carbohydrate and fat stores 
followed by protein catabolism. There is general weakness, emaciation and 
anaemia referred to as cachexia seen in cancer and severely-ill patients. 
Local atrophy may develop due to different causes: 
1. Ischaemic atrophy. Gradual diminution of blood supply due to 
atherosclerosis may result in shrinkage of the affected organ e.g. 
i) Small atrophic kidney in atherosclerosis of renal artery. 
ii) Atrophy of brain in cerebral atherosclerosis. 
2. Disuse atrophy. Prolonged diminished functional activity is asso-
ciated with disuse atrophy of the organ e.g. 
i) Wasting of muscles of limb immobilised in cast, 
ii) Atrophy of the pancreas in obstruction of pancreatic duct. 
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3. Neuropathic atrophy. Interruption in nerve supply leads to wasting 
of muscles e.g. 
i) Poliomyelitis 
ii) Motor neuron disease 
iii) Nerve section. 
4. Endocrine atrophy. Loss of endocrine regulatory mechanism re-
sults in reduced metabolic activity of tissues and hence atrophy e.g. 
i) Hypopituitarism may lead to atrophy of thyroid, adrenal and 
gonads. 
ii) Hypothyroidism may cause atrophy of the skin and its adnexal 
structures. 
5. Pressure atrophy. Prolonged pressure from benign tumours or cyst 
or aneurysm may cause compression and atrophy of the tissues e.g. 
i) Atrophy of kidney parenchyma by tumor or stone in urolithiasis. 
ii) Atrophy of sternum by aneurysm of aorta arch. 
6. Idiopathic atrophy. There are some examples of atrophy where no 
obvious cause is present e.g. 
i) Myopathies 
ii) Testicular atrophy. 
7. Atrophy due to chemical and physical factors. For example: ac-
tion of the radiation lead to atrophy of bone marrow and genital organs. 
Pathologic changes. Irrespective of the underlying cause for atrophy, 
the pathologic changes are similar. The organ is small, often shrunken. The 
cells become smaller in size but they are not dead. Shrinkage in cell size is 
due to reduction in cell organelles, chiefly mitochondria, myofilaments and 
endoplasmic reticulum. There is often increase in the number of autophagic 
vacuoles containing cell debris. These autophagic vacuoles may persist to 
form 'residual bodies' in the cell cytoplasm e.g. lipofuscin pigment granules 
in brown atrophy. 
 
HYPERTROPHY 
Hypertrophy is an increase in the size of parenchymal cells resulting 
in enlargement of the organ or tissue without any change in the number of 
cells. 
Pathogenesis: A stimulus inducing increased function activates pro-
to-oncogenes. The resulting expression of transcription factors increases the 
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synthesis of RNA and proteins and later DNA as well (causing nuclear pol-
yploidy). This accelerates intracellular growth processes and proliferation of 
organelles while growth inhibitors simultaneously prevent mitosis. The lim-
iting factor for organ function is density of capillaries in the tissue, which 
does not increase proportionally. 
Causes: Hypertrophy may be physiologic or pathologic. In both cas-
es, it is caused either by increased functional demand or by hormonal stimu-
lation. Hypertrophy without accompanying hyperplasia affects mainly mus-
cles. In non-dividing cells too, only hypertrophy occurs. 
A. Physiologic hypertrophy. It results from the increased workload 
on an organ. Examples include weight training, which produces hypertro-
phy of skeletal muscle (e.g. hypertrophied muscles in athletes and manual 
labourers), pregnancy with enlarged size of the uterus. All physiologic hy-
pertrophies are reversible once the triggering stimulus is removed. 
 
B. Pathologic hypertrophy.  
Pathologic hypertrophy can be classified as: 
1. Neurohumoral hypertrophy develops due to impairment of endo-
crine functions.  
Examples are endometrial glandular hyperplasia following estrogen 
excess production which results in metrorrhagia; atrophy of testis leads to 
increase of breast (gynecomastia); hyperfunction of anterior hypophysis 
lobe (adenoma) leads to increased skeleton (acromegaly).  
2. Compensatory working hypertrophy develops in tissues consisting 
of stable undivided cells due to increase of their size. It may be often in car-
diac muscle at some cardiac diseases (systemic hypertension, aortic valve 
disease (stenosis and insufficiency), mitral insufficiency), in smooth muscle 
(e.g. cardiac achalasia (in esophagus), pyloric stenosis (in stomach), and in-
testinal stricture; hypertrophy of urine bladder in adenoma of prostatic 
glands). 
3. Compensatory vicarious (substitutional) hypertrophy may occur in 
an organ when the contralateral organ is removed. Examples are:  
i) Following nephrectomy on one side in a young patient, there is 
compensatory hypertrophy as well as hyperplasia of the nephrons of the 
other kidney. 
ii) Adrenal hyperplasia following removal of one adrenal gland. 
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4. Compensatory reparative hyperplasia. E.g. regeneration of the liv-
er following partial hepatectomy, regeneration of epidermis after skin abra-
sion; bone marrow after blood loss. 
5. Hypertrophic vegetations develop due to chronic inflammation in 
mucous membranes (polyps and condylomas); lymphostasis leads to in-
growth of connective tissue, examples of false hypertrophy. In wound heal-
ing, there is formation of granulation tissue. 
Pathologic changes. The affected organ is enlarged and heavy. For 
example a hypertrophied heart of a patient with systemic hypertension may 
weigh 700-800 g as compared to average normal adult weight of 350 g. 
There is enlargement of muscle fibres as well as of nuclei. At ultra-
structural level, there is increased synthesis of DNA and RNA, increased 
protein synthesis and increased number of organelles like mitochondria, en-
doplasmic reticulum and myofibrils. 
 
HYPERPLASIA 
Hyperplasia is an increase in the number of parenchymal cells result-
ing in enlargement of the organ or tissue. Quite often, both hyperplasia and 
hypertrophy occur together. Hyperplasia occurs due to increased recruit-
ment of cells from GQ (resting) phase of the cell cycle to undergo mitosis, 
when stimulated. Labile cells (e.g. epithelial cells of the skin and mucous 
membranes, cells of the bone marrow and lymph nodes) and stable cells 
(e.g. parenchymal cells of the liver, pancreas, kidney, adrenal, and thyroid) 
can undergo hyperplasia, while permanent cells (e.g. neurons, cardiac and 
skeletal muscle) have little or no capacity for regenerative hyperplastic 
growth. Neoplasia differs from hyperplasia in having hyperplastic growth 
with loss of growth-regulatory mechanism due to change in genetic compo-
sition of the cell. Hyperplasia, on the other hand, persists so long as stimu-
lus presents. 
Pathogenesis: Increased load on the tissue causes cellular hypertro-
phy. When the critical cell mass is exceeded, proto-oncogenes are activated 
and factors triggering mitosis (mitogenes) are expressed. This results in cell 
proliferation. The limiting factor for organ function is density of capillaries 
in the tissue, which does not increase proportionally. 
Causes. As with other non-neoplastic disorders of growth, hyperplas-
ia has also been divided into physiologic and pathologic. 
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A. Physiologic hy-
perplasia. The two most 
common types are as fol-
lows: 
1. Hormonal hy-
perplasia i.e. hyperplasia 
occurring under the influ-
ence of hormonal stimula-
tion e.g. 
i) Hyperplasia of 
female breast at puberty, 
during pregnancy and lac-
tation. 
ii) Hyperplasia of 
pregnant uterus. 
iii) Proliferative activity of normal endometrium after a normal men-
strual cycle. 
iv) Prostatic hyperplasia in old age. 
2. Compensatory hyperplasia i.e. hyperplasia occurring following 
removal of part of an organ or a contralateral organ in paired organ e.g. 
i) Regeneration of the liver following partial hepatectomy 
ii) Regeneration of epidermis after skin abrasion iii) Following nephrec-
tomy on one side, there is hyperplasia of nephrons of the other kidney. 
 
B. Pathologic hyperplasia. Most examples of pathologic hyperplasia 
are due to excessive stimulation of hormones or growth factors e.g. 
i) Endometrial hyperplasia following oestrogen excess. 
ii) In wound healing, there is formation of granulation tissue due to 
proliferation of fibroblasts and endothelial cells. 
iii) Formation of skin warts from hyperplasia of epidermis due to 
human papilloma virus.  
iv) Pseudocarcinomatous hyperplasia of the skin. 
Pathologic changes. There is enlargement of the affected organ or 
tissue and increase in the number of cells. This is due to increased rate of 
DNA synthesis and hence increased mitoses of the cells. 
 
Fig. 13. Hyperplasia of uterus endometrium. H and E 




Metaplasia (meta = transformation, plasia = growth) is defined as a 
reversible change of one type of epithelial or mesenchymal adult cells to 
another type of adult epithelial or mesenchymal cells, usually in response to 
abnormal stimuli, and often reverts back to normal on removal of stimulus. 
However, if the stimulus persists for a long time, epithelial metaplasia may 
transform into cancer. 
Metaplasia is broadly divided into 2 types: epithelial and mesen-
chymal. 
A. Epithelial metaplasia. This is more common type. The metaplas-
tic change may be patchy or diffuse and usually results in replacement by 
stronger but less well-specialised epithelium. However, the metaplastic epi-
thelium being less well-specialised such as squamous type, results in depri-
vation of protective mucus secretion and hence more prone to infection. 
Some common types of epithelial metaplasia are as under: 
1. Squamous metaplasia. Various types of epithelium are capable of 
undergoing squamous metaplastic change due to chronic irritation that may 
be mechanical, chemical or infective in origin. Some common examples of 
squamous metaplasia are seen at following sites: 
i) In bronchus (normally lined by pseudostratified columnar ciliated 
epithelium) in chronic smokers. 
ii) In uterine endocervix (normally lined by simple columnar epithe-
lium) in prolapse of the uterus and in old age. 
iii) In gall bladder (normally lined by simple columnar epithelium) in 
chronic cholecystitis with cholelithiasis.  
iv) In prostate (ducts normally lined by simple columnar epithelium) 
in chronic prostatitis and oestrogen therapy.  
v) In renal pelvis and urinary bladder (normally lined by transitional 
epithelium) in chronic infection and stones.  
vi) In vitamin A deficiency, apart from xerophthalmia, there is squa-
mous metaplasia in the nose, bronchi, urinary tract, lacrimal and salivary 
glands. 
2. Columnar metaplasia. There are some conditions in which there is 
transformation to columnar epithelium. For example: 
i) Intestinal metaplasia in healed chronic gastric ulcer.  
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ii) Conversion of pseudostratified columnar epithelium in chronic 
bronchitis and bronchiectasis to columnar type.  
iii) In cervical erosion (congenital and adult type), there is variable 
area of endocervical glandular mucosa everted into the vagina. 
 
B. Mesenchymal metaplasia. Less often, there is transformation of one 
adult type of mesenchymal tissue to another. The examples are as under: 
1. Osseous metaplasia. Osseous metaplasia is formation of bone in 
fibrous tissue, cartilage and myxoid tissue. Examples of osseous metaplasia 
are as under:  
i) In arterial wall in old age (Monckeberg's medial calcific sclerosis), 
ii) In soft tissues in myositis ossificans, 
iii) In cartilage of larynx and bronchi in elderly people, 
iv) In scar of chronic inflammation of prolonged duration, 
v) In the fibrous stroma of tumour. 
2. Cartilaginous metaplasia. In healing of fractures, cartilaginous 
metaplasia may occur where there is undue mobility. 
DYSPLASIA 
Dysplasia means “disordered cellular development”, often accompa-
nied with metaplasia and hyperplasia; it is therefore also referred to as atyp-
ical hyperplasia. Dysplasia occurs most often in epithelial cells. Epithelial 
dysplasia is characterized by cellular proliferation and cytologic changes. 
These changes include: 
1. Hyperplasia of epithelial layers, 
2. Disorderly arrangement of cells from basal layer to the surface layer, 
3. Cellular and nuclear pleomorphism, 
4. Increased nucleocytoplasmic ratio, 
5. Nuclear hyperchromatism, 
6. Increased mitotic activity. 
The most common two examples of dysplastic changes are the uter-
ine cervix and respiratory tract. Dysplastic changes often occur due to 
chronic irritation or prolonged inflammation. On removal of the inciting 
stimulus, the changes may disappear. In a proportion of cases, however, 
dysplasia progresses into carcinoma in situ (cancer confined to layers super-
ficial to basement membrane) or invasive cancer. 
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REGENERATION OF SOME TISSUES AND ORGANS 
Regeneration of blood. Blood plasma is compensated by tissue liquid, 
blood cells - due to formation of new cells from hemopoietic tissue. Ex-
tramedullar haemopoiesis (the appearance of hemopoietic centers in internal 
organs as in embryonal period) and myeloid transformation of yellow bone 
marrow (replacement of fatty bone marrow by hemopoietic tissue) take 
place at reparative regeneration of blood. At some diseases haemopoiesis 
can be heavily depressed (radiation sickness, agranulocytosis) or perverted 
(leukemia). In these cases pathological regeneration of blood is observed. 
Bone marrow regenerates well and quickly; it can be restored even at 
great damages. 
 
Regeneration of vessels. Small vessels (capillaries, arterioles) regener-
ate by gemmation (there is a lateral outpouching of endothelium cells in the 
vessels wall with the formation of cellular bar). Then there is a formation of 
lumen and a development of vessel in it). Another way of regeneration is 
autogenic (due to reproduction of connective tissue cells, which afterwards 
differentiate in endothelium). Large vessels regenerate worse: the injured 
media and external membrane are replaced by connective tissue. 
Fig. 14.  Granulation tissue. H and E stained sec-
tion, x 200. 
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Regeneration of connective tissue. The process begins with formation 
of granulation tissue (a young tissue with a lot of thin-walled vessels). At 
maturing of granulation tissue the quantity of vessels decreases, a number 
of fibroblasts increases, there are a synthesis of fibrous structures and for-
mation of fibrous connective tissue scar on the place of granulation tissue. 
At retardation of granulation tissue maturing (due to inflammatory process) 
there is a formation of keloid - a cicatricial tissue of bright red color elevat-
ed above a surface of the skin. 
 
Regeneration of bone tissue. At simple fractures of bones there is pri-
mary bone fusion. Thus the young connective tissue grows into the area of 
fracture (preliminary connective tissue clavus) which then transforms to a 
bone clavus. Then under action of physical activity the new formed bone 
tissue is reconstructed with the formation of mature bone. At the complicat-
ed fractures the secondary bone fusion is observed: thus at first there is a 
formation of new cartilage tissue from connective tissue clavus, and only 
then a bone tissue. At suppuration the disturbance of bone tissue formation 
in a place of fracture and formation of a false joint are possible. Thus bone 
fragments are connected by fibrous tissue and are mobile. 
 
Regeneration of nervous tissue 
Central nervous system. The nerve cells of brain, spinal cord and ganglia 
once destroyed are not replaced. Axons of CNS also do not show any sig-
nificant regeneration. The damaged neuroglial cells, however, may show 
proliferation of astrocytes called gliosis. 
Peripheral nervous system. In contrast to the cells of CNS, the peripheral 
nerves show regeneration, mainly from proliferation of Schwann cells and 
fibrils from distal end. Briefly, it consists of the following: 
• myelin sheath and axon of the intact distal nerve undergo Wallerian 
degeneration up to the next node of Ranvier towards the proximal end; 
• the degenerated debris are cleared away by macrophages; 
• regeneration in the form of sprouting of fibrils takes place from the vi-
able end of axon. These fibrils grow along the track of degenerated nerves 
so that in about 6-7 weeks, the peripheral stump consists of tube filled with 
elongated Schwann cells; 
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• one of the fibrils from the proximal stump enters the old neural tube 
and develops into new functional axon. 
 
Regeneration of muscle 
All three types of muscle fibers have limited capacity to regenerate. 
Skeletal muscles. The regeneration of striated muscle is similar to pe-
ripheral nerves. On injury, the cut ends of muscle fibers retract but are held 
together by stromal connective tissue. The injured site is filled with fibrin-
ous material, polymorphs and macrophages. After clearance of damaged fi-
bres by macrophages, one of the following two types of regeneration of 
muscle fibres can occur. If the muscle sheath is intact, sarcolemmal tubes 
containing histiocytes appear along the endomysial tube which, in about 3 
months time, restores properly oriented muscle fibres e.g. in Zenker's de-
generation of muscle in typhoid fever. If the muscle sheath is damaged, it 
forms a disorganized multinucleate mass and scar composed of fibrovascu-
lar tissue, e.g. in Volkman's ischaemic contracture. 
Smooth muscles. Non-striated muscle has limited regenerative capacity, 
e.g. appearance of smooth muscle in the arterioles in granulation tissue. 
However, in large destructive lesions, the smooth muscle is replaced by 
permanent scar tissue. 
 
Regeneration of mucous membrans 
The cells of mucosa have very good regeneration and are normally being 
lost and replaced continuously, e.g. mucosa of alimentary tract, respiratory 
tract, urinary tract, uterine endometrium, etc. This occurs by proliferation 
from margins, migration, multilayering and differentiation of epithelial cells 
in the same way as in the epidermal cells in healing of skin wounds. 
 
Regeneration of solid epithelial organs 
Following gross tissue damage to organs like kidney, liver and thyroid, 
the replacement is by fibrous scar, e.g. in chronic pyelonephritis and cirrho-
sis of liver. However, in parenchymal cell damage with intact basement 
membrane or intact supporting stromal tissue, regeneration may occur. For 
example, in tubular necrosis of kidney with intact basement membrane, pro-
liferation and slow migration of tubular epithelial cells may occur to form 
renal tubules; in viral hepatitis if part of the liver lobule is damaged with in-
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tact stromal network, proliferation of hepatocytes may result in restoration 
of liver lobule. 
ORGANIZATION 
Organization is the replacement of sites with pathological changes by 
mature connective tissue that leads to the sclerosis. Sclerosis is a pathologi-
cal process which leads to the diffusive or focal induration of internal or-
gans, connective tissue, blood vessels due to excessive growth of mature 
dense connective tissue. 
Classification of sclerosis. 
– according to etiology and pathogenesis. 
1. Sclerosis is the outcome of chronic proliferative inflammation (at 
infectious, infectious-allergic, immune diseases, encapsulation of foreign 
substances). 
2. Sclerosis is the outcome of connective tissue disorganization (at 
rheumatic diseases). 
3. The substitutive sclerosis. It is the outcome of necrosis and atrophy. 
4. Scars as the result of wounds and ulcers healing.  
5. Organization of blood clots, hematomas, formation of adhesions. 
– according to morphogenesis three mechanisms are revealed. 
1. Neoformation of young connective tissue due to proliferation of fi-
broblasts (at proliferative inflammation, necrosis). 
2. Increased collagen synthesis by fibroblasts without significant hy-
perplasia of cells; transformation of loose connective tissue into fibrous tis-




There are three main basic requirements for normal circulatory func-
tion: normal anatomic features, normal physiologic controls, and normal bi-
ochemical composition of the blood. These are essential to maintain normal 
blood flow and perfusion of tissues. 
Derangements of blood flow or haemodynamic disturbances are con-
sidered under 2 broad headings: 
I. Disturbances in the volume of the circulating blood. These include: 
hyperaemia and congestion, haemorrhage and shock. 
II. Circulatory disturbances of obstructive nature. These are: throm-
bosis, embolism, ischaemia and infarction. 
 
I. DISTURBANCES IN THE VOLUME OF CIRCULATING 
BLOOD. HYPERAEMIA AND CONGESTION 
Hyperaemia and congestion are the terms used for increased volume 
of blood within dilated vessels of an organ or tissue; the increased volume 
from arterial and arteriolar dilatation being referred to as hyperaemia or ac-
tive hyperaemia, whereas the impaired venous drainage is called venous 
congestion or passive hyperaemia. If the condition develops rapidly it is 
called acute, while more prolonged and gradual response is known as 
chronic. 
 
ACTIVE (OR ARTERIAL) HYPERAEMIA 
The dilatation of arteries, arterioles and capillaries is effected either 
through sympathetic neurogenic mechanism or via the release of vasoactive 
substances. The affected tissue or organ is pink or red in appearance (ery-
thema). 
Active hyperaemia is classified into physiological and pathological, 
local and general, aqute and chronic. 
The examples of active physiological hyperaemia are seen in the fol-
lowing conditions: 
• blushing i.e. flushing of the skin of face in response to emotions, 
• muscular exercise, 
• menopausal flush. 
The active pathological hyperaemia is classified into next subtypes: 
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• inflammatory (dilation of the vessels due to mediators discharge), 
• collateral, 
• angioneurotic (or neuroparalytic), 
• hyperaemia after ischemia, 
• vacatous (vacuus – empty), 
• due to arteio-venous fistula, 
The general active pathological hyperaemia may be as the result of 
polycythemia, erythrocythemia. 
 
PASSIVE HYPERAEMIA (VENOUS CONGESTION) 
The dilatation of veins and capillaries due to impaired venous drain-
age results in passive hyperaemia or venous congestion, commonly referred 
to as congestion. Congestion may be acute or chronic, the latter being more 
common and called chronic venous congestion (CVC). The affected tissue 
or organ is bluish in colour due to accumulation of venous blood (cyanosis). 
Obstruction to the venous outflow may be local or systemic. Accordingly, 
venous congestion is of 2 types: 
• Local venous congestion results from obstruction to the venous out-
flow from an organ or part of the body e.g. portal venous obstruction in cir-
rhosis of the liver, outside pressure on the vessel wall as occurs in tight 
bandage, plasters, tumours, pregnancy, hernia etc, or intraluminal occlusion 
by thrombosis. 
• Systemic (General) venous congestion is engorgement of systemic 
veins e.g. in left-sided and right-sided heart failure and diseases of the lungs 
which interfere with pulmonary blood flow like pulmonary fibrosis, emphy-
sema etc. Usually the fluid accumulates upstream to the specific chamber of 
the heart which is initially affected. For example, in left-sided heart failure 
(such as due to mechanical overload in aortic stenosis, or due to weakened 
left venticular wall as in myocardial infarction) pulmonary congestion re-
sults, whereas in right-sided heart failure (such as due to pulmonary stenosis 
or pulmonary hypertension) systemic venous congestion results. 
 
Morphology of chronic venous congestion of organs 
Morphologic changes seen in CVC of the lungs, liver, spleen and 
kidney are discussed below. 
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Chronic venous congestion of lung occurs in left heart failure, espe-
cially in rheumatic mitral stenosis so that there is consequent rise in pulmo-
nary venous pressure. 
Grossly, the lungs are heavy and firm in consistency. The sectioned 
surface is dark brown in colour referred to as brown induration of the lungs. 
Histologically, the alveolar septa are widened due to the presence of inter-
stitial oedema as well as due to dilated and congested capillaries. The septa 
are mildly thickened due to slight increase in fibrous connective tissue. 
Rupture of dilated and congested capillaries may result in minute intra-
alveolar haemorrhages. The breakdown of erythrocytes liberates haemo-
siderin pigment which is taken up by alveolar macrophages, so called heart 
failure cells, present in the alveolar lumina. The brown induration of the cut 
surface of the lungs is due to the pigmentation and fibrosis. 
Chronic venous congestion of the liver occurs in right heart failure 
and sometimes due to occlusion of inferior vena cava and hepatic vein. 
Grossly, the liver is enlarged and tender and the capsule is tense. Cut 
surface shows characteristic nutmeg liver due to red and yellow mottled ap-
pearance, corresponding to congested centre of lobules and fatty peripheral 
zone respectively. Microscopically, the changes of congestion are more 
marked in the centrilobular zone due to severe hypoxia than in the peripher-
al zone. The central veins as well as the adjacent sinusoids are distended 
and filled with blood. The centrilobular hepatocytes undergo degenerative 
changes, and eventually centrilobular haemorrhagic necrosis may be seen. 
Long-standing cases may show fine centrilobular fibrosis and regeneration 
of hepatocytes, resulting in cardiac cirrhosis. The peripheral zone of the 
lobule is less severely affected by chronic hypoxia and shows some fatty 
change in the hepatocytes. 
Chronic venous congestion of spleen occurs in right heart failure and 
in portal hypertension from cirrhosis of liver. 
Grossly, the spleen in early stage is slightly to moderately enlarged (up-
to 250 g as compared to normal 150 g), while in long-standing cases there is 
progressive enlargement and may weigh upto 500 g to 1000 g. The organ is 
deeply congested, tense and cyanotic. Sectioned surface is gray tan. 
Microscopically, the red pulp shows congestion and marked sinusoi-
dal dilatation with areas of recent and old haemorrhages. These haemor-
rhages may get organised and form Gamna-Gandy bodies or sidero-fibrotic 
nodules which are deposits of haemosiderin pigment and calcium salts on 
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fibrous connective tissue and elastic fibres. In the late stage, there is hyper-
plasia of macrophages and fibroblasts resulting in increase in fibrous tissue 
of the capsule and hyperplasia of red pulp all of which account for firmness 
of the spleen. This advanced stage seen more commonly in hepatic cirrhosis 
is called congestive splenomegaly and is the commonest cause of hyper-
splenism.  
Chronic venous congestion of kidney. Grossly, the kidneys are 
slightly enlarged and the medulla is congested. Microscopically, the chang-
es are rather mild. The tubules may show degenerative changes like cloudy 
swelling and fatty change. The glomeruli may show mesangial proliferation. 
Edema and ascites: venous congestion impedes the flow of blood in 
the capillaries, thereby increasing hydrostatic pressure and promoting ede-
ma formation. The accumulation of edema fluid in heart failure is particu-
larly noticeable in dependent tissues: the legs and feet in ambulatory pa-
tients and the back in bedridden persons. Ascites, the accumulation of fluid 
in the peritoneal space, reflects (among other factors) the lack of tissue ri-
gor, a condition in which there is no countervailing external pressure to op-
pose hydrostatic pressure. 
 
Stasis (stasis – stop) is the arrest of blood flow in the vessels of mi-
crocirculatory system (capillaries).  
Causes of stasis: physical factors (temperature elevation, cold), chem-
ical factors, infection, infectious-allergic factors, autoimmune factors. 
 
Plasmorrhagia means outflow of plasma from vessels. The cause of 
plasmorrhagia is increased vascular permeability. 
 
Lymph circulation disturbance manifests itself as lymphatic system 
insufficiency (mechanical, dynamic and resorption). 
HAEMORRHAGE 
Hemorrhage (i.e., bleeding) is a discharge of blood from the vascular 
compartment to the exterior of the body or into novascular body spaces. 
Causes of haemorrhage: the blood loss may be large and sudden 
(acute), or small repeated bleeds may occur over a period of time (chronic). 
The various causes of haemorrhage are listed below: 
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1. Trauma to the vessel wall, e.g. penetrating wound in the heart or 
great vessels, during labour etc. 
2. Spontaneous haemorrhage e.g. rupture of an aneurysm, septicae-
mia, bleeding diathesis (such as purpura), acute leukaemias, pernicious 
anaemia, scurvy. 
3. Inflammatory lesions of the vessel wall, e.g. bleeding from chronic 
peptic ulcer, typhoid ulcers, blood vessels traversing a tuberculous cavity in 
the lung, syphilitic involvement of the aorta, polyarteritis nodosa. 
4. Neoplastic invasion, e.g. haemorrhage following vascular invasion 
in carcinoma of the tongue. 
5. Vascular diseases, e.g. atherosclerosis. 
6. Elevated pressure within the vessels, e.g. cerebral and retinal 
haemorrhage in systemic hypertension, severe haemorrhage from varicose 
veins due to high pressure in the veins of legs or oesophagus. 
The most common and obvious cause is trauma. An artery may be 
ruptured in ways other than laceration. For instance, severe atherosclerosis 
may so weaken the wall of the abdominal aorta that it balloons to form an 
aneurysm, which than ruptures and bleeds in to the retroperitoneal space. 
By the same token, an aneurysm may complicate a congenitally weak cere-
bral artery (berry aneurysm) and lead to subarachnoid hemorrhage. Certain 
infections (e.g., pulmonary tuberculosis) erode blood vessels; a similar vas-
cular injury is caused by invasive tumors. 
Hemorrhage also results from damage at the level of the capillaries. 
For instance, the rupture of capillaries by blunt trauma is evidenced by the 
appearance of a bruise. Increased venous pressure also causes extravasation 
of blood from capillaries in the lung. 
Vitamin C deficiency is associated with capillary fragility and bleed-
ing, owing to a defect in the supporting structures. It is important to recog-
nize that the capillary barrier by itself is not sufficient to contain the blood 
within the intravascular space. The minor trauma imposed on small vessels 
and capillaries by normal movement requires an intact coagulation system 
to prevent hemorrhage. Thus, a severe decrease in the number of platelets 
(thrombocytopenia) or a deficiency of a coagulation factor (e.g., factor VIII 
in hemophilia) is associated with spontaneous hemorrhages unrelated to any 
apparent trauma.  
A person may exsanguinate into an internal cavity, as in the case of 
gastrointestinal hemorrhage from a peptic ulcer (arterial hemorrhage) or 
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esophageal varices (venous hemorrhage). In such cases large amounts of 
fresh blood fill the entire gastrointestinal tract. Bleeding into a serous cavity 
can result in the accumulation of a large amount of blood, even to the point 
of exsanguination. A few definitions are in order: 
• Hemothorax: Hemorrhage into the pleural cavity. 
• Hemopericardium: Hemorrhage into the pericardial space. 
• Hemoperitoneum: Bleeding into the peritoneal cavity. 
• Hemarthrosis: Bleeding into a joint space. 
• Hematoma: Hemorrhage into the soft tissues. Such collections of 
blood can be merely painful, as in a muscle bruise, or fatal, if located in the 
brain. 
• Purpura: Diffuse superficial hemorrhages in the skin, up to 1 cm 
in diameter. 
• Ecchymosis: A larger superficial hemorrhage. Following a bruise or 
in association with a coagulation defect, an initially purple discoloration of the 
skin turns green and then yellow before resolving. This sequence reflects the 
progressive oxidation of bilirubin released from the hemoglobin of degraded 
erythrocytes. A good example of an ecchymosis is a "black eye." 
• Petechia: A pinpoint hemorrhage, usually in the skin or conjuc-
tiva. This lesion represents the rupture of a capillary or arteriole and occurs 
in conjunction with coagulopathies or vasculitis, the latter classically asso-
ciated with infections of the heart valves (bacterial endocarditis).  
Effects of haemorrhage: The effects of blood loss depend upon 3 
main factors: 
• The amount of blood loss; 
• The speed of blood loss; and 
• The site of the haemorrhage. 
The loss up to 20% of blood volume suddenly or slowly generally has 
little clinical effects because of compensatory mechanisms. A sudden loss 
of 33% of blood volume may cause death, while loss of upto 50% of blood 
volume over a period of 24 hours may not be necessarily fatal. However, 
chronic blood loss generally produces iron deficiency anaemia, whereas 





Shock is defined as a clinical state of cardiovascular collapse charac-
terised by: 
• An acute reduction of effective circulating blood volume; and 
• An inadequate perfusion of cells and tissues. 
The end result is hypotension and cellular hypoxia and, if uncompen-
sated, may lead to impaired cellular metabolism and death. Shock may be of 
2 main types: primary (initial) and secondary (true) shock. 
Primary or initial shock: It is transient and usually a benign vasova-
gal attack resulting from sudden reduction of venous return to the heart 
caused by neurogenic vasodilatation and consequent peripheral pooling of 
blood. It can occur immediately following trauma, severe pain or emotional 
over-reaction such as due to fear, sorrow or surprise. Clinically, the patient 
generally develops unconsciousness, weakness, sinking sensation, pale and 
clammy limbs, weak and rapid pulse, and low blood pressure. The attack 
usually lasts for a few seconds or minutes. 
Secondary or true shock: this is the form of shock which occurs due 
to haemodynamic derangements with hypoperfusion of the cells. This type 
of shock is the true shock which is commonly referred to as 'shock' if not 
specified and is the type described below. 
Etiology and Classification. Many types of injuries and diseases can 
cause shock. These causes are broadly grouped under 3 major headings, and 
accordingly shock is classified into 3 main etiologic forms: hypovolaemic, 
cardiogenic, and septic. 
1. Hypovolaemic shock. Reduction in blood volume induces 
hypovolaemic shock. The causes of hypovolaemia include the following:  
i) Severe haemorrhage (external or internal) e.g. in trauma, surgery. 
ii) Fluid loss e.g. in severe burns, crush injury to a limb, persistent 
vomitings and severe diarrhoea causing dehydration. 
2. Septic shock. Severe bacterial infections or septicaemia induce sep-
tic shock. The predominant causes are as under: 
i) Gram-negative septicaemia (endotoxic shock) e.g. infection with E. 
coli, Proteus, Klebsiella, Pseudomonas and bacteroides. Endotoxins of 
gram-negative bacilli have been implicated as the most important mediator 
of septic shock. 
ii) Gram-positive septicaemia (exotoxic shock) is less common e.g. 
infection with streptococci, pneumococci. Lysis of gram-negative bacteria 
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releases endotoxin, a lipopolysaccharide (LPS), into circulation where it 
binds to lipopolysaccharide-binding protein (LBP). The complex of LPS-
LBP binds to CD14 molecule on the surface of the monocyte/macrophage 
which in turn is stimulated to elaborate tumour necrosis factor-a (TNF-a). 
TNF-a induces septic shock by endothelial cell injury by many mechanisms 
which include: 
a) Direct cytotoxicity 
b) Promotes the adherence of polymorphs to endothelium 
c) Stimulates the release of interleukin-1 (IL-1) 
d) Promotes the release of procoagulant tissue factor that causes 
thrombosis and local ischaemia. 
3. Cardiogenic shock. Acute circulatory failure with sudden fall in 
cardiac output from acute diseases of the heart without actual reduction of 
blood volume (normovolaemia) results in cardiogenic shock. The causes in-
clude the following: 
i) Deficient emptying, e.g. 
• Myocardial infarction 
• Rupture of the heart 
• Cardiac arrhythmias 
ii) Deficient filling e.g. 
• Cardiac tamponade from haemopericardium  
iii) Obstruction to the outflow, e.g. 
• Pulmonary embolism 
• Ball valve thrombus. 
Besides the three major forms of shock described above, traumatic 
shock (following severe trauma with the tissues compression),  neurogenic 
shock (following anaesthesia or spinal cord injury) and anaphylactic shock 
are other types of shock. The last 2 ones result from peripheral vasodilation 
with pooling of blood. 
Pathogenesis. There are 2 basic features in the pathogenesis of shock: 
• reduced effective circulating blood volume; and 
• reduced supply of oxygen to the cells and tissues with resultant anoxia. 
1. Reduced effective circulating volume. It may result by either of the 
following mechanisms: 
i) by actual loss of blood volume as occurs in hypovolaemic shock; or 
ii) by decreased cardiac output without actual loss of blood 
(normovolaemia) as occurs in cardiogenic shock and septic shock. 
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2. Tissue anoxia. Following reduction in the effective circulating 
blood volume from either of the above two mechanisms and from any of the 
etiologic agents, there is decreased venous return to the heart resulting in de-
creased cardiac output. This consequently causes reduced supply of oxygen to 
the organs and tissues and hence tissue anoxia, and shock ensues. 
In contrast to hypovolaemic and cardiogenic shock, patients in septic 
shock have hyperdynamic circulation due to peripheral vasodilatation and 
pooling of blood, as well as there is increased vascular permeability. This 
result in reduction of effective circulating blood volume, lowered cardiac 
output, reduced blood flow (hypotension) and inadequate perfusion of cells 
and tissues. Disseminated intravascular coagulation (DIC) is prone to de-
velop in septic shock due to endothelial cell injury by toxins. 
Stages of Shock. Deterioration of the circulation in shock is a pro-
gressive phenomenon and can be divided arbitrarily into 3 stages: 
1. Non-progressive (initial, compensated reversible) shock. 
2. Progressive decompensated shock. 
3. Decompensated (irreversible) shock. 
1. Non-progressive (initial, compensated reversible) shock. In the 
early stage of shock, an attempt is made to maintain adequate cerebral and 
coronary blood supply by redistribution of blood so that the vital organs 
(brain and heart) are adequately perfused and oxygenated. This is achieved 
by activation of various neurohormonal mechanisms causing widespread 
vasoconstriction and by fluid conservation by the kidney. If the condition 
that caused the shock is adequately treated, the compensatory mechanism 
may be able to bring about recovery and re-establish the normal circulation; 
this is called compensated or reversible shock. These compensatory mecha-
nisms are as under: 
i) Widespread vasoconstriction. In response to reduced blood flow 
(hypotension) and tissue anoxia, the neural and humoral factors (e.g. baro-
receptors, chemoreceptors, catecholamines, renin, and VEM or vasoexcitor 
material from hypoxic kidney) are activated. All these bring about vasocon-
striction, particularly in the vessels of the skin and abdominal viscera. 
Widespread vasoconstriction is a protective mechanism as it causes in-
creased peripheral resistance, increased heart rate and increased blood pres-
sure. However, in septic shock, there is initial vasodilatation followed by 
vasoconstriction. Besides, in severe septic shock there is elevated level of 
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thromboxane A2 which is a potent vasoconstrictor and may augment the 
cardiac output along with other sympathetic mechanisms. 
ii) Fluid conservation by the kidney. In order to compensate the actu-
al loss of blood volume in hypo-volaemic shock, the following factors may 
assist in restoring the blood volume and improve venous return to the heart: 
• Release of aldosterone from hypoxic kidney. 
• Release of ADH due to decreased effective circulating blood vol-
ume. 
• Reduced glomerular filtration rate (GFR) due to arteriolar con-
striction. 
• Shifting of tissue fluids into the plasma due to lowered capillary 
hydrostatic pressure (hypotension). 
iii) Vascular autoregulation. In response to hypoxia and acidosis, re-
gional blood flow to the heart and brain is preserved by vasodilatation of 
the coronary and cerebral circulation. 
2. Progressive decompensated shock. 
This is a stage when the patient suffers from some other stress or risk 
factors (e.g. pre-existing cardiovascular and lung disease) besides persis-
tence of the shock so that there is progressive deterioration. The effects of 
progressive decompensated shock include the following: 
a) Pulmonary hypoperfusion with resultant tachypnoea and adult res-
piratory distress syndrome. 
b) Tissue anoxia causing anaerobic glycolysis resulting in metabolic 
lactic acidosis. 
c) Anoxia of liver causing reduced clearance of lactate from it lead-
ing to acidosis. 
3. Decompensated (irreversible) shock. 
When the shock is so severe that in spite of compensatory mecha-
nisms and despite therapy and control of etiologic agent which caused the 
shock, no recovery takes place, it is called decompensated or irreversible 
shock. Its effects include the following: 
a) Progressive fall in the blood pressure due to deterioration in cardi-
ac output attributed to release of myocardial depressant factor (MDF). 
b) Severe metabolic acidosis due to anaerobic glycolysis. 
c) Respiratory distress due to pulmonary oedema, tachypnoea and 
adult respiratory distress syndrome (ARDS). 
 79 
d) Ischaemic cell death of brain, heart and kidneys due to reduced 
blood supply to these organs resulting in coma, worsened heart function and 
progressive renal failure. 
 
A number of hypotheses or factors have been described in irreversi-
bility of shock, with tissue anoxia occupying the central role. These are as 
under: 
i) Persistence of widespread vasoconstriction. 
Although widespread vasoconstriction is a compensatory mechanism, 
its persistence for prolonged duration can cause anoxia of tissues and organs 
like liver, spleen, kidney and intestine. Particularly significant is the postca-
pillary venular constriction contributing to tissue anoxia. 
ii) Vasodilatation and increased vascular permeability. Anoxia dam-
ages the capillary and venular wall so that there is vasodilatation and in-
creased vascular permeability. Vasodilatation results in peripheral pooling 
of blood while increased vascular permeability causes escape of fluid from 
circulation into the interstitial tissues, both of which further deteriorate the 
effective circulating blood volume. 
iii) Myocardial ischaemia. Persistently reduced blood flow to myo-
cardium causes coronary insufficiency and myocardial ischaemia due to re-
lease of myocardial depressant factor (MDF). This results in depression of 
cardiac function, reduced cardiac output and decreased blood flow. 
iv) Cerebral ischaemia. Cerebral ischaemia resulting from persistent 
reduction of blood flow causes depression of the vasomotor centre. This re-
sults in vasodilatation and peripheral pooling of blood, thus reducing the 
venous return to the heart and consequent lowered cardiac output. 
v) Vasodepressor material (VDM). VDM is a substance produced by 
the spleen and skeletal muscle and is normally inactivated in the liver. In 
severe hypoxia of the liver as occurs in irreversible shock, the mechanism 
of inactivation of VDM in liver is damaged so that its blood levels rise. 
VDM causes peripheral vasodilatation (reverse of VEM) and thus diverts 
blood from the systemic circulation, resulting in deterioration of the circula-
tion. 
vi) Tumour necrosis factor (TNF). In septic shock, monocyte-
macrophage cell system gets activated by bacterial products causing release 
of substances like prostaglandins, leukotrienes, platelet activating factor and 
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interleukins-1, 6 and 18. These substances have been implicated in produc-
ing irreversibility of endotoxic shock. 
vii) Intestinal factor. Due to prolonged vasoconstriction, haemorrhag-
ic necrosis of the intestinal tract occurs. This results in loss of blood and 
plasma into the intestine from haemorrhagic lesions, causing further reduc-
tion in effective circulating blood volume. 
viii) Bacterial factor. Prolonged anoxic injury to the reticuloendothe-
lial organs like the liver and spleen impairs the normal antibacterial defense 
mechanism of these organs. This results in release of undetoxified endotox-
ins derived from intestinal bacteria into the circulation, which cause further 
vasoconstriction and its harmful effects. 
ix) Hypercoagulability of blood. Excessive accumulation of lactic ac-
id in the blood in prolonged shock enhances the release of catecholamines 
(e.g. epinephrine) into the circulation. The effects of catecholamines include 
the release of clot promoting factor, release of thromboplastin and release of 
platelet aggregator, ADP. Excess lactic acid in the blood can also cause en-
dothelial injury and thus initiate thrombosis. In this way, hypercoagulability 
of blood with consequent microthrombi impair the blood flow and may 
even cause tissue necrosis. 
 
Morphologic Complications in Shock. Eventually, shock is charac-
terised by multisystem failure. The morphologic changes in shock develop 
due to hypoxia resulting in degeneration and necrosis in various organs. The 
major organs affected are the brain, heart, lungs and kidneys. Morphologic 
changes are also noted in the adrenals, gastrointestinal tract, liver and other 
organs. 
1. Hypoxic encephalopathy. Cerebral ischaemia in compensated 
shock may produce altered state of consciousness. However, if the blood 
pressure falls below 50 mmHg as occurs in systemic hypotension in pro-
longed shock and cardiac arrest, brain suffers from serious ischaemic dam-
age with loss of cortical functions, coma, and a vegetative state. 
Grossly, the area supplied by the most distal branches of the cerebral 
arteries suffers from severe ischaemic necrosis which is usually the border 
zone between the anterior and middle cerebral arteries. 
Microscopically, the changes are noticeable if ischaemia is prolonged 
for 12 to 24 hours. Neurons, particularly Purkinje cells, are more prone to 
develop the effects of ischaemia. The cytoplasm of the affected neurons is 
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intensely eosinophilic and the nucleus is small pyknotic. Dead and dying 
nerve cells are replaced by gliosis. 
2. Heart in shock. Heart is more vulnerable to the effects of hypoxia 
than any other organ. Heart is affected in cardiogenic as well as in other 
forms of shock. There are 2 types of morphologic changes in heart in all 
types of shock: 
i) Haemorrhages and necrosis. There may be small or large ischaemic 
areas or infarcts, particularly located in the subepicardial and subendocardi-
al region. 
ii) Zonal lesions. These are opaque transverse contraction bands in 
the myocytes near the intercalated disc. 
3. Shock lung. Lungs due to dual blood supply are generally not af-
fected by hypovolaemic shock but in septic shock the morphologic changes 
in lungs are quite prominent termed 'shock lung'. 
Grossly, the lungs are heavy and wet. Microscopically, changes of 
adult respiratory distress syndrome (ARDS) are seen. Briefly, the changes 
include congestion, interstitial and alveolar oedema, interstitial lymphocytic 
infiltrate, alveolar hyaline membranes, thickening and fibrosis of alveolar 
septa, and fibrin and platelet thrombi in the pulmonary microvasculature. 
4. Shock kidney. One of the important complications of shock is irre-
versible renal injury, first noted in persons who sustained crush injuries in 
building collapses in air raids in World War II. The renal ischaemia follow-
ing systemic hypotension is considered responsible for renal changes in 
shock. The end-result is generally anuria and death. 
Grossly, the kidneys are soft and swollen. Sectioned surface shows 
blurred architectural markings. Microscopically, the tubular lesions are seen 
at all levels of nephron and are referred to as acute tubular necrosis (ATN) 
which can occur following other causes besides shock. If extensive muscle 
injury or intravascular haemolysis are also associated, peculiar brown tubu-
lar casts are seen. 
5. Adrenals in shock. The adrenals show stress response in shock. 
This includes release of aldosterone in response to hypoxic kidney, release 
of glucocorticoids from adrenal cortex and catecholamines like adrenaline 
from adrenal medulla. In severe shock, adrenal haemorrhages may occur. 
6. Haemorrhagic gastroenteropathy. 
The hypoperfusion of the alimentary tract in conditions such as shock 
and cardiac failure may result in mucosal and mural infarction called haem-
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orrhagic gastroentero-pathy. This type of non-occlusive ischaemic injury of 
bowel must be distinguished from full-fledged infarction in which case the 
deeper layers of gut (muscularis and serosa) are also damaged. In shock due 
to burns, acute stress ulcers of the stomach or duodenum may occur and are 
known as Curling's ulcers. 
Grossly, the lesions are multifocal and widely distributed throughout 
the bowel. The lesions are superficial ulcers, reddish purple in colour. The 
adjoining bowel mucosa is oedematous and haemorrhagic. Microscopically, 
the involved areas show dilated and congested vessels and haemorrhagic ne-
crosis of the mucosa and sometimes submucosa. Secondary infection may 
supervene and condition may progress into pseudomembranous enterocolitis. 
7. Liver in shock. Due to effects of hypoxia on liver, VDM is released 
from the liver which causes vasodilatation. Besides, focal necrosis may be 
seen, fatty change may occur and the liver function may be impaired. 
8. Other organs. Other organs such as lymph nodes, spleen and pan-
creas may also show foci of necrosis in shock. In addition, the patients who 
survive acute phase of shock succumb to overwhelming infection due to al-
tered immune status and host defense mechanism. 
Clinical Features. The classical features of decompensated shock are 
characterised by depression of 4 vital processes: 
• Very low blood pressure 
• Subnormal temperature 
• Feeble and irregular pulse 
• Shallow and sighing respiration 
In addition, the patients in shock have pale face, sunken eyes, weak-
ness, cold and clammy skin. Renal dysfunction in shock is clinically charac-
terised by a phase of oliguria due to ATM and a later phase of diuresis due 
to regeneration of tubular epithelium. Haemo-concentration is present in 
early oliguric phase while marked electrolyte imbalance occurs in diuretic 
phase. With progression of the condition, the patient may develop stupor, 
coma and death. 
 
 83 
II. CIRCULATORY DISTURBANCES OF OBSTRUCTIVE NA-
TURE 
THROMBOSIS 
Thrombosis is the process of formation of solid mass in circulation 
from the constituents of flowing blood; the mass itself is called a thrombus. 
A blood clot is the mass of coagulated blood formed in vitro e.g. in a test 
tube. Haematoma is the extravascular accumulation of blood clot e.g. into 
the tissues. Haemostatic plugs are the blood clots formed in healthy indi-
viduals at the site of bleeding e.g. in injury to the blood vessel. In other 
words, haemostatic plug at the cut end of a blood vessel may be considered 
the simplest form of thrombosis. Haemostatic plugs are useful as they stop 
the escape of blood and plasma, whereas thrombi developing in the unrup-
tured cardiovascular system may be life-threatening by causing one of the 
following harmful effects: 
1. Ischaemic injury. Thrombi may decrease or stop the blood supply 
to part of an organ or tissue and cause ischaemia which may subsequently 
result in infarction. 
2. Thromboembolism. The thrombus or its part may get dislodged and 
be carried along in the blood stream as embolus to lodge in a distant vessel. 
Pathophysiology. Since the protective haemostatic plug formed as a 
result of normal haemostasis is an example of thrombosis, it is essential to 
describe thrombogenesis in relation to the normal haemostatic mechanism. 
Human beings possess inbuilt system by which the blood remains in 
fluid state normally and guards against the hazards of thrombosis and 
haemorrhage. However, injury to the blood vessel initiates haemostatic re-
pair mechanism or thrombogenesis. Virchow described three primary events 
which predispose to thrombus formation (Virchow's triad): endothelial inju-
ry, alteration in flow of blood, and hypercoagulability of blood. These 
events are discussed below: 
1. Role of blood vessel wall. The integrity of blood vessel wall is im-
portant for maintaining normal blood flow. An intact endothelium has the 
following functions: 
i) It protects the flowing blood from the thrombogenic influence of 
subendothelium. 
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ii) It elaborates a few anti-thrombotic factors (thrombosis inhibitory 
factors) e.g. 
a) Heparin-like substance which accelerates the action of an-
tithrombin III and inactivates some other clotting factors. 
b) Thrombomodulin which converts thrombin into activator of 
protein C, an anticoagulant. 
c) Inhibitors of platelet aggregation such as ADPase, PGI2 or 
prostacyclin. 
d) Tissue plasminogen activator which accelerates the fibrinolytic 
activity. 
iii) It can release a few prothrombotic factors which have procoagu-
lant properties (thrombosis favouring factors) 
a) Thromboplastin or tissue factor released from endothelial cells. 
b) von Willebrand factor that causes adherence of platelets to the 
subendothelium. 
c) Platelet activating factor which is activator and aggregator of 
platelets. 
d) Inhibitor of plasminogen activator that suppresses fibrinolysis. 
Vascular injury exposes the subendothelial connective tissue (e.g. 
collagen, elastin, fibronectin, laminin and glycosaminoglycans) which are 
thrombogenic and thus plays important role in initiating haemostasis as well 
as thrombosis. Injury to vessel wall also causes vasoconstriction of small 
blood vessels briefly so as to reduce the blood loss. Endothelial injury is of 
major significance in the formation of arterial thrombi and thrombi of the 
heart, especially of the left ventricle. A number of factors and conditions 
may cause vascular injury and predispose to the formation of thrombi. The-
se are as under: 
i) Endocardial injury in myocardial infarction, myocarditis, cardiac 
surgery, prosthetic valves. 
ii) Ulcerated plaques in advanced atherosclerosis.  
iii) Haemodynamic stress in hypertension.  
iv) Arterial diseases.  
v) Diabetes mellitus. 
vi) Endogenous chemical agents such as hypercholesterolaemia, en-
dotoxins. 
vii) Exogenous chemical agents such as cigarette smoke. 
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2. Role of platelets. Following endothelial cell injury, platelets come 
to play a central role in normal haemostasis as well as in thrombosis. The 
sequence of events is as under: 
i) Platelet adhesion. The platelets in circulation recognise the site of 
endothelial injury and adhere to exposed subendothelial collagen (primary 
aggregation), von Willebrand's factor is required for such adhesion between 
platelets and collagen. Normal non-activated platelets have open canalicular 
system with cytoplasmic organelles (granules, mitochondria, endoplasmic 
reticulum) dispersed throughout the cytoplasm. During the early adhesion 
process, there is dilatation of canalicular system with formation of pseudo-
pods and the cytoplasmic organelles shift to the centre of the cell. 
ii) Platelet release reaction. The activated platelets then undergo re-
lease reaction by which the platelet granules are released to the exterior. 
Two main types of platelet granules are released: 
a) Alpha granules containing fibrinogen, fibronectin, platelet-derived 
growth factor, platelet factor 4 (an anti-heparin) and cationic proteins. 
b) Dense bodies containing ADP (adenosine diphosphate), ionic 
calcium, 5-HT (serotonin), histamine and epinephrine. 
As a sequel to platelet activation and release reaction, the phospholip-
id complex-platelet factor 3 gets activated which plays important role in the 
intrinsic pathway of coagulation. 
iii) Platelet aggregation. Following release of ADP, a potent platelet 
aggregating agent, aggregation of additional platelets takes place (secondary 
aggregation). This results in formation of temporary haemostatic plug. 
However, stable haemostatic plug is formed by the action of fibrin, throm-
bin and thromboxane A2. 
3. Role of coagulation system. Coagulation mechanism is the conver-
sion of the plasma fibrinogen into solid mass of fibrin. The coagulation sys-
tem is involved in both haemostatic process and thrombus formation. 
i) In the intrinsic pathway, contact with abnormal surface leads to acti-
vation of factor XII and the sequential interactions of factors XI, IX, VIII and 
finally factor X, alongwith calcium ions (factor IV) and platelet factor 3. 
ii) In the extrinsic pathway, tissue damage results in the release of tissue 
factor or thromboplastin. Tissue factor on interaction with factor VII activates 
factor X. 
iii) The common pathway begins where both intrinsic and extrinsic 
pathways converge to activate factor X which forms a complex with factor 
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Va and platelet factor 3, in the presence of calcium ions. This complex acti-
vates prothrombin (factor II) to thrombin (factor lla) which, in turn, con-
verts fibrinogen to fibrin. Initial monomeric fibrin is polymerised to form 
insoluble fibrin by activation of factor XIII. 
iv) Regulation of coagulation system. The blood is kept in fluid state 
normally and coagulation system kept in check by controlling mechanisms. 
These are as under:  
a) Protease inhibitors. These act on coagulation factors so as to op-
pose the formation of thrombin e.g. antithrombin III, protein C, C1 inactiva-
tor, α1-antitrypsin, α2-macroglobulin. 
b) Fibrinolytic system. Plasmin, a potent fibrinolytic enzyme, is 
formed by the action of plasminogen activator on plasminogen present in the 
normal plasma. Two types of plasminogen activators (PA) are identified: 
• Tissue-type PA derived from endothelial cells and leucocytes. 
• Urokinase-like PA present in the plasma. Plasmin so formed acts on 
fibrin to destroy the clot and produces fibrin split products (FSP). 
4. Hypercoagulability of blood. The occurrence of thrombosis in 
some conditions such as in nephrotic syndrome, advanced cancers, exten-
sive trauma, burns and during puerperium is explained on the basis of hy-
percoagulability of blood. The effect of hypercoagulability on thrombosis is 
favoured by advancing age, smoking, use of oral contraceptives and obesity. 
Hypercoagulability may occur by the following changes in the composition 
of blood:  
i) Increase in coagulation factors e.g. fibrinogen, prothrombin, factor 
Vila, Villa and Xa.  
ii) Increase in platelet count and their adhesiveness.  
iii) Decreased levels of coagulation inhibitors e.g. antithrombin III, 
fibrin split products. 
5. Alteration of blood flow. Formation of arterial and cardiac thrombi 
is facilitated by turbulence in the blood flow, while stasis initiates the ve-
nous thrombi even without evidence of endothelial injury.  
i) Normally, there is axial flow of blood in which the most rapidly-
moving central stream consists of leucocytes and red cells. The platelets are 
present in the slow-moving laminar stream adjacent to the central stream 
while the peripheral stream consists of most slow-moving cell-free plasma 
close to endothelial layer. 
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ii) In turbulence and stasis, the normal axial flow of blood is dis-
turbed so that the platelets come into contact with the endothelium. 
Besides, the inhibitors of coagulation fail to reach the site of throm-
bus resulting in enlargement of thrombus size. Turbulence may actually in-
jure the endothelium resulting in deposition of platelets and fibrin. 
Morphology of various types. Thrombosis may occur in the heart, 
arteries, veins and the capillaries. Beside the differences in mechanisms of 
thrombus formation at these sites, the clinical effects of these are even more 
different. Arterial thrombi produce ischaemia and infarction, whereas cardi-
ac and venous thrombi cause embolism. 
The general morphologic features of thrombi are as under: 
Grossly, thrombi may be of various shapes, sizes and composition 
depending upon the site of origin. Arterial (or white) thrombi tend to be 
white and mural while the venous thrombi are red and occlusive. Mixed or 
laminated thrombi are also common and consist of alternate white and red 
layers called lines of Zahn. Red (or venous) thrombi are soft, red and gelati-
nous whereas white thrombi are firm and pale. 
Microscopically, the composition of thrombus is determined by the 
rate of flow of blood i.e. whether it is formed in the rapid arterial and cardi-
ac circulation, or in the slow moving flow in veins. The lines of Zahn are 
formed by alternate layers of light-staining aggregated platelets admixed 
with fibrin meshwork and dark-staining layer of red cells. Red (venous) 
thrombi have more abundant red cells, leucocytes and platelets entrapped in 
fibrin meshwork. Thus, red thrombi closely resemble blood clots in vitro. 
Red thrombi (ante-mortem) have to be distinguished from postmor-
tem clots. 
Cardiac thrombi. Thrombi may form in any of the chambers of heart 
and on the valve cusps. They are more common in the atrial appendages, 
especially of the right atrium, and on mitral and aortic valves called vegeta-
tions which may be seen in infective endocarditis and non-bacterial throm-
botic endocarditis. Cardiac thrombi are mural (non-occlusive) as are the 
mural thrombi encountered in the aorta in atherosclerosis and in aneurysmal 
dilatations. Rarely, large round thrombus may form and obstruct the mitral 
valve and is called ball-valve thrombus. Agonal thrombi are formed shortly 
before death and may occur in either or both the ventricles. They are com-
posed mainly of fibrin. 
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Arterial and venous thrombi. The distinguishing features between 
thrombi formed in rapidly-flowing arterial circulation and slow-moving ve-
nous blood. 
Capillary thrombi. Minute thrombi composed mainly of packed red 
cells are formed in the capillaries in acute inflammatory lesions, vasculitis 
and in disseminated intravascular coagulation (DIC). 
Fate of thrombus. The possible fate of thrombi: 
1. Resolution. Thrombus activates the fibrinolytic system with conse-
quent release of plasmin which may dissolve the thrombus completely result-
ing in resolution. Usually, lysis is completed in small venous thrombi while 
large thrombi may not be 
dissolved. Fibrinolytic 
activity can be accentuat-
ed by administration of 
thrombolytic substances 
(e.g. urokinase, strepto-
kinase), especially in the 
early stage when fibrin is 
in monomeric form. 
2. Organization. 
If the thrombus is not 
removed, it starts getting 
organized. Phagocytic 
cells (neutrophils and 
macrophages) appear 
and begin to phagocy-
tose fibrin and cell de-
bris. The proteolytic en-
zymes liberated by leu-
cocytes and endothelial 
cells start digesting co-
agulum. Capillaries 
grow into the thrombus 
from the site of its at-
tachment and fibroblasts 
start invading the 
thrombus. Thus, fibro-
Fig. 15. Organization of trombus. H and E stained 
section, x 200. 




vascular granulation tissue is formed which subsequently becomes dense 
and less vascular and is covered over by endothelial cells. The thrombus in 
this way is excluded from the vascular lumen and becomes part of vessel 
wall. The new vascular channels in it may be able to re-establish the blood 
flow, called recanalization. The fibrosed thrombus may undergo hyalini-
aation and calcification e.g. phleboliths in the pelvic veins. 
3. Propagation. The thrombus may enlarge in size due to more and 
more deposition from the constituents of flowing blood. In this way, it may 
ultimately cause obstruction of some important vessel. 
4. Thromboembolism. The thrombi in early stage and infected throm-
bi are quite friable and may get detached from the vessel wall. These are re-
leased in part or completely in blood stream as emboli which produce ill-
effects at the site of their lodgement. 
Factors predisposing to thrombosis. A number of primary (genetic) 
and secondary (acquired) factors favour thrombosis. 
Primary (Genetic) factors: 
i) Deficiency of antithrombin  
ii) Deficiency of protein C or S. 
iii) Defects in fibrinolysis  
iv) Mutation in factor V 
Secondary (acquired) factors: 
a) Risk factors are:  
i) Advanced age 
ii) Prolonged bed-rest 
iii) Immobilisation 
iv) Use of oral contraceptives 
v) Cigarette smoking 
vi) Tissue damage e.g. trauma, fractures, burns 
b) Clinical conditions predisposing to thrombosis: 
i) Heart diseases e.g. myocardial infarction, CHF, rheumatic 
mitral stenosis, cardiomyopathy. 
ii) Atherosclerosis 
iii) Aneurysms of the aorta and other vessels 
iv) Varicosities of leg veins 
v) Nephrotic syndrome 
vi) Disseminated cancers 
vii) Late pregnancy and puerperium. 
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Clinical effects of thrombosis. These depend upon the site of 
thrombi, rapidity of formation, and nature of thrombi. 
1. Cardiac thrombi. Large thrombi in the heart may cause sudden 
death by mechanical obstruction of blood flow or through thromboembo-
lism to vital organs. 
2. Arterial thrombi. These cause ischaemic necrosis of the deprived 
part (infarct) which may lead to gangrene. Sudden death may occur follow-
ing thrombosis of coronary artery. 
3. Venous thrombi (Phlebothrombosis). These may cause various ef-
fects such as: 
i) Thromboembolism 
ii) Oedema of area drained 
iii) Poor wound healing 
iv) Skin ulcer 
v) Painful thrombosed veins (thrombophlebitis) 
vi) Painful white leg (phlegmasia alba dolens) due to ileofemoral ve-
nous thrombosis in post-partum cases 
vii)Thrombophlebitis migrans in cancer. 
4. Capillary thrombi. Microthrombi in microcirculation may give rise 
to disseminated intravascular coagulation (DIG). 
 
EMBOLISM 
Embolism is the process of partial or complete obstruction of some 
parts of the cardiovascular system by any mass carried in the circulation; 
the transported intravascular mass detached from its site of origin is called 
an embolus. Most usual forms of emboli (90%) are thromboemboli i.e. orig-
inating from thrombi or their parts detached from the vessel wall. Emboli 
may be of various types: 
A. Depending upon the matter in the emboli, they can be: 
i) Solid e.g. detached thrombi (thromboemboli), atheromatous ma-
terial, tumour cell clumps, tissue fragments, parasites, bacterial clumps, for-
eign bodies. 
ii) Liquid e.g. fat globules, amniotic fluid, bone marrow.  
iii) Gaseous e.g. air, other gases. 
B. Depending upon whether infected or not, they are called: 
i) Land, when sterile.  
 91 
ii) Septic, when infected. 
C. Depending upon the source of the emboli, they are classified as: 
i) Cardiac emboli from left side of heart e.g. emboli originating 
from atrium and atrial appendages, infarct in the left ventricle, vegetations 
of endocarditis.  
ii) Arterial emboli e.g. in systemic arteries in the brain, spleen, 
kidney, intestine. 
iii) Venous emboli e.g. in pulmonary arteries.  
iv) Lymphatic emboli can also occur. 
D. Depending upon the flow of blood, two special types of emboli are 
mentioned: 
i) Paradoxical embolus. An embolus which is carried from the ve-
nous side of circulation to the arterial side or vice versa is called paradoxi-
cal or crossed embolus e.g. through arteriovenous communication such as in 
patent foramen ovale, septal defect of the heart, and arteriovenous shunts in 
the lungs.  
ii) Retrograde embolus. An embolus which travels against the 
flow of blood is called retrograde embolus e.g. metastatic deposits in the 
spine from carcinoma prostate. The spread occurs by retrograde embolism 
through intraspinal veins which carry rumour emboli from large thoracic 
and abdominal veins due to increased pressure in body cavities e.g. during 
coughing or straining. 
 
Thromboembolism.  
It is the most frequent kind of embolism. There are three main ways 
of blood clot moving: 
1)  From venous part of the systemic circle (venous thromboembo-
lism) to the right chambers of heart and then to the vessels of a pulmonary 
circle; 
2)  From the left chambers of the heart to the aorta and large arteries 
(arterial (systemic) thromboembolism) and then to the small arteries of sys-
temic circle (thromboembolic syndrome); 
3) From branches of portal system to the portal vein of liver. 
A detached thrombus or part of thrombus constitutes the most com-
mon type of embolism. These may arise in the arterial or venous circulation: 
Arterial (systemic) thromboembolism. Arterial emboli may be derived 
from the following sources: 
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A. Causes within the heart (80-85%): These are mural thrombi in the 
left atrium or left ventricle, vegetations on the mitral or aortic valves, pros-
thetic heart valves and cardiomyopathy. 
B. Causes within the arteries: these include emboli developing in re-
lation to atherosclerotic plaques, aortic aneurysms, pulmonary veins and 
paradoxical arterial emboli from the systemic venous circulation. 
The effects of arterial emboli depend upon their size, site of lodge-
ment, and adequacy of collateral circulation. If the vascular occlusion oc-
curs, the following ill-effects may happen: 
i) Infarction of the organ or its affected part e.g. ischaemic necrosis in 
the lower limbs (70-75%), spleen, kidneys, brain, intestine. 
ii) Gangrene following infarction in the lower limbs if the collateral 
circulation is inadequate.  
iii) Arteritis and mycotic aneurysm formation from bacterial endo-
carditis. 
iv) Myocardial infarction may occur following coronary embolism. 
v) Sudden death may result from coronary embolism or embolism in 
the middle cerebral artery. 
Venous thromboembolism. Venous emboli may arise from the follow-
ing sources: 
i) Thrombi in the veins of the lower legs are the most common cause 
of venous emboli. 
ii) Thrombi in the pelvic veins. 
iii) Thrombi in the veins of the upper limbs. 
iv) Thrombosis in cavernous sinus of the brain. 
v) Thrombi in the right side of heart. 
The most significant effect of venous embolism is obstruction of pul-
monary arterial circulation leading to pulmonary embolism described below. 
 
Pulmonary embolism 
Pulmonary embolism is the most common and fatal form of venous 
thromboembolism in which there is occlusion of pulmonary arterial tree by 
thromboemboli. Pulmonary thrombosis as such is uncommon and may oc-
cur in pulmonary atherosclerosis and pulmonary hypertension. 
Etiology. Pulmonary emboli are more common in hospitalised or 
bed-ridden patients, though they can occur in ambulatory patients as well. 
The causes are as follows: 
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i) Thrombi originating from large veins of lower legs (such as poplit-
eal, femoral and iliac) are the cause in 95% of pulmonary emboli. 
ii) Less common sources include thrombi in varicosities of superficial 
veins of the legs, and pelvic veins such as periprostatic, periovarian, uterine 
and broad ligament veins. 
Pathogenesis. Detachment of thrombi from any of the above-
mentioned sites produces a thromboembolus that flows through venous 
drainage into the larger veins draining into right side of the heart. 
• If the thrombus is large, it is impacted at the bifurcation of the main 
pulmonary artery (saddle embolus), or may be found in the right ventricle or 
its outflow tract. 
• More commonly, there are multiple emboli, or a large embolus may 
be fragmented into many smaller emboli which are then impacted in a num-
ber of vessels, particularly affecting the lower lobes of lungs. 
• Rarely, paradoxical embolism may occur by passage of an embolus 
from right heart into the left heart through atrial or ventricular septal defect. 
In this way, pulmonary emboli may reach systemic circulation. 
 
Consequences of pulmonary embolism.  
Pulmonary embolism occurs more commonly as a complication in 
patients of acute or chronic debilitating diseases who are immobilised for a 
long duration. Women in their reproductive period are at higher risk such as 
in late pregnancy, following delivery and with use of contraceptive pills. 
The effects of pulmonary embolism depend mainly on the size of the oc-
cluded vessel, the number of emboli, and on the cardiovascular status of the 
patient. The following consequences can result: 
i) Sudden death. Massive pulmonary embolism results in instantane-
ous death, without occurrence of chest pain or dyspnoea. However, if the 
death is somewhat delayed, the clinical features resemble myocardial in-
farction i.e. severe chest pain, dyspnoea and shock. 
ii) Acute cor pulmonale. Numerous small emboli may obstruct most 
of the pulmonary circulation resulting in acute right heart failure. Another 
mechanism is by release of vasoconstrictor substances from platelets or by 
reflex vasoconstriction of pulmonary vessels. 
iii) Pulmonary infarction. Obstruction of relatively small-sized pul-
monary arterial branches may result in pulmonary infarction. The clinical 
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features include chest pain due to fibrinous pleuritis, haemoptysis and 
dyspnoea due to reduced functioning pulmonary parenchyma. 
iv) Pulmonary haemorrhage. Obstruction of terminal branches 
(endarteries) leads to central pulmonary haemorrhage. The clinical features 
are haemoptysis, dyspnoea, and less commonly, chest pain due to central 
location of pulmonary haemorrhage. Sometimes, there may be concomitant 
pulmonary infarction. 
v) Resolution. Vast majority of small pulmonary emboli (60-80%) are 
resolved by fibrinolytic activity. These patients are clinically silent owing to 
bronchial circulation so that lung parenchyma is adequately perfused. 
vi) Pulmonary hypertension, chronic cor pulmonale and pulmonary 
arteriosclerosis. These are the sequelae of multiple small thromboemboli 
undergoing healing rather than resolution. 
 
Systemic embolism. 
This is the type of arterial embolism that originates commonly from 
thrombi in the diseased heart, especially in the left ventricle. These diseases 
of heart include myocardial infraction, cardiomyopathy, RHD, congenital 
heart disease, infective endocarditis, and prosthetic cardiac valves. These 
arterial emboli invariably cause infarction at the sites of lodgement which 
include, in descending order of frequency, lower extremity, brain, and in-
ternal visceral organs (spleen, kidneys, intestines). Thus, the effects and 
sites of arterial emboli are in striking contrast to venous emboli which are 
often lodged in the lungs. 
 
Fat embolism. 
Obstruction of arterioles and capillaries by fat globules constitutes fat 
embolism. If the obstruction in the circulation is by fragments of adipose 
tissue, it is called fat-tissue embolism. 
Etiology. Following are the important causes of fat embolism: 
i) Traumatic causes: 
• Trauma to bones is the most common cause of fat embolism e.g. in 
fractures of long bones leading to passage of fatty marrow in circulation, 
concussions of bones, after orthopaedic surgical procedures etc. 
• Trauma to soft tissue e.g. laceration of adipose tissue and in puer-
perium due to injury to pelvic fatty tissue. 
ii) Non-traumatic causes: 
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• Extensive burns 
• Diabetes mellitus 
• Fatty liver 
• Pancreatitis 
• Sickle cell anaemia 
• Decompression sickness 
• Inflammation of bones and soft tissues 
• Extrinsic fat or oils introduced into the body. 
Pathogenesis. The following mechanisms are hypothesised to explain 
the pathogenesis of fat embolism. These may be acting singly or in combi-
nation. 
i) Mechanical theory. Mobilisation of fluid fat may occur following 
trauma to the bone or soft tissues. The fat globules released from the injured 
area may enter venous circulation and finally most of the fat is arrested in 
the small vessels in the lungs. Some of the fat globules may further pass 
through into the systemic circulation to lodge in other organs. 
ii) Emulsion instability theory. This theory explains the pathogenesis 
of fat embolism in non-traumatic cases. According to this theory, fat emboli 
are formed by aggregation of plasma lipids (chylomicrons and fatty acids) 
due to disturbance in natural emulsification of fat. 
iii) Intravascular coagulation theory. In stress, release of some factor 
activates disseminated intravascular coagulation (DIG) and aggregation of 
fat emboli. 
iv) Toxic injury theory. According to this theory, the small blood ves-
sels of lungs are chemically injured by high plasma levels of free fatty acid, 
resulting in increased vascular permeability and consequent pulmonary oe-
dema. 
Consequences of fat embolism. The effects of fat embolism depend 
upon the size and quantity of fat globules, and whether or not the emboli 
pass through the lungs into the systemic circulation. 
i) Pulmonary fat embolism. In patients dying after fractures of bones, 
presence of numerous fat emboli in the capillaries of the lung is a frequent 
autopsy finding because the small fat globules are not likely to appreciably 
obstruct the vast pulmonary vascular bed. However, widespread obstruction 
of pulmonary circulation due to extensive pulmonary embolism can occur 
and result in sudden death. 
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Microscopically, the lungs show hyperaemia, oedema, patechial 
haemorrhages and changes of adult respiratory distress syndrome (ARDS). 
Pulmonary infarction is usually not a feature of fat embolism because of the 
small size of globules. In routine stains, the fat globules in the pulmonary 
arteries, capillaries and alveolar spaces appear as vacuoles. Frozen section 
is essential for confirmation of globules by fat stains such as Sudan dyes 
(Sudan black, Sudan III and IV), oil red O and osmic acid. 
ii) Systemic fat embolism. Some of the fat globules may pass through 
the pulmonary circulation such as via patent foramen ovale, arteriovenous 
shunts in the lungs and vertebral venous plexuses, and get lodged in the ca-
pillaries of organs like the brain, kidney, skin etc. 
• Brain. The pathologic findings in the brain are patechial haemor-
rhages on the leptomeninges and minute haemorrhages in the parenchyma.  
Microscopically, microinfarct of brain, oedema and haemorrhages are 
seen. The CNS manifestations include delirium, convulsions, stupor, coma 
and sudden death. 
• Kidney. Renal fat embolism present in the glomerular capillaries, 
may cause decreased glomerular filtration. Other effects include tubular 
damage and renal insufficiency. 
• Other organs. Besides the brain and kidneys, other findings in sys-
temic fat embolism are patechiae in the skin, conjunctivae, serosal surfaces, 
fat globules in the urine and sputum. 
 
Gas embolism 
Air, nitrogen and other gases can produce bubbles within the circula-
tion and obstruct the blood vessels causing damage to tissue. Two main 
forms of gas embolism – air embolism and decompression sickness are de-
scribed below. 
 
Air embolism occurs when air is introduced into venous or arterial 
circulation. 
Venous air embolism. Air may be sucked into systemic veins under 
the following circumstances: 
i) Operations on head and neck, and trauma. The accidental opening 
of a major vein of the neck like jugular, or neck wounds involving the ma-
jor neck veins, may allow air to be drawn into venous circulation. 
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ii) Obstetrical operations and trauma. During childbirth by normal 
vaginal delivery, caesarean section, abortions and other procedures, fatal air 
embolism may result from the entrance of air into the opened-up uterine ve-
nous sinuses and endometrial veins. 
iii) Intravenous infusion of blood and fluid. Air embolism may occur 
during intravenous blood or fluid infusions if only positive pressure is em-
ployed. 
iv) Angiography. During angiographic procedures, air may be en-
trapped into a large vein causing air embolism. 
The effects of venous air embolism depend upon the following fac-
tors: 
i) Amount of air introduced into the circulation. The volume of air 
necessary to cause death is variable but usually 100-150 ml of air entry is 
considered fatal. 
ii) Rapidity of entry of a smaller volume of air is important determi-
nant of a fatal outcome.  
iii) Position of the patient during or soon after entry of air is another 
factor. The air bubbles may ascend into the superior vena cava if the posi-
tion of head is higher than the trunk (e.g. in upright position) and reach the 
brain. 
iv) General condition of the patient e.g. in severely ill patients, as lit-
tle as 40 ml of air may have serious results. 
The mechanism of death is caused by entrapment of air emboli in the 
pulmonary arterial trunk in the right heart. If bubbles of air in the form of 
froth pass further out into pulmonary arterioles, they cause widespread vas-
cular occlusions. If death from pulmonary air embolism is suspected, the 
heart and pulmonary artery should be opened in situ under water so that es-
caping froth or foam formed by mixture of air and blood can be detected. 
 
Arterial air embolism. Entry of air into pulmonary vein or its tribu-
taries may occur in the following conditions: 
i) Cardiothoracic surgery and trauma. Arterial air embolism may oc-
cur following thoracic operations, thoracocentesis, rupture of the lung, pen-
etrating wounds of the lung, artificial pneumothorax etc. 
ii) Paradoxical air embolism. This may occur due to passage of ve-
nous air emboli to the arterial side of circulation through a patent foramen 
ovale or via pulmonary arteriovenous shunts. 
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iii) Arteriography. During arteriographic procedures, air embolism 
may occur. 
The effects of arterial air embolism are in the form of certain charac-
teristic features:  
i) Marble skin due to blockage of cutaneous vessels. 
ii) Air bubbles in the retinal vessels seen ophthalmoscopically. 
iii) Pallor of the tongue due to occlusion of a branch of lingual artery. 
iv) Coronary or cerebral arterial air embolism may cause sudden 
death by much smaller amounts of air than in the venous air embolism. 
Decompression Sickness. This is a specialised form of gas embolism 
known by various names such as Caisson's disease, divers' palsy or aeroem-
bolism. 
Pathogenesis. Decompression sickness is produced when the indi-
vidual decompresses suddenly, either from high atmospheric pressure to 
normal level, or from normal pressure to low atmospheric pressure. 
• In divers, workers in caissons (diving-bells), offshore drilling and 
runnels, who descend to high atmospheric pressure, increased amount of 
atmospheric gases (mainly nitrogen; others are O2, CO2) are dissolved in 
blood and tissue fluids. When such an individual ascends too rapidly i.e. 
comes to normal level suddenly from high atmospheric pressure, the gases 
come out of the solution as minute bubbles, particularly in fatty tissues 
which have affinity for nitrogen. These bubbles may coalesce together to 
form large emboli. 
• In aeroembolism, seen in those who ascend to high altitudes or air 
flight in unpressurised cabins, the individuals are exposed to sudden de-
compression from low atmospheric pressure to normal levels. This results 
in similar effects as in divers and workers in caissons. 
Effects. The effects of decompression sickness depend upon the fol-
lowing: 
• Depth or altitude reached 
• Duration of exposure to altered pressure 
• Rate of ascent or descent 
• General condition of the individual 
The pathologic changes are more pronounced in sudden decompres-
sion from high pressure to normal levels than in those who decompress 
from low pressure to normal levels. The changes are more serious in obese 
persons as nitrogen gas is more soluble in fat than in body fluids. 
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Clinical effects of decompression sickness are of 2 types – acute and 
chronic. 
• Acute form occurs due to acute obstruction of small blood vessels in 
the vicinity of joints and skeletal muscles. The condition is clinically char-
acterised by the following: 
i) The bends, as the patient doubles up in bed due to acute pain in 
joints, ligaments and tendons, 
ii) The chokes occur due to accumulation of bubbles in the lungs, re-
sulting in acute respiratory distress, 
iii) Cerebral effects may manifest in the form of vertigo, coma, and 
sometimes death. 
• Chronic form is due to foci of ischaemic necrosis throughout body, 
especially the skeletal system. Ischaemic necrosis may be due to embolism per 
se, but other factors such as platelet activation, intravascular coagulation and 
hypoxia might contribute. The features of chronic form are as under: 
i) Avascular necrosis of bones e.g. head of femur, tibia, humerus. 
ii) Neurological symptoms may occur due to ischaemic necrosis in 
the central nervous system. These include paraesthesias and paraplegia. 
iii) Lung involvement in the form of haemorrhage, oedema, emphy-
sema and atelactasis may be seen. These result in dyspnoea, nonproductive 
cough and chest pain. 
iv) Skin manifestations include itching, patchy erythema, cyanosis 
and oedema. 
v) Other organs like parenchymal cells of the liver and pancreas may 
show lipid vacuoles. 
 
Amniotic fluid embolism 
This is the most serious, unpredictable and unpreven-tible cause of 
maternal mortality. During labour and in the immediate post-partum period, 
the contents of amniotic fluid may enter the uterine veins and reach right 
side of the heart resulting in fatal complications. The amniotic fluid compo-
nents which may be found in uterine veins, pulmonary artery and vessels of 
other organs are: epithelial squames, vernix caseosa, lanugo hair, bile from 
meconium, and mucus. The mechanism by which these amniotic fluid con-
tents enter the maternal circulation is not clear. Possibly, they gain entry ei-
ther through tears in the myometrium and endocervix, or the amniotic fluid 
is forced into uterine sinusoids by vigorous uterine contractions. 
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Pathologic changes. Notable changes are seen in the lungs such as 
haemorrhages, congestion, oedema and changes of ARDS, and dilatation of 
right side of the heart. 
These changes are associated with identifiable amniotic fluid contents 
within the pulmonary microcirculation. 
The clinical syndrome is characterised by the following features: 
• Sudden respiratory distress and dyspnoea, 
• Deep cyanosis, 
• Cardiovascular shock, 
• Convulsions, 
• Coma, 
• Unexpected death. 
The cause of death may not be obvious but can occur as a result of 
the following mechanisms:  
i) Mechanical blockage of the pulmonary circulation in extensive 
embolism. 
ii) Anaphylactoid reaction to amniotic fluid components. 
iii) Disseminated intravascular coagulation (DIC) due to liberation of 
thromboplastin by amniotic fluid.  




Atheromatous plaques, especially from aorta, may get eroded to form 
atherosclerotic emboli which are then lodged in medium-sized and small 
arteries. These emboli consist of cholesterol crystals, hyaline debris and 
calcified material, and may evoke foreign body reaction at the site of 
lodgement. 
The pathologic changes and their effects in atheroembolism are as 
under: 
i) Ischaemia, atrophy and necrosis of tissue distal to the occluded 
vessel. 
ii) Infarcts in the organs affected such as the kidneys, spleen, brain 
and heart. 
iii) Gangrene in the lower limbs. 




Malignant tumour cells invade the local blood vessels and may form 
tumour emboli to be lodged elsewhere, producing metastatic tumour depos-
its. Notable examples are clear cell carcinoma of kidney, carcinoma of the 
lung, malignant melanoma etc. 
Miscellaneous emboli. 
Various other endogenous and exogenous substances may act as em-
boli. These are: 
i) Fragments of tissue, 
ii) Placental fragments, 
iii) Red cell aggregates (sludging), 
iv) Bacteria, 
v) Parasites, 
vi) Barium emboli following enema, 
vii) Foreign bodies e.g. needles, talc, sutures, bullets, catheters etc. 
 
Microbial embolism takes place when microbes or fungi occlude ca-
pillaries, thus abscesses are formed in different organs. 
 
ISCHAEMIA 
Definition. Ischaemia is defined as deficient blood supply to part of a 
tissue. The cessation of blood supply may be complete (complete ischae-
mia) or partial (partial ishcaemia). The harmful effects of ischaemia may 
result from 3 ways: 
1. Hypoxia due to deprivation of oxygen to tissues. 
2. Inadequate supply of nutrients to the tissue such as glucose and 
aminoacids. 
3. Inadequate clearance of metabolites resulting in accumulation of 
metabolic waste-products in the affected tissue. 
Etiology. A number of causes may produce ischaemia. These are as un-
der: 
1. Causes in the heart. Inadequate cardiac output resulting from heart 
block, ventricular arrest and fibrillation may cause hypoxic injury to brain. 
• If the arrest continues for 15 seconds, consciousness is lost. 
• If the condition lasts for more than 4 minutes, irreversible ischaemic 
damage to brain occurs. 
• If it is prolonged for more than 8 minutes, death is inevitable. 
 102 
2. Causes in the arteries. The most common and most important causes 
of ischaemia are due to obstruction in arterial blood supply. These are: 
i) Luminal occlusion such as due to: 
• Thrombosis, 
• Embolism. 
ii) Causes in the arterial wall such as: 
• Vasospasm (e.g. in Raynaud's disease), 
• Hypothermia, ergotism, 
• Arteriosclerosis, 
• Polyarteritis nodosa, 
• Thromboangiitis obliterans (Buerger's disease), 
• Severed vessel wall. 
iii) Outside pressure on an artery such as:  
• Ligature, 
• Tourniquet, 
• Tight plaster, bandages, 
• Torsion. 
3. Causes in the veins. Blockage of venous drainage may lead to en-
gorgement and obstruction to arterial blood supply resulting in ischaemia. 
The examples include the following: 
i) Luminal occlusion such as in: 
• Thrombosis of mesenteric veins, 
• Cavernous sinus thrombosis. 
ii) Causes in the vessel wall such as in: 
• Varicose veins of the legs. 
iii) Outside pressure on a vein as in: 
• Strangulated hernia, 
• Intussusception, 
• Volvulus. 
4. Causes in the microcirculation. Ischaemia may result from occlu-
sion of arterioles, capillaries and venules. The causes are as under: 
i) Luminal occlusion such as: 
• By red cells e.g. in sickle cell anaemia, red cells parasitised by 
malaria, acquired haemolytic anaemia, sludging of the blood. 
• By white cells e.g. in chronic myeloid leukaemia, 
• By fibrin e.g. defibrination syndrome, 
• By precipitated cryoglobulins 
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• By fat embolism, 
• In decompression sickness. 
ii) Causes in the microvasculature wall such as: 
• Vasculitis e.g. in polyarteritis nodosa, Henoch-Schonlein purpura, 
Arthus reaction, septicaemia. 
• Frost-bite injuring of the wall of small blood vessels. 
iii) Outside pressure on microvasculature as in: 
• Bedsores. 
 
Factors determining the severity of ischaemic injury. The extent 
of damage produced by ischaemia due to occlusion of arterial or venous 
blood vessels depends upon a number of factors. These are as under: 
1. Anatomic pattern. The extent of injury by ischaemia depends upon 
the anatomic pattern of arterial blood supply of the organ or tissue affected. 
There are 4 different patterns of arterial blood supply: 
i) Single arterial supply without anastomosis. Some organs receive 
blood supply from arteries which do not have significant anastomosis and 
are thus functional endarteries. Occlusion of such vessels invariably results 
in ischaemic necrosis. The examples are: 
• Central artery of the retina, 
• Interlobular arteries of the kidneys. 
ii) Single arterial supply with rich anastomosis. Arterial supply to 
some organs has rich interarterial anastomoses so that blockage of one ves-
sel can re-establish blood supply bypassing the blocked arterial branch, and 
hence the infarction is less common in such circumstances. For example: 
• Superior mesenteric artery supplying blood to the small intestine. 
• Inferior mesenteric artery supplying blood to distal colon. 
• Arterial supply to the stomach by 3 separate vessels derived from 
coeliac axis. 
• Interarterial anastomoses in the 3 main trunks of the coronary arte-
rial system. 
iii) Parallel arterial supply. Blood supply to some organs and tissues 
is such that the vitality of the tissue is maintained by alternative blood sup-
ply in case of occlusion of one. The examples are: 
• Blood supply to brain in the region of circle of Willis. 
• Arterial supply to forearm by radial and ulnar arteries. 
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iv) Double blood supply. The effect of occlusion of one set of vessels 
is modified if an organ has dual blood supply. For example: 
• Lungs are perfused by bronchial circulation as well as by pulmo-
nary arterial branches. 
• Liver is supplied by both portal circulation and hepatic arterial flow. 
However, collateral circulation is of little value if the vessels are se-
verely affected with spasm, atheroma or any other condition. 
2. General and cardiovascular status. The general status of an indi-
vidual as regards cardiovascular function is an important determinant to as-
sess the effect of ischaemia. Some of the factors which render the tissues 
more vulnerable to the effects of ischaemia are: 
i) Anaemias (sickle cell anaemia, in particular) 
ii) Lowered oxygenation of blood (hypoxaemia) 
iii) Senility with marked coronary atherosclerosis 
iv) Cardiac failure 
v) Blood loss 
vi) Shock. 
3. Type of tissue affected. The vulnerability of tissue of the body to 
the effect of ischaemia is variable. The mesenchymal tissues are quite re-
sistant to the effect of ischaemia as compared to parenchymal cells of the 
organs. The following tissues are more vulnerable to ischaemia: 
i) Brain (cerebral cortical neurons, in particular).  
ii) Heart (myocardial cells). 
iii) Kidney (especially epithelial cells of proximal convoluted tu-
bules). 
4. Rapidity of development. Sudden vascular obstruction results in 
more severe effects of ischaemia than if it is gradual since there is less time 
for collaterals to develop. 
5. Degree of vascular occlusion. Complete vascular obstruction re-
sults in more severe ischaemic injury than the partial occlusion. 
Effects. The effects of ischaemia are variable and range from ‘no 
change’ to ‘sudden death’. 
1. No effects on the tissues, if the collateral channels develop ade-
quately so that the effect of ischaemia fails to occur. 
2. Functional disturbances. These result when collateral channels are 
able to supply blood during normal activity but the supply is not adequate to 
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withstand the effect of exertion. The examples are angina pectoris and in-
termittent claudication. 
3. Cellular changes. Partial ischaemia may produce cellular changes 
such as cloudy swelling, fatty change, atrophy and replacement fibrosis. In-
farction results when the deprivation of blood supply is complete so as to 
cause necrosis of tissue affected. 
4. Sudden death. The cause of sudden death from ischaemia is usual-
ly myocardial and cerebral infarction. 
 
INFARCTION 
Definition. Infarction is the process of tissue necrosis resulting from 
some form of circulatory insufficiency; the localised area of necrosis so de-
veloped is called an infarct. 
Etiology. All the causes of ischaemia discussed above can cause in-
farction. There are a few other noteworthy features in infarcts: 
• Most commonly, infarcts are caused by interrupted arterial blood 
supply, called ischaemic necrosis. 
• Less commonly, venous obstruction can produce infarcts termed 
stagnant hypoxia. 
• Generally, sudden, complete, and continuous occlusion by throm-
bosis or embolism produces infarcts. 
• Infarcts may be produced by nonexclusive circulatory insufficiency 
as well e.g. incomplete atherosclerotic narrowing of coronary arteries may 
produce myocardial infarction due to acute coronary insufficiency. 
Types of infarcts see above.  
Pathogenesis. The process of infarction takes place as follows: 
i) Localised hyperaemia due to local anoxaemia occurs immediately 
after obstruction of the blood supply. 
ii) Within a few hours, the affected part becomes swollen due to oe-
dema and haemorrhage. The amount of haemorrhage is variable, being 
more marked in the lungs and spleen, and less extensive in the kidneys and 
heart. 
iii) Cellular changes such as cloudy swelling and degeneration appear 
early, while death of the cells or necrosis occurs in 12-48 hours. 
iv) There is progressive autolysis of the necrotic tissue and haemoly-
sis of the red cells. 
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v) An acute inflammatory reaction and hyperaemia appear at the 
same time in the surrounding tissues in response to products of autolysis. 
vi) Blood pigments, haematoidin and haemosiderin, liberated by 
haemolysis are deposited in the infarct. At this stage, most infarcts become 
pale due to loss of red cells. 
vii) Following this, there is progressive in growth of granulation tis-
sue from the margin of the infarct so that eventually the infarct is replaced 
by a fibrous scar. Dystrophic calcification may occur sometimes. However, 
in the case of infarct brain, there is liquefactive necrosis which heals by 
gliosis. 
Pathologic changes. Some general morphological features of infarcts 
are described below, followed by pathologic changes in infarcts of different 
organs. 
Grossly, infarcts of solid organs are usually wedge-shaped, the apex 
pointing towards the occluded artery and the wide base on the surface of the 
organ. Infarcts due to arterial occlusion are generally pale while those due 
to venous obstruction are haemorrhagic. Most infarcts become pale later as 
the red cell are lysed but pulmonary infarcts never become pale due to ex-
tensive amount of blood. 
Cerebral infarcts are poor-
ly defined with central 
softening (encephaloma-
lacia). Recent infarcts are 
generally slightly elevated 
over the surface while the 
old infarcts are shrunken 
and depressed under the 
surface of the organ. 
Microscopically, 
the pathognomonic cyto-
logic change in all infarcts 
is coagulative necrosis of 
the affected area of tissue 
or organ. In cerebral infarcts, however, there is characteristic liquefactive 
necrosis. Some amount of haemorrhage is generally present in any infarct. 
At the periphery of an infarct, inflammatory reaction is noted. Initially, neu-
trophils predominate but subsequently macrophages and fibroblasts appear. 
Fig. 17. Myocardium infarction. H and E stained sec-
tion, x 200. 
otic area, 





Eventually, the necrotic area is replaced by fibrous scar tissue, which at 
times may show dystrophic calcification. In cerebral infarcts, the liquefac-
tive necrosis is followed by gliosis i.e. replacement by microglial cells dis-
tended by fatty material (gitter cells). 
 
Infarcts of different organs. A few representative examples of in-
farction of some organs (lungs, kidney, liver and spleen) are discussed be-
low. Myocardial infarction, cerebral infarction and infarction of small intes-
tines are covered in detail later in respective chapters of Systemic Patholo-
gy. 
 
Infarct of the lung. Embolism of the pulmonary arteries may pro-
duce pulmonary infarction, though not always. This is because lungs re-
ceive blood supply from bronchial arteries as well, and thus occlusion of 
pulmonary artery ordinarily does not produce infarcts. However, it may oc-
cur in patients who have inadequate circulation such as in chronic lung dis-
eases and congestive heart failure. 
Grossly, the pulmonary infarcts are classically wedge-shaped with 
base on the pleura, haemorrhagic, variable in size, and most often in the 
lower lobes. Fibrinous pleuritis usually covers the area of infarct. Cut sur-
face is dark purple and may 
show the blocked vessel 
near the apex of the infarct-
ed area. Old organised and 
healed pulmonary infarcts 




ture is coagulative necrosis 
of the alveolar walls (see 
Fig. 18). Initially, there is 
infiltration by neutrophils 
and intense alveolar capillary congestion, but later their place is taken by 
haemosiderin, phagocytes and granulation tissue. 
 
Fig. 18 . pulmonary infarct. H and E stained sec-
tion, x 200. 
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Infarct of the kidney. Renal infarction is common, found in upto 5% 
of autopsies. Majority of them are caused by thromboemboli, most com-
monly originating from the heart such as in mural thrombi in the left atrium, 
myocardial infarction, vegetative endocarditis and aortic aneurysm. Less 
commonly, renal infarcts may occur due to advanced renal artery athero-
sclerosis, arteritis and sickle cell anaemia. 
Grossly, renal infarcts are often multiple and may be bilateral. Char-
acteristically, they are pale or anaemic and wedge-shaped with base resting 
under the capsule and apex pointing towards the medulla. Generally, a nar-
row rim of preserved renal tissue under the capsule is spared because it 
draws its blood supply from the capsular vessels. Cut surface of renal in-
farct in the first 2 to 3 days is red and congested but by 4th day the centre 
becomes pale yellow. At the end of one week, the infarct is typically anae-
mic and depressed below the surface of the kidney. 
Microscopically, the affected area shows characteristic coagulative 
necrosis of renal parenchyma i.e. there are ghosts of renal tubules and glo-
meruli without intact nuclei and cytoplasmic content. The margin of the in-
farct shows inflammatory reaction – initially acute but later macrophages 
and fibrous tissue predominate. 
 
Infarct of the spleen. Spleen is one of the common sites for infarc-
tion. Splenic infarction results from occlusion of the splenic artery or its 
branches. Occlusion is caused most commonly by thromboemboli arising in 
the heart (e.g. in mural thrombi in the left atrium, vegetative endocarditis, 
myocardial infarction), and less frequently by obstruction of microcircula-
tion (e.g. in myeloproliferative diseases, sickle cell anaemia, arteritis, 
Hodgkin's disease, bacterial infections). 
Grossly, splenic infarcts are often multiple. They are characteristical-
ly pale or anaemic and wedge-shaped with their base at the periphery and 
apex pointing towards hilum. 
Microscopically, the features are similar to those found in anaemic 
infarcts in kidney. Coagulative necrosis and inflammatory reaction are seen. 
Later, the necrotic tissue is replaced by shrunken fibrous scar. 
Infarct of the liver. Just as in lungs, infarcts in the liver are uncom-
mon due to dual blood supply – from portal vein and from hepatic artery. 
Obstruction of the portal vein is usually secondary to other diseases such as 
hepatic cirrhosis, intravenous invasion of primary carcinoma of the liver, 
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carcinoma of the pancreas and pylephlebitis. Occlusion of portal vein or its 
branches generally does not produce ischaemic infarction but instead re-
duced blood supply to hepatic parenchyma causes non-ischaemic infarct 
called infarct of Zahn. Obstruction of the hepatic artery or its branches, on 
the other hand, caused by arteritis, arteriosclerosis, bland or septic emboli, 
results in ischaemic infarcts of the liver. 
Grossly, ischaemic infarcts of the liver are usually anaemic but some-
times may be haemorrhagic due to stuffing of the site by blood from the 
portal vein. Infarcts of Zahn (non-ischaemic infarcts) produce sharply de-
fined red-blue area in liver parenchyma. 
Microscopically, ischaemic infarcts show characteristics of pale or 
anaemic infarcts as in kidney or spleen. Infarcts of Zahn occurring due to 
reduced portal blood flow result in atrophy of hepatocytes and dilatation of 
sinusoids. 
DISSEMINATED INTRAVASCULAR COAGULATION (DIVC) 
Disseminated intravascular coagulation (DIVC), also termed defib-
rination syndrome or consumption coagulopathy, is a complex thrombo- 
haemorrhagic disorder (intravascular coagulation and haemorrhage) occur-
ring as a secondary complication in some systemic diseases. 
Etiology: although there are numerous conditions associated with 
DIC, most frequent causes are listed below: 
1. Massive tissue injury: in obstetrical syndromes (e.g., abruption 
placentae, amniotic fluid embolism, retained dead foetus), massive trauma, 
metastatic malignancies, surgery. 
2. Infections: especially endotoxaemia, gram-negative and meningo-
coccal septicaemia, certain viral infections, malaria, aspergillosis. 
3. Widespread endothelial damage: in aortic aneurysm, haemolytic-
uraemic syndrome, severe burns, acute glomerulonephritis. 
4. Miscellaneous: snake bite, shock, acute intravascular haemolysis, 
heat stroke. 
Pathogenesis: Although in each case, a distinct triggering mechanism 
has been identified, the sequence of events, in general, can be summarised: 
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1. Activation of coagulation. The etiologic factors listed above initiate 
widespread activation of coagulation pathway 
by release of tissue factor. 
2. Thrombotic phase. Endothelial 
damage from the various thrombogenic stim-
uli causes generalised platelet aggregation 
and adhesion with resultant deposition of 
small thrombi and emboli throughout the mi-
cro vasculature. 
3. Consumption phase. The early 
thrombotic phase is followed by a phase of 
consumption of coagulation factors and plate-
lets. 
4. Secondary fibrinolysis. As a protec-
tive mechanism, fibrinolytic system is sec-
ondarily activated at the site of intravascular 
coagulation. Secondary fibrinolysis causes 
breakdown of fibrin resulting in formation of 
FDPs in the circulation. 
 
Clinical features: There are 2 main features of DIC – bleeding as the 
most common manifestation, and organ damage due to ischaemia caused 
by the effect of widespread in-
travascular thrombosis such as 
in the kidney and brain. Less 
common manifestations in-
clude: microangiopathic haemo-
lytic anaemia and thrombosis in 
larger arteries and veins. 
 
Fig. 20. Intravascular thrombosis of pulmonary 
vessels. H and E stained section, x 200. 
 
Fig. 19. Multiple hemorrhages 
in the heart and pericardium. 
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INFLAMMATION 
DEFINITION AND CAUSES 
Inflammation is defined as the local response of living mammalian 
tissues to injury due to any agent. Inflammation is a complex vascular-
mesenchymal reaction in order to eliminate or limit the spread of injurious 
agent as well as to remove the consequent necrotized cells and tissues. 
The agents causing inflammation may be as under:  
1. Physical agents like heat, cold, radiation, mechanical trauma. 
2. Chemical agents like organic and inorganic poisons. 
3. Infective agents like bacteria, viruses and their toxins. 
4. Immunological agents like cell-mediated and antigen-antibody re-
actions. 
Thus inflammation is distinct from infection – the former being a 
protective response by the body while the latter is invasion into the body by 
harmful microbes and their resultant ill-effects by toxins. Inflammation in-
volves 2 basic processes with some overlapping, viz. early inflammatory 
response and later followed by healing. Though both these processes gener-
ally have protective role against injurious agents, inflammation and healing 
may cause considerable harm to the body as well e.g. anaphylaxis to bites 
by insects or reptiles, drugs, toxins, atherosclerosis, chronic rheumatoid ar-
thritis, fibrous bands and adhesions in intestinal obstruction. 
SIGNS OF INFLAMMATION 
The Roman writer Celsus in 1st century A.D. named the famous 4 
cardinal signs of inflammation as: 
• rubor (redness); 
• tumor (swelling); 
• calor (heat); and 
• dolor (pain). 
To these, fifth sign functio laesa (loss of function) was later added by 
Virchow. The word inflammation means burning. This nomenclature had its 
origin in old times but now we know that burning is only one of the signs of 
inflammation. 
Types of inflammation: Depending upon the defense capacity of the 
host and duration of response, inflammation can be classified as acute and 
chronic. 
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I. Acute inflammation is of short duration and represents the early 
body reaction and is usually followed by repair. 
The main features of acute inflammation are: 
1. Accumulation of fluid and plasma at the affected site. 
2. Intravascular activation of platelets. 
3. Polymorphonuclear neutrophils as inflammatory cells. 
II. Chronic inflammation is of longer duration and occurs either after 
the causative agent of acute inflammation persists for a long time, or the 
stimulus is such that it induces chronic inflammation from the beginning. 
The characteristic feature of chronic inflammation is presence of 




The changes in acute inflammation can be conveniently described 
under the following 2 headings: 
I. Vascular events; and 
II. Cellular events. 
 
I. Vascular events 
Alteration in the microvasculature (arterioles, capillaries and venules) 
is the earliest response to tissue injury. These alterations include: haemody-
namic changes and changes in vascular permeability. 
Haemodynamic changes. The earliest features of inflammatory re-
sponse result from changes in the vascular flow and calibre of small blood 
vessels in the injured tissue. The sequence of these changes is as under: 
1. Irrespective of the type of injury, immediate vascular response is 
of transient vasoconstriction of arterioles. With mild form of injury, the 
blood flow may be re-established in 3-5 seconds while with more severe in-
jury the vasoconstriction may last for about 5 minutes. 
2. Next follows persistent progressive vasodilatation which involves 
mainly the arterioles, but to a lesser extent, affects other components of the 
microcirculation like venules and capillaries. This change is obvious within 
half an hour of injury. Vasodilatation results in increased blood volume in 
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microvascular bed of the area, which is responsible for redness and warmth 
at the site of acute inflammation. 
3. Progressive vasodilatation, in turn, may elevate the local hydrostat-
ic pressure resulting in transudation of fluid into the extracellular space. 
This is responsible for swelling at the local site of acute inflammation. 
4. Slowing or stasis of microcirculation occurs next. Slowing is at-
tributed to increased permeability of microvasculature that results in in-
creased concentration of red cells, and thus, raised blood viscosity. 
5. Stasis or slowing is followed by leucocytic margination or peripheral 
orientation of leucocytes (mainly neutrophils) along the vascular endothelium. 
The leucocytes stick to the vascular endothelium briefly, and then move and 
migrate through the gaps between the endothelial cells into the extravascular 
space. This process is known as emigration (discussed later in detail). 
The features of haemodynamic changes in inflammation are best 
demonstrated by the Lewis experiment. Lewis induced the changes in the 
skin of inner aspect of forearm by firm stroking with a blunt point. The re-
action so elicited is known as triple response or red line response consisting 
of the following:  
i) Red line appears within a few seconds following stroking and re-
sults from local vasodilatation of capillaries and venules. 
ii) Flare is the bright reddish appearance or flush surrounding the red-
line and results from vasodilatation of the adjacent arterioles. 
iii) Wheal is the swelling or oedema of the surrounding skin occur-
ring due to transudation of fluid into the extravascular space. 
These features, thus, elicit the classical signs of inflammation –
redness, heat, swelling and pain. 
Altered vascular permeability. In and around the inflamed tissue, 
there is accumulation of oedema fluid in the interstitial compartment which 
comes from blood plasma by its escape through the endothelial wall of pe-
ripheral vascular bed. In the initial stage, the escape of fluid is due to vaso-
dilatation and consequent elevation in hydrostatic pressure. This is transu-
date in nature. But subsequently, the characteristic inflammatory oedema, 
exudate, appears by increased vascular permeability of microcirculation. 
The appearance of inflammatory oedema due to increased vascular 
permeability of microvascular bed is explained on the basis of Starling's 
hypothesis. In normal circumstances, the fluid balance is maintained by two 
opposing sets of forces: 
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i) Forces that cause outward movement of fluid from microcircula-
tion are intravascular hydrostatic pressure and osmotic pressure of intersti-
tial fluid, 
ii) Forces that cause inward movement of interstitial fluid into circu-
lation are intravascular osmotic pressure and hydrostatic pressure of intersti-
tial fluid. Whatever little fluid is left in the interstitial compartment is 
drained away by lymphatics and, thus, no oedema results normally. Howev-
er, in inflamed tissues, the endothelial lining of microvasculature becomes 
leakier. Consequently, intravascular osmotic pressure decreases and osmotic 
pressure of the interstitial fluid increases resulting in excessive outward 
flow of fluid into the interstitial compartment which is exudative inflamma-
tory oedema. 
Mechanisms of increased vascular permeability: In acute inflam-
mation, normally non-permeable endothelial layer of microvasculature be-
comes leaky. This is explained by one or more of the following mecha-
nisms: 
i) Contraction of endothelial cells. This is the most common mecha-
nism of increased leakiness that affects venules exclusively while capillaries 
and arterioles remain unaffected. The endothelial cells develop temporary 
gaps between them due to their contraction resulting in vascular leakiness. 
It is mediated by the release of histamine, bradykinin and other chemical 
mediators. The response begins immediately after injury, is usually reversi-
ble, and is for short duration (15-30 minutes). Example of such immediate 
transient leakage is mild thermal injury of skin of forearm. 
ii) Retraction of endothelial cells. In this mechanism, there is struc-
tural re-organisation of the cytoskeleton of endothelial cells that causes re-
versible retraction at the intercellular junctions. This change too affects ven-
ules and is mediated by cytokines such as interleukin-1 (IL-1) and tumour ne-
crosis factor (TNF). The onset of response takes 4-6 hours after injury and 
lasts for 2-4 hours or more (somewhat delayed and prolonged leakage). The 
example of this type of response exists in vitro experimental work only. 
iii) Direct injury to endothelial cells. Direct injury to the endothelium 
causes cell necrosis and appearance of physical gaps at the sites of detached 
endothelial cells. Process of thrombosis is initiated at the site of damaged 
endothelial cells. The change affects all levels of microvasculature (venules, 
capillaries and arterioles). The increased permeability may either appear 
immediately after injury and last for several hours or days (immediate sus-
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tained leakage), or may occur after a delay of 2-12 hours and last for hours 
or days (delayed prolonged leakage). The examples of immediate sustained 
leakage are severe bacterial infections while delayed prolonged leakage 
may occur following moderate thermal injury and radiation injury. 
iv) Endothelial injury mediated by leucocytes. Adherence of leuco-
cytes to the endothelium at the site of inflammation may result in activation 
of leucocytes. The activated leucocytes release proteolytic enzymes and 
toxic oxygen species which may cause endothelial injury and increased vas-
cular leakiness. This form of increased vascular leakiness is a late response. 
The examples are seen in sites where leucocytes adhere to the vascular en-
dothelium e.g. in pulmonary venules and capillaries. 
v) Other mechanisms. In addition, the newly formed capillaries dur-
ing the process of repair are excessively leaky. Vesicles and vacuoles within 
the cytoplasm of endothelial cells of blood vessels in tumours may account 
for leakage of fluid across the cytoplasm. 
 
II. Cellular events 
The cellular phase of inflammation consists of 2 processes: 
1. Exudation of leucocytes; and 
2. Phagocytosis. 
 
Exudation of leucocytes. The escape of leucocytes from the lumen 
of microvasculature to the interstitial tissue is the most important feature of 
inflammatory response. In acute inflammation, polymorphonuclear neutro-
phils (PMNs) comprise the first line of body defense, followed later by 
monocytes and macrophages. 
The changes leading to migration of leucocytes are as follows: 
1. Changes in the formed elements of blood. In the early stage of in-
flammation, the rate of flow of blood is increased due to vasodilatation. But 
subsequently, there is slowing or stasis of blood stream. With stasis, chang-
es in the normal axial flow of blood in the microcirculation take place. The 
normal axial flow consists of central stream of cells comprised by leuco-
cytes and RBCs and peripheral cell-free layer of plasma close to vessel 
wall. Due to slowing and stasis, the central stream of cells widens and pe-
ripheral plasma zone becomes narrower because of loss of plasma by exu-
dation. This phenomenon is known as margination. As a result of this redis-
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tribution, the neutrophils of the central column come close to the vessel 
wall; this is known as pavementing. 
2. Adhesion or rolling. Peripherally marginated and pavemented neu-
trophils stick briefly to the endothelial cells lining the vessel wall or roll 
over it. Injury leads to neutralisation of the normal negative charge on leu-
cocytes and endothelial cells so as to cause adhesion. The phenomenon of 
loose and transient adhesions between endothelial cells and leucocytes and 
later tight adherence of the leucocytes to the vascular endothelium is 
brought about by 4 types of distinct adhesion molecules. 
i) Selectins partake in rolling of PMNs over endothelial surface. The-
se consist of P-selectin (preformed and stored in endothelial cells and plate-
lets), E-selectin (synthesised by cytokine-activated endothelial cells) and L-
selectin (also termed Leu-8 antigenase expressed on the surface of lympho-
cytes and neutrophils). 
ii) Addressins expressed on the surface of leucocytes and endotheli-
um and regulate the localisation of subpopulation of leucocytes. 
iii) Integrins consisting of (β1 and β2 molecules bring about firm ad-
hesion between leukocyte and endothelium. 
iv) Immunoglobulin superfamily adhesion molecule such as intercel-
lular adhesion molecule (ICAM-1, 2) helps in localising leucocytes to the 
site of tissue injury and thus helps in transmigration of PMNs. 
 
3. Emigration. After sticking of neutrophils to endothelium, the for-
mer move along the endothelial surface till a suitable site between the endo-
thelial cells is found where the neutrophils throw out cytoplasmic pseudo-
pods. Subsequently, the neutrophils lodged between the endothelial cells 
and basement membrane cross the basement membrane by damaging it local-
ly with secreted collagenases and escape out into the extravascular space; this 
is known as emigration. The damaged basement membrane is repaired almost 
immediately. As already mentioned, neutrophils are the dominant cells in 
acute inflammatory exudate in the first 24 hours, and monocyte-macrophages 
appear in the next 24-48 hours. However, neutrophils are short-lived (24-48 
hours) while monocyte-macrophages survive much longer. 
Simultaneous to emigration of leucocytes, escape of red cells through 
gaps between the endothelial cells, diapedesis, takes place. It is a passive phe-
nomenon – RBCs being forced out either by raised hydrostatic pressure or may 
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escape through the endothelial defects left after emigration of leucocytes. Dia-
pedesis gives haemorrhagic appearance to the inflammatory exudate. 
4. Chemotaxis. The chemotactic factor-mediated transmigration of 
leucocytes after crossing several barriers (endothelium, basement mem-
brane, perivascular myofibroblasts and matrix) to reach the interstitial-
tissues is called chemotaxis. The concept of chemotaxis is well illustrated 
by Boyden's chamber experiment. In this, a millipore filter (3 um pore size) 
separates the suspension of leucocytes from the test solution in tissue cul-
ture chamber. If the test solution contains chemotactic agent, the leucocytes 
migrate through the pores of filter towards the chemotactic agent. 
The agents acting as potent chemotactic substances for different leu-
cocytes called chemokines are as follows:  
i) Leukotriene B4 (LTB4)  
ii) Platelet factor 4 (PF4) 
iii) Components of complement system (C5a in particular) 
iv) Cytokines (particularly IL-8) 
v) Soluble bacterial products (such as formylated peptides) 
vi) Monocyte chemoattractant protein (MCP-1) 
vii) Chemotactic factor for CD4 + T cells 
viii) Exotaxin chemotactic tor eosinophils. 
There are specific receptors for each of the chemoattractants listed 
above. In addition, chemotactic agents also induce leukocyte activation that 
includes: the production of arachidonic acid metabolites, degranulation and 
secretion of lysosomal enzymes, generation of oxygen metabolites, in-
creased intracellular calcium, and increase in leukocyte surface adhesion 
molecules. 
Phagocytosis. Phagocytosis is defined as the process of engulfment of 
solid particulate material by the cells (cell-eating). The cells performing this 
function are called phagocytes. There are 2 main types of phagocytic cells: 
i) Polymorphonuclear neutrophils (PMNs) which appear early in 
acute inflammatory response, also called as microphages. 
ii) Circulating monocytes and fixed tissue mononuclear phagocytes 
called as macrophages. 
The process of phagocytosis is similar for both polymorphs and mac-
rophages and involves the following 4 steps: 
1. Attachment stage (opsonisation). 
2. Engulfment stage. 
 118 
3. Secretion (degranulation) stage. 
4. Killing or degradation stage. 
1. Attachment stage (opsonisation). The phagocytic cells as well as 
microorganisms to be ingested have usually negatively-charged surface and, 
thus, they repel each other. In order to establish a bond between bacteria 
and the cell membrane of phagocytic cell, the microorganisms get coated 
with opsonins which are naturally-occurring factors in the serum. The two 
main opsonins present in the serum and their corresponding receptors on the 
surface of phagocytic cells are as under: 
i) IgG opsonin and its corresponding receptor on the surface of poly-
morphs and monocytes is Fc fragment of immunoglobulin. 
ii) C3b opsonin fragment of complement and corresponding receptor 
for C3b on the surface of phagocytic cells. 
2. Engulfment stage. The opsonised particle bound to the surface of 
phagocyte is ready to be engulfed. This is accomplished by formation of cy-
toplasmic pseudopods around the particle, enveloping it in a phagocytic 
vacuole. Eventually, the plasma membrane enclosing the phagocytic vacu-
ole breaks from the cell surface so that membrane lined phagocytic vacuole 
lies free in the cell cytoplasm. The lysosomes of the cell fuse with the phag-
ocytic vacuole and form phagolysosome or phagosome. 
3. Secretion (degranulation) stage. During this process, the pre-
formed granule-stored products of PMNs are discharged or secreted into the 
phagosome and the extracellular environment. In particular, the specific or 
secondary granules of PMNs are discharged (e.g. lysosomes) while the az-
urophilic granules are fused with phagosomes. Besides the discharge of pre-
formed granules, mononuclear phagocytes synthesise and secrete certain 
enzymes (e.g. interleukin 2 and 6,TNF), arachidonic acid metabolites (e.g. 
prostaglandins, leukotrienes, platelet activating factor) and oxygen metabo-
lites (e.g. superoxide oxygen, hydrogen peroxide, hypochlorous acid). 
4. Killing or degradation stage. Next the stage of killing comes and 
digestion of microorganism completing the role of phagocytes as scavenger 
cells. The microorganisms after being killed by antibacterial substances are 
degraded by hydrolytic enzymes. However, this mechanism fails to kill and 
degrade some bacteria like tubercle bacilli. 
The antimicrobial agents act by either of the following mechanisms: 
i) Oxygen-dependent bactericidal mechanism;  
ii) Oxygen-independent bactericidal mechanism; and  
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iii) Nitric oxide mechanism. 
i) Oxygen-dependent bactericidal mechanism. An important mecha-
nism of microbicidal killing is by the production of reactive oxygen metab-
olites (O'2 H2O2, OH', HOC1, HOI, HOBr). 
A phase of increased oxygen consumption ('respiratory burst') by activat-
ed phagocytic leucocytes requires the essential presence of NADPH oxidase. 
NADPH-oxidase present in the cell membrane of phagosome reduces 
oxygen to superoxide ion (O'2). 
This type of bactericidal activity is carried out either via enzyme 
myeloperoxidase (MPO) present in the granules of neutrophils and mono-
cytes, or independent of enzyme MPO, as under: 
a) MPO-dependent killing (HA-MPO-halide system). In this mecha-
nism, the enzyme MPO acts on H2O2 in the presence of halides (chloride, 
iodide or bromide) to form hypohalous acid (HOC1, HOI, HOBr) which is 
more potent antibacterial agent than H2O2. 
b) MPO-independent killing. Mature macrophages lack the enzyme 
MPO and they carry out bactericidal activity by producing OH'ions and su-
peroxide singlet oxygen (O') from H2O2 in the presence of O'2 (Haber-Weiss 
reaction) or in the presence of Fe++ (Fenton reaction). 
Reactive oxygen metabolites are particularly useful in eliminating 
microbial organisms that grow within phagocytes e.g. M. tuberculosis, His-
toplasma capsulatum. 
ii) Oxygen-independent bactericidal mechanism. Some agents re-
leased from the granules of phagocytic cells do not require oxygen for bac-
tericidal activity. These include lysosomal hydrolases, permeability increas-
ing factors, defensins and cationic proteins. 
iii) Nitric oxide mechanism. In addition to oxygen-dependent and ox-
ygen-independent mechanisms, recently role of nitric oxide (NO) in in-
flammatory reaction has been emphasised. NO is produced by endothelial 
cells as well as by activated macrophages. In experimental animals, NO has 
been shown to have fungicidal and anti-parasitic action but its role in bacte-
ricidal activity in human beings is yet not clear. 
Chemical mediators of inflammation. Also called as permeability 
factors or endogenous mediators of increased vascular permeability, these 
are a large and increasing number of endogenous compounds which can en-
hance vascular permeability. However, currently many chemical mediators 
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have been identified which partake in other processes of acute inflammation 
as well e.g. vasodilatation, chemotaxis, fever, pain and cause tissue damage. 
The substances acting as chemical mediators of inflammation may be 
released from the cells, the plasma, or damaged tissue itself. They are 
broadly classified into 2 groups: 
i) mediators released by cells; and  
ii) mediators originating from plasma. 
I. Cell-derived mediators 
1. Vasoactive amines. Two important pharmacologically active 
amines that have role in the early inflammatory response (first one hour) are 
histamine and 5-hydroxytryptamine (5-HT) or serotonin. 
i) Histamine. It is stored in the granules of mast cells, basophils and 
platelets. Histamine is released from these cells by various agents like: 
a) Stimuli or substances inducing acute inflammation e.g. heat, cold, 
irradiation, trauma, irritant chemicals, immunologic reactions etc. 
b) Anaphylatoxins like fragments of complement C3a, and C-a, 
which increase vascular permeability and cause oedema in tissues. 
c) Histamine-releasing factors from neutrophils, monocytes and 
platelets. 
d) Neuropeptides such as substance P. 
e) Interleukins. 
The main actions of histamine are: vasodilatation, increased vascular 
(venular) permeability, itching and pain. Stimulation of mast cells and ba-
sophils also releases products of arachidonic acid metabolism including the 
release of slow-reacting substances of anaphylaxis (SRS-As). The SRS-As 
consist of various leukotrienes (LTC4, LTD4 and LTE4). 
ii) 5-Hydroxytryptamine (5-HT or serotonin). It is present in tissues 
like chromaffin cells of GIT, spleen, nervous tissue, mast cells and platelets. 
The actions of 5-HT are similar to histamine but it is a less potent mediator 
of increased vascular permeability and vasodilatation than histamine. 
 
2. Arachidonic acid metabolites. Arachidonic acid is a fatty acid, 
eicosatetraenoic acid, and its 2 main sources are: 
• from diet directly; and 
• conversion of essential fatty acid, linoleic acid to arachidonic acid. 
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Arachidonic acid must be first activated by stimuli or other mediators 
like C5a so as to form arachidonic acid metabolites by one of the following 
2 pathways: via cyclo-oxygenase pathway and via lipo-oxygenase pathway. 
i) Metabolites via cyclo-oxygenase pathway (prostaglandins, throm-
boxane A2, prostacyclin). The name 'prostaglandin' was first given to a sub-
stance found in human seminal fluid but now the same substance has been 
isolated from a number of other body tissues. Prostaglandins and related 
compounds are also called autocoids. 
Cyclo-oxygenase is a fatty acid enzyme which acts on activated ara-
chidonic acid to form prostaglandin endoperoxide (PGG2). PGG2 is enzy-
matically transformed into PGH2 with generation of free radical of oxygen. 
PGH2 is further acted upon by enzymes and results in formation of the fol-
lowing 3 metabolites: 
a) Prostaglandins (PGD2, PGE2 and PGF2-α). PGD2 and PGE2 act 
on blood vessels to cause increased venular permeability, vasodilatation and 
bronchodilatation and inhibit inflammatory cell function. PGF2-α induces 
vasodilatation and bronchoconstriction. 
b) Thromboxane A2 (TXA2). It is a vasoconstrictor and broncho-
constrictor and enhances inflammatory cell function by causing platelet ag-
gregation. 
c) Prostacyclin (PGI2). PGI2 induces vasodilatation, bronchodilata-
tion and inhibits inflammatory cell function by acting as anti-aggregating 
agent for platelets. 
 
ii) Metabolites via lipo-oxygenase pathway (5-HETE, leukotrienes). 
The enzyme, lipo-oxygenase, acts on activated arachidonic acid to form hy-
droperoxy compound, 5-HPETE (hydroperoxy eicosatetraenoic acid) which 
on further peroxidation forms the following 2 metabolites: 
a) 5-HETE (hydroxy compound) which is a potent chemotactic agent 
for neutrophils. 
b) Leukotrienes (LT) or slow-reacting substances of anaphylaxis 
(SRS-As) are so named as they were first isolated from leucocytes. Firstly, 
unstable Leukotriene A4 (LTA4) is formed which is acted upon by enzymes 
to form LTB4 (chemotactic for phagocyte cells and stimulates phagocyte 
cell adherence) while LTC4, LTD4 and LTE4 have common actions by 
causing smooth muscle contraction and thereby induce vasoconstriction, 
bronchoconstriction and increased vascular permeability. 
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3. Lysosomal components. The inflammatory cells – neutrophils and 
monocytes, contain lysosomal granules which on release elaborate a variety 
of mediators of inflammation. These are as under: 
i) Granules of neutrophils. These are of two types: specific or sec-
ondary, and azurophil or primary. The specific granules contain lactoferrin, 
lysozyme, alkaline phosphatase and collagenase while the large azurophil 
granules have myeloperoxidase, acid hydrolases and neutral proteases such 
as elastase, collagenase and proteinase. 
Acid proteases act within the cell to cause destruction of bacteria in 
phagolysosome while neutral proteases attack on the extracellular constitu-
ents such as basement membrane, collagen, elastin, cartilage etc. 
However, degradation of extracellular components like collagen, 
basement membrane, fibrin and cartilage by proteases results in harmful tis-
sue destruction which is kept in check by antiproteases like α1-antitrypsin 
and α2-macroglobulin. 
ii) Granules of monocytes and tissue macrophages. These cells on 
degranulation also release mediators of inflammation like acid proteases, col-
lagenase, elastase and plasminogen activator. However they are more active in 
chronic inflammation than acting as mediators of acute inflammation. 
 
4. Platelet activating factor (PAF). It is released from IgE-sensitised 
basophils or mast cells, other leucocytes, endothelium and platelets. Apart 
from its action on platelet aggregation and release reaction, the actions of 
PAF as mediator of inflammation are: 
• increased vascular permeability; 
• vasodilatation in low concentration and vasoconstriction otherwise; 
• bronchoconstriction; 
• adhesion of leucocytes to endothelium; and 
• chemotaxis. 
 
5. Cytokines. Cytokines are polypeptide substances produced by acti-
vated lymphocytes (lymphokines) and activated monocytes (monokines). 
These agents may act on 'self cells producing them or on other cells. Cur-
rently, main cytokines acting as mediators of inflammation are: interleukin-
1 (IL-1), tumour necrosis factor (TNF) α and β interferon (IF)-γ, and chem-
okines (IL-8, PF-4). 
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IL-1 and TNF-α are formed by activated macrophages while TNF-β 
and IF-γ are produced by activated T cells. The chemokines include inter-
leukin 8 (released from activated macrophages) and platelet factor-4 from 
activated platelets, both of which are potent chemoattractant for inflamma-
tory cells and hence their name. 
The actions of various cytokines as mediator of inflammation are as under: 
i) IL-1 and TNF-α, TNF-β induce endothelial effects in the form of 
increased leucocyte adherence, thrombogenicity, elaboration of other cyto-
kines, fibroblastic proliferation and acute phase reactions. 
ii) IF-γ causes activation of macrophages and neutrophils and is asso-
ciated with synthesis of nitric acid synthase. 
iii) Chemokines are a family of chemoattractants for inflammatory 
cells and include 
• IL-8 chemotactic for neutrophils; 
• platelet factor-4 chemotactic for neutrophils, monocytes and eosin-
ophils; 
• MCP-1 chemotactic for monocytes; and 
• eotaxin chemotactic for eosinophils. 
 
6. Nitric oxide and oxygen metabolites. Nitric oxide (NO) was origi-
nally described as vascular relaxation factor produced by endothelial cells. 
It has recently been included as a mediator of inflammatory responses since 
activated macrophages also produce NO during the oxidation of arginine by 
the action of enzyme, NO synthase. 
NO plays the following role in inflammation: 
• Vasodilatation 
• Anti-platelet activating agent 
• Possibly microbicidal action. Oxygen-derived metabolites are re-
leased from activated neutrophils and macrophages and include superoxide 
oxygen (O'2), H2O2, OH' and toxic NO products. These oxygen-derived 
free radicals have the following action in inflammation: 
• Endothelial cell damage and thereby increased vascular permeability. 
• Activation of protease and inactivation of antiprotease causing tis-
sue matrix damage. 
• Damage to other cells. 
The actions of free radicals are counteracted by antioxidants present 
in tissues and serum which play a protective role. 
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II. Plasma-derived mediators (Plasma proteases) 
These include the various products derived from activation and inter-
action of 4 interlinked systems: kinin, clotting, fibrinolytic and complement. 
Each of these systems has its inhibitors and accelerators in plasma with 
negative and positive feedback mechanisms respectively. 
Hageman factor (factor XII) of clotting system plays a key role in in-
teractions of the four systems. Activation of factor XII in vivo by contact 
with basement membrane and bacterial end toxins, and in vitro with glass or 
kaolin, leads to activation of clotting, fibrinolytic and kinin systems. In in-
flammation, activation of factor XII is brought about by contact of the fac-
tor leaking through the endothelial gaps. The end-products of the activated 
clotting, fibrinolytic and kinin systems activate the complement system that 
generate permeability factors. These permeability factors, in turn, further 
activate clotting system. 
The inter-relationship between 4 systems. 
1. The kinin system. This system on activation by factor Xlla gener-
ates bradykinin, so named because of the slow contraction of smooth mus-
cle it induces. First, kallikrein is formed from plasma prekallikrein by the 
action of prekallikrein activator which is a fragment of factor Xlla. Kal-
likrein then acts on high molecular weight kininogen to form bradykinin. 
Bradykinin acts in the early stage of inflammation and its effects in-
clude: 
• smooth muscle contraction; 
• vasodilatation; 
• increased vascular permeability; and 
• pain. 
2. The clotting system. Factor Xlla initiates the cascade of the clotting 
system resulting in formation of fibrinogen which is acted upon by throm-
bin to form fibrin and fibrinopeptides. 
The actions of fibrinopeptides in inflammation are: 
• increased vascular permeability; 
• chemotaxis for leucocyte; and 
• anticoagulant activity. 
 
3. The fibrinolytic system. This system is activated by plasminogen 
activator, the sources of which include kallikrein of the kinin system, endo-
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thelial cells and leucocytes. Plasminogen activator acts on plasminogen pre-
sent as component of plasma proteins to form plasmin. Further breakdown 
of fibrin by plasmin forms fibrinopeptides or fibrin split products. 
The actions of plasmin in inflammation are: 
• activation of factor XII to form prekallikrein activator that stimu-
lates the kinin system to generate bradykinin; 
• splits off complement C3 to form C3a which is a permeability fac-
tor; and 
• degrades fibrin to form fibrin split products which increase vascular 
permeability and are chemotactic to leucocytes. 
 
4. The complement system. The activation of complement system can 
occur either: 
i) by classic pathway through antigen-antibody complexes; or 
ii) by alternate pathway via non-immunologic agents such as bacteri-
al toxins, cobra venoms and IgA. 
Complement system on activation by either of these two pathways 
yields anaphylatoxins C3a, C4a and C5a, and membrane attack complex 
(MAC). The relative potencies of anaphylatoxins are in the descending se-
quence of C3a, C5a and C4a. 
The actions of anaphylatoxins in inflammation are: 
• release of histamine from mast cells and basophils; 
• increased vascular permeability causing oedema in tissues; 
• C3b augments phagocytosis; and 
• C5a is chemotactic for leucocytes. 
The action of MAC is to cause pores in the cell membrane of the in-
vading microorganisms. 
Regulation of inflammation. The onset of inflammatory responses 
outlined above may have potentially damaging influence on the host tissues 
as evident in hypersensitivity conditions. Such self-damaging effects are 
kept in check by the host mechanisms so as to resolve inflammation. These 
include the following mechanisms: 
i) Acute phase proteins. A variety of acute phase proteins (APP) are 
released in plasma in response to tissue trauma and infection. These in-
clude: α1-anti-trypsin, α1-acid glycoprotein, protease inhibitor, haptoglobin, 
C-reactive protein, serum amyloid A and P component etc. The APP are 
synthesised in the liver and their release occurs in response to circulating 
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cytokines produced during inflammation. APP combined with systemic fea-
tures of fever and leucocytosis is termed 'acute phase response'. Deficient 
synthesis of APP leads to severe form of disease in chronic and repeated in-
flammatory responses. 
ii) Corticosteroids. The endogenous glucocorticoids act as anti-
inflammatory agents. Their levels are raised in infection and trauma by self-
regulating mechanism. 
iii) Free cytokine receptors. The presence of free receptors for cyto-
kines in the serum correlates directly with disease activity. 
iv) Suppressor T cells. A prohibition of suppressor T cells is seen 
which inhibits the function of T and B cells. 
v) Anti-inflammatory chemical mediators. As already described, 
PGE2 and prostacyclin have both pro-inflammatory as well as anti-
inflammatory actions. 
 
Inflammatory cells. The cells participating in acute and chronic in-
flammation are circulating leucocytes, plasma cells and tissue macrophages.  
1. Polymorphonuclear neutrophils (PMN). Commonly called as neu-
trophils or polymorphs, these cells along with basophils and eosinophils are 
known as granulocytes due to the presence of granules in the cytoplasm. 
These granules contain many substances like proteases, myeloperoxidase, 
lysozyme, esterase, arylsulfatase, acid and alkaline phosphatase, and cation-
ic proteins. The diameter of neutrophils ranges from 10 to 15 mm and are 
actively motile. These cells comprise 40-75% of circulating leucocytes and 
their number is increased in blood (neutrophilia) and tissues in acute bacte-
rial infections. These cells arise in the bone marrow from stem cells. 
The functions of neutrophils in inflammation are as follows: 
i) Initial phagocytosis of microorganisms as they form the first line of 
body defense in bacterial infection. The steps involved are adhesion of neu-
trophils to vascular endothelium, emigration through the vessel wall, chem-
otaxis, engulfment, degranulation, killing and degradation of the foreign 
material. 
ii) Engulfment of antigen-antibody complexes and non-microbial ma-
terial. 
iii) Harmful effect of neutrophils is destruction of the basement 
membranes of glomeruli and small blood vessels. 
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2. Eosinophils. These are larger than neutrophils but are fewer in 
number, comprising 1 to 6% of total blood leucocytes. Eosinophils share 
many structural and functional similarities with neutrophils like their pro-
duction in the bone marrow, locomotion, phagocytosis, lobed nucleus and 
presence of granules in the cytoplasm containing a variety of enzymes, of 
which major basic protein and eosinophil cationic protein are the most im-
portant which have bactericidal and toxic action against helminthic para-
sites. However, granules of eosinophils are richer in myeloperoxidase than 
neutrophils and lack lysozyme. High level of steroid hormones leads to fall 
in number of eosinophils and even disappearance from blood. 
The absolute number of eosinophils is increased in the following 
conditions and, thus, they partake in inflammatory responses associated 
with these conditions: 
i) allergic conditions;  
ii) parasitic infestations;  
iii) skin diseases; and  
iv) certain malignant lymphomas. 
 
3. Basophils (Mast Cells). The basophils comprise about 1% of circu-
lating leucocytes and are morphologically and pharmacologically similar to 
mast cells of tissue. These cells contain coarse basophilic granules in the 
cytoplasm and a polymorphonuclear nucleus. These granules are laden with 
heparin and histamine. Basophils and mast cells have receptors for IgE and 
degranulate when cross-linked with antigen. 
The role of these cells in inflammation is: 
i) in immediate and delayed type of hypersensitivity reactions; and 
ii) release of histamine by IgE-sensitised basophils. 
 
4. Lymphocytes. Next to neutrophils, these cells are most numerous 
of the circulating leucocytes (20-45%). Apart from blood, lymphocytes are 
present in large numbers in spleen, thymus, lymph nodes and mucosa-
associated lymphoid tissue (MALT). They have scanty cytoplasm and con-
sist almost entirely of nucleus. 
Besides their role in antibody formation (B lymphocytes) and in cell-
mediated immunity (T lymphocytes), these cells participate in the following 
types of inflammatory responses: 
i) In tissues, they are dominant cells in chronic inflammation and late 
stage of acute inflammation. 
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ii) In blood, their number is increased (lymphocytosis) in chronic in-
fections like tuberculosis. 
 
5. Plasma Cells. These cells are larger than lymphocytes with more 
abundant cytoplasm and an eccentric nucleus which has cart-wheel pattern 
of chromatin. Plasma cells are normally not seen in peripheral blood. They 
develop from lymphocytes and are rich in RNA and y-globulin in their cy-
toplasm. There is interrelationship between plasmacytosis and hyper-
globulinaemia. These cells are most active in antibody synthesis. 
Their number is increased in: 
i) prolonged infection with immunological responses e.g. in syphilis, 
rheumatoid arthritis, tuberculosis; 
ii) hypersensitivity states; and 
iii) multiple myeloma. 
 
6. Mononuclear-phagocyte system (Reticuloendothelial system). This 
cell system includes cells derived from 2 sources with common morpholo-
gy, function and origin. These are as under: 
i) Blood monocytes. These comprise 4-8% of circulating leucocytes. 
ii) Tissue macrophages. These include the following cells in different 
tissues: 
a) Macrophages in inflammation, 
b) Histiocytes which are macrophages present in connective tissues, 
c) Kupffer cells which are macrophages of liver, 
d) Alveolar macrophages present in lungs, 
e) Free and fixed macrophages and sinusoidal lining cells of 
spleen, lymph node and bone marrow, 
f) Macrophages of serous cavities, 
g) Microglial cells of nervous system, 
i) Langerhans' cells of skin, 
j) Dendritic cells found in lymphoid tissue. 
The mononuclear phagocytes are the scavenger cells of the body as 
well as participate in immune system of the body.  
 
Role of macrophages in inflammation. The functions of mononucle-
ar-phagocyte cells are as under: 
i) Phagocytosis (cell eating) and pinocytosis (cell drinking). 
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ii) Macrophages on activation by lymphokines released by T lym-
phocytes or by non-immunologic stimuli elaborate a variety of biologically 
active substances such as: 
a) Proteases like collagenase and elastase which degrade collagen 
and elastic tissue. 
b) Plasminogen activator which activates the fibrinolytic system. 
c) Products of complement. 
d) Some coagulation factors (factor V and thromboplastin) which 
convert fibrinogen to fibrin. 
e) Chemotactic agents for other leucocytes. 
f) Metabolites of arachidonic acid. 
g) Growth promoting factors for fibroblasts, blood vessels and 
granulocytes. 
h) Cytokines like interleukin-1 and tumour necrosis factor, 
i) Oxygen-derived free radicals. 
 
7. Giant Cells. When the macrophages fail to deal with particles to be 
removed, they fuse together and form multinucleated giant cells. Various 
types of giant cells seen in inflammation and in certain tumours are de-
scribed below: 
i) Foreign body giant cells. These contain numerous nuclei (up to 
100) which are uniform in size and shape and resemble the nuclei of macro-
phages. These nuclei are scattered throughout the cytoplasm. 
These are seen in chronic infective granulomas, leprosy and tuberculosis. 
ii) Langhans' giant cells. These are seen in tuberculosis and sarcoido-
sis. Their nuclei are like the nuclei of macrophages and epithelioid cells. 
These nuclei are arranged either around the periphery in the form of horse-
shoe or ring, or are clustered at the two poles of the giant cell. 
iii) Teuton giant cells. These multinucleated cells have vacuolated cy-
toplasm due to lipid content e.g. in xanthoma. 
iv) Tumour giant cells. These are larger, have numerous nuclei which 
are hyperchromatic and vary in size and shape. These giant cells are not de-
rived from macrophages but are formed from dividing nuclei of the neo-
plastic cells e.g. carcinoma of liver, various soft tissue sarcomas etc. 
v) Miscellaneous types. These include presence of numerous nuclei 
in mesodermal cells e.g. Aschoff cells of rheumatic nodule, Reed-Sternberg 
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cells of Hodgkin's disease, osteoclasts. These are described later in respec-
tive chapters to which they pertain. 
Factors determining variation in inflammatory response. Alt-
hough acute inflammation is typically characterised by vascular and cellular 
events with emigration of neutrophilic leucocytes, not all examples of acute 
inflammation show infiltration by neutrophils, and vice versa some chronic 
inflammatory conditions are characterised by neutrophilic infiltration. For ex-
ample, typhoid fever is an example of acute inflammatory process but the cel-
lular response in it is lymphocytic; osteomyelitis is an example of chronic in-
flammation but the cellular response in this condition is mainly neutrophilic. 
The morphologic variation in inflammation depends upon a number 
of factors and processes. These are discussed below: 
1. Factors involving the organisms: 
i) Type of injury and infection. For example, skin reacts to herpes sim-
plex infection by formation of vesicle and to streptococcal infection by for-
mation of boil; lung reacts to pneumococci by occurrence of lobar pneumo-
nia while to tubercle bacilli it reacts by glaucomatous inflammation. 
ii) Virulence. Many species and strains of organisms may have vary-
ing virulence e.g. the three strains of C. diphtheriae (gravis, intercedes and 
mites) produce the same diphtheria serotoxin but in different amount. 
iii) Dose. The concentration of organism in small doses produces 
usually local lesions while larger dose results in more severe spreading in-
fections. 
iv) Portal of entry. Some organisms are infective only if administered 
by particular route e.g. Vibrio cholerae is not pathogenic if injected subcu-
taneously but causes cholera if swallowed. 
v) Product of organisms. Some organisms produce enzymes that help 
in spread of infections e.g. hyaluronidase by Cl. welchii, streptokinase by 
Streptococci, staphylokinase and coagulase by Staphylococci. 
 
2. Factors involving the host: 
i) General health of host. For example, starvation, haemorrhagic 
shock, chronic debilitating diseases like diabetes mellitus, alcoholism etc 
render the host more susceptible to infections. 
ii) Immune state of host. Immunodeficiency helps in spread of infec-
tions rapidly e.g. in AIDS. 
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iii) Leukopenia. Patients with low WBC count with neutropenia or 
agranulocytosis develop spreading infection. 
iv) Site or type of tissue involved. For example, the lung has loose 
texture as compared to bone and, thus, both tissues react differently to acute 
inflammation. 
v) Local host factors. For instance, ischaemia, presence of foreign 
bodies and chemicals cause necrosis and are thus harmful. 
 
3. Type of exudation: 
The appearance of escaped plasma determines the morphologic type 
of inflammation. These are: 
i) Catarrhal, when the surface inflammation of epithelium produces 
increased secretion of mucus e.g. common cold. Thus it develops only in 
the mucous membranes. 
ii) Serous, when the fluid exudate resembles serum or is watery e.g. 
pleural effusion in tuberculosis, blister formation in burns. 
iii) Fibrinous, when 
the fibrin content of the 
fluid exudate is high e.g. in 
pneumococcal and rheu-
matic pericarditis. Depend-
ing on the type of epitheli-
um (monolayer or multi-
layer) and depth of necro-
sis two forms of fibrinous 
inflammation are dis-
cussed: croupous, or sim-
ple, and diphtheritic. 
iv) Purulent, or 
suppurative exudate is 
formation of creamy pus 
as seen in infection with pyogenic bacteria e.g. abscess, acute appendicitis. 
There are several types of purulent inflammation: 
Fig. 21. Fibrinous pericarditis. H and E stained sec-
tion, x 200. 
1 – deposition of fibrin, 2- inflammatory infiltra-





Abscess is a localized collection of pus in a tissue or organ. Abscess 
is bounded purulent inflamma-
tion in which a cavity with pus 
is formed. 
The bacteria which 
cause suppuration are called 
pyogenic. Pus is creamy or 
opaque in appearance and is 
composed of numerous dead as 
well as living neutrophils, some 
red cells, fragments of tissue 
debris and fibrin. In old pus, 
macrophages and cholesterol 
crystals are also present. The 
wall of abscess is called pyo-
genic membrane. An abscess 
may be discharged to the surface due to increased pressure inside or may 
require drainage by the surgeon. Due to tissue destruction, resolution does 
not occur but instead healing by fibrous scarring takes place. 
Phlegmon is unbounded purulent inflammation in which pus spreads 
diffusely between different components of tissue owing to fusion and tissue 
Рис. 22. Purulent meningitis. H and E stained sec-
tion, x 200. 
1 - inflammatory infiltration and hyperermia of menin-
geal coat. 
1 
Fig. 23. Abscess in the myocardium. H and E 
stained section, x 200. 
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lysis. Phlegmon frequently occurs along the muscular bands, tendons, fas-
cias, vascular-nerves bands and in subcutaneous fat. Two types of phleg-
mon have been described: soft and dense. 
If purulent exudate appears in the human cavities it is called empy-
ema. 
Furuncle is an acute inflammation via hair follicles in the dermal 
tissues. 
Carbuncle is seen in untreated diabetics and occurs as a located ab-
scess in the dermis and soft tissues of the neck. 
 
v) Haemorrhagic, when there is a vascular damage e.g. acute haemor-
rhagic pneumonia in influenza. 
vi) Putrefactive, when inflammatory reaction results from action of 
putrefactive bacteria. 
vii) Mixed, when exudete contains different components. 
 
4. Cellular proliferation 
Variable cellular proliferation is seen in different types of inflammations. 
i) There is no significant cellular proliferation in acute bacterial infec-
tions except in typhoid fever in which there is intestinal lymphoid hyper-
plasia.  
Рис. 24. acute haemorrhagic inflammation of menin-
geal coat in influenza. H and E stained section, x 200. 
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ii) Viral infections have the ability to stimulate cellular proliferation e.g. 
epidermal cell proliferation in herpes simplex, chickenpox and smallpox. 
iii) In rapidly progressive glomerulonephritis, there is proliferation of 
glomerular capsular epithelial cells resulting in formation of 'crescents'. 
iv) In chronic inflammation, cellular proliferation of macrophages, 
fibroblasts and endothelial cells occurs. 
5. Necrosis 
The extent and type of necrosis in inflammation is variable. 
i) In gas gangrene, there is extensive necrosis with discoloured and 
foul smelling tissues. 
ii) In acute appendicitis, there is necrosis as a result of vascular ob-
struction. 
iii) In chronic inflammation such as tuberculosis, there is characteris-
tic caseous necrosis. 
Morphology of acute inflammation. Inflammation of an organ is 
usually named by adding the suffix “itis” to its Latin name e.g. appendici-
tis, hepatitis, cholecystitis, meningitis etc. A few morphologic varieties of 
acute inflammation are described below: 
1. Pseudomembranous inflammation. It is inflammatory response of 
mucous surface (oral, respiratory, bowel) to toxins of diphtheria or irritant 
gases. As a result of denudation of epithelium, plasma exudes on the surface 
where it coagulates, and together with necrosed epithelium, forms false 
membrane that gives this type of inflammation its name. 
2. Ulcer. Ulcers are local defects on the surface of an organ produced 
by inflammation. Common sites for ulcerations are the stomach, duodenum, 
intestinal ulcers in typhoid fever, intestinal tuberculosis, bacillary and 
amoebic dysentery, ulcers of legs due to varicose veins etc. In the acute 
stage, there is infiltration by polymorphs with vasodilatation while long-
standing ulcers develop infiltration by lymphocytes, plasma cells and mac-
rophages with associated fibroblastic proliferation and scarring. 
3. Suppuration (abscess formation). When acute bacterial infection is 
accompanied by intense neutrophilic infiltrate in the inflamed tissue, it re-
sults in tissue necrosis. A cavity is formed which is called an abscess and 
contains purulent exudate or pus and the process of abscess formation is 
known as suppuration. The bacteria which cause suppuration are called py-
ogenic. 
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Microscopically, pus is creamy or opaque in appearance and is com-
posed of numerous dead as well as living neutrophils, some red cells, frag-
ments of tissue debris and fibrin. 
An abscess may be discharged to the surface due to increased pres-
sure inside or may require drainage by the surgeon. Due to tissue destruction, 
resolution does not occur but instead healing by fibrous scarring takes place. 
Some of the common examples of abscess formation are as under: 
i) Boil or furruncle which is an acute inflammation via hair follicles 
in the dermal tissues. 
ii) Carbuncle is seen in untreated diabetics and occurs as a loculated 
abscess in the dermis and soft tissues of the neck. 
4. Cellulitis. It is a diffuse inflammation of soft tissues resulting from 
spreading effects of substances like hyaluronidase released by some bacteria. 
5. Bacterial infection of the blood. This includes the following 3 con-
ditions: 
i) Bacteraemia is defined as presence of small number of bacteria in 
the blood which do not multiply significantly. They are commonly not de-
tected by direct microscopy. Blood culture is done for their detection e.g. 
infection with Salmonella typhi, Escherichia coli, Streptococcus viridans. 
Рис. 25. Changes of the gut wall at necrotic stage. H and E stained section, x 200, 
х100. 









ii) Septicaemia means presence of rapidly multiplying, highly patho-
genic bacteria in the blood e.g. pyogenic cocci, bacilli of plague etc. Septi-
caemia is generally accompanied by systemic effects like toxaemia, multi-
ple small haemorrhages, neutrophilic leucocytosis and disseminated intra-
vascular coagulation (DIC). 
iii) Pyaemia is the dissemination of small septic thrombi in the blood 
which cause their effects at the site where they are lodged. This can result in 
pyaemic abscesses or septic infarcts. 
a) Pyaemic abscesses are multiple small abscesses in various or-
gans such as in cerebral cortex, myocardium, lungs and renal cortex, result-
ing from very small emboli fragmented from septic thrombus. Microscopy 
of pyaemic abscess shows a central zone of necrosis containing numerous 
bacteria, surrounded by a zone of suppuration and an outer zone of acute 
inflammatory cells. 
b) Septic infarcts result from lodgement of larger fragments of septic 
thrombi in the arteries with relatively larger foci of necrosis, suppuration and 
acute inflammation e.g. septic infarcts of the lungs, liver, brain, and kidneys 
from septic thrombi of leg veins or from acute bacterial endocarditis. 
 
Systemic effects of acute inflammation. The account of acute in-
flammation given up to now above is based on local tissue responses. How-
ever, acute inflammation is associated with systemic effects as well. These 
include fever, leucocytosis and lymphangitis-lymphadenitis. 
1. Fever occurs due to bacteraemia. It is thought to be mediated 
through release of factors like prostaglandins, interleukin-1 and tumour ne-
crosis factor in response to infection. 
2. Leucocytosis commonly accompanies the acute inflammatory reac-
tions, usually of the range of 15,000-20,000/μl. When the counts are higher 
than this with 'shift to left' of myeloid cells, the blood picture is described as 
leukaemoid reaction. Usually, in bacterial infections there is neutrophilia; in 
viral infections lymphocytosis; and in parasitic infestations, eosinophilia. 
Typhoid fever, an example of acute inflammation, however, induces leuco-
penia with relative lymphocytosis. 
3. Lymphangitis-lymphadenitis is one of the important manifestations 
of localised inflammatory injury. The lymphatics and lymph nodes that drain 
the inflamed tissue show reactive inflammatory changes in the form of lym-
phangitis and lymphadenitis. This response represents either a nonspecific 
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reaction to mediators released from inflamed tissue or is an immunologic re-
sponse to a foreign antigen. The affected lymph nodes may show hyperplasia 
of lymphoid follicles (follicular hyperplasia) and proliferation of mononucle-
ar phagocytic cells in the sinuses of lymph node (sinus histiocytosis). 
4. Shock may occur in severe cases. Massive release of cytokine 
TNF-α, a mediator of inflammation, in response to severe tissue injury or 
infection results in profuse systemic vasodilatation, increased vascular per-
meability and intravascular volume loss. The net effect of these changes is 
hypotension and shock. Systemic activation of coagulation pathway may 
occur leading to microthrombi throughout the body and result in dissemi-
nated intravascular coagulation (DIC), bleeding and death. 
Fate of acute inflammation. The acute inflammatory process can 
culminate in one of the following 4 outcomes: 
1. Resolution, 
2. Healing by scarring, 
3. Progression to suppuration, 
4. Progression to chronic inflammation. 
1. Resolution. It means complete return to normal tissue following 
acute inflammation. This occurs when tissue changes are slight and the cel-
lular changes are reversible e.g. resolution in lobar pneumonia. 
2. Healing by scarring. This takes place when the tissue destruction 
in acute inflammation is extensive so that there is no tissue regeneration but 
actually there is healing by fibrosis. 
3. Suppuration. When the pyogenic bacteria causing acute inflamma-
tion result in severe tissue necrosis, the process progresses to suppuration. 
Initially, there is intense neutrophilic infiltration. Subsequently, mixture of 
neutrophils, bacteria, fragments of necrotic tissue, cell debris and fibrin 
comprise pus which is contained in a cavity to form an abscess. The ab-
scess, if not drained, may get organised by dense fibrous tissue, and in time, 
get calcified. 
4. Chronic inflammation. The acute inflammation may progress to 
chronic inflammation in which the processes of inflammation and healing 
proceed side by side. 
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CHRONIC (PRODUCTIVE, PROLIFERATIVE) INFLAMMATION 
Chronic inflammation is defined as prolonged process in which tissue 
destruction and inflammation occur at the same time. Chronic inflammation 
can be caused by one of the following 3 ways: 
1. Chronic inflammation following acute inflammation. When the tis-
sue destruction is extensive, or the bacteria survive and persist in small 
numbers at the site of acute inflammation e.g. in osteomyelitis, pneumonia 
terminating in lung abscess. 
2. Recurrent attacks of acute inflammation. When repeated bouts of 
acute inflammation culminate in chronicity of the process e.g. in recurrent 
urinary tract infection leading to chronic pyelonephritis, repeated acute in-
fection of gall bladder leading to chronic cholecystitis. 
3. Chronic inflammation starting de novo. When the infection with 
organisms of low pathogenicity is chronic from the beginning e.g. infection 
with Mycobacterium tuberculosis. 
There are three types of productive inflammation: 
1) Interstitial; 
2) Granulomatous; 
3) Inflammation with the formation of polyps and pointed condylomas. 
General features of chronic inflammation. Though there may be 
differences in chronic inflammatory response depending upon the tissue in-
volved and causative organisms, there are some basic similarities amongst 
various types of chronic inflammation. These general features characterise 
any chronic inflammation. 
1. Mononuclear cell infiltration. Chronic inflammatory lesions are in-
filtrated by mononuclear inflammatory cells like phagocytes and lymphoid 
cells. Phagocytes are represented by circulating monocytes, tissue macro-
phages, epithelioid cells and sometimes, multinucleated giant cells. The 
macrophages comprise the most important cells in chronic inflammation. 
These may appear at the site of chronic inflammation from:  
i) chemotactic factors for macrophages as already described; 
ii) local proliferation of macrophages; and  
iii) longer survival of macrophages at the site of inflammation. 
The blood monocytes on reaching the extravascular space transform 
into tissue macrophages. Besides the role of macrophages in phagocytosis, 
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they may get activated in response to stimuli such as cytokines (lym-
phokines) and bacterial endotoxins. On activation, macrophages release 
several biologically active substances e.g. acid and neutral proteases, oxy-
gen-derived reactive metabolites and cytokines. These products bring about 
tissue destruction, neovascularisation and fibrosis. 
Other chronic inflammatory cells include lymphocytes, plasma cells, 
eosinophils and mast cells. In chronic inflammation, lymphocytes and mac-
rophages influence each other and release mediators of inflammation. 
2. Tissue destruction or necrosis. Tissue destruction and necrosis are 
common in many chronic inflammatory lesions and are brought about by acti-
vated macrophages by release of a variety of biologically active substances. 
3. Proliferative changes. As a result of necrosis, proliferation of 
small blood vessels and fibroblasts is stimulated resulting in formation of 
inflammatory granulation tissue. Eventually, healing by fibrosis and colla-
gen laying takes place. 
Types of chronic inflammation. Conventionally, chronic inflamma-
tion is subdivided into 2 types: 
1. Nonspecific, when the irritant substance produces a non-specific 
chronic inflammatory reaction with formation of granulation tissue and 
healing by fibrosis e.g. chronic osteomyelitis, chronic ulcer. 
2. Specific, when the injurious agent causes a characteristic histologi-
cal tissue response e.g. tuberculosis, leprosy, syphilis. 
However, for a more descriptive classification, histological features 
are used for classifying chronic inflammation into 2 corresponding types: 
1. Chronic nonspecific interstitial inflammation. It is characterised by 
nonspecific inflammatory cell infiltration e.g. chronic osteomyelitis, lung 
abscess. A variant of this type of chronic inflammatory response is chronic 
suppurative inflammation in which infiltration by polymorphs and abscess 
formation are additional features e.g. actinomycosis. The inflammatory cell 
infiltration consists of lymphocytes, monocytes, plasmocytes, eosinophils 
and other cells. 
2. Chronic granulomatous inflammation. It is characterised by for-




Granuloma is defined as a circumscribed, tiny lesion, about 1 mm in 
diameter, composed predominantly of collection of modified macrophages 
called epithelioid cells, and rimmed at the periphery by lymphoid cells. The 
word 'granuloma' is derived from granule meaning circumscribed granule-
like lesion, and -oma which is a suffix commonly used for true tumours but 
here indicates inflammatory mass or collection of macrophages. Epithelioid 
cells, so called because of their epithelial cell-like appearance, are modified 
macrophages which are somewhat elongated, having pale-staining abundant 
cytoplasm, lightly-staining slipper-shaped nucleus and the cell membrane of 
adjacent epithelioid cells is closely apposed. Epithelioid cells are weakly 
phagocytic. 
Besides the presence of epithelioid cells and lymphoid cells, granu-
lomas may have giant cells, necrosis and fibrosis: 
1. The giant cells are formed by fusion of adjacent epithelioid cells 
and may have 20 or more nuclei. These nuclei may be arranged at the pe-
riphery like horseshoe or ring or clustered at the two poles (Langhans' giant 
cells), or they may be present centrally (foreign body giant cells). The for-
mer are commonly seen in tuberculosis while the latter are common in for-
eign body tissue reactions. Like epithelioid cells these giant cells are weakly 
phagocytic but produce secretory products which help in removing the in-
vading agents. 
2. Necrosis may be a feature of some granulomatous conditions e.g. 
central caseation necrosis of tuberculosis, so called because of cheese-like 
appearance and consistency of necrosis. 
3. Fibrosis is due to proliferation of fibroblasts at the periphery of 
granuloma. 
The following two factors favour the formation of granulomas: 
i) Presence of poorly digestible irritant which may be organisms like 
Mycobacterium tuberculosis, particles of talc etc. 
ii) Presence of cell-mediated immunity to the irritant, implying there-
by the role of hypersensitivity in granulomatous inflammation. 
 A fully-developed tubercle is about 1 mm in diameter with central area 
of caseation necrosis, surrounded by epithelioid cells and one to several multi-
nucleated giant cells (commonly Langhans' type), surrounded at the periphery 
by lymphocytes and bounded by fibroblasts and fibrous tissue. 
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Granulomatous inflammation is typical of reaction to poorly digesti-
ble agents elicited by tuberculosis, leprosy, fungal infections, schistosomia-
sis, foreign particles etc.  
 
TUBERCULOSIS 
Tissue response in tuberculo-
sis represents classical example of 
chronic granulomatous inflammation 
in humans. 
Causative organism: Tuber-
cle bacillus or Koch's bacillus 
(named after discovery of the organ-
ism by Robert Koch in 1882) called 
Mycobacterium tuberculosis causes 
tuberculosis in the lungs and other 
tissues of the human body. The or-
ganism is a strict aerobe and thrives 
best in tissues with high oxygen ten-
sion like in the apex of the lung. 
The organism has 5 distinct 
pathogenic strains: hominis, bovis, 
avium, murine, and cold-blooded vertebrate strain. A sixth non-pathogenic 
strains, M. smegmatis, is found in the smegma and as contaminant in the 
urine of both men and women. Out of these, the first two strains (hominis 
and bovis) are definitely infective to human beings while infection with 
avium strain (M. avium intracellulare) is common in patients with AIDS. 
Hypersensitivity or allergy, and immunity or resistance, play a major 
role in the development of lesions in tuberculosis. Tubercle bacilli as such 
do not produce any toxins. Tissue changes seen in tuberculosis are not the 
result of any exotoxin or endotoxin but are instead the result of host re-
sponse to the organism which is in the form of development of cell-
mediated hypersensitivity (or type IV hypersensitivity) and immunity. 
Evolution of tubercle: The sequence of events which take place 
when tubercle bacilli are introduced into the tissue. These are as under: 
Рис. 26. Tuberculosis of  lungs. 
1 – large tuberculosis cavity. 
1 
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1. When the tubercle bacilli are injected intravenously into the guinea 
pig, the bacilli are lodged in pulmonary capillaries where an initial response 
of neutrophils is evoked which are rapidly destroyed by the organisms. 
2. After about 12 hours, there is progressive infiltration by macro-
phages which dominate the picture throughout the remaining life of the le-
sions. If the tubercle bacilli are, however, inhaled into the lung alveoli, mac-
rophages predominate the picture from the beginning. 
3. The macrophages 
start phagocytosing the tu-
bercle bacilli. In 2-3 days, 
the macrophages undergo 
structural changes as a re-
sult of immune mecha-
nisms – the cytoplasm be-
comes pale and eosino-
philic and their nuclei be-
come elongated and vesic-
ular. These modified mac-
rophages resemble epithe-
lial cells and are called ep-
ithelioid cells. 
4. The macrophages 
continue to enter the tissue 
either from circulating monocytes or from local proliferation and undergo 
changes to form more epithelioid cells. The epithelioid cells in time aggre-
gate into tight clusters or granulomas. 
Release of cytokines in response to sensitised CD 4 + T cells and 
some constituents of mycobacterial cell wall play a role in formation of 
granuloma. 
5. Some of the macrophages form multinucleated giant cells by fu-
sion of adjacent cells. The giant cells may be Langhans' type having periph-
erally arranged nuclei in the form of horseshoe or ring, or clustered at the 
two poles of the giant cell; or they may be foreign body type having central-
ly-placed nuclei. 
6. Around the mass of epithelioid cells and giant cells is a zone of 
lymphocytes, plasma cells and fibroblasts. The lesion at this stage is called 
hard tubercle due to absence of central necrosis. 
Рис. 27. Tuberculosis of thyroid gland. H and E 
stained section, x 200. 






7. Within 10 -14 days, the centre of the cellular mass begins to un-
dergo caseation necrosis, characterised by cheesy appearance and high lipid 
content. This stage is called soft tubercle which is the hallmark of tubercu-
lous lesions. The development of caseation necrosis is possibly due to inter-
action of mycobacteria with activated T cells (CD 4 + helper T cells via IF-
y and CD 8 + suppressor T cells directly) as well as by direct toxicity of 
mycobacteria on macrophages. Microscopically, caseation necrosis is struc-
tureless, eosinophilic and granular material with nuclear debris. 
8. The soft tubercle which is a fully-developed granuloma with case-
ous centre does not favour rapid proliferation of tubercle bacilli. Acid fast 
bacilli are difficult to find in these lesions and may be demonstrated at the 
margins of recent necrotic foci and in the walls of the cavities. 
The fate of a granuloma is variable:  
i) The caseous material may undergo liquefaction and extend into 
surrounding soft tissues, discharging the contents on the surface. This is 
called cold abscess although there are no pus cells in it.  
ii) In tuberculosis of tissues like bones, joints, lymph nodes and epi-
didymis, sinuses are formed and the sinus tracts are lined by tuberculous 
granulation tissue,  
iii) The adjacent granulomas may coalesce together enlarging the le-
sion which is surrounded by progressive fibrosis. 
iv) In the granuloma enclosed by fibrous tissue, calcium salts may get 
deposited in the caseous material (dystrophic calcification) and sometimes 
the lesion may even get ossified over the years. 
LEPROSY 
Leprosy or Hansen's disease (after discovery of the causative organ-
ism by Hansen in 1874) is a chronic infectious disease affecting mainly the 
cooler parts of the body such as the skin, mouth, respiratory tract, eyes, periph-
eral nerves, superficial lymph nodes and testis. Though the earliest and main 
involvement in leprosy is of the skin and nerves but in bacteraemia from endo-
thelial colonisation or by bacilli filtered from blood by reticuloendothelial sys-
tem, other organs such as the liver, spleen, bone marrow and regional lymph 
nodes are also involved. Advanced cases may develop secondary amyloidosis 
and renal disease, both of which are of immunologic origin. 
Causative organism. The disease is caused by Mycobacterium 
leprae which closely resembles Mycobacterium tuberculosis but is less acid-
 144 
fast. The organisms in tissues appear as compact rounded masses (globi) or 
are arranged in parallel fashion like cigarettes-in-pack. 
Incidence. The disease is endemic in areas with hot and moist cli-
mates and in poor tropical countries. According to the WHO, five countries 
– India, Brazil, Indonesia, Mayanmar (Burma) and Nigeria, together consti-
tute vast majority of leprosy cases, of which India accounts for about one-
third of all registered leprosy cases globally. In India, the disease is seen 
more commonly in regions like Tamil Nadu, Bihar, Pondicherry, Andhra 
Pradesh, Orissa, West Bengal and Assam. Very few cases are now seen in 
Europe and the United States. 
Mode of transmission. Leprosy is a slow communicable disease and 
the incubation period between first exposure and appearance of signs of dis-
ease varies from 2 to 20 years (average about 3 years). The infectivity may 
be from the following sources: 
1. Direct contact with untreated leprosy patients who shed numerous 
bacilli from damaged skin, nasal secretions, mucous membrane of mouth 
and hair follicles. 
2. Materno-foetal transmission across the placenta. 
3. Transmission from milk of leprosy patient to infant. 
Classification. Leprosy is broadly classified into 2 main types: 
• Lepromatous type representing low resistance; and 
• Tuberculoid type representing high resistance. 
 There may be two types of lepra reaction: type I (borderline reac-
tions), and type II (erythema nodosum leprosum). 
Type I: Borderline reactions. The polar forms of leprosy do not un-
dergo any change in clinical and histopathological picture. The borderline 
groups are unstable and may move across the spectrum in either direction 
with upgrading or downgrading of patient's immune state. Accordingly, 
there may be two types of borderline reaction: 
1. Upgrading reaction is characterised by increased cell-mediated 
immunity and occurs in patients of borderline lepromatous (BL) type on 
treatment who upgrade or shift towards tuberculoid type. 
Histologically, the upgrading reaction shows an increase of lympho-
cytes, oedema of the lesions and reduced B.I. 
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2. Downgrading reaction is characterised by lowering of cellular im-
munity and is seen in borderline tuberculoid (BT) type who downgrade or 
shift towards lepromatous type. 
Histologically, the lesions show dispersal and spread of the granulo-
mas and increased presence of lepra bacilli. 
Type II: Erythema nodosum leprosum (ENL). ENL occurs in lep-
romatous patients after treatment. It is characterised by tender cutaneous 
nodules, fever, iridocyclitis, synovitis and lymph node involvement. 
Histologically, the lesions in ENL show infiltration by neutrophils 
and prominence of vasculitis. Secondary amyloidosis may follow repeated 
attacks of ENL in leprosy. 
Histopathology of Leprosy. Usually, skin biopsy from the margin of 
lesions is submitted for diagnosis and for classification of leprosy. The his-
topathologic diagnosis of multibacillary leprosy like LL and BL offers no 
problem while the indeterminate leprosy and tuberculoid lesions are pauci-
bacillary and their diagnosis is made together with clinical evidence. 
In general, for histopathologic evaluation in all suspected cases of 
leprosy the following broad guidelines should be followed: 
• cell type of granuloma; 
• nerve involvement; and 
• bacterial load. 
The main features in various groups are given below. 
1. Lepromatous leprosy: 
The following features characterise lepromatous polar leprosy: 
i) In the dermis, there is proliferation of macrophages with foamy 
change, particularly around the blood vessels, nerves and dermal appendag-
es. The foamy macrophages are called 'lepra cells' or Virchow cells. 
ii) The lepra cells are heavily laden with acid-fast bacilli demonstrat-
ed with AFB staining. The AFB may be seen as compact globular masses 
(globi) or arranged in parallel fashion like 'cigarettes in a pack'. 
iii) The dermal infiltrate of lepra cells characteristically does not en-
croach upon the basal layer of epidermis and is separated from epidermis by 
a subepidermal uninvolved clear zone. 
iv) The epidermis overlying the lesions is thinned out, flat and may 
even ulcerate 
2. Tuberculoid leprosy: 
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The polar tuberculoid form presents the following histological fea-
tures: 
i) The dermal lesions show granulomas resembling hard tubercles 
composed of epithelioid cells, Langhans' giant cells and peripheral mantle 
of lymphocytes. 
ii) Lesions of tuberculoid leprosy have predilection for dermal nerves 
which may be destroyed and infiltrated by epithelioid cells and lympho-
cytes. 
iii) The granulomatous infiltrate erodes the basal layer of epidermis 
i.e. there is no clear zone. 
iv) The lepra bacilli are few and seen in destroyed nerves. 
3. Borderline leprosy: 
The histopathologic features of the three forms of borderline leprosy 
are as under: 
i) Borderline tuberculoid (BT) form shows epithelioid cells and plen-
tiful lymphocytes. There is a narrow clear subepidermal zone. Lepra bacilli 
are scanty and found in nerves. 
ii) Borderline lepromatous (BL) form shows predominance of histio-
cytes, a few epithelioid cells and some irregularly dispersed lymphocytes. 
Numerous lepra bacilli are seen. 
iii) Midborderline (BB) form shows sheets of epithelioid cells with 
no giant cells. Some lymphocytes are seen in the perineurium. Lepra bacilli 
are present, mostly in nerves. 
4. Indeterminate leprosy: 
The histopathologic features are nonspecific so that the diagnosis of 
nonspecific chronic dermatitis may be made. However, a few features help 
in suspecting leprosy like: 
i) Lymphocytic or mononuclear cell infiltrate, focalised particularly 
around skin adnexal structures like hair follicles and sweat glands or around 
blood vessels. 
ii) Nerve involvement, if present, is strongly supportive of diagnosis. 
iii) Confirmation of diagnosis is made by finding of lepra bacilli. 
 
ACTINOMYCOSIS 
Actinomycosis is a chronic suppurative disease caused by anaerobic 
bacteria, Actinomycetes israelii. The disease is conventionally included in 
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mycology though the causative organism is filamentous bacteria and not 
true fungus. The disease is worldwide in distribution. The organisms are 
commensals in the oral cavity, alimentary tract and vagina. The infection is 
always endogeneous in origin and not person-to-person. The organisms in-
vade, proliferate and disseminate in favourable conditions like break in mu-
cocutaneous continuity, some underlying disease etc. 
 
Microscopically, ir-
respective of the location of 
actinomycosis, the follow-
ing features are seen:  
i) The inflammatory 
reaction is a granuloma with 
central suppuration. There is 
formation of abscesses in 
the centre of lesions and at 
the periphery are seen 
chronic inflammatory cells, 
giant cells and fibroblasts. 
ii) The centre of each 
abscess contain the bacterial 
colony, 'sulfur granule', 
characterised by radiating 
filaments (hence previously known as ray fungus) with hyaline, eosino-
philic, club-like ends representative of secreted immunoglobulins.  
iii) Bacterial stains reveal the organisms as gram-positive filaments, 
non-acid fast, which stain positively with Gomori's methenamine silver 
(GMS) staining. 
SARCOIDOSIS (BOECK'S SARCOID) 
 Sarcoidosis is a systemic disease of unknown etiology. It is world-
wide in distribution and affects adults from 20-40 years of age. The disease 
is characterised by the presence of non-caseating epithelioid cell granulo-
mas ('sarcoid granuloma') in the affected tissues and organs, notably lymph 
nodes and lungs. Other sites are skin, spleen, uvea of the eyes, salivary 
glands, liver and bones of hands and feet. The histologic diagnosis is gener-
ally made by exclusion. 
Fig. 28. Thoracic actinomycosis. H and E stained 
section, x 200. 
1 - the bacterial colony with characterised 




Etiology and pathogenesis: The cause of sarcoidosis remains un-
known. Since the disease is characterised by granulomatous tissue reaction, 
possibility of cell-mediated immune mechanisms has been suggested. The fol-
lowing observations point towards a possible immune origin of sarcoidosis: 
1. Cells lavaged from lung lesions show increased helper T cells that 
elaborate lymphokines which initiate the formation of non-caseating granu-
lomas. 
2. The peripheral blood, however, shows lymphopenia with reduction 
in helper T cells and increase in suppressor T cells, accounting for cutane-
ous unresponsive-ness to tuberculin and dinitrochlorobenzene (DNCB). 
3. Circulating B cells are normal in number but there is hyperglobuli-
naemia due to B cell hyperplasia in lymphoid tissue. 
Pathologic changes: The lesions in sarcoidosis are generalised and 
may affect various organs and tissues at sometime in the course of disease, 
but brunt of the disease is borne by lungs and lymph nodes: 
Microscopically, the following features are present: 
1. The diagnostic feature in sarcoidosis of any organ or tissue is the 
non-caseating sarcoid granuloma, composed of epithelioid cells, Langhans' 
and foreign body giant cells and surrounded peripherally by fibroblasts. 
2. Typically, granulomas of sarcoidosis are 'naked' i.e. either devoid 
of peripheral rim of lymphocytes or there is paucity of lymphocytes. 
3. In late stage, the granuloma is either enclosed by hyalinised fibrous 
tissue or is replaced by hyalinised fibrous mass. 
4. The giant cells in sarcoid granulomas contain certain cytoplasmic 
inclusions like: 
i) Asteroid bodies which are eosinophilic and stellate-shaped structures. 
ii) Schaumann's bodies or conchoid (conch like) bodies which are con-
centric laminations of calcium and of iron salts, complexed with proteins. 
iii) Birefringent cytoplasmic crystal which are colourless. 
Similar types of inclusions are also observed in chronic berylliosis. 
Kviem`s test: it is a useful intradermal diagnostic test. The antigens pre-
pared from involved lymph node or spleen is injected intradermally. In a posi-
tive test, nodular lesion appears in 3-6 weeks at the inoculation site which on 
microscopic examination shows presence of non-caseating granulomas. 
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RHINOSCLEROMA 
The nose, the granuloma (scleroma) consists of the plasma cells, epi-
thelioid cells, lymphocytes, and hyaline spheres. Large macrophages with 
light cytoplasm containing Klebsiella Rhinoscleromatis are called Miku-
licz's cells, sclerosis and hyalinosis take place. 
GLANDERS 
Glanders can be acute and chronic. Acute glanders is characterized 
by the appearance of granulation tissue nodules comprised of macrophages, 
epithelioid cells and neutrophils. These nodules undergo the necrosis and 
suppuration. Thus there is formation of abscesses in different organs. 
Chronic glanders is characterized by the proliferative nodules formation in 
different organs which resemble tuberculous granulomas. 
PROLIFERATIVE INFLAMMATION WITH THE FORMATION OF POLYPS 
AND POINTED CONDYLOMAS 
This kind of inflammation is characterized by chronic course and it is 
accompanied by formation of polyps and pointed condylomas on the mu-
cous membranes. Integumentary epithelium is underwent to hyperplasia, 
thus there is a growth of it in the form of polyps, connective tissue.  Basis of 
polyps is diffusely infiltrated by lymphocytes, plasmocytes, macrophages 
and other cells. Similar formations arise in nasal cavity, sinus of Highmore, 
bronchial tubes, on the mucous membrane of stomach, intestine, and uterus. 
If similar process develops in the area of junction of squamous and 
columnar epithelium it is a condyloma. The surface of condyloma is cov-
ered by squamous epithelium. Such outgrowths frequently arise in anus, 
genitals, and typical for syphilis and gonorrhoea. 
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IMMUNOPATHOLOGICAL PROCESSES 
Immunopathological processes are pathological states which are as-
sociated with disturbances of structure and function of the lymphoid tissue. 
THYMUS 
Thymus is the central organ of immune system. In case of disturb-
ances immunogenesis usually the following processes and pathology are 
seen in the thymus. 
1. Accidental thymus transformation (involution), that is reduction in 
the size and mass due to thymocytes migration to the peripheral immune 
organs and blood as well as due to their partial decomposition and engulf-
ment by macrophages (this is called apoptosis). 
According to T. Ivanovskaya (1976), there are 5 stages of accidental 
thymus evolution. 
Stage 1 – «holey clearing» – accumulation of lymphocytes around the 
macrophages. It occurs in the cortex. 
Stage 2 – transition of the lymphocytes from the cortex to the medul-
lar substance. The boundary between the layers is either poorly seen or not 
seen at all. 
Stage 3 – «layer inversion», when the cortex layer looks light, and 
medullar layer looks dark as a result of transition of lymphocytes from the 
cortex to the medullar substance. 
Stage 4 – reduction in the lymphocyte amount in the both layers, re-
ticular stroma growth. 
Stage 5 – collapse of the thymus lobe, sclerosis and atrophy. 
Accidental transformation more often occurs in the newborn suffering 
from stress factors. The more powerful the stimulus, the more pronounced 
the degree of involution. Accidental involution occurs in severe infections, 
intoxications, in children born from sick mothers. The process is reversible. 
Elimination of pathological agent results in thymus normalization. 
2. Thymus hyperplasia (thymolymphatic state, thymomegaly). The 
weight and the size of thymus are considerably increased. Microscopic ex-
amination reveals a large number of immature lobules (zones are not dis-
tinct). The density of the thymocytes is high. If this condition is accompa-
nied by hypoplasia of adrenal and sexual glands as well as narrowing of the 
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aorta and arteries, this pathological process is called «thymo-lymphatic 
state». 
3. Thymus hypoplasia is characterized by absence of lobule division 
into cortical and medullar layers, poor development of reticuloepithelial 
component responsible for hormonal function, as well as lymphocyte com-
ponent. As a rule thymus hypoplasia is typical for congenital immune defi-
ciency. 
4. Aplasia – total congenital lack of organ or its part.  
5. Agenesis – congenital disorder which is characterized by absence 
of thymus germ. 
6. Dysplasia of thymus means morphological structure disorders: 
there is no cortex and medulla in lobules, the boundary between lobules is 
poorly seen, etc. 
Thymus hypoplasia, aplasia, agenesis and dysplasia are congenital 
disturbances.  
7. Thymus hyperplasia   is characterized by  increase of lymphoid fol-
licles. 
 
CHANGES IN LYMPHOID TISSUE AT ANTIGEN STIMULATION 
At first in the bone marrow hyperplasia of B-lymphocytes is ob-
served, and then it becomes empty, as a result of increased transition of 
lymphocytes. 
At antigen stimulation the morphologic processes developing in 
lymph nodes and spleen of healthy person and sick man are similar. Never-
theless they differ by the quantity of the involved in pathological process 
cells, as well as by the character and grade of immune inflammatory reac-
tions. 
These changes are characterized by: macrophage reactions; hyper-
plasia of B-lymphocytes with following transformation of them into plasma 
cells. 
The number of plasma cells shows the intensity of immunogenesis 
and corresponds to the level of antibodies production. 
Lymph nodes are: hyperplastic, edematous; follicular centers are pale 
(germinal centers are enlarged), contain numerous blasts and macrophages; 
macrophage aggregations are seen; there are a lot of plasma cells and mac-
rophages in sinuses. 
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If cellular immune reaction develops in response to antigen the fol-
lowing morphologic changes occur: proliferation of sensitized T-




A state of balance in the immune response (humoral or cell-mediated) 
is essential for protection against endogenous and exogenous antigens. Hy-
persensitivity is defined as a state of exaggerated immune response to an 
antigen. The lesions of hypersensitivity (immunologic tissue injury) are 
produced due to interaction between antigen and product of the immune re-
sponse. 
Depending upon the rapidity and duration of the immune response, 
four distinct forms of hypersensitivity reactions are recognized: 
Hypersensitivity of immediate type. Immediate type of hypersensi-
tivity is further of three types – type I, II and III. 
Immediate hypersensitivity reaction morphologically manifests by 
the picture of acute immune inflammation which develops rapidly, altera-
tion and exudation stages prevail, and proliferation increases slowly. The 
vessels and connective tissues are involved first. Alteration manifests by 
mucoid, fibrinoid swelling and fibrinoid necrosis. The exudate is either fi-
brinous or fibrino-hemorrhagic. Acute immune inflammation is observed in 
some forms of leprosy and syphilis. It is responsible for vascular reaction in 
lupus erythematosus, glomerulonephritis, and nodular periarteritis. 
Hypersensitivity of delayed type. Morphologically it manifests by 
chronic immune inflammation characterized by lymphocyte-macrophage 
infiltration. When the lymphocyte-macrophage infiltration accompanied by 
vascular plasmorrhagic and degenerative processes is seen the conclusion of 
immune inflammation can be made. The condition occurs in autoimmune 
diseases, tuberculosis, brucellosis, dermatitis. 
Type I reaction, or immediate-type, hypersensitivity reactions, IgE 
antibody is formed and binds to receptors on mast cells and basophils. The 
binding of antigen that reacts with the IgE releases products from these cells 
and results in characteristic symptoms of diseases such as asthma or ana-
phylaxis (anaphylactic shock). Immediate type in which on administration 
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of antigen, the reaction occurs immediately (within seconds to minutes). 
Immune response this type is mediated largely by humoral antibodies. 
Type II reaction (Cytotoxic Type): antibody-mediated cytotoxicity. 
In this type, IgG or IgM antibody is formed against an antigen, usually a 
protein on a cell surface or (less commonly) a component of extracellular 
matrix, such as basement membrane. This antigen-antibody coupling leads 
to complement activation, which in turn is responsible for the lysis (cyto-
toxicity) of the cell or damage to the extracellular matrix (e.g. Autoimmune 
hemolytic anemias, Goodpasture disease). 
Type III reaction: immune complex disease. In this type of reaction, 
the antibody responsible for tissue injury is also IgM or IgG but here the 
mechanism of tissue injury differs. The antigen is usually not fixed to the 
cell surface but circulates in the vascular compartment and is eventually de-
posited in tissues. Circulating antigen–antibody (immune) complexes 
(which normally are removed by the reticuloendothelial system) are depos-
ited in tissues, leading to complement activation. Complement activation at 
sites of antigen localization leads to recruitment of leukocytes, which are 
responsible for the subsequent tissue injury. (e.g. Autoimmune diseases 
(SLE - lupus еrythematosus, rheumatoid arthritis), most types of glomeru-
lonephritis).Immune complexes may also develop in situ (i.e., antibodies 
are directed against antigens that are endogenous to the tissues or have been 
planted there), thus triggering localized tissue damage. 
Type IV hypersensitivity: Type IV reactions, also known as cell-
mediated or delayed hypersensitivity reactions, do not require the formation 
of an antibody. Rather, antigenic activation of T lymphocytes, usually with 
the help of macrophages, causes the release of products by these cells, thus 
leading to subsequent tissue injury (e.g. Granulomatous diseases (tuberculo-
sis, sarcoidosis). Granulomatosis is morphological manifestation of delayed 
hypersensitivity reaction. 
Reaction of transplant rejection resembles slow hypersensitivity 
reaction. Transplant antigens induce the production of antibodies and sensi-
tized lymphocytes which infiltrate the transplant. 
Microscopically, lymphohistiocyte infiltration is observed in the 
transplant. Cellular infiltration causes the disturbance of blood circulation 
and edema; as a result degenerations and necrosis of transplant develop. 
The neutrophils and macrophages appear in the transplant. Enzymatic de-
struction of the transplant begins which is followed by its rejection. 
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AUTOIMMUNE DISEASES 
Immunologic tolerance and autoimmunity. An immune response 
generated against self antigens is an aberrancy that implies the loss of im-
munologic ability to distinguish self and alien antigens. The normal status 
of immunologic unresponsiveness to self antigens is termed tolerance. Tol-
erance probably represents an active process involving continuous genera-
tion of cellular and humoral inhibitory regulators. Loss of tolerance to self 
antigen is referred to as autoimmunity. The mechanisms by which toler-
ance is generated and lost are poorly understood. Theories of autoimmunity 
include: 
1. Recognition of previously hidden (physiological isolation) or se-
questered antigen. 
2. Diminution of suppressor T-cell function. 
3. Increase in helper T-cell activity. 
4. T-cell-independent polyclonal B-cell activation by complex anti-
gens. 
5. Modification of self antigens by drugs or microorganisms. 
6. Cross-reactivity between autologous antigens and microbial anti-
gens. 
Autoimmune diseases are those occurring as a result of the reaction 
of autoantibodies and sensitized lymphocytes against normal antigens of the 
own tissue. The causes of autoimmune diseases are not clearly known. 
Chronic viral infections, radiation and genetic factors may be responsible 
for them. 
In the pathogenesis of autoimmune diseases the following factors are 
distinguished: 
• predisposing (HLA genes, hormonal background, genetically de-
pendent features of the target cells); 
• initiating (viral and bacterial infections, exposure of immune system 
and target organs to chemical and physical factors); 
• contributing (dysfunction of immune system, T-lymphocyte sup-
pressor activity). 
In the pathogenesis 2 mechanisms can be distinguished; therefore all 
the autoimmune diseases can be divided into 2 groups. 
Group 1. Organ specific diseases. They are characterized by disturb-
ance of physiological isolation of the organs and tissues due to absence of 
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immune tolerance. Lymphohistiocyte infiltration occurs in the tissues (like 
at delayed hypersensitivity reaction). The main organ specific diseases are: 
1. Endocrine glands:  
Hashimoto's (autoimmune) thyroiditis.  
Graves' disease. 
Insulin-dependent diabetes mellitus.  
Idiopathic Addison's disease. 
2. Alimentary tract: 
Autoimmune atrophic gastritis in pernicious anemia. 
Ulcerative colitis.  
Crohn's disease. 
3. Blood cells: 
Autoimmune hemolytic anemia.  
Autoimmune thrombocytopenia. 
4. Others:  
Myasthenia gravis.  
Autoimmune orchitis.  
Autoimmune encephalomyelitis.  
Goodpasture's syndrome.  
Primary biliary cirrhosis.  
Chronic active hepatitis.  
Membranous glomerulonephritis.  
Autoimmune skin diseases.  
Group 2. Organ non-specific diseases. Primary disturbances in the 
immune system causing the loss of ability to distinguish «own» and «for-
eign» antigens, they are: 
Systemic lupus erythematosus.  
Rheumatoid arthritis. 
Scleroderma (Progressive systemic sclerosis).  
Polymyositis-Dermatomyositis. 
Polyarteritis nodosa (PAN).  
Sjogren's syndrome.  
Reiter's syndrome.  
Mixed connective tissue disease.  
The diseases with autoimmune disturbances. In these diseases anti-
genic properties of the tissues are changed, that causes immune reaction de-
velopment. Autoimmunization is responsible not for the beginning but the 
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progress of the disease as autoimmune antibodies appear during the disease. 
It is observed in glomerulonephritis, hepatitis, chronic gastritis, burn dis-
ease, rheumatism, liver cirrhosis. 
IMMUNODEFICIENCY SYNDROMES (IDS) 
Immune deficiency syndromes result from immune system insuffi-
ciency. 
All immune deficiencies are divided into 2 groups: primary or con-
genital immune deficiencies and secondary or acquired immune deficien-
cies. 
Primary IDS may be understood as primary defects in development 
of the immune system. Secondary ones result from diseases or drugs that 
affect immune system. 
Primary IDS may be classified into the following 4 general groups 
depending on the stage in development at which the defect occurs: 
• T-cell deficiencies; 
• B-cell deficiencies; 
• Combined (T-, B-cell) deficiencies; 
• Deficiency in inflammatory cells (agranulocytosis). 
T-cell deficiencies manifests by agenesis, hypoplasia of the thymus 
and T-dependent zones of the immune system. They are inherited according 
to autosomal dominant type, e.g. MacCusic syndrome. Except for the pa-
thology of thymus and primary lymphatic tissue, defects of development 
occur. 
DiGeorge syndrome is a selective deficiency of T-cells. This lack re-
sults from failure of the third and fourth pharyngeal pouches to develop and 
become thymus and parathyroid glands. DiGeorge syndrome is thought to 
be the result of an early intrauterine growth defect. It is not genetically 
linked. Affected infants have total absence of T-cell immunity, in associa-
tion with hypocalcemia and tetany. All lymphocytes are B-cells. Plasma 
cells are present in normal numbers. T-cell areas, such as paracortical areas 
of lymph nodes and periarteriolar sheaths are depressed. 
Chronic mucocutaneous candidiasis is a selective defect of T-cell 
immunity characterized by recurrent candidal infections involving the skin 
and mucous membranes. The remainder of T-cell functions are intact, as is 
B-cell immunity. The defect may be inherited as an autosomal recessive 
gene. Chronic mucocutaneous candidiasis is associated with endocrinopa-
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thies. Hypoparathyroidism is most common. Addison's disease, hypothy-
roidism, diabetes mellitus, and pernicious anemia are also seen. This associ-
ation suggests a multiorgan endocrinopathy with selective thymic dysfunc-
tion. 
B-cell deficiencies. This type of inheritance is connected with X-
chromosome, e.g. agammaglobulinemia – Bruton's syndrome. The thymus 
is preserved. B-zones in the peripheral lymphatic organs are absent. Immu-
noglobulins synthesis is absent. 
Bruton's (X-Iinked) agammaglobulinemia 
In 1952, Bruton described an X-linked deficiency immunoglobulin 
production. These patients suffered from recurrent bacteria-related bronchi-
tis, otitis, and skin infections. Infections usually began around the 6th month 
of life, as circulating maternal antibodies in the infants subsided. All immu-
noglobulins were either markedly decreased or absent. Circulating mature 
B-cells were also absent. 
It is now recognized that pre-B-cells are present in patients with Bru-
ton's agammaglobulinemia, and there seems to be a defect in the B-cell 
maturation sequence. Morphologically, there are no germinal centers in 
lymph nodes, the spleen, and the tonsils. Plasma cells are absent. 
Transient hypogammaglobulinemia of infancy is characterized by di-
minished levels of immunoglobulin but the ability to produce certain anti-
body. The disorder appears to be related to an abnormally long delay in the 
production of serum immunoglobulin. (Maternal antibodies normally de-
cline in the infant over the first 6 months of life.) Defects in helper T-cell 
function are thought to be responsible. 
Common variable immunodeficiency is a somewhat poorly defined 
entity characterized by hypogammaglobulinemia despite normal numbers of 
circulating B-cells. In most cases, there is no clear-cut genetic predisposi-
tion. Patients range in age from very young to elderly, although young 
adults are most commonly affected. 
Selective IgA deficiency is the most common immunodeficiency dis-
order, occurring in about 1 in 700 people. Serum IgA levels are low, but the 
numbers of circulating IgA-cells are normal. However, these IgA-cells pos-
sess an immature phenotype that coexpresses IgD and IgM. Thus, the defect 
seems to be in the maturation of IgA-bearing cells. Similar selective defi-
ciencies in IgM are reported but rare. 
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Combined syndromes – insufficiency of cellular and humoral im-
munity (T-, B-cell insufficiency). This is inherited according to autosomal-
recessive type, e.g. Glanzmann-Riniker syndrome (agammaglobulinemia of 
Swiss type); severe combined immunodeficiency (SCID); hypoplasia of 
thymus and peripheral lymphatic tissue. 
Severe combined immunodeficiency (SCID) is a severe disorder char-
acterized by nearly total absence of both T-cell and B-cell immunity. In-
fants present early with recurrent opportunistic infections. SCID may be 
transmitted as either an X-linked or autosomal recessive way. 
Morphologically, there is a virtual absence of lymphoid tissue in the 
form of lymph nodes, spleen, and tonsils. The thymus gland fails to descend 
from the neck into the mediastinum and lacks lymphoid cells and Hassall's 
corpuscles. 
These patients appear to have a stem-cell defect; deficiency in the 
enyzme adenosine deaminase (ADA) is found in the cells of many patients 
with the autosomal recessive form of SCID. ADA converts  adenosine to 
inosine, or deoxyadenosine to deoxyinosine. Without this enzyme, there is 
an accumulation of adenosine, deoxyadenosine, and deoxyadenosine tri-
phosphate (dATP). This latter compound inhibits ribonucleotide reductase, 
causing depletion of dezoxyribonucleotide triphosphates and abnormal 
lymphocyte function. SCID with ADA deficiency may be diagnosed prena-
tally by amniocentesis. 
Secondary deficiencies occur after full development of the immune 
system. Some of these are secondary to immunosuppressive therapy, e.g. in 
tumors, autoimmune diseases, glomerulonephritis, etc. Chronic virus infec-




The term “neoplasia”, “neoplasm” or “tumor” means new growth. 
However, all “new growths” are not neoplasms since examples of new 
growth of tissues and cells also exist in the processes of embryogenesis, re-
generation and repair, hyperplasia and hormonal stimulation. The prolifera-
tion and maturation of cells in normal adults is controlled as a result of 
which some cells proliferate throughout life (labile cells), some have limited 
proliferation (stable cells), while others do not replicate (permanent cells). 
On the other hand, neoplastic cells lose control and regulation of replication 
and form an abnormal mass of tissue. 
Therefore, satisfactory definition of a neoplasm or tumor is “a mass of 
tissue formed as a result of abnormal, excessive, uncoordinated, autonomous 
and purposeless proliferation of cells”. The branch of science dealing with 
the study of neoplasms or tumors is called oncology (oncos = tumor, logos = 
study). Neoplasms may be benign when they are slow-growing and localized 
without causing much difficulty to the host, or malignant when they prolifer-
ate rapidly, spread throughout the body and may eventually cause death of 
the host. The common term used for all malignant tumors is cancer. Hippoc-
rates (460-377 BC) proposed the term “karkinos” for cancer of the breast. The 
word “cancer” means crab, thus reflecting the true character of cancer since it 
sticks to the part stubbornly like a “crab”. 
All tumors, benign as well as malignant, have 2 basic components: 
• Parenchyma comprised by proliferating tumour cells; parenchyma 
determines the nature and evolution of the tumour. 
• Supportive stroma composed of fibrous connective tissue and blood 
vessels; it provides the framework on which the parenchymal tumour cells 
grow. 
The tumours derive their nomenclature on the basis of the parenchy-
mal component comprising them. The suffix “-oma” is added to denote be-
nign tumours. Malignant tumours of epithelial origin are called carcinomas, 
while malignant mesenchymal tumours are named sarcomas (sarcos = 
fleshy). However, some cancers are composed of highly undifferentiated 
cells and are referred to as undifferentiated malignant tumours. Rarely, 
combinations of carcinoma and sarcoma are encountered called as carcino-
sarcoma. Although, this broad generalization regarding nomenclature of tu-
mours usually holds true in majority of instances, some examples contrary to 
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this concept are: melanoma for carcinoma of the melanocytes, hepatoma for 
carcinoma of the hepatocytes, lymphoma for malignant tumour of the lym-
phoid tissue, and seminoma for malignant tumour of the testis. 
Tumours composed of a single type of parenchymal cells that differen-
tiate towards more than one cell line are called mixed tumours. Teratomas, on 
the other hand, are made up of a number of parenchymal cell types arising 
from totipotent cells derived from more than one germ cell layer. Choristoma 
refers to the ectopic rests of normal tissue. Hamartoma is a mass of disor-
ganized but mature cells of tissues indigenous to the particular site. 
CLASSIFICATION OF TUMOURS 
The currently used classification of tumours is based on the histogen-
esis (i.e. tissue of origin) and on the anticipated behaviour. However, it 
must be mentioned here that the classification described here is only a 
summary. Detailed classifications of benign and malignant tumours pertain-
ing to different tissues and body systems along with morphologic features 
of specific tumours appear in the specific chapters of Systemic Pathology 
later. 
HISTOGENETIC CLASSIFICATION OF TUMORS: 
1. Epithelial tumors without specific localization (organ-nonspecific), 
2. Epithelial tumors of exo- and endocrine glands, epithelial coats (or-
gan-specific), 
3. Mesenchimal tumors, 
4. Tumors of melanin forming tissue, 
5. Tumors of nerve system and coats, 
6. Tumors of blood system, 
7. Tumors of  APUD- system, 
8. Teratomas. 
CHARACTERISTICS OF TUMOURS 
Majority of neoplasms can be categorized morphologically into be-
nign and malignant on the basis of certain characteristics, the most im-
portant being the degree of differentiation of the tumour cells. However, 
there are exceptions. A small proportion of tumours have some features 
suggesting innocent growth while other features point towards a more omi-
nous behaviour. Therefore, it must be borne in mind before describing char-
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acteristics of neoplasm that there is a wide variation in the degree of devia-
tion from the normal in all the tumours. 
The characteristics of tumours are described under the following 
headings: 
I. Macroscopic features 
II. Microscopic features 
III. Growth rate 
IV. Local invasion (Direct spread) 
V. Metastasis (Distant spread) 
I. MACROSCOPIC FEATURES 
The macroscopic appearance of tumours within the same group may 
be quite variable and the features may not be diagnostic on the basis of 
gross appearance alone. However, certain distinctive features characterize 
almost all tumours – they have a different colour, texture and consistency as 
compared to the surrounding tissue of origin. Gross terms such as papillary, 
fungating, infiltrating, haemorrhagic, ulcerative and cystic are used to de-
scribe the macroscopic appearance of the tumours. 
• Benign tumours are generally spherical or ovoid in shape. They are 
encapsulated or well-circumscribed, freely movable, more often firm and 
uniform, unless secondary changes like haemorrhage or infarction super-
vene. 
• Malignant tumours, on the other hand, are usually irregular in 
shape, poorly-circumscribed and extend into the adjacent tissues. Secondary 
changes like haemorrhage, infarction and ulceration are seen more often. 
Sarcomas typically have fish-flesh like consistency while carcinomas are 
generally firm. 
There are 3 types of tumor growth: 
1. Expansive growth – tumor increases in size and squeezes the sur-
rounding tissues. It mainly occurs in benign tumors. 
2. Opposition growth – tumor increases in size by the transformation 
of adjacent normal cells into tumor cells. 
3. Infiltrative, or invasive growth – in this type tumor grows and 
leads destruction of the surrounding tissues. It mainly occurs in malignant 
tumors with rapid growth. 
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In tube organs, tumors can grow into organ lumen (exophitic growth), 
or in the organ wall (endophitic growth), or in both directions (mixed 
growth). 
II. MICROSCOPIC FEATURES 
1. Microscopic Pattern 
The tumour cells may be arranged in a variety of patterns in different 
tumours. For example: 
• The epithelial tumours generally consist of acini, sheets, columns or 
cords of epithelial tumour cells that may be arranged in solid or papillary 
pattern. 
• The mesenchymal tumours have mesenchymal tumour cells lying 
separated from each other usually by the intercellular substance such as car-
tilaginous matrix in chondroma, osteoid in osteosarcoma, reticulin network 
in soft tissue sarcomas etc. 
• Haematopoietic tumours such as leukaemias and lymphomas often 
have none or little stromal support. 
• Generally, most benign tumours and low-grade malignant tumours 
reduplicate the normal structure of origin more closely so that there is little 
difficulty in identifying and classifying such tumours. However, anaplastic 
tumours differ greatly from the arrangement in normal tissue of origin of 
the tumour and may occasionally pose problems in classifying the tumour. 
• Other cellular deviations from the normal cellular arrangement in 
malignant tumours are: loss of basal orientation (polarity), altered alignment 
of tumour cells to each other, and stromal invasion by tumour cells. 
• Certain tumours have mixed patterns, e.g. teratoma arising from to-
tipotent cells, pleomorphic adenoma of salivary gland (mixed salivary tu-
mour), fibroadenoma of the breast, carcinosarcoma of the uterus and vari-
ous other combinations of tumour types. 
 
2. Tumour Cytomorphology (Differentiation and Anaplasia) 
The neoplastic cell is characterized by morphologic and functional al-
terations, the most significant of which are “differentiation” and “anaplasia”. 
• Differentiation is defined as the extent of morphological and func-
tional resemblance of parenchymal tumour cells to corresponding normal 
cells. If the deviation of neoplastic cell in structure and function is minimal 
as compared to normal cell, the tumour is described as “well-differentiated” 
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such as most benign and low-grade malignant tumours. “Poorly differenti-
ated”, “undifferentiated” or “dedifferentiated” are synonymous terms for 
poor structural and functional resemblance to corresponding normal cell. 
• Anaplasia (atypia) is lack of differentiation and is a characteristic 
feature of most malignant tumours. 
There are 2 types of morphological atypia – tissue and cellular. 
Tissue atypia is characterized by conservation of cells structure (ex-
ternally they look like normal) but changes of their mutual position in tis-
sue. And in whole tissue looks unusually. 
Cellular atypia means changes of cell structure. Cells are polymor-
phic, contain hyperchromic polymorphic nucleus, multiple mitosis (patho-
logical too), and have increased nucleo-cytoplasm relation. 
As a result of anaplasia, noticeable morphological and functional al-
terations in the neoplastic cells are observed. These are considered below: 
i) Pleomorphism. The term pleomorphism means variation in size 
and shape of the tumour cells. The extent of cellular pleomorphism general-
ly correlates with the degree of anaplasia. Tumour cells are often bigger 
than normal but in some tumours they can be of normal size or smaller than 
normal. 
ii) Nucleocytoplasmic changes. The nuclei of tumour cells show 
most conspicuous changes compared to normal cells: 
a) Generally, the nuclei of malignant tumour cells are enlarged, dis-
proportionate to the cell size so that the nucleocytoplasmic ratio is increased 
from normal 1:5 to 1:1. 
b) Just like cellular pleomorphism, the nuclei too, show variation in 
size (anisonucleosis) and shape in malignant tumour cells. 
c) Characteristically, the nuclear chromatin of malignant cell is in-
creased and coarsely clumped. This is due to increase in the amount of nu-
cleoprotein resulting in dark-staining nuclei, referred to as hyper-
chromatism. Besides, a prominent nucleolus or nucleoli may be present in 
these nuclei reflecting increased nucleoprotein synthesis. Nuclear shape 
may vary and nuclear chromatin is clumped along the nuclear membrane. 
d) The parenchymal cells of poorly-differentiated tumours often show 
large number of mitoses as compared with benign tumours and well-
differentiated malignant tumours. However, it is most important to identify 
abnormal and atypical mitotic figures such as tripolar, quadripolar and multi-
polar spindles in malignant tumour cells because increased number of normal 
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mitoses may be present in non-neoplastic proliferations such as in haemato-
poietic cells of the bone marrow, intestinal epithelium, hepatocytes etc. 
e) Multinucleate tumour giant cells or giant cells containing a single 
large and bizarre nucleus, possessing nuclear characters of the adjacent tu-
mour cells, are another important feature of anaplasia in malignant tumours. 
f) The cytoplasm of tumour cells in better-differentiated cancers and 
in benign tumours may show the normal constituents from which the tu-
mour is derived, e.g. the presence of mucus, keratin, cross striations etc. But 
the more anaplastic tumour cells lose such features. 
iii) Genetic abnormalities. All tumour cells have abnormal genetic 
composition and on division they transmit the genetic abnormality to their 
progeny. The first tumour cell is perhaps produced by mutation in the origi-
nal normal cell resulting in abnormal gene/genes. Other possible hypotheses 
for genetic abnormality in neoplastic cells are the activation of a normally 
suppressed oncogene present in all the cells of the body, or a virus adding 
new genetic material to the cell (discussed later). The chromosomal abnor-
malities are more marked in more malignant tumours which include devia-
tions in both morphology and number of chromosomes. Most malignant 
tumours show aneuploidy, often in the form of an increase in the number of 
chromosomes, reflected morphologically by the increase in the size of nu-
clei. One of the most important examples of a consistent chromosomal ab-
normality in human malignancy is the presence of Philadelphia chromo-
some (named after the city in which it was first described) in 95% cases of 
chronic myeloid leukaemia. In this, part of the long arm of chromosome 9 is 
translocated to part of the long arm of chromosome 22 (t 9; 22). Other ex-
amples of neoplasms showing chromosomal abnormalities are Burkitt`s 
lymphoma, acute lymphoid leukaemia, multiple myeloma, retinoblastoma, 
oat cell carcinoma, Wilm`s tumour etc. 
iv) Functional changes. Structural anaplasia in tumours is accompa-
nied with functional anaplasia. The functional abnormality in neoplasms 
may be quantitative, qualitative, or both. 
Generally, benign tumours and better-differentiated malignant tu-
mours continue to function well qualitatively, though there may be quantita-
tive abnormality in the product, e.g. large or small amount of collagen pro-
duced by benign tumours of fibrous tissue, keratin formation in well-
differentiated squamous cell carcinoma. In more anaplastic tumours, there is 
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usually quantitative fall in the product made by the tumour cells, e.g. ab-
sence of keratin in anaplastic squamous cell carcinoma. 
There may be both qualitative and quantitative abnormality of the 
cellular function in some anaplastic tumours, e.g. multiple myeloma pro-
ducing abnormal immunoglobulin in large quantities. 
Endocrine tumours may cause excessive hormone production leading 
to characteristic clinical syndromes. Besides the production of hormones by 
endocrine tumours, hormones or hormone-like substances may be produced 
by certain tumours quite unrelated to the endocrine glands. This property of 
tumours is called ectopic hormone production, e.g. oat cell carcinoma of the 
lung can secrete ACTH and ADH; less often it may produce gonadotropin, 
thyrotropin, parathormone, calcitonin and growth hormone. Ectopic eryth-
ropoietin may be produced by carcinoma of kidneys, hepato-cellular carci-
noma and cerebellar haemangioblastoma. 
3. Angiogenesis and Tumour Stroma 
The connective tissue along with its blood supply forms the support-
ive framework on which the parenchymal tumour cells grow and receive 
nourishment. In addition to variable amount of connective tissue and vascu-
larity, the stroma may have nerves and metaplastic bone or cartilage but no 
lymphatics. In order to provide nourishment to growing tumour, new blood 
vessels are formed from pre-existing ones (angiogenesis) that is probably 
stimulated by secretion of tumour angiogenesis factors from the parenchy-
mal tumour cells such as vascular endothelial growth factor (VEGF). How-
ever, if the tumour outgrows its blood supply as occurs in rapidly growing 
tumours, its core undergoes ischaemic necrosis. The collagenous tissue in 
the stroma may be scanty so that the tumour is soft and fleshy such as in 
sarcomas, lymphomas etc. If the tumour is almost entirely composed of 
parenchymal cells, it is called medullary, if there is excessive connective 
tissue stroma, it is referred to as desmoplasia and the tumour is hard or scir-
rhous. Growth of fibrous tissue in tumour is stimulated by basic fibroblast 
growth factor (bFGF) elaborated by tumour cells. 
4. Inflammatory Reaction 
At times, prominent inflammatory reaction is present in and around 
the tumours. It could he the result of ulceration in the cancer when there is 
secondary infection. The inflammatory reaction in such instances may be 
acute or chronic. However, some tumours show chronic inflammatory reac-
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tion, chiefly of lymphocytes, plasma cells and macrophages, and in some 
instances, granulomatous reaction, in the absence of ulceration. This could 
possibly be due to cell-mediated immunologic response by the host in an 
attempt to destroy the tumour. 
The examples of such reaction are: seminoma testis, malignant mela-
noma of the skin, lymphoepithelioma of the throat, medullary carcinoma of 
the breast, Warthin`s tumour of salivary glands etc. In some cases, such an 
immune response improves the prognosis. 
III. GROWTH RATE 
The tumour cells generally proliferate more rapidly than the normal 
cells. In general, benign tumours grow slowly and malignant tumours rapid-
ly. However, there are exceptions to this generalization. The rate at which 
the tumour enlarges depends upon 3 main factors: 
1.  Rate of division and destruction of tumour cells 
2.  Non-neoplastic elements in the tumour 
3.  Degree of differentiation of the tumour. 
1. Rate of division and destruction of tumour cells. 
The rate of division of tumour cells depends upon 2 factors –
proportion of cells undergoing mitosis (mitotic index), and the duration tak-
en to complete the mitotic cell cycle. If the rate of cell division is high, it is 
likely that the cells in the centre of the tumour are not adequately nourished 
and may undergo ischaemic necrosis. Thereafter, the rate of tumour en-
largement slows in spite of rapid division of tumour cells. 
2. Non-neoplastic elements within the tumours. 
These are the connective tissue stroma, abundant mucoid material, 
cartilaginous matrix etc all of which add to the bulk of the tumours. 
3. Degree of differentiation. In general, rate of growth of malignant 
tumour is directly proportionate to the degree of differentiation. Some tu-
mours growing steadily for years may suddenly show spurt in their growth 
which is due to appearance of aggressive clone of malignant cells in the tu-
mour. On the other hand, some tumours may cease to grow after sometime. 
Rarely, a malignant tumour such as choriocarcinoma and malignant mela-
noma may disappear spontaneously from the primary site, possibly due to 
necrosis caused by good host immune attack, only to reappear as secondar-
ies elsewhere in the body. 
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The regulation of tumour growth is under the control of growth fac-
tors secreted by the tumour cells. Out of more than 100 growth factors de-
scribed so far, important ones modulating tumour biology are: 
i) Epidermal growth factor (EGF) 
ii) Fibroblast growth factor (FGF) 
iii) Platelet-derived growth factor (PDGF) 
iv) Colony stimulating factor (CSF) 
v) Transforming growth factors-β (TGF-β) 
vi) Interleukins (IL). 
IV. LOCAL INVASION (DIRECT SPREAD) 
Most benign tumours form encapsulated or circumscribed masses that 
push aside the surrounding normal tissues without actually invading, infil-
trating or metastasising. Malignant tumours also enlarge by expansion and 
some well-differentiated tumours may be partially encapsulated as well. But 
characteristically, they are distinguished from benign tumours by invasion, 
infiltration and destruction of the surrounding tissue, besides distant metas-
tasis (described below). In general, tumours invade via the route of least re-
sistance, though eventually most cancers recognize no anatomic boundaries. 
Often, cancers extend through tissue spaces, permeate lymphatics, blood 
vessels, perineural spaces and may penetrate a bone by growing through nu-
trient foramina. More commonly, the tumours invade thin-walled capillaries 
and veins than thick-walled arteries. Dense compact collagen, elastic tissue 
and cartilage are some of the tissues which are sufficiently resistant to inva-
sion by tumours. Certain tumours such as carcinoma of the cervix arise 
from pre-invasive stage called carcinoma in situ when the cancer cells are 
confined to layers superficial to the basement membrane. When the tumour 
cells cross the basement membrane, it is referred to as invasive cancer. 
Mechanism of local invasion by malignant tumours is discussed in 
the next section along with mechanism of metastasis. 
V. METASTASIS (DISTANT SPREAD) 
Metastasis (meta = transformation, stasis = residence) is defined as 
spread of tumour by invasion in such a way that discontinuous secondary 
tumour mass/masses are formed at the site of lodgement. Metastasis is the 
most important feature to distinguish malignant from benign tumours. Be-
nign tumours do not metastasize while all the malignant tumours with a few 
exceptions like gliomas of the central nervous system and basal cell carci-
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noma of the skin can metastasize. Generally, larger, more aggressive and 
rapidly-growing tumours are more likely to metastasize but there are nu-
merous exceptions. 
Metastasis is a common event in malignant tumours which greatly 
reduces the survival of patient. In the biology of tumour, metastasis is a 
form of unusual cell differentiation in which the tumour cells form disorder-
ly masses at ectopic sites and start growing there. This random phenomenon 
takes place in a stepwise manner involving only a subpopulation of tumour 
cells selectively. The process is governed by inappropriate expression of 
genes which normally partake in physiologic processes, i.e. it is a genetical-
ly programmed phenomenon. 
Recent evidence has shown that in metastatic tumours, survival of 
host is correlated with some clinical and molecular features of tumours 
which act as prognostic markers. These are as under: 
i) Clinical prognostic markers: Size, grade, vascular invasion and 
nodal involvement by the tumour. 
ii) Molecular prognostic markers: Molecular markers indicative of 
poor prognosis in certain specific tumours are: 
a) expression of an oncogene by tumour cells (C-met); 
b) CD 44 molecule; 
c) oestrogen receptors; 
d) epidermal growth factor receptor; 
e) angiogenesis factors and degree of neovascularisation; and 
f) expression of metastasis associated gene or nucleic acid 
(MAGNA) in the DNA fragment in metastasising tumour. 
 
ROUTES OF METASTASIS 
Cancers may spread to distant sites by following pathways: 
1. Lymphatic spread 
2. Haematogenous spread 
3. Other routes (transcoelomic spread, spread along epithelium-lined 
surfaces, spread via cerebrospinal fluid, implantation). 
1. LYMPHATIC SPREAD. In general, carcinomas metastasise by lymphatic 
route while sarcomas favour haematogenous route. However, sarcomas may 
also spread by lymphatic pathway. The walls of lymphatics are readily in-
vaded by cancer cells and may form a continuous growth in the lymphatic 
channels called lymphatic permeation, or may detach to form tumour embo-
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li so as to be carried along the lymph to the next draining lymph node. The 
tumour emboli enter the lymph node at its convex surface and are lodged in 
the subcapsular sinus. Later, of course, the whole lymph node may be re-
placed and enlarged by the metastatic tumour. Generally, regional lymph 
nodes draining the tumour are invariably involved, but sometimes lymphat-
ic metastases do not develop first in the lymph node nearest to the tumour 
because of venous-lymphatic anastomoses or due to obliteration of lym-
phatics by inflammation or radiation, so called skip metastasis. Other times, 
due to obstruction of the lymphatics by tumour cells, the lymph flow is dis-
turbed and retrograde metastases may be seen at unusual sites e.g. metasta-
sis of carcinoma prostate to the supraclavicular lymph nodes, metastatic de-
posits in the adrenals from carcinoma lung etc. 
It is believed that lymph nodes in the vicinity of tumour perform mul-
tiple roles – as initial barrier filter, and in destruction of tumour cells, while 
later provide fertile soil for growth of tumour cells. Detailed mechanism of 
lymphatic route of metastasis is given at the end of this section under biolo-
gy of invasion and metastasis. 
 
2. HAEMATOGENOUS SPREAD. Metastasis through blood vessels is the 
common route for sarcomas but certain carcinomas also frequently metasta-
sise by this mode, especially those of the lung, breast, thyroid, kidney and 
prostate. The common sites for blood-borne metastasis are the liver, lungs, 
kidneys, brain and bones, all of which provide “good soil” for the growth of 
“good seeds” (seed-soil theory) than are the unfavourable sites like the 
spleen and muscles. Only a proportion of cancer cells are capable of clonal 
proliferation in the proper environment; others die without establishing a 
metastasis. The cancer cells readily invade the walls of capillaries, venules 
and veins than the arteries which are thick-walled and contain elastic tissue 
resistant to invasion. Nevertheless, arterial spread may occur in some in-
stances such as when tumour cells pass through pulmonary capillary bed or 
through pulmonary arterio-venous shunts.  
The tumour embolus may occlude a small vessel in the microcircula-
tion, extend through the vessel wall and then establish a metastasis at the 
new site of lodgement. Thus, cancers of the organs draining into portal 
veins frequently establish metastasis in the liver, while cancers of organs 
draining into caval veins metastasise to the lungs. As with lymphatic metas-
tases, haematogenous metastases may also occur at unusual sites due to ret-
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rograde spread after venous obstruction. Important examples of this type of 
spread are seen in vertebral metastases in cancers of the thyroid and pros-
tate. 
Macroscopically, blood-borne metastases in an organ appear as mul-
tiple, rounded nodules of varying size, scattered throughout the organ. 
Sometimes, the metastasis may grow bigger than the primary tumour. Meta-
static deposits just like primary tumour may cause further dissemination via 
lymphatics and blood vessels. 
Microscopically, the secondary deposits generally reproduce the 
structure of primary tumour. 
 
3. OTHER ROUTES OF METASTASIS. Some uncommon routes of distant 
spread are as under: 
i) Transcoelomic spread. Certain cancers invade through the serosal 
wall of the coelomic cavity so that humour fragments or clusters of tumour 
cells break off to be carried in the coelomic fluid and are implanted else-
where in the body cavity. Peritoneal cavity is involved most often, but occa-
sionally pleural and pericardial cavities are also affected. Transcoelomic 
spread in peritoneum by carcinoma of the stomach and ovary are important 
examples, while pleura and pericardium are often involved by carcinoma of 
the bronchus and breast. 
ii) Spread along epithelium-lined surfaces. It is unusual for a ma-
lignant tumour to spread along the epithelium-lined surfaces because intact 
epithelium and mucus coat are quite resistant to penetration by humour 
cells. However, exceptionally a malignant tumour may spread through the 
fallopian tube from the endometrium to the ovaries or vice-versa, through 
the bronchus into alveoli, and through the ureters from the kidneys into 
lower urinary tract. 
iii) Spread via cerebrospinal fluid. Malignant humour of the epen-
dyma and leptomeninges may spread by release of tumour fragments and 
tumour cells into the CSF and produce metastases at other sites in the cen-
tral nervous system. 
iv) Implantation. Rarely, a tumour may spread by implantation by 
surgeon's scalpel, needles, sutures, or be implanted by direct contact such as 
transfer of cancer of the lower lip to the apposing upper lip. 
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MECHANISM AND BIOLOGY OF INVASION AND METASTASIS 
Malignant tumours are distinguished from benign tumours by two of 
the most characteristic features: 
• development of metastasis; and 
• invasiveness. 
The process of local invasion and distant spread (lymphatic and 
haematogenous) involves the following steps: 
1. Invasion of the basement membrane 
2. Passage through the extracellular matrix 
3. Invasion of lymphatic or vascular channels 
4. Extravasation of tumour cells 
5. Survival and growth of metastatic deposit. However, malignant 
cells in large numbers are released into circulation from the primary tumour 
while only a few are able to establish the metastasis. This is explained on 
the basis of tumour heterogeneity, i.e. in the population of monoclonal tu-
mours cells, a subpopulation or clone of tumour cells has the right biologic 
characteristics to complete the above steps involved in the development of 
metastasis. 
1. Invasion of the basement membrane. The tumour is termed “in-
vasive” when the epithelial tumour cells have breached through the underly-
ing basement membrane, while malignant cells confined to the layers above 
the basement membrane is termed “carcinoma in situ”. 
Normal epithelial cells adhere to each other and to other components 
by various adhesion molecules. These include the following: 
i) Epithelial (E) cadherins (cell-cell adhesion molecule) and catenins 
(E cadherin-cytoskeleton interaction), both suppress invasion and metasta-
sis. In most carcinomas, the expression of E-cathedrin and catenin is re-
duced or even lost which allows individual malignant cells to “loosen up” 
and leave the primary tumour. 
ii) Integrins are transmembrane receptors causing adhesive interac-
tion between individual tumour cells and in tumour cell-components of ex-
tracellular matrix interaction. The expression of integrins on the cell surface 
in human melanoma cells has been highlighted in invasion and metastasis 
of this tumour. 
iii) Immunoglobulin supergene family includes several intercellular 
adhesion molecules which include intercellular adhesion molecule-1 
(ICAM-1), MUC-18, CD44 and vascular cell adhesion molecule (VCAM-
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1). Expression of ICAM-1, MUC-18 and CD44 is directly correlated with 
invasion and metastatic potential of tumours, while VCAM-1 (adhesion 
molecule between tumour cell-endothelium) is downregulated and hence 
results in detachment of tumour cells in invasion and metastatic clone of 
tumour. 
2. Passage through the extracellular matrix. The tumour cells after 
attachment to the basement membrane migrate through it by the following 
mechanisms: 
i) Autocrine motility factor (AMF), a type of tumour cell cytokine, 
stimulates receptor-mediated motility of tumour cells, increased adhesion of 
tumour cells to the matrix and release of lysosomal enzyme,  
ii) Proteolytic enzymes such as urokinase type plasminogen activator 
and matrix metalloproteins (MMP) of collagenase family are elaborated by 
malignant cells which bring about degradation of basement membrane 
components such as collagen type IV, laminin and proteoglycans. 
3. Invasion of lymphatic and vascular channels. After the malig-
nant cells have breached the basement membrane and invaded the extracel-
lular matrix, these cells penetrate the lymphatic and vascular channels and 
hence reach the systemic circulation. However, a very small proportion of 
malignant cells (less then 0.1%) in the blood stream actually survive to de-
velop into metastasis. 
4. Extravasation of tumour cells. Tumour cells in the circulation (ca-
pillaries, venules, lymphatics) may mechanically block these vascular channels 
and attach to vascular endothelium. In this way, the sequence similar to local 
invasion is repeated and the basement membrane in exposed. 
5. Survival and growth of metastatic deposit. The extravasated ma-
lignant cells on lodgement in the right environment grow further under the 
influence of growth factors produced by host tissues, tumour cells and by 
cleavage products of matrix components. These growth factors in particular 
include: PDGF, FGF, and TGF-p. The last one, TGF-p stimulates growth of 
newer vessels in the host tissue termed angiogenesis. The metastatic depos-
its grow further if the host immune defense mechanism fails to eliminate it. 
Metastatic deposits may further metastasise to the same organ or to other 
sites by similar mechanisms. 
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GRADING AND STAGING OF CANCER 
“Grading” and “staging” are the two systems to determine the prog-
nosis and choice of treatment after a malignant tumour is detected. Grading 
is defined as the macroscopic and microscopic degree of differentiation of 
the tumour, while staging means extent of spread of the tumour within the 
patient. 
GRADING 
Cancers may be graded grossly and microscopically. Gross features 
like exophytic or fungating appearance are indicative of less malignant 
growth than diffusely infiltrating tumours. However, grading is largely 
based on 2 important histologic features: the degree of anaplasia, and the 
rate of growth. Based on these features, cancers are categorized from grade 
I as the most differentiated, to grade III or IV as the most undifferentiated or 
anaplastic. Many systems of grading have been proposed but the one de-
scribed by Broders for dividing squamous cell carcinoma into 4 grades de-
pending upon the degree of differentiation is followed for other malignant 
tumours as well. Broders' grading is as under: 
Grade I: Well-differentiated (less than 25% anaplastic cells). 
Grade II: Moderately-differentiated (25-50% anaplastic cells). 
Grade III: Moderately-differentiated (50-75% anaplastic cells). 
Grade IV: Poorly-differentiated or anaplastic (more than 75% ana-
plastic cells). 
However, grading of tumours has several short-comings. It is subjec-
tive and the degree of differentiation may vary from one area of tumour to 
the other. Therefore, it is common practice with pathologists to grade can-
cers in descriptive terms (e.g. well-differentiated, undifferentiated, keratin-
izing, non-keratinizing etc) rather than giving the tumours grade numbers. 
 
STAGING 
The extent of spread of cancers can be assessed by 3 ways – by clini-
cal examination, by investigations, and by pathologic examination of the 
tissue removed. Two important staging systems currently followed are: 
TNM staging and AJC staging. 
TNM staging. (T for primary tumour, N for regional nodal involve-
ment, and M for distant metastases) was developed by the UICC (Union In-
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ternationale Centre Cancer, Geneva). For each of the 3 components namely 
T, N and M, numbers are added to indicate the extent of involvement, as 
under: 
T0 to T4: In situ lesion to largest and most extensive primary tumour. 
N0 to N3: No nodal involvement to widespread lymph node involvement. 
M0 to M2: No metastasis to disseminated haematogenous metastases. 
 
Staging of Malignant Neoplasms 
 
Stage Definition 
Tis In situ, non-invasive (contined epithelium) 
T1 Small, minimally invasive within primary organ site 
T2 Larger, more invasive within the primary organ site 
T3 Larger and/or invasive beyond margins of primary organ site 
T4 Very larger and/or very invasive, spread to adjacent organs  
N0 No lymph node involvement 
N1 Regional lymph node involvement 
N2 Extensive regional lymph node involvement 
N3 More distant lymph node involvement 
M0 No distant metastases 
M1 Distant metastases present 
 
AJC staging. (American Joint Committee staging) divides all can-
cers into stage O to IV, and takes into account all the 3 components of the 
preceding system (primary tumour, nodal involvement and distant metasta-
ses) in each stage. 
TNM and AJC staging systems can be applied for staging most ma-
lignant tumours. 
 
ETIOLOGY AND PATHOGENESIS OF NEOPLASIA 
A lot of clinical and experimental research and epidemiological stud-
ies have been carried out in the field of oncology so as to know the possible 
causes of cancer and mechanisms involved in transformation of a normal 
cell into a neoplastic cell. It is widely known that no single factor is respon-
sible for development of tumours. The role of some factors in production of 
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neoplasia is established while that of others is epidemiological and many 
others are still unknown. Based on the current state of knowledge, these fac-
tors are broadly described under 2 main headings: 
I. Predisposing epidemiologic factors or cofactors in carcinogenesis, 
which include a number of endogenous host factors and exogenous envi-
ronmental factors. 
II. Carcinogenesis, that encompasses exogenous agents like chemical, 
physical, hormonal and biological substances. 
 
EPIDEMIOLOGIC FACTORS 
Cancer incidence. The overall incidence of cancer in a population or 
country is known by registration of all cancer cases (cancer registry) and by 
rate of death from cancer. It is estimated that about 20% of all deaths are 
cancer-related. There have been changing patterns in incidence of cancers in 
both the sexes and in different geographic locations as outlined below. 
1. Familial and genetic factors. It has long been suspected that fa-
milial predisposition and heredity play a role in the development of cancers. 
In general, the risk of developing cancer in relatives of a known cancer pa-
tient is almost three times higher as compared to control subjects. The over-
all estimates suggest that genetic cancers comprise not greater than 5% of 
all cancers. Some of the common examples are as under: 
i) Retinoblastoma. About 40% of retinoblastomas are familial and 
show an autosomal dominant inheritance. Carriers of such genetic composi-
tion have 10000 times higher risk of developing retinoblastoma which is of-
ten bilateral. Such patients are predisposed to develop another primary ma-
lignant tumour, notably osteogenic sarcoma. Retinoblastoma susceptibility 
gene, Rb gene, located on chromosome 13 was the first cancer-predisposing 
gene identified. 
ii) Familial polyposis coli. This condition has autosomal dominant inher-
itance. The polypoid adenomas may be seen at birth or in early age. By the 
age of 50 years, almost 100% cases of familial polyposis coli develop can-
cer of the colon. 
iii) Multiple endocrine neoplasia (MEN). A combination of adenomas of 
pituitary, parathyroid and pancreatic islets (MEN-I) or syndrome of medul-
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lary carcinoma thyroid, pheochromocytoma and parathyroid tumour (MEN-
II) are encountered in families. 
iv) Neurofibromatosis or von Recklinghausen's disease. This condition is 
characterized by multiple neurofibromas and pigmented skin spots (cafe au 
lait spots). These patients have family history consistent with autosomal 
dominant inheritance in 50% of patients. 
v) Cancer of the breast. Female relatives of breast cancer patients have 
2 to 3 times higher risk of developing breast cancer. 
vi) DNA-chromosomal instability syndromes. These are a group of pre-
neoplastic conditions having defect in DNA repair mechanism. A classical 
example is xeroderma pigmentosum, an autosomal recessive disorder, char-
acterized by extreme sensitivity to ultraviolet radiation. The patients may 
develop various types of skin cancers such as basal cell carcinoma, squa-
mous cell carcinoma and malignant melanoma. 
2. Racial and geographic factors. Differences in racial incidence of 
some cancers may be partly attributed to the role of genetic composition but 
are largely due to influence of the environment and geographic differences 
affecting the whole population such as climate, soil, water, diet, habits, cus-
toms etc. Some of the examples of racial and geographic variations in vari-
ous cancers are as under: 
i) White Europeans and Americans develop most commonly malignan-
cies of the lung, breast, and colon. Liver cancer is uncommon in these races. 
Breast cancer is uncommon in Japanese women but is more common in 
American women. 
ii) Black Africans, on the other hand, have more commonly cancers of 
the skin, penis, cervix and liver. 
iii) Japanese have five times higher incidence of carcinoma of the 
stomach than the Americans. 
iv) South-East Asians, especially of Chinese origin have more com-
monly nasopharyngeal cancer. 
3. Environmental and cultural factors. Surprising as it may seem, 
we are surrounded by an environment of carcinogens which we eat, drink, 
inhale and touch. Some of the examples are given below: 
i) Cigarette smoking is the single most important environmental factor 
implicated in the etiology of cancer of the oral cavity, pharynx, larynx, oe-
sophagus, lungs, pancreas and urinary bladder. 
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ii) Alcohol abuse predisposes to the development of cancer of orophar-
ynx, larynx, oesophagus and liver. 
iii) Alcohol and tobacco together further accentuate the risk of develop-
ing cancer of the upper aerodigestive tract. 
iv) Cancer of the cervix is linked to a number of factors such as age at 
first coitus, frequency of coitus, multiplicity of partners, parity etc. Sexual 
partners of circumcised males have lower incidence of cervical cancer than 
the partners of uncircumcised males. 
v) Penile cancer is rare in the Jews and Muslims as they are customari-
ly circumcised. Carcinogenic component of smegma appears to play a role 
in the etiology of penile cancer. 
vi) Betel nut cancer of the cheek and tongue is quite common in some 
parts of India due to habitual practice of keeping the bolus of paan in a par-
ticular place in mouth for a long time. 
vii) A large number of industrial and environmental substances are car-
cinogenic and are occupational hazard for some populations. These include 
exposure to substances like arsenic, asbestos, benzene, vinyl chloride, naph-
thylamine etc. 
viii) Certain constituents of diet have also been implicated in the causa-
tion of cancer. Overweight individuals, deficiency of vitamin A and people 
consuming diet rich in animal fats and low in fibre content are more at risk 
of developing certain cancers such as colonic cancer. Diet rich in vitamin E, 
on the other hand, possibly has some protective influence by its antioxidant 
action. 
4. Age. Generally, cancers occur in older individuals past 5th decade 
of life, though there are variations in age incidence in different forms of 
cancers. It is not clear whether higher incidence of cancer in advanced age 
is due to alteration in the cells of the host, longer exposure to the effect of 
carcinogen, or decreased ability of the host immune response. Some tu-
mours have two peaks of incidence e.g. acute leukaemias occur in children 
and in older age group. The biologic behaviour of tumours in children does 
not always correlate with histologic features. Besides acute leukaemias, 
other tumours in infancy and childhood are: neuroblastoma, nephroblasto-
ma (Wilms' tumour), retinoblastoma, hepatoblastoma, rhabdomyosarcoma, 
Ewing's sarcoma, teratoma and CNS tumours. 
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5. Sex. Apart from the malignant tumours of organs peculiar to each 
sex, most tumours are generally more common in men than in women ex-
cept cancer of the breast, gall bladder, thyroid and hypopharynx. Although 
there are geographic and racial variations, cancer of the breast is the com-
monest cancer in women throughout the world while lung cancer is the 
commonest cancer in men. The differences in incidence of certain cancers 
in the two sexes may be related to the presence of specific sex hormones. 
6. Premalignant lesions (tumour progression). Premalignant le-
sions are a group of conditions which predispose to the subsequent devel-
opment of cancer. Such conditions are important to recognize so as to pre-
vent the subsequent occurrence of an invasive cancer. Many of these condi-
tions are characterized by morphologic changes in the cells such as in-
creased nuclear-cytoplasmic ratio, pleomorphism of cells and nuclei, in-
creased mitotic activity, poor differentiation, and sometimes accompanied 
by chronic inflammatory cells. 
Some examples of premalignant lesions are given below: 
1. Carcinoma in situ (intraepithelial neoplasia). When the cytological fea-
tures of malignancy are present but the malignant cells are confined to epi-
thelium without invasion across the basement membrane, it is called as car-
cinoma in situ or intraepithelial neoplasia (CIN). The common sites are: 
i) Uterine cervix at the junction of ecto and endocervix, 
ii) Bowen's disease of the skin, 
iii) Actinic or solar keratosis, 
iv) Oral leukoplakia, 
v) Intralobular and intraductal carcinoma of the breast. The area in-
volved in carcinoma in situ may be single and small, or multifocal. As re-
gards the behaviour of CIN, it may regress and return to normal or may de-
velop into invasive cancer. In some instances such as in cervical cancer, 
there is a sequential transformation from squamous metaplasia, to epithelial 
dysplasia, to carcinoma in situ, and eventually to invasive cancer. 
2. Some benign tumours. Commonly, benign tumours do not become 
malignant. However, there are some exceptions e.g. 
i) Multiple adenomas of the large intestine have high incidence of 
developing adenocarcinoma. 
ii) Neurofibromatosis (von Recklinghausen`s disease) may develop 
into sarcoma. 
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3. Miscellaneous conditions. Certain inflammatory and hyperplastic 
conditions are prone to development of cancer, e.g. 
i) Patients of long-standing ulcerative colitis are predisposed to de-
velop colorectal cancer. 
ii) Cirrhosis of the liver has predisposition to develop hepatocellular 
carcinoma. 
iii) Chronic bronchitis in heavy cigarette smokers may develop can-
cer of the bronchus. 
iv) Chronic irritation from jagged tooth or ill-fitting denture may lead 
to cancer of the oral cavity. 
 
CARCINOGENESIS 
Carcinogenesis means induction of tumours; agents which can induce 
tumours are called carcinogens. These terms are used for neoplastic prolif-
eration of benign as well as malignant tumours, though the word 'carcino' 
implies cancer. Other terms used synonymously with carcinogenesis are on-
cogenesis and tumorogenesis. 
Carcinogens are a variety of extrinsic agents which are broadly divid-
ed into 4 groups: 
A. Chemical carcinogens, 
B. Physical carcinogens (mainly radiation), 
C. Hormonal carcinogens, 
D. Biologic carcinogens (chiefly viruses). 
Many of these agents have been shown to induce tumours in experi-
mental animals, while some have evidence of their role in human beings. 
A. CHEMICAL CARCINOGENESIS 
The first ever evidence of any cause for neoplasia came from the ob-
servation of Sir Percival Pott in 1775 that there was higher incidence of 
cancer of the scrotum in chimney-sweeps in London than in the general 
population. This invoked wide interest in soot and coal tar as possible car-
cinogenic agent and the possibility of other occupational cancers. The first 
successful experimental induction of cancer was produced by two Japanese 
workers (Yamagiwa and Ichikawa) in 1914 in the rabbit`s skin by repeated-
ly painting with coal tar. Since then the list of chemical carcinogens which 
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can experimentally induce cancer in animals and have epidemiological evi-
dence in causing human neoplasia, is ever increasing. 
Stages in Chemical Carcinogenesis 
The induction of cancer by chemical carcinogens occurs after a delay 
– weeks to months in the case of experimental animals, and often several 
years in man. Other factors that influence the induction of cancer are the 
dose and mode of administration of carcinogenic chemical, individual sus-
ceptibility and various predisposing factors explained above. 
Though the initial event is the conversion of “the target cell” into the 
“neoplastic cell”, the subsequent changes of cellular proliferation are quite 
important in the evolution of clinical cancer. The phenomena of cellular 
transformation by chemical carcinogens is a progressive process involving 2 
distinct sequential stages: initiation and promotion of carcinogenesis. 
1. Initiation of carcinogenesis 
Initiation is the first stage in carcinogenesis induced by chemical car-
cinogens. The change can be produced by a single dose of the initiating 
agent for a short time, though larger dose for longer duration is more effec-
tive. 
The change so induced is sudden, irreversible and permanent. Chem-
ical carcinogens acting as initiators of carcinogenesis can be grouped into 2 
categories: 
I. Direct-acting carcinogens. These are a few chemical substances 
(e.g. Alkylating agents, acylating agents) which can induce cellular trans-
formation without undergoing any prior metabolic activation. 
II. Indirect-acting carcinogens or pro-carcinogens. These require 
metabolic conversion within the body so as to become “ultimate” carcino-
gens having carcinogenicity e.g. polycyclic aromatic hydrocarbons, aro-
matic amines, azo dyes, naturally-occurring products and others. 
In either case, the following steps are involved in transforming “the 
target cell” into “the initiated cell”: 
a) Metabolic activation. Vast majority of chemical carcinogens are indi-
rect-acting or procarcinogens requiring metabolic activation, while direc-
tacting carcinogens do not require this activation. Most carcinogens are ac-
tivated chiefly by the mixed oxidases of the cytochrome P-450 system lo-
cated in the microsomal component of the endoplasmic reticulum or in the 
nucleus. The activity of the enzyme system and potency of the procarcino-
 181 
gen are affected by genetic and environmental influences, and stimulated by 
administration of drugs such as phenobarbital. In some circumstances, the 
procarcinogen may be detoxified and rendered inactive metabolically. 
b) Reactive electrophiles. The two types of initiating carcinogens – di-
rectacting and procarcinogens, behave alike following metabolic activation 
of the latter. These substances become electron-deficient i.e. reactive elec-
trophiles, which bind to electron-rich portions of other molecules of the cell 
such as DNA, RNA and other proteins. 
c) Target molecules. The primary target of electrophiles is DNA, pro-
ducing mutagenesis. The change in DNA may lead to 'the initiated cell' or 
some form of cellular enzymes may be able to repair the damage in DNA. 
The classic example of the latter situation as xeroderma pigmentosum, a 
precancerous condition, in which there is hereditary defect in DNA repair 
mechanism of the cell. 
d) The initiated cell. The unrepaired damage produced in the DNA of 
the cell becomes permanent only if the altered cell undergoes at least one 
cycle of proliferation. This results in transferring the change to the next 
progeny of cells so that the DNA damage becomes permanent and irreversi-
ble, which are the characteristics of the initiated cell, vulnerable to the ac-
tion of promoters of carcinogenesis. 
2. Promotion of carcinogenesis 
Promotion is the next sequential stage in the chemical carcinogenesis. 
Promoters of carcinogenesis are substances such as phorbol esters, phenols, 
hormones, artificial sweeteners and drugs like phenobarbital. They differ 
from initiators in the following respects: 
i) They do not produce sudden change, 
ii) They require application or administration, as the case may be, for 
sufficient time and in sufficient dose, 
iii) The change induced may be reversible, 
iv) They do not damage the DNA per se but instead enhance the ef-
fect of direct-acting carcinogens or procarcinogens. 
v) Tumour promoters act by activation of growth factor pathways lead-
ing to further clonal proliferation and expansion of initiated (mutated) cells. 
Though tumour promoters themselves are not mutagenic, they can cause DNA 
breaks in some cells by formation of oxygen-derived free radicals. 
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CO-CARCINOGENS. When the process of carcinogenesis is continued 
uninterrupted by replacing one chemical carcinogen with another, or alter-
natively, when two carcinogens are administered simultaneously to enhance 
the effect it is called co-carcinogenesis and such substances are called co-
carcinogens. 
CARCINOGENIC CHEMICALS IN HUMANS 
The list of diverse chemical compounds which can produce cancer in 
experimental animals is a long one but only some of them have sufficient 
epidemiological evidence in human neoplasia. 
Depending upon the mode of action of carcinogenic chemicals, they 
are divided into 2 broad groups: 
1. Initiators of carcinogenesis, 
2. Promoters of carcinogenesis 
1. INITIATORS OF CARCINOGENESIS 
Chemical carcinogens which can initiate the process of neoplastic 
transformation are further categorized into 2 subgroups – direct-acting car-
cinogens and indirect-acting carcinogens or procarcinogens. 
I. Direct-acting carcinogens. These chemical carcinogens do not re-
quire metabolic activation and fall into 2 classes: 
a) Alkylating agents. This group includes mainly various anti-cancer 
drugs (e.g. cyclophosphamide, chlorambucil, busulfan, melphalan, nitro-
sourea etc), 5-propiolactone and epoxides. They are weakly carcinogenic 
and are implicated in the etiology of the lymphomas and leukaemias in hu-
man beings. 
b) Acylating agents. These are substances like acetyl imidazole 
which is a direct-acting chemical carcinogen. 
 
II. Indirect-acting carcinogens (pro-carcinogens). These are chem-
ical substances requiring metabolic activation for becoming potent “ulti-
mate” carcinogens. Majority of carcinogenic chemicals fall into this group. 
These include the following classes: 
a) Polycyclic aromatic hydrocarbons. They comprise the largest 
group of common procarcinogens which, after metabolic activation, can in-
duce neoplasia in many tissues in experimental animals and are also impli-
cated in a number of human neoplasms. Main sources of polycyclic aro-
matic hydrocarbons are tobacco, smoke, fossil fuel (e.g. coal), soot, tar, 
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mineral oil, smoked animal foods, industrial and atmospheric pollutants. 
Important chemical compounds included are benzanthracene, benzapyrene 
and methylcholanthrene. The following examples have evidence to support 
the etiologic role of these substances: 
• Smoking: There is 20 times higher incidence of lung cancer in 
smokers of 2 packs (40 cigarettes) per day for 20 years. 
• Skin cancer: Direct contact of polycyclic aromatic hydrocarbon 
compounds with skin is associated with higher incidence of skin cancer. For 
example, the natives of Kashmir carry an earthen pot containing embers, the 
kangri, under their clothes close to abdomen for purposes of warmth, and 
skin cancer of the abdominal wall termed kangri cancer is common among 
them. 
• Tobacco and betel nut chewing: Cancer of the oral cavity is more 
common in people chewing tobacco and betel nuts. The chutta is a cigar 
that is smoked in South India (in Andhra Pradesh) with the lighted end in 
the mouth (i.e. reversed smoking) and such individuals have higher inci-
dence of cancer of the mouth. 
b) Aromatic amines and azodyes. This category includes the fol-
lowing substances implicated in chemical carcinogenesis: 
• 3-naphthylamine in the causation of bladder cancer, especially in 
aniline dye and rubber industry workers. 
• Benzidine in the induction of bladder cancer. 
• Azo-dyes used for colouring foods (e.g. butter yellow for colouring 
margarine and butter, scarlet red for colouring cherries etc) in the causation 
of hepato-cellular carcinoma. 
• Acetyl aminofluorene in experimental induction of hepatocellular 
carcinoma. 
c) Naturally-occurring products. Some of the important chemical 
carcinogens derived from plant and microbial sources are aflatoxin Bl, acti-
nomycin D, mitomycin C, safrole and betel nuts. Out of these, aflatoxin Bl 
implicated in causing human hepatocellular carcinoma is the most im-
portant. It is derived from the fungus, Aspergillus flavus, that grows in 
stored grains and plants. 
d) Miscellaneous. A variety of other chemical carcinogens having a 
role in the etiology of human cancer are as under: 
• Nitroso-compounds like nitrosamines involved in gastric carcino-
ma. 
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• Vinyl chloride monomer derived from PVC (polyvinyrchloride) 
polymer in the causation of haemangio-sarcoma of the liver. 
• Asbestos in bronchogenic carcinoma and mesothelioma. 
• Arsenical compounds in causing epidermal hyperplasia and basal 
cell carcinoma. 
• Metals like nickel, lead, cobalt chromium etc. in industrial workers 
causing lung cancer. 
• Insecticides and fungicides (e.g. aldrin, dieldrin, chlordane) in car-
cinogenesis in experimental animals. 
 
2. PROMOTERS OF CARCINOGENESIS 
Certain chemical substances lacking the intrinsic carcinogenic poten-
tial but helping the initiated cell to proliferate further are called promoters 
of carcinogenesis. Some of such substances which are either known pro-
moters in experimental animals or are implicated as promoters in human 
neoplasia are: 
a) Phorbol esters such as TPA, 
b) Phenols, 
c) Hormones, e.g. effect of oestrogen on endometrium or breast, 
d) Drugs, e.g. Phenobarbital, 
e) Artificial sweeteners, e.g. saccharin and cyclamates. 
 
Tests for Chemical Carcinogenicity 
There are 2 main methods of testing chemical compound for its car-
cinogenicity: 
1. EXPERIMENTAL INDUCTION. The traditional method is to administer 
the chemical compound under test to a batch of experimental animals like 
mice or other rodents by an appropriate route e.g. painting on the skin, giv-
ing orally or parenterally, or by inhalation. 
The chemical is administered repeatedly, the dose varied, and pro-
moting agents are administered subsequently. After many months, the ani-
mal is autopsied and results obtained. However, all positive or negative 
tests cannot be applied to humans since there is sufficient species variation 
in susceptibility to particular carcinogen. Besides, the test is rather pro-
longed and expensive. 
2. TESTS FOR MUTAGENICITY (AMES` TEST). A mutagen is a substance 
that can permanently alter the genetic composition of a cell. Ames` test 
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evaluates the ability of a chemical to induce mutation in the mutant strain of 
Salmonella typhimurium that cannot synthesise histidine. Such strains are 
incubated with the potential carcinogen to which liver homogenate is added 
to supply enzymes required to convert procarcinogen to ultimate carcino-
gen. If the chemical under test is mutagenic, it will induce mutation in the 
mutant strains of S. typhimurium in the form of functional histidine gene, 
which will be reflected by the number of bacterial colonies growing on his-
tidine-free culture medium. Most of the carcinogenic chemicals tested posi-
tive in Ames` test are carcinogenic in vivo. 
 
B. PHYSICAL CARCINOGENESIS 
Physical agents in carcinogenesis are divided into 2 groups: 
1. Radiation both ultraviolet light and ionising radiation, is the most 
important physical agent. 
2. Non-radiation physical agents are the various forms of injury and 
are less important. 
1. Radiation Carcinogenesis 
Ultraviolet (UV) light and ionising radiation are the two main forms 
of radiation carcinogens which can induce cancer in experimental animals 
and are implicated in causation of some forms of human cancers. A proper-
ty common between the two forms of radiation carcinogens is the appear-
ance of carcinogenic effects long after exposure, often 10-20- years or even 
later. Also, radiation carcinogens may act to enhance the effect of another 
carcinogen i.e. they may act as co-carcinogens. Ultraviolet light and ionis-
inig radiation differ in their mode of action as described below: 
i) ULTRAVIOLET LIGHT. The main source of UV radiation is the sun-
light; others are UV lamps and Welder`s arcs. UV light penetrates the skin 
for a few millimetres only so that its effect is limited to epidermis. The effi-
ciency of UV light as carcinogen depends upon the extent of light-absorbing 
protective melanin pigmentation of the skin. In humans, excessive exposure 
to UV rays can cause various forms of skin cancers – squamous cell carci-
noma, basal cell carcinoma and malignant melanoma. In support of this is 
the epidemiological evidence of high incidence of these skin cancers in fair-
skinned Europeans, albinos who do not tan readily, in people of Queensland 
in Australia living close to the equator who receive more sunlight, and in 
farmers and outdoor workers due to the effect of actinic light radiation. 
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Mechanism. UV radiation may have various effects on the cells. The 
most important is induction of mutation; others are inhibition of cell divi-
sion, inactivation of enzymes and sometimes killing of the cells. The most 
important biochemical effect of UV radiation is the formation of pyrimidine 
dimers in DNA but such UV-induced DNA damage in normal individuals is 
repaired. The proof in favour of mutagenic effect of UV radiation comes 
from recessive hereditary diseases characterized by a defect in DNA repair 
mechanism and associated with high incidence of cancers. Such examples 
are as under: 
a) Xeroderma pigmentosum is predisposed to skin cancers at younger 
age (under 20 years of age). 
b) Ataxia telangiectasia is predisposed to leukaemia. 
c) Bloom's syndrome is predisposed to all types of cancers. 
 
ii) IONISING RADIATION. Ionising radiation of all kinds like X-rays, α-
, β- and γ-rays, radioactive isotopes, protons and neutrons can cause cancer 
in animals and in man. Most frequently radiation-induced cancers are all 
forms of leukaemias (except chronic lymphocytic leukaemia); others are 
cancers of the thyroid, skin, breast, lung and salivary glands. The risk is in-
creased by higher dose and with high LET (linear energy transfer) such as 
in neutrons and a-rays than with low LET as in X-rays and γ-rays. The evi-
dence in support of carcinogenic role of ionising radiation is cited in the fol-
lowing examples: 
a) Higher incidence of radiation dermatitis and subsequent malignant 
tumours of the skin was noted in X-ray workers and radiotherapists who did 
initial pioneering work in these fields before the advent of safety measures. 
b) High incidence of osteosarcoma was observed in young American 
watch-working girls engaged in painting the dials with luminous radium 
who unknowingly ingested radium while using lips to point their brushes. 
c) Miners in radioactive elements have higher incidence of cancers. 
d) Japanese atom bomb survivors of the twin cities of Hiroshima and 
Nagasaki after World War II have increased frequency of malignant tu-
mours, notably acute and chronic myeloid leukaemias, and various solid 
tumours of breast, colon, thyroid and lung. 
e) More recently in 1985, about 5000 people fell victim to hazardous 
effects of radioactive material due to leakage of nuclear reactor at Cherno-
byl (in erstwhile USSR, now in Ukraine). 
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f) Therapeutic X-ray irradiation may result in increased frequency of 
cancers such as in patients of ankylosing spondylitis, in children with en-
larged thymus, and in children irradiated in utero during investigations on 
the mother. 
Mechanism. How ionising radiation induces cancer is not clearly 
known. Radiation damages the DNA of the cell by one of the 2 possible 
mechanisms: 
a) It may directly alter the cellular DNA. 
b) It may dislodge ions from water and other molecules of the cell 
and result in formation of highly reactive free radicals that may bring about 
the damage. 
Damage to the DNA resulting in mutagenesis is the most important 
action of ionising radiation. The effect depends upon a number of factors 
such as type of radiation, dose, dose-rate and various host factors such as 
age, individual susceptibility, immune competence, hormonal influences 
and type of cells irradiated. 
 
2. Non-radiation Physical Carcinogenesis 
Mechanical injury to the tissues such as from stones in the gallblad-
der, stones in the urinary tract, and healed scars following burns or trauma, 
has been suggested as the cause of increased risk of carcinoma in these tis-
sues but the evidence is not convincing. Asbestosis and asbestos-associated 
tumours of the lung are discussed on page 462; the characteristic tumour be-
ing malignant mesothelioma of the pleura. Other examples of physical 
agents in carcinogenesis are the implants of inert materials such as plastic, 
glass etc in prostheses or otherwise, and foreign bodies observed to cause 
tumour development in experimental animals. However, tumorogenesis by 
these materials in humans is rare. 
 
C. HORMONAL CARCINOGENESIS 
Cancer is more likely to develop in organs and tissues which undergo 
proliferation under the influence of excessive hormonal stimulation. On 
cessation of hormonal stimulation, such tissues become atrophic. Hormone-
sensitive tissues developing tumours are the breast, endometrium, myome-
trium, vagina, thyroid, liver, prostate and testis. Some examples of hor-
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mones influencing carcinogenesis in experimental animals and humans are 
given below. 
1. OESTROGEN. Examples of oestrogen-induced cancers are as under: 
i) In experimental animals. Induction of breast cancer in mice by ad-
ministration of high dose of oestrogen and reduction of the tumour devel-
opment following oophorectomy is the most important example. Associated 
infection with mouse mammary tumour virus (MMTV, Bittner milk factor) 
has an added influence on the development of breast cancer in mice. Other 
cancers which can be experimentally induced in mice by oestrogens are 
squamous cell carcinoma of the cervix, connective tissue tumour of the my-
ometrium, Leydig cell tumour of the testis in male mice, tumour of the kid-
ney in hamsters, and benign as well as malignant tumours of the liver in 
rats. 
ii) In humans. Women receiving oestrogen therapy and women with 
oestrogen-secreting granulosa cell tumour of the ovary have increased risk 
of developing endometrial carcinoma. Adenocarcinoma of the vagina is 
seen with increased frequency in adolescent daughters of mothers who had 
received oestrogen-therapy during pregnancy. 
2. CONTRACEPTIVE HORMONES. The sequential types of oral contra-
ceptives increase the risk of developing breast cancer. Other tumours show-
ing a slightly increased frequency in women receiving contraceptive pills 
for long durations are benign tumours of the liver, and a few patients have 
been reported to have developed hepatocellular carcinoma. 
3. ANABOLIC STEROIDS. Consumption of anabolic steroids by athletes 
to increase the muscle mass is not only unethical athletic practice but also 
increases the risk of developing benign and malignant tumours of the liver. 
4. HORMONE-DEPENDENT TUMOURS. It has been shown in experi-
mental animals that induction of hyperfunction of adenohypophysis is asso-
ciated with increased risk of developing neoplasia of the target organs fol-
lowing preceding functional hyperplasia. There is tumour regression on re-
moval of the stimulus for excessive hormonal secretion. A few examples of 
such phenomena are seen in humans: 
i) Prostatic cancer usually responds to the administration of oestro-
gens. 
ii) Breast cancer may regress with oophorectomy, hypo-physectomy 
or on administration of male hormones,  
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iii) Thyroid cancer may slow down in growth with administration of 
thyroxine that suppresses the secretion of TSH by the pituitary. 
 
D. BIOLOGIC CARCINOGENESIS 
The epidemiological studies on different types of cancers indicate the 
involvement of transmissible biologic agents in their development, chiefly 
viruses. Other biologic agents implicated in carcinogenesis are parasites 
(e.g. schistosomiasis) which is associated with high incidence of cancer of 
the urinary bladder in some parts of the world such as in Egypt) and more 
recently bacteria (Helicobacter pylori infection in the causation of gastric 
lymphoma and gastric carcinoma). The role of viruses in the causation of 
cancer is more significant. It has been estimated that about 20% of all can-
cers worldwide are virus-associated cancers. Therefore, biologic carcino-
genesis is largely viral carcinogenesis, described below. 
 
VIRAL CARCINOGENESIS 
The association of oncogenic viruses with neoplasia was first ob-
served by an Italian physician Sanarelli in 1889 who noted association be-
tween myxomatosis of rabbits with poxvirus. The contagious nature of the 
common human wart was first established in 1907. Since then, a number of 
viruses capable of inducing tumours (oncogenic viruses) in experimental 
animals, and some implicated in man, have been identified. 
Oncogenic viruses can be transmitted by one of the 3 routes: 
i) Vertical transmission, when the infection is genetically transmitted 
from infected parents to offsprings,  
ii) Horizontal transmission, when the infection passes from one to 
another by direct contact as occurs in most contagious diseases. 
iii) By inoculation as is done in experimental animals. 
When target cells are grown in vitro with oncogenic virus, the cul-
tured cells lose contact inhibition and are piled on top of one another rather 
than growing in regular monolayer which the normal cells do. Such virus-
induced altered cells are called “transformed cells” which are capable of 
growing into a neoplasm. Recent advances in molecular biology of carcino-
genesis have greatly enhanced our knowledge of virus-induced neo-plastic 
processes. 
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Based on their nucleic acid content, oncogenic viruses fall into 2 
broad groups: 
1. Those containing deoxyribonucleic acid are called DNA oncogenic 
viruses. 
2. Those containing ribonucleic acid are termed RNA oncogenic vi-
ruses. 
The two types of oncogenic viruses are described separately below, 
followed by their mechanisms of action. Most of the work is based on stud-
ies in experimental animals and only some have a role in human neoplasia. 
 
DNA Oncogenic Viruses 
DNA oncogenic viruses are classified into 5 subgroups, each of 
which is capable of producing neoplasms in different hosts. These are: 
Papovaviruses, Herpesviruses, Adenoviruses, Poxviruses and Hepadna vi-
ruses. 
1. PAPOVAVIRUSES. This group consists of the papilloma virus in-
cluding the human papilloma virus (HPV), polyoma virus and SV-40 (simi-
an vacuolating) virus. These viruses have an etiologic role in a variety of 
benign and malignant neoplasms in animals and in humans: 
i) Papilloma viruses. These viruses were the first to be implicated in 
the etiology of any human neoplasia. These viruses appear to replicate in 
the layers of stratified squamous epithelium. About 50 different types of 
HPV have been identified. Those implicated in the causation of benign 
squamous papillomas include types 1, 2, 4 and 7, while DNA sequence of 
types 16 and 18 are found in squamous cell carcinoma. The following ex-
amples are cited to demonstrate their role in oncogenesis: 
In humans: 
• HPV was first detected as etiologic agent in common skin warts or 
papillomas by Shope in 1933. The condition is infectious. 
• HPV is responsible for causing an uncommon condition, epidermo-
dysplasia verruciformis. The condition is characterized by multiple skin 
warts and a genetic defect in the cell-mediated immunity. About one third 
of cases develop squamous cell carcinoma in the sun-exposed warts. 
• The same virus HPV (types 6 and 11) may cause genital warts or 
condyloma acuminata. 
• Some strains of HPV are responsible for causing multiple juvenile 
papillomas of the larynx. 
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• There is strong association between HPV infection with high risk 
types (HPV types 16 and 18) and development of genital neoplasia, espe-
cially cervical cancer. 
In animals: 
• Benign warty lesions similar to those seen in humans are produced 
by different members of the papilloma virus family in susceptible animals 
such as in rabbits by cottontail rabbit papilloma virus, and in cattle by bo-
vine papilloma virus (BPV). 
• There is evidence to suggest the association of BPV and cancer of 
the alimentary tract in cattle. 
ii) Polyoma virus. Polyoma virus occurs as a natural infection in mice. 
• In animals: 
Polyoma virus infection is responsible for various kinds of carcino-
mas and sarcomas in immunodeficient (nude) mice and other rodents. 
• In humans: 
Polyoma virus infection is not known to produce any human tumour 
but can cause progressive demyelinating leucoencephalopathy which is a 
fatal demyelinating disease. 
iii) SV-40 virus. As the name suggests, simian vacuolating virus oc-
curs in monkeys without causing any harm but can induce sarcoma in ham-
sters. There is no evidence of involvement of SV-40 infection in causing 
any human tumours. 
 
2. HERPESVIRUSES. Important members of herpesvirus family are 
Epstein-Barr virus, herpes simplex virus type 2 (HSV-2) and human her-
pesvirus 8 (HHV8), cytomegalovirus (CMV), Lucke's frog virus and Ma-
rek's disease virus. Of these, Lucke's frog virus and Marek's disease virus 
are implicated in animal tumours only (renal cell carcinoma and T-cell leu-
kaemia-lymphoma respectively) while the oncogenic role of HSV-2 and 
CMV in human tumours has been refuted. The other two – EBV and HHV 
are implicated in human tumours as follows. Primary infection of all the 
herpes viruses in man persists probably for life in a latent stage which can 
get reactivated later. 
EPSTEIN-BARR VIRUS (EBV). EBV infects human B-lymphocytes and 
stimulates them to proliferate. EBV is implicated in 2 human tumours – 
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Burkitt`s lymphoma and anaplastic nasopharyngeal carcinoma. It is also 
shown to be the cause of infectious mononucleosis in man. 
Burkitt's lymphoma. Burkitt`s lymphoma was initially noticed in 
African children by Burkitt in 1958 but is now known to occur in 2 forms – 
African endemic form, and sporadic form seen elsewhere in the world. The 
morphological aspects of the tumour are explained on page 419 while onco-
genesis is described here. 
There is strong evidence linking Burkitt's lymphoma, a B- lympho-
cyte neoplasm, with EBV as observed from the following features: 
a) Over 90% of Burkitt's lymphomas are EBV-positive in which each 
tumour cell carries the virus. 
b) 100% cases of Burkitt's lymphoma show elevated levels of anti-
body titers to various EBV antigens. 
c) EBV has strong tropism for B lymphocytes. EBV-infected B cells 
grown in cultures are immortalized i.e. they continue to develop further 
along B cell-line to propagate their progeny in the altered form. 
d) Though EBV infection is almost worldwide in all adults and is also 
known to cause self-limiting infectious mononucleosis, but the fraction of 
EBV-infected circulating B cells in such individuals is extremely small. 
e) Linkage between Burkitt's lymphoma and EBV infection is very 
high in African endemic form of the disease and probably in cases of AIDS 
than in sporadic form of the disease. 
However, a few observations, especially regarding sporadic cases of 
Burkitt's lymphoma, suggest that certain other supportive factors may be 
contributing. Immunosuppression appears to be one such most significant 
factor. The evidence in favour is as follows: 
• The normal EBV-infected individuals as well as cases developing 
infectious mononucleosis are able to mount good immune response so that 
they do not develop Burkitt's lymphoma. 
• Therejis prevalence of Burkitt's lymphoma in cases of AIDS in 
which there is marked reduction in body's T-cell immune response. 
• It is observed that malaria, which confers immuno-suppressive effect 
on the host, is prevalent in endemic proportions in regions where endemic 
form of Burkitt's lymphoma is frequent. This supports the linkage of EBV in-
fection and immunosuppression in the etiology of Burkitt's lymphoma. 
Anaplastic nasopharyngeal carcinoma. This is the other tumour 
having close association with EBV infection. The tumour is prevalent in 
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South-East Asia and in Eskimos. The evidence linking EBV infection with 
this tumour is as follows: 
a) 100% cases of nasopharyngeal carcinoma carry DNA of EBV. 
b) Individuals with this tumour have high titers of antibodies to vari-
ous EBV antigens. 
However, like in case of Burkitt's lymphoma, there may be some co-
factors that account for the unusual geographic distribution. 
 
HUMAN HERPESVIRUS 8 (HHV 8). Recently it has been shown that in-
fection with a new virus, HHV 8 or Kaposi's sarcoma-associated herpesvi-
rus (KSHV) is associated with Kaposi's sarcoma, a vascular neoplasm 
common in patients of AIDS. HHV 8 has lymphotropism and is also impli-
cated in causation of B cell lymphoma and multicentric variant of Cas-
tleman's disease. 
3. ADENOVIRUSES. The human adenoviruses cause upper respiratory 
infections and pharyngitis. 
• In man, they are not known to be involved in any tumour. 
• In hamsters, they may induce sarcomas. 
4. POXVIRUSES. This group of oncogenic viruses is involved in the 
etiology of following lesions: 
• In rabbits – poxviruses cause myxomatosis. 
• In humans – poxviruses cause molluscum contagiosum and may in-
duce squamous cell papilloma. 
5. HEPADNAVIRUSES. Hepatitis B virus (HBV) is a member of 
hepadnavirus family. HBV infection in man causes an acute hepatitis and is 
responsible for a carrier state, which can result in some cases to chronic 
hepatitis progressing to hepatic cirrhosis, and onto hepatocellular carcino-
ma. Suffice this to say here that there is strong epidemiological evidence 
linking HBV infection to development of hepatocellular carcinoma as evi-
denced by the following: 
a) The geographic differences in the incidence of hepatocellular car-
cinoma closely match the variation in prevalence of HBV infection e.g. high 
incidence in Far-East and Africa. 
b) Epidemiological studies in high incidence regions indicate about 
200 times higher risk of developing hepatocellular carcinoma in HBV-
infected cases as compared to uninfected population in the same area. 
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Posssible mechanism of hepatocellular carcinoma occurring in those 
harbouring long association with HBV is chronic destruction of HBV-
infected hepatocytes followed by continued hepatocyte proliferation. This 
process renders the hepatocytes vulnerable to the action of other risk factors 
such as to aflatoxin causing mutation and neoplastic proliferation. 
More recent evidence has assigned an oncogenic role to another 
hepatotropic virus, hepatitis C virus (HCV), ah RNA virus unrelated to 
HBV. HCV is implicated in about half the cases of hepatocellular carcino-
ma in much the same way as HBV. 
 
RNA ONCOGENIC VIRUSES 
RNA oncogenic viruses are retroviruses i.e. they contain the enzyme re-
verse transcriptase, though all retroviruses are not oncogenic. The enzyme, re-
verse transcriptase, is required for reverse transcription of viral RNA to synthe-
sise, viral DNA strands i.e. reverse of normal in which DNA is transcribed into 
messenger RNA. Based on their activity to transform target cells into neoplastic 
cells, they are divided into 3 subgroups: acute transforming viruses, slow trans-
forming viruses, and human T-cell lymphotropic viruses (HTLV). The former 
two are implicated in inducing a variety of tumours in animals while HTLV is 
causative for human T-cell leukaemia and lymphoma. 
1. Acute transforming viruses. This group includes retroviruses 
which transform all the cells infected by them into malignant cells rapidly 
(“acute”). All the viruses in this group possess one or more viral oncogenes 
(v-oncs). All the members of acute transforming viruses discovered so far 
are defective viruses in which the particular v-onc has substituted other es-
sential genetic material such as gag, pol and env. These defective viruses 
cannot replicate by themselves unless the host cell is infected by another 
“helper virus”. Acute oncogenic viruses have-not been detected in any hu-
man tumour so far, though they have been identified in tumours in different 
animals, e.g. 
a) Rous sarcoma virus in chickens. 
b) Leukaemia-sarcoma viruses of various types such as avian, feline, 
bovine and primate. 
2. Slow transforming viruses. These oncogenic retroviruses cause 
development of leukaemias and lymphomas in different species of animals 
(e.g. in mice, cats and bovine) and include the mouse mammary tumour vi-
rus (MMTV) that causes breast cancer in the daughter-mice suckled by the 
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MMTV- infected mother via the causal agent in the mother's milk (Bittner 
milk factor). These viruses have long incubation period between infection 
and development of neoplastic transformation (“slow”). Slow transforming 
viruses cause neoplastic transformation by insertional mutagenesis i.e. viral 
DNA synthesized by viral RNA via reverse transcriptase is inserted or inte-
grated near the proto-oncogenes of the host cell resulting in enhanced ex-
pression of proto-oncogenes as well as causes genetic damage (mutagene-
sis) to the host cell genome leading to neoplastic transformation. 
3. Human t-cell lymphotropic viruses (HTLV). HTLV is a form of 
slow transforming virus but is described separately because cf 2 reasons: 
i) This is the only retrovirus implicated in human cancer. 
ii) The mechanism of neoplastic transformation is different from slow 
transforming as well as from acute transforming viruses. 
 
Four types of HTLVs are recognized – HTLV-I, HTLV-II, HTLV-III 
and HTLV-IV. It may be mentioned in passing here that the etiologic agent 
for AIDS, HIV, is also an HTLV (HTLV-III). 
A link between HTLV-I infection and adult T-cell leukaemia-
lymphoma syndrome (ATLL) has been identified while HTLV-II is impli-
cated in causation of T-cell variant of hairy cell leukaemia. HTLV-I is 
transmitted through sexual contact, by blood, or to infants during breast 
feeding. The highlights of this association and mode of neoplastic transfor-
mation are as under: 
i) Epidemiological studies by tests for antibodies have shown that 
HTLV-I infection is endemic in parts of Japan and West Indies where the 
incidence of ATLL is high. The latent period after HTLV-I infection is, 
however, very long (20-30 years). 
ii) The initiation of neoplastic process is similar to that for Burkitt's 
lymphoma except that HTLV-I has tropism for T-lymphocytes (especially 
CD4 subset of T cells similar to HIV infection in AIDS), while EBV of 
Burkitt's lymphoma has tropism for B lymphocytes. 
iii) As in Burkitt's lymphoma, immunosuppression plays a supportive 
role in the neoplastic transformation by HTLV-I infection. 
The underlying molecular mechanism of neoplastic transformation by 
HTLV-I infection differs from acute transforming viruses because it does 
not contain v-onc, and from other slow transforming viruses because it does 
not have fixed site of insertion for insertional mutagenesis. 
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The genome of HTLV-I contains gag, pol, env and long terminal repeat 
(LTR) regions similar to other retro-viruses but in addition it contains tat gene 
region as well which stimulates neoplastic cell proliferation of T cells. Initial-
ly, this proliferation of T cells is polyclonal which then undergoes new muta-
tions and leads to monoclonal T cell leukaemia-lymphoma. Chronic leukaemia 
retrovirus, HTLV-II, brings about transformation by 'promoter insertion' that 
produces onco-genesis by oncogenes and growth factors. 
 
MECHANISMS OF VIRAL ONCOGENESIS 
1. Mode of DNA viral oncogenesis. Host cells infected by DNA on-
cogenic viruses may have one of the following 2 results: 
i) Replication. The virus may replicate in the host cell with conse-
quent lysis of the infected cell and release of virions. 
ii) Integration. The viral DNA may integrate into the host cell DNA. 
The latter event (integration) results in neoplastic transformation of 
the host cell, while the former (replication) brings about cell death but no 
neoplastic transformation. A feature essential for host cell transformation is 
the expression of virus-specific (transforming protein) antigens immediately 
after infection of the host cell by DNA oncogenic virus. 
2. Mode of RNA viral oncogenesis. As the name suggests, RNA vi-
ruses or retroviruses contain two identical strands of RNA and the enzyme, 
reverse transcriptase. The steps involved in transformation of host cells by 
RNA oncogenic viruses are as under:  
i) Reverse transcriptase is RNA-dependent DNA synthetase that acts 
as a template to synthesise a single strand of matching viral DNA i.e. re-
verse of the normal in which DNA is transcribed into messenger RNA.  
ii) The single strand of viral DNA is then copied by DNA dependent 
DNA synthetase to form another strand of complementary DNA resulting in 
double-stranded viral DNA or provirus. 
iii) The provirus is then integrated into the DNA of the host cell ge-
nome and may transform the cell into neoplastic cell. 
iv) Retroviruses are replication-competent. The host cells which al-
low replication of integrated retrovirus are called permissive cells. Non-
permissible cells do not permit replication of the integrated retrovirus. 
v) Viral replication begins after integration of the pro-virus into host 
cell genome. Integration results in transcription of proviral genes or pro-
genes into messenger RNA which then forms components of the virus par-
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ticle – virion core protein from gag gene, reverse transcriptase from pol 
gene, and envelope glycoprotein from env gene. The three components of 
virus particle are then assembled at the plasma membrane of the host cell 
and the virus particles released by budding off from the plasma membrane, 
thus completing the process of replication. 
VIRUSES AND HUMAN CANCER: A SUMMARY 
In man, epidemiological as well as circumstantial evidence has been 
accumulating since the discovery of contagious nature of common human 
wart (papilloma) in 1907 that cancer may have viral etiology. Presently, 
about 20% of all human cancers worldwide are believed to have 'virus asso-
ciation'. Aside from experimental evidence, the etiologic role of DNA and 
RNA viruses in a variety of human neoplasms has already been explained 
above. Here, a summary of different viruses implicated in human tumours is 
presented: 
1. There are 2 conditions which are actually doubtful as tumours in 
which definite viral etiology is established. These are: 
i) Human wart (papilloma) caused by human papilloma virus; and  
ii) Molluscum coritagiosum caused by poxvirus. 
2. The following 8 human cancers have enough epidemiological and 
serological evidence that viruses, in addition to other concomitant factors, 
are implicated in their etiology: 
i) Burkitt's lymphoma by Epstein-Barr virus. 
ii) Nasopharyngeal carcinoma by Epstein-Barr virus. 
iii) Primary hepatocellular carcinoma by hepatitis B virus and hepati-
tis C virus. 
iv) Cervical cancer by high risk human papilloma virus types (HPV 
16 and 18). 
v) Kaposi's sarcoma by human herpes virus type 8 (HHV 8). 
vi) B cell lymphoma by HHV8. 
vii) Adult T-cell leukaemia and lymphoma by HTLV-I. 
viii) T-cell variant of hairy cell leukaemia by HTLV-II. 
 
MOLECULAR GENETICS OF CANCER 
Genetic basis for cancer has long been suspected due to the following 
observations: 
1. Hereditary predisposition in some cancers. 
 198 
2. Chromosomal abnormalities in many forms of cancers. 
3. Correlation of syndrome of defective DNA repair mechanisms and 
occurrence of cancers. 
4. Genetic damage (mutagenesis) by the action of various exogenous 
agents followed by progression to carcinogenesis. 
However, in the last decade of 20th Century, there has been vast accu-
mulation of literature to explain the genetic basis of cancer at molecular level. 
Broadly speaking, genes and molecular factors involved in the patho-
genesis of cancer can be grouped into 4 categories. 
1. Oncogenes (i.e. cancer causing genses). 
2. Anti-oncogenes ( i.e, cancer suppressor genes). 
3. Mutator genes (i.e. genes that regulate DNA repair). 
4. Telomerase in cancer (i.e. telomere shortening as cancer suppres-
sor mechanisms). 
Oncogenes are cancer causing genes. They are derived from proto-
oncogenes or cellular oncogenes (abbreviated as c-oncs) which are detected on 
normal animal and human cells and promote normal growth and differentia-
tion of cells. Historically, c-oncs were first discovered in the genome of animal 
tumours caused by viruses. In the case of DNA oncogenic viruses in animal 
tumours (e.g. chicken leukaemia-lymphoma virus, Shope papilloma virus, 
polyoma virus, SV 40 virus), viral DNA is incorporated into the cellular ge-
nome, while retroviruses in animal tumours (e.g. Rous sarcoma virus, Bittner 
milk factor) are transduced during their passage through cellular DNA. Since 
these genes were initially discovered as viral genes, proto-oncogenes are also 
called viral oncogenes abbreviated as v-oncs. Thus proto-oncogenes become 
oncogenic by retroviral transduction (v-oncs) and change them into cellular 
oncogenes (c-oncs) in animal tumour induction experiments. 
Different types of v-oncs are named by three letter word derived from 
the oncogenic virus e.g. v-ras for Rat Sarcoma virus, v-fes for Feline Sar-
coma virus etc., while their corresponding proto-oncogenes are termed 
simply as ras and fes respectively. 
While in animals, identification of v-onc genes is by induction of tu-
mours by acute and slow transforming retroviruses, predictably human tu-
mours of viral as well as nonviral etiology too would have similar mutations 
termed human oncogenes. Such human oncogenes are identified by DNA 
transfection (i.e. gene transfer in vitro into cultured mouse fibroblasts) and by 
non-random chromosomal abnormalities (e.g. translocations). 
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Mechanisms of activation of cellular oncogenes. As stated above, 
there is similarity between normal genes coding for proteins for growth and 
differentiation on one hand, and oncogenes of viral and tumour origin on 
the other. How these “normal genes” are activated to become “oncogenes” 
is explained on the basis of two types of mechanisms: 
• change in the structure of gene; and 
• change in the regulation of gene expression. 
Based on this, examples of activation of human oncogenes in human 
tumours are as under: 
i) Point mutations and deletion. Mutations of v-onc sequences in-
crease the tumorigenic ability of acute transforming retroviruses. The most 
important example is ras oncogene carried in many human tumours such as 
bladder cancer, pancreatic adenocarcinoma, cholangiocarcinoma. 
ii) Chromosomal translocation. Mechanism of transfer of a portion of 
one chromosome to another is implicated in the pathogenesis of leukaemias 
and lymphomas e.g. 
• Philadelphia chromosome seen in 95% cases of chronic mye-
logenous leukaemia in which c-abl proto-oncogene on chromosome 9 is 
translocated to chromosome 22. 
• In 75% cases of Burkitt's lymphoma, translocation of c-myc proto-
oncogene from its site on chromosome 8 to a portion on chromosome 14. 
iii) Gene amplification. Chromosomal alterations that result in in-
crease in the number of copies of a gene is found in some examples of solid 
human tumours e.g. 
• Neuroblastoma having n-myc HSR region. 
• erb-B in breast and ovarian cancer. 
Mechanism of action of oncogenes. Oncogenes have oncoproteins 
which are altered form of their normal counterparts, proto-oncogenes, regu-
lating growth and differentiation. Thus proliferation of cells by oncogenes 
is discussed in the context of alteration in the normal cell proliferation that 
includes the following steps: 
i) Extracellular growth factor: Binding of growth factor to specific 
receptor on cell membrane. 
ii) Transmembrane cell surface receptors: Activation of growth factor 
receptor on the cell surface that triggers activation of signal-transducing 
proteins on the inner layer of plasma membrane. 
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iii) Intracellular signal transduction proteins: Transduced signal 
transmitted from cytosol to the nucleus. 
iv) Transcription proteins: DNA binding nuclear regulatory proteins. 
v) Cell cycle regulatory proteins: Cyclins and cyclin-dependent kinases. 
vi) Apoptotic inhibitors: bcl-2. 
Anti-oncogenes (Tumour-suppressor genes) 
Tumour suppressor genes or anti-oncogenes, just as proto-oncogenes, 
are also a pair of normal genes which perform the physiologic function of 
regulation of cell growth. Mechanism of stimulation of carcinogenesis by 
tumour-suppressor genes is mutation in both alleles producing deficiency of 
normal gene product which normally suppresses tumour formation. Evi-
dence for the presence of tumour-suppressor genes comes largely from 
studies of about 50 human hereditary cancers identified so far. Homozygous 
deletion or mutation at specific genetic loci are seen in such tumour cells 
e.g. in retinoblastoma, Wilms` tumour, familial adenomatous polyposis coli 
(APC), breast cancer etc. Tumour-suppressor genes are also implicated in 
some spontaneous human cancers. 
Two of the most widely studied tumour-suppressor genes are reti-
noblastoma (Rb) gene and p53 gene products, besides some others. 
 
Oncogene Associated Neoplasms 
c-erb-B2 Breast and ovarian carcinomas 
ras Many carcinomas and leukemias 
c-sis  Gliomas 
c-abl Chronic myelogenous leukemia, acute lymphocytic leu-
kemia 
c-myc Lymphomas 
BRCA-1 Breast and ovarian carcinomas 
APC Colonic adenocarcinomas 
NF-1 Neurofibromas and neurofibrosarcomas 
Rb Retinoblastomas, osteosarcomas, small cell lung carci-
nomas 
p53 Many carcinomas 
bcl-2 Chronic lymphocytic leukemia, lymphomas 
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i) Rb gene. Rb gene is the first ever tumour suppressor gene identi-
fied. In patients of hereditary retinoblastoma which comprise 40% of all 
such tumours, all somatic cells have one defective allele of Rb gene located 
on long arm of chromosome 13, while all the retinoblastoma tumour cells 
have both alleles of Rb gene as inactive i.e. hereditary retinoblastoma is due 
to two genetic defects (two hit hypothesis). Besides, children inheriting mu-
tated Rb gene have 200 times greater risk of development of mesenchymal 
tumour in early adult life, most notably osteosarcoma. 
ii) p53 gene. p53 gene, the other well studied tumour suppressor gene, 
is located on small arm of chromosome 17. Protein product of p53 gene is pre-
sent in all normal tissues. p53 is the most common target for mutation or dele-
tion in human tumours, occurring in more than 50% of all human cancers. 
Normally, p53 is a negative regulator of cell division. Mutation of p53 permits 
cells with damaged DNA to progress through the cell cycle. 
Deletion of both alleles of p53 is seen in 80% cases of colorectal can-
cer. Cases of germline mutation in one p53 allele have inherited predisposi-
tion to develop cancers in many organs, termed Li-Fraumeni syndrome. 
iii) Other tumour-suppressor genes. Besides these two common an-
tioncogenes, a few other tumour-suppressor genes having mutated germline 
are as under: 
a) APC gene: Implicated in the pathogenesis of familial adenomatous 
polyposis coli. 
b) WT 1 gene: WT 1 gene is seen in hereditary Wilms' tumour. 
c) NF 1 gene: Neurofibromatosis type 1 is characterized by altered 
NF 1 gene. 
d) BRCA 1 and BRCA 2 genes: These are breast (BR) cancer (CA) 
susceptibility genes which are also implicated in ovarian cancer. 
 
Mutator Genes 
Normal cells have caretaker genes to take care of integrity of genetic 
information in response to DNA damage. The mutated version “imitator 
gene” is characterized by loss of normal surveillance function and render 
the DNA susceptible to accumulation of mutations and, therefore, progres-
sion to cancer. 
The examples of mutator genes exist in two hereditary syndromes 
with cancer: 
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i) Hereditary non-polyposis colon cancer (Lynch syndrome) is char-
acterized by hereditary predisposition to develop colorectal cancer in cases 
unassociated with APC. 
ii) Ataxia telangiectasia has ATM (M for mutated) gene. These patients 
have multiple cancers besides other features such as cerebellar degeneration, 
immunologic derangements and oculo-cutaneous manifestations. 
Telomerase in Cancer 
As discussed in pathology of aging, telomeres are the terminal tips of 
chromosomes which progressively shorten due to repetitive cell division. 
Telomerase is the enzyme required for continued recognition of telomere in 
successive cell divisions. Cancer cells express telomerase with consequent 
telomerase lengthening and further immortalization of cancer cells. 
 
THEORIES OF CARCINOGENESIS 
Different carcinogens may induce neoplasms by different mechanisms, 
and in many tumours more than one mechanism is involved in carcinogene-










IC THEORY. This is 
the most popular the-
ory which suggests 
that cells become ne-
oplastic because of 
alterations in the 
DNA. The mutated 
cells transmit their characters to the next progeny of cells. 
Evidence in support of genetic theory comes from all types of etio-
logic agents in carcinogenesis: 
Fig. 29. Scheme of  Oncogenesis. 
 203 
i) Many physical (e.g. radiation) and chemical agents causing cancer 
bring about mutation in the host cells, 
ii) Patients of xeroderma pigmentosum, a rare hereditary disorder, are 
excessively prone to develop skin cancer due to the inherent inability to re-
pair DNA damaged by the ultraviolet rays, 
iii) In many examples of viral oncogenesis (e.g. in leukaemia, lym-
phoma, sarcoma) the viral DNA is integrated into the host cell genome pro-
ducing transformed cells, 
iv) Some examples of cancer are associated with specific chromosomal 
abnormalities e.g. Philadelphia chromosome in chronic myeloid leukaemia, 
v) Recent concept of activation of growth-promoting oncogenes in 
induction of some cancers and inactivation of growth-suppressing anti-
oncogenes in a few others (e.g. in retinoblastoma) further supports the ge-
netic theory of carcinogenesis. 
2. THE EPIGENETIC THEORY. This theory is less well supported than 
the genetic theory. According to the epigenetic theory, the carcinogenic 
agents act on activators or suppressors of genes and not on the genes them-
selves and result in the abnormal expression of genes. Possibly, in most 
cases the initial mutation by the carcinogen superimposes on the epigenetic 
phenomena, because examples of tumorigenesis based on the epigenetic 
theory alone are rare. 
3. THE MULTI-STEP THEORY. This is the other well-accepted and doc-
umented theory. According to this theory, carcinogenesis is a multi-step 
process. This is substantiated by in vitro changes in experimental animals as 
well as in vivo changes in human cancers. For example: 
i) In chemical carcinogenesis, there are 2 essential features in proper 
sequence – initiation and promotion, 
ii) Most cancers arise after several mutations which have been ac-
quired in proper sequence,  
iii) It is possible that many tumours arise from combination of activa-
tion of growth-promoting oncogenes and inactivation of growth-
suppressing anti-oncogenes, 
iv) In some cancers, there is stepwise an initial dysplastic change that 
may progress onto carcinoma in situ, and then into invasive carcinoma. 
4. IMMUNE SURVEILLANCE THEORY. This hypothesis suggests that an 
immune-competent host mounts an attack on developing tumour cells so as 
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to destroy them while an immune-incompetent host fails to do so. Unproven 
support in favour of this theory comes from the following examples: 
i) There is high incidence of cancer in immunodeficient individuals 
e.g. in AIDS. 
ii) Most cancers occur more frequently in old age when the host im-
mune responses are weak. 
iii) In experimental animals, there is rising titer of circulating im-
mune complexes in the initial few weeks of tumour induction when the tu-
mour is growing, followed by decline in the levels. 
iv) Certain tumours accompanied by good host immune response in 
the form of stromal infiltration by lymphocytes and plasma cells have better 
prognosis e.g. medullary carcinoma of the breast, seminoma of the testis etc. 
v) Some tumours may disappear spontaneously from the primary site 
due to good immune attack by the host to reappear as metastasis subse-
quently, e.g. malignant melanoma. 
5. MONOCLONAL HYPOTHESIS. Currently, there is strong evidence on 
studies of human and experimental tumours that most cancers arise from a 
single clone of transformed cells. This theory is supported by the following 
examples: 
i) In a case of multiple myeloma (a malignant disorder of plasma 
cells), there is production of a single type of immunoglobulin or its chain as 
seen by monoclonal spike in serum electrophoresis. 
ii) In many other haematopoietic malignancies too, cell surface mark-
ers can be used to establish their monoclonal origin. 
iii) The best documentation of monoclonal origin of cancer cells 
comes from the study of glucose-6-phosphatase dehydrogenase (G6PD) in 
women who are heterozygous for its two isoenzymes, A and B. These iso-
enzymes are encoded on genes located on X chromosome for the purpose of 
study. It is observed that all the tumour cells in benign uterine tumours 
(leiomyoma) contain either A or B genotype of G6PD i.e. the tumour cells 
are derived from a single progenitor cell. 
 
CLINICAL ASPECTS OF NEOPLASIA 
Two major aspects of clinical significance in assessing the course and 
management of neoplasia are: tumour-host inter-relationship (i.e. the effect 




The natural history of a neoplasm depends upon 2 features: 
i) Effect of tumour on host, 
ii) Host response against tumour (Immunology of cancer) 
EFFECT OF TUMOUR ON HOST 
Malignant tumours produce more ill-effects than the benign tumours. 
The effects may be local, or generalized and more widespread. 
1. LOCAL EFFECTS. Both benign and malignant tumours cause local 
effects on the host due to their size or location. Malignant tumours due to 
rapid and invasive growth potential have more serious effects. Some of the 
local effects of tumours are as under:  
i) Compression. Many benign tumours pose only a cosmetic problem. 
Some benign tumours, however, due to their critical location, have more seri-
ous consequences e.g. pituitary adenoma may lead to serious endocrinopathy; 
a small benign tumour in ampulla of Vater may lead to biliary obstruction. 
ii) Mechanical obstruction. Benign and malignant tumours in the gut 
may produce intestinal obstruction.  
iii) Tissue destruction. Malignant tumours, both primary and meta-
static, infiltrate and destroy the vital structures. 
iv) Infarction, ulceration, haemorrhage. Cancers have a greater ten-
dency to undergo infarction, surface ulceration and haemorrhage than the 
benign tumours. Secondary bacterial infection may supervene. Large tu-
mours in mobile organs (e.g. an ovarian tumour) may undergo torsion and 
produce infarction and haemorrhage. 
2. CANCER CACHEXIA. Patients with advanced and disseminated can-
cers terminally have asthenia (emaciation), and anorexia, together referred 
to as cancer cachexia. Exact mechanism of cachexia is not clear but it does 
not occur due to increased nutritional demands of the tumour. Possibly, ca-
chectin or tumour necrosis factor a (TNF-a) derived from macrophages 
plays a contributory role in cachexia. The various other causes include ne-
crosis, ulceration, haemorrhage, infection, malabsorption, anxiety, pain, in-
somnia, hyper-metabolism and pyrexia. 
3. FEVER. Fever of unexplained origin may be presenting feature in 
some malignancies such as in Hodgkin's disease, adenocarcinoma kidney, 
osteogenic sarcoma and many other tumours. The exact mechanism of tu-
mour associated fever is not known but probably the tumour cells them-
selves elaborate pyrogens. 
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4. PARANEOPLASTIC SYNDROMES. Paraneoplas-tic syndromes (PNS) 
are a group of conditions developing in patients with advanced cancer 
which are neither explained by direct and distant spread of the tumour, nor 
by the usual hormone elaboration by the tissue of origin of the tumour. 
About 10-15% of the patients with advanced cancer develop one or more of 
the syndromes included in the PNS. Rarely, PNS may be the earliest mani-
festation of a latent cancer. 
The various clinical syndromes included: 
i) Endocrine syndrome. Elaboration of hormones or hormone-like 
substances by cancer cells of non-endocrine origin is called as ectopic hor-
mone production. Some examples are given below: 
a) Hypercalcaemia. Symptomatic hypercalcaemia unrelated to hy-
perparathyroidism is the most common syndrome in PNS. It occurs from 
elaboration of parathormone-like substance by tumours such as squamous 
cell carcinoma of the lung, carcinoma kidney, breast and adult T-cell leu-
kaemia lymphoma. 
b) Cushing's syndrome About 10% patients of small cell carcinoma 
of the lung elaborate ACTH or ACTH-like substance producing Cushing's 
syndrome. In addition, cases with pancreatic carcinoma and neurogenic tu-
mours may be associated with Cushing's syndrome. 
c) Polycythaemia. Secretion of erythropoietin by certain tumours 
such as renal cell carcinoma, hepatocellular carcinoma and cerebellar hae-
mangioma may cause polycythaemia. 
d) Hypoglycaemia. Elaboration of insulin-like substance by fibrosar-
comas, islet cell tumours of pancreas and mesothelioma may cause hypo-
glycaemia. 
ii) Neuromyopathic syndromes. About 5% of cancers are associated 
with progressive destruction of neurons throughout the nervous system with-
out evidence of metastasis in the brain and spinal cord. This is probably medi-
ated by immunologic mechanisms. The changes in the neurons may affect the 
muscles as well. The changes are: peripheral neuropathy, cortical cerebellar 
degeneration, myasthenia gravis syndrome, polymyositis. 
iii) Effects on osseous, joints and soft tissue, e.g. hypertrophic oste-
oarthropathy and clubbing of fingers in cases of bronchogenic carcinoma by 
unknown mechanism. 
iv) Haematologic and vascular syndrome, e.g. venous thrombosis 
(Trousseau's phenomenon), non-bacterial thrombotic endocarditis, dissemi-
 207 
nated intravascular coagulation (DIC), leukemoid reaction and normocytic 
normochromic anaemia occurring in advanced cancers. Autoimmune hae-
molytic anaemia may be associated with B-cell tumours. 
v) Gastrointestinal syndromes. Malabsorption of various dietary 
components as well as hypoalbuminaemia may be associated with a variety 
of cancers which do not directly involve small bowel. 
vi) Renal syndromes. Renal vein thrombosis or systemic amyloido-
sis may produce nephrotic syndrome in patients with cancer. 
vii) Cutaneous syndromes. Acanthosis nigricans characterized by 
the appearance of black warty lesions in the axillae and the groins may ap-
pear in the course of adenocarcinoma of gastrointestinal tract. Other cutane-
ous lesions in PNS include seborrheric dermatitis in advanced malignant 
tumours and exfoliative dermatitis in lymphomas and Hodgkin's disease. 
viii) Amyloidosis. Primary amyloid deposits may occur in multiple 
myeloma whereas renal cell carcinoma and other solid tumours may be as-
sociated with secondary systemic amyloidosis. 
HOST RESPONSE AGAINSTTUMOUR (IMMUNOLOGY OF CANCER) 
It has long been thought that host defense mechanism in the form of 
immunological response exists so as to counter the growth and spread of 
cancer, albeit, more often partially. The following observations provide ba-
sis for this thinking: 
1. Certain cancers evoke significant lymphocytic infiltrates composed 
of immunocompetent cells and such tumours have somewhat better progno-
sis e.g. medullary carcinoma breast, seminoma testis. 
2. Rarely, a cancer may spontaneously regress partially or complete-
ly, probably under the influence of host defense mechanism. One such ex-
ample is rare spontaneous disappearance of malignant melanoma from the 
primary site only to reappear as metastasis. 
3. It is highly unusual to have primary and secondary tumours in the 
spleen due to its ability to destroy the growth and proliferation of tumour cells. 
4. There is increased frequency of cancers in immunodeficient hosts, 
e.g. in AIDS. 
In an attempt to substantiate the above observations and to under-
stand the underlying host defense mechanisms, experimental animal studies 
involving tumour transplants were carried out. The findings of animal ex-
periments coupled with research on human cancers have led to the concept 
of immunology of cancer described below under the following headings: 
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1. Tumour antigens, 
2. Immune responses, 
3. Prospects of immunotherapy. 
1. TUMOUR ANTIGENS. There are two types of tumour antigens: 
i) Tumour-specific antigens (TSA) are located on tumour cells but 
are not present on normal cells. They are unique or specific antigens for par-
ticular tumour and not shared by normal cells. Therefore, TSAs are targets of 
attack by tumour-specific cytotoxic T cells. Examples of TSAs include: 
• mutant form of ras and p53 proteins, and 
• bcr-abl gene. 
ii) Tumour associated antigen (TAA) are present on tumour cells as 
well as on some normal cells. TAA are, thus, antigens shared by tumour 
cells and normal host cells from where the tumour originated. These anti-
gens represent the stage at which the differentiation of tumour cells is ar-
rested. Examples of TAAs are: 
• CD-10 antigen on early B lymphocytes expressed in B cell leukae-
mia, lymphoma (CALLA);  
• prostate-specific antigen (PSA) expressed by normal as well as ma-
lignant prostatic epithelium. 
2. IMMUNE RESPONSES. The nature of host immune response to tu-
mours demonstrated in animal studies and in patients with various types of 
cancers can be categorized as under: 
i) Cell-mediated mechanism, 
ii) Humoral mechanism, 
iii) Inhibitory (regulatory) mechanism. 
i) Cell-mediated mechanism. This is the main mechanism of destruction 
of tumour cells by the host. The following cellular responses can destroy 
the tumour cells and induce tumour immunity in humans: 
a) Specifically sensitized cytotoxic T lymphocytes (CTL) which are 
directly cytotoxic requiring contact between cytotoxic T lymphocyte and 
tumour cell. 
b) Natural killer (NK) cells destroy tumour cells without sensitiza-
tion, either directly or by antibody-dependent cellular cytotoxicity (ADCC). 
They are the first line of defense against tumour cells. 
c) Macrophage mediated cytotoxicity by ADCC or by cytotoxic 
products. 
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ii) Humoral mechanism. Humoral antibodies which are capable of kill-
ing free tumour cells in the blood and in the serosal cavities have been sug-
gested to play a role in reducing tumour metastases. 
iii) Inhibitory (Regulatory) mechanism. Paradoxically, both cell-
mediated and humoral mechanisms may have inhibitory influence on host 
immune response to cancer. Although the exact mechanism is uncertain, 
following possibilities have been suggested: 
a) CD8+ T-suppressor cells may play a regulatory role in humoral 
and cell-mediated tumour immunity. 
b) Humoral blocking factors, possibly antigen-antibody complexes, 
may either block the antigen sites on the tumour cells or block the receptors 
on immunocompetent cells. 
3. PROSPECTS OF IMMUNOTHERAPY. Despite the existence of anti-
tumour immune responses, the cancers still progress and eventually cause 
death of the host. The immune responses to be effective enough must elimi-
nate the tumour cells more rapidly than their rate of proliferation and hence 
the role of boosting the immune response or immunotherapy. 
i) Non-specific stimulation of the host immune response was initial-
ly attempted with BCG, Corynebacterium parvum and levamisole, but ex-
cept slight effect in acute lymphoid leukaemia, it failed to have any signifi-
cant influence in any other tumour. 
ii) Specific stimulation of the immune system was attempted next by 
immunising the host with irradiated tumour cells but failed to yield desired re-
sults because if the patient's tumour within the body failed to stimulate effective 
immunity, the implanted cells of the same tumour are unlikely to do so. 
iii) Current status of immunotherapy is focused on following three 
main approaches: 
a) Cellular immunotherapy consists of infusion of tumour-specific 
cytotoxic T cells which will increase the population of tumour-infiltrating 
lymphocytes. The patient's peripheral blood lymphocytes are cultured with 
interleukin-2 which generates lymphokine-activated killer cells having po-
tent anti-tumour effect. 
b) Cytokine therapy is used to build up specific and non-specific host 
defenses. These include: interleukin-2, interferon-cc and -y, tumour necrosis 
factor-a, and granulocyte-monocyte colony stimulating factor (GM-CSF). 
c) Monoclonal antibody therapy is currently being tried as tumour 
cell toxin in the treatment of leukaemias and lymphomas. 
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DIAGNOSIS OF CANCER 
When the diagnosis of cancer is suspected on clinical examination 
and on other investigations, it must be confirmed. The most certain and reli-
able method which has stood the test of time is the histological examination 
of biopsy, though recently many other methods to arrive at the correct diag-
nosis or confirm the histological diagnosis are available. 
1. Histological Methods 
These methods are based on microscopic examination of properly 
fixed tissue (excised tumour mass or open/ needle biopsy from the mass), 
supported with complete clinical and investigative data. These methods are 
most valuable in arriving at the accurate diagnosis. The tissue must be fixed 
in 10% formalin for light microscopic examination and in glutaraldehyde 
for electron microscopic studies, while quick-frozen section and hormonal 
analysis are carried out on fresh unfixed tissues. 
The histological diagnosis by either of these methods is made on the 
basis that cytological features of benign tumours resemble those of normal 
tissue and that they are unable to invade and metastasise, while malignant 
tumours are identified by lack of differentiation in cancer cells termed “an-
aplasia” or “cellular atypia” and may invade as well as metastasise. 
2. Cytological Methods 
Cytological methods for diagnosis consist of study of cells shed off 
into body cavities (exfoliative cytology) and study of cells by putting a fine 
needle introduced under vacuum into the lesion (fine needle aspiration cy-
tology, FNAC). 
i) Exfoliative cytology. Cytologic smear (Papanicolaou Pap smear) 
method was initially employed for detecting dysplasia, carcinoma in situ 
and invasive carcinoma of the uterine cervix. However, its use has now 
been widely extended to include examination of sputum and bronchial 
washings; pleural, peritoneal and pericardial effusions; urine, gastric se-
cretions, and CSF. The method is based on microscopic identification of 
the characteristics of malignant cells which are incohesive and loose and 
are thus shed off or “exfoliated” into the lumen. However, a “negative 
diagnosis” does not altogether rule out malignancy due to possibility of 
sampling error. 
ii) Fine needle aspiration cytology (FNAC). Currently, cytopathol-
ogy includes not only study of exfoliated cells but also materials obtained 
from superficial and deep-seated lesions in the body which do not shed off 
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cells freely. The latter method consists of study of cells obtained by a fine 
needle introduced under vacuum into the lesion, so called fine needle aspi-
ration cytology (FNAC). The superficial masses can be aspirated under di-
rect vision while deep-seated masses such as intraabdominal, pelvic organs 
and retroperitoneum are frequently investigated by ultrasound (US) or com-
puted tomography (CT) guided fine needle aspirations. The smears are fixed 
in 95% ethanol by wet fixation or may be air-dried unfixed. While Papani-
colaou method of staining is routinely employed in most laboratories for 
wet fixed smears, others prefer H and E due to similarity in staining charac-
teristics in the sections obtained by paraffin embedding. Air-dried smears 
are stained by May-Grunwald-Giemsa or Leishman stain. FNAC has a di-
agnostic reliability between 80-97% but it must not be substituted for clini-
cal judgement or compete with an indicated histopathologic biopsy. 
3. Histochemistry and Cytochemistry 
Histochemistry and cytochemistry are additional diagnostic tools 
which help the pathologist in identifying the chemical composition of cells, 
their constituents and their products by special staining methods. 
Though immunohistochemical techniques are more useful for tumour 
diagnosis (see below), histochemical and cytochemical methods are still 
employed for this purpose. 
4. Immunohistochemistry 
This is an immunological method of recognizing a cell by one or 
more of its specific components in the cytoplasm, cell membrane or nucle-
us. These cell components (called antigens) combine with specific antibod-
ies on the formalin-fixed paraffin sections or cytological smears. The com-
plex of antigen-antibody on slide is made visible for light microscopic iden-
tification by either fluorescent dyes (“fluorochromes”) or by enzyme system 
(“chromogens”). The specific antibody against a particular cellular antigen 
is now-a-days obtained by hybridoma technique for monoclonal antibody 
production. These monoclonal antibodies, besides being specific against an-
tigen, are highly sensitive in detection of antigenic component, and, there-
fore, impart objectivity to the subjective tumour diagnosis made by the sur-
gical pathologist. 
Though the list of immunohistochemical stains is ever increasing, one 
important group of such antibody stains is directed against various classes 
of intermediate filaments which is useful in classification of poorly-
differentiated tumours of epithelial or mesenchymal origin. 
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5. Electron Microscopy 
Ultrastructural examination of tumour cells offers selective role in di-
agnostic pathology. EM examination may be helpful in confirming or sub-
stantiating a tumour diagnosis arrived at by light microscopy and immuno-
histochemistry. A few general features of malignant tumour cells by EM 
examination are: 
i) Cell junctions – their presence and type. 
ii) Cell surface, e.g. presence of microvilli. 
iii) Cell shape and cytoplasmic extensions. 
iv) Shape of the nucleus and features of nuclear membrane. 
v) Nucleoli – size and density. 
vi) Cytoplasmic organelles – their number is generally reduced. 
vii) Dense bodies in the cytoplasm. 
viii) Any other secretory product in the cytoplasm, e.g. melanosomes 
in melanoma and membrane-bound granules in endocrine tumours. 
6. Tumour Markers (Biochemical Assays) 
In order to distinguish from the preceding techniques of tumour diag-
nosis in which “stains” are imparted on the tumour cells in section or smear, 
tumour markers are biochemical assays of products elaborated by the tumour 
cells in blood or other body fluids. It is, therefore, pertinent to keep in mind 
that many of these products are produced by normal body cells too, and thus 
the biochemical estimation of the product in blood reflects the total substance 
and not by the tumour cells alone. These methods, therefore, lack sensitivity 
as well as specificity and can only be employed for: 
• firstly, as an adjunct to the pathologic diagnosis arrived at by other 
methods and not for primary diagnosis of cancer; and 
• secondly, can be used for prognostic and therapeutic purposes. 
Tumour markers include: cell surface antigens (or oncofoetal anti-
gens), cytoplasmic proteins, enzymes, hormones and cancer antigens. How-
ever, two of the best known examples of oncofoetal antigens secreted by 
fetal tissues as well as by tumours are alpha-fetoproteins (AFP) and carci-
noembryonic antigens (CEA): 
a) Alpha-fetoprotein (AFP): This is a glycoprotein synthesized 
normally by fetal liver cells. Their, levels are elevated in hepatocellular car-
cinoma and non-seminomatous germ cell tumours of the testis. Certain non-
neoplastic conditions also have increased levels of AFP e.g. in hepatitis, cir-
rhosis, toxic liver injury and pregnancy. 
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b) Carcino-embryonic antigen (CEA): CEA is also a glycoprotein 
normally synthesized in embryonic tissue of the gut, pancreas and liver. 
Their levels are high in cancers of the gastrointestinal tract, pancreas and 
breast. As in AFP, CEA levels are also elevated in certain non-neoplastic 
conditions e.g. in ulcerative colitis, Crohn's disease, hepatitis and chronic 
bronchitis. 
7. Modern Aids in Tumour Diagnosis 
In addition to the methods described above, some more modern diag-
nostic techniques have emerged for pathologic diagnosis but their availabil-
ity as well as applicability are limited. Briefly, their role in tumour diagno-
sis is outlined below. 
i) Flow cytometry. This is a computerized technique by which the 
detailed characteristics of individual tumour cells are recognized and quan-
tified and the data can be stored for subsequent comparison too. Since for 
flow cytometry, single cell suspensions are required to “flow” through the 
“cytometer”, it can be employed on blood cells and their precursors in bone 
marrow aspirates and body fluids, and sometimes on fresh-frozen unfixed 
tissue. The method employs either identification of cell surface antigen (e.g. 
in classification of leukaemias and lymphomas), or by the DNA content 
analysis (e.g. aneuploidy in various cancers). 
ii) In situ hybridization. This is a molecular technique by which nu-
cleic acid sequences (cellular/viral DNA and RNA) can be localized by spe-
cifically-labeled nucleic acid probe directly in the intact cell (in situ) rather 
than by DNA extraction (see below). In situ hybridization may be used for 
analysis of certain human tumours by the study of oncogenes aside from its 
use in diagnosis of viral infection. 
iii) Molecular diagnostic techniques. The group of molecular bio-
logic methods in the tumour diagnostic laboratory are a variety of 
DNA/RNA-based molecular techniques in which the DNA/RNA are ex-
tracted (compared from in situ above) from the cell and then analyzed. The-
se techniques are highly sensitive, specific and rapid and have revolution-
ized diagnostic pathology in neoplastic as well as non-neoplastic conditions 
(e.g. in infectious and inherited disorders, and in identity diagnosis). Mo-
lecular diagnostic techniques include: DNA analysis by Southern blot, RNA 
analysis by northern blot, and polymerase chain reaction (PCR). The mo-
lecular methods in tumour diagnosis can be applied in haematologic as well 
as non-haematologic malignancies by: 
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• analysis of molecular cytogenetic abnormalities; 
• mutational analysis; 
• antigen receptor gene rearrangement; and 
• by study of oncogenic viruses at molecular level. 
MESENCHYMAL TUMORS 
In ontogenesis, mesenchyma is the origin of connective tissue, blood 
and lymphatic vessels, adipose tissue, smooth and striated muscles, serous 
membranes, hemopoietic system, bone and cartilage tissue. 
So, mesenchymal tumors develop from: 1) connective (fibrous) tis-
sue, 2) fat tissue, 3) muscular tissue, 4) blood and lymphatic vessels, 5) 
synovial tissue, 6) mesothelial tissue, 7) bone and cartilage. 
They may be benign (name of the tissue + oma) and malignant (name 
of the tissue + sarcoma). There are also special terms (e.g. desmoid, granu-
lar-cell tumor). 
 
Connective (fibrous) tissue tumors 
Main benign connective (fibrous) tissue tumors are:  
1. Fibroma – usually looks as a node of differentiated connective tis-
sue with different direction of the cellular bands: 
a) dense: fibrous structures prevail over the cellular elements; 
b) soft: loose connective tissue with great amount of stroma cells (fi-
broblasts and fibrocytes). 
Localization of fibroma is varied: skin, breast, spinal canal, orbit, etc. 
Fibroma of the skin may have a pedicle. 
2. Desmoid fibroma is a kind of dense fibroma that is character-
ized by infiltrating growth and relapses. More often it is located in the ante-
rior abdominal wall. 
3. Dermatofibroma (histiocytoma) is a small fibrous node with 
yellow-brown colour. More often it is located in the skin of the limbs. It 
consists of capillaries and connective tissue with fibrous structures and fi-
broblasts, fibrocytes, histiocytes, macrophages. There are giant multinuclear 
cells containing lipids and hemosiderin among cells. Fibroblasts are ar-
ranged in a cart-wheel or storiform pattern. 
Malignant connective (fibrous) tissue tumors are characterized by 
atypical cells. 
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Macroscopically sarcoma looks like fish flesh. As a rule sarcoma me-
tastases disseminate by haematogenous route. 
1. Fibrosarcoma looks like an irregular node. There are 3 types of fi-
brosarcoma: 
a) differentiated fibrosarcoma, termed cellular-fibrous fibrosar-
coma, when fibrous component prevails over the cellular component; 
b) poorly differentiated fibrosarcoma, termed cellular sarcoma. It 
produces metastases more frequently; 
c) round cell tumors of unknown origin, termed unclassified tumor. 
2. Malignant fibrous hystiocytoma consists of numerous polymorphic 
fibroblast-like and histiocyte-like cells, multinucleate bizarre giant cells, 
and numerous mitotic figures. There is a tendency for the spindle shape 
cells to be arranged in a characteristic cart-wheel or storiform pattern. It 
grows slowly though its growth is infiltrating. Metastases are frequent. 
 
Tumors of adipose tissue 
Benign 
1. Lipoma: a soft yellow node, sometimes in a capsule, composed 
of lobules of mature adipose cells of different size separated by thin fibrous 
septa. It may develop in any place where adipose tissue is present. 
Intramuscular infiltrating lipoma is an infrequent benign tumor with-
out distinct borders, it infiltrates the striated muscle. 
2. Hibernoma is a rare tumor of brown fat. It consists of large 
round cells with granular or foamy cytoplasm (fat vacuoles). 
Malignant 
1. Liposarcoma is a rare, large tumor, which is composed mostly of 
lipoblasts and small amount of lipocytes of different degree of maturity.It 
grows slowly.  
There are several types of liposarcoma: 
• well-differentiated liposarcoma; 
• myxoid (embryonic); 
• round cell liposarcoma; 
• pleomorphic liposarcoma. 
The prognosis of liposarcoma depends upon the location and histo-
logic type. For instance, round cell and pleomorphic liposarcomas metasta-
size frequently. 
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2. Malignant hibernoma is a very rare tumor with cellular polymor-
phism and lots of giant cells. 
Tumors of muscles 
Benign 
1. Leiomyoma consists of smooth muscle with chaotic location of the 
muscular bands separated by the stroma with blood vessels and nerves. If 
stroma prevails this tumor is termed fibromyoma. Secondary changes such 
as necrosis, hemorrhages, cysts, hyalinosis, petrifaction are characteristic 
for leiomyoma. 
2. Rhabdomyoma consists of striated muscle fibers, which resemble 
to embryonic muscular fibres and myoblasts. Cardiac rhabdomyoma ap-
pears as a hamartomatous lesion and is accompanied by other developmen-
tal defects (large masses of striated muscles). Soft tissue rhabdomyomas are 
predominantly located in the head and neck, tongue, etc. and composed of 
large, round to oval cells, having abundant, granular cytoplasm. 
3. Granular-cell tumor (Abrikosow's tumor) is a small tumor in a cap-
sule, which consists of large, round or polygonal, uniform, with granular cyto-
plasm (no lipids) cells. Usually it occures in the tongue, esophagus, and skin.  
Malignant 
1. Leiomyosarcoma (malignant leiomyoma) is a tumor with cellular 
and tissue atypia and high mitotic index. 
2. Rhabdomyosarcoma (malignant rhabdomyoma) is characterized by 
severe pleomorphism, loss of muscular tissue characteristic (it is necessary 
to use special immune antibodies to verify the histogenesis of tumor). 
3. Malignant granular-cell tumor (malignant myoblastoma) resembles 
malignant rhabdomyoma but the cytoplasm is granular. 
 
Tumors of blood and lymph vessels 
Benign tumors of blood  vessels 
1. Hemangioma is a benign tumor of blood vessels. There are 
several types of hemangioma: 
a) capillary - it develops in the skin, mucous membranes, gastrointesti-
nal tract, liver, more often in children. It looks like cyanotic node comprised of 
branching blood-filled capillaries with narrow lumen, and thin walls; 
b) venous – it consists of vascular bands with smooth muscles in their 
wall, resembling veins; 
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c) cavernous hemangioma is common in the liver, skin, bones, mus-
cles, gastrointestinal tract, brain. Tumor consists of thin-walled cavernous 
vascular spaces, filled partly or completely with blood. The vascular spaces 
are lined by flattened endothelial cells. They are separated by scanty con-
nective tissue stroma; 
d) benign hemangiopericytoma arises in the skin and intramuscular 
space of the extremities. The tumor is composed of capillaries surrounded 
by pericytes outside the vascular basement membrane. 
2. Glomus tumor (glomangioma). More often develops in hands 
and feet (fingers and toes). It consists of vessels with endothelium, sur-
rounded by ferrules of epithelioid (glomus) cells. Tumor is rich in nerves 
thus it is usually painful. 
Malignant tumors of blood vessels. 
Angiosarcoma: 
a) malignant hemangioendothelioma; 
b)  malignant hemangiopericytoma - is a highly malignant tumor 
with high mitotic cells rate and areas of necrosis. It has early metastases. 
 
Benign tumors from lymph vessels. 
Lymphangioma - is characterized by growth of lymphatic vessels in 
different direction with the formation of a node or enlargement of the organ. 
If lymphangioma develops in the tongue, it is termed macroglossia. If lym-
phangioma develops in the lip it is termed macrocheilia. Microscopically 
tumor looks consistes of cavities filled with lymph. 
Malignant tumors from lymph vessels.  
Lymphangiosarcoma. It appears as a result of chronic lymphatic stasis 
and is composed of lymph clefts with proliferating atypical endothelial cells. 
 
Tumors of synovial tissue 
1. Benign synovioma develops in the tendons and tendon sheath. 
It contains a lot of stroma with hyalinosis, and a little number of vessels. It 
may have xanthome cells and clefts. 
2. Synovial sarcoma (malignant synovioma) develops in the large 
joints. It has irregular structure. Some tumors have pleomorphic cells and 
pseudoepithelial gland formations with cysts, the other have fibroblast-like 
atypical cells and collagen fibers, structures resembling tendons. 
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Tumors of mesothelial tissue 
1. Benign mesothelioma resembles a dense node in serous membrane 
(pleura), its structure is similar to fibroma (fibroid mesothelioma). 
2. Malignant mesothelioma (peritoneum, pleura, and pericardium) 
microscopically looks like atypical large cells with vacuolated cytoplasm. 
Malignant mesothelioma may have tubular and papillary structures. In this 




1. Osteoma develops as a rule in spongy and tubular bones, skull 
included. 2 types of osteoma are known: a) spongy osteoma, b) compact os-
teoma. 
This benign tumor almost exclusively involves the skull and facial 
bones; the frontal sinus is the most common location. Males are affected more 
often than females, the tumor can occur at any age. Although osteoma is pre-
dominantly a solitary lesion, multiple osteomas can occur in association with 
intestinal polyposis and soft tissue tumors. The tumor of normal bone origi-
nates from the periosteum. There is little evidence of osteoblastic activity. 
2. Osteoid osteoma is common in young persons, mostly males. 
Macroscopically, an osteoid osteoma appears as a small round or oval mass 
containing a central red-brown, friable area. Microscopically, the tumor ap-
pears as a mass of irregular bone trabeculae, fibrous tissue, and vessels. The 
center of the tumor is rich in osteoblasts, calcification, and multinucleate 
giant cells. 
3. Benign osteoblastoma predominantly affects the vertebrae and long 
bones of young males in the first three decades of life. Macroscopically, the 
neoplasm varys in size from a few to several centimeters. Microscopically, 
osteoblasts proliferate and osteoid production increases. Osteoclasts and 




1. Osteosarcoma (osteogenic sarcoma) consists of osteogenic tissue 
rich in atypical cells of osteoblastic type with a lot of mitoses, the bone is 
primitive. 2 types of osteosarcoma are known: a) osteoblastic type (bone 
formation), b) osteolytic type (bone destruction). 
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Osteosarcoma is a highly malignant bone tumor characterized by the 
production of osteoid and bone. Most osteosarcomas arise in the metaph-
yseal end of long bones (predominantly the femur, humerus, and tibia), but 
they can involve any bone, including the small bones of the hands, feet and 
face. Osteosarcoma is the most common primary malignant tumor of a bone 
(next to multiple myeloma), accounting for approximately 16% of all bone 
malignancies. The disease predominantly affects young males between age 
10 and 20. 
Gross appearance. The tumor appears as a large necrotic and hemor-
rhagic mass. The lesion usually ends in the epiphyseal cartilage and rarely 
extends into the nearby joint space. 
Microscopic appearance. Three types of osteosarcomas have been 
differentiated according to their predominant histologic patterns: osteo-
blastic, fibroblastic and chondroblastic. The hallmark of the tumor is the 
presence of a malignant stroma that contains osteoid and bone. The stroma 
shows bizarre pleomorphic cells, with hyperchromatic, irregular nuclei and 
abundant mitoses. Multinucleate giant cells are seen most often  near zones 
of necrosis and calcification. Malignant cartilage may be present as well as 
a small foci or as a large proportion of the tumor. 
2. Giant cell tumor of bone (osteoclastoma) is an uncommon malignant 
tumor characterized by multinucleate giant cells. It occurs predominantly in 
women over age 19 and peaks in the third decade of life. The neoplasm is al-
most always localized in the distal part of the long bones (femur or humerus), 
and 50% of these tumors occur in the area of the knee. Occasionally, the tumor 
involves the skull, pelvis, or small bones of the hands and feet. 
Macroscopically, the tumor characteristically appears as multiple 
hemorrhagic cystic cavities that destroy the adjacent bone and are enclosed 
by a thin shell of new bone formation. 
Microscopically, it represents as a vascularized stroma composed of 
spindle cells. It contains multinucleate giant cells, areas of hemorrhage, in-




1. Chondroma derives from hyaline cartilage in the feet, spine, 
breastbone, and pelvis. If tumor is located in the peripheral area of the bone 
it is termed exchondroma, if in the center area of the bone - enchondroma. 
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Ollier's disease (enchondromatosis) is a rare, nonhereditary disorder 
in which multiple chondromas are present in the metaphysis and diaphysis 
of various bones. 
Maffucci's syndrome is a congenital disease characterized by 
dyschondroplasia and multiple hemangiomas in the skin and viscera. 
This neoplasm is thought to originate from heterotropic cartilaginous 
cell; nests in the medullary cavities of bones. Macroscopically, the lesion 
appears as a confluent mass of bluish hyaline cartilage with a lobular con-
figuration. Microscopically, the cartilage appears moderately cellular, with 
occasional binucleate cells. Mitoses are absent. 
2. Osteochondroma is the most common benign tumor of bone af-
fecting patients under age 20-21. The lesions may be single or multiple and 
predominantly involve the metaphysis of long bones. Macroscopically, the 
tumor may range in size from 1 to several centimeters and appears as a 
stalked protuberance, with a lobulated surface jutting from the affected 
bone. The periosteum of the adjacent bone covers the lesion. Microscopical-
ly, the cartilaginous cells appear lined up, mimicking the orientation of car-
tilaginous cells in a normal epiphysis. Mitoses are absent. 
3. Benign chondroblastoma consists of chondroblasts, interstitial sub-
stance, marked osteoclast reaction. Chondroblastoma is a rare cartilaginous 
tumor that almost always involves the epiphyseal portion of the long bones. 
The tumor predominantly affects males in the second decade of life. Macro-
scopically, the tumor is round or oval in shape, with areas of cystic degen-
eration and hemorrhage. Microscopically, proliferation of chondroblasts is 
intermixed with varying amounts of fibrous stroma and chondroid material. 
Multinucleate giant cells and calcifications are present. Mitoses are virtually 
absent. 
4. Chondromyxoid fibroma is most commonly located in the metaph-
ysis of long bones but occasionally can involve the epiphysis. It primarily 
affects males in the first and second decades of life. Macroscopically, the 
tumor is a well-circumscribed, looks as a solid mass with a cartilaginous 
appearance. The cortex of the bone is expanded by the tumor, which is lim-
ited by the periosteum. Microscopically, a variety of fibrous, myxomatous, 
and chondroid elements are seen together with multinucleate giant cells and 
macrophages that contain hemosiderin. When the tumor forms lobules, a 




Chondrosarcoma is a malignant cartilaginous tumor. The most com-
mon locations are the spine, pelvic bones, and upper ends of the femur and 
humerus. The tumor may arise de novo (primary chondrosarcoma) or origi-
nate from a preexisting benign cartilaginous lesion (secondary chondrosar-
coma). Chondrosarcomas comprise between 7% and 15% of all bone neo-
plasms. The tumor occurs in patients between age 30 and 60 and in men 
three times more often than in women. 
Macroscopically, a chondrosarcoma appears as a lobulated white or 
gray mass that contains mucoid material and foci of calcification. 
Microscopically, there are islands of immature or poorly developed 
cartilage in which anaplastic cells with two or more nuclei are present with-
in the lacunar space. 
The neoplasm grows slowly and can remain locally aggressive for 
years, with a high tendency to recur and implant into soft tissues. Hematog-
enous dissemination to the lungs, liver, and kidneys takes place over the 
years, with eventual death of the patient. The 10-year survival rate ranges 
from 50% to 60%. 
TUMORS OF EPITHELIAL TISSUES 
Organ non-specific epithelial tumors develop in squamous, transi-
tional or glandular epithelium which doesn’t perform any specific function.  
Depending on epithelium type benign organ non-specific epithelial 
tumors are subdivided into papillomas (the tumors of squamous and transi-
tional epithelium) and adenomas (tumors of glandular epithelium). 
Papilloma occurs in the skin and mucous membranes, covered with 
squamous or transitional epithelium; it looks like a ledge or a bush of 
branching papillae. It is a good example of an exophytic tumor. The base of 
the tumor consists of connective tissue containing blood vessels. It is a con-
tinuation of subepithelial connective tissue covered with epithelium like 
with a glove. 
Adenoma is a benign epithelial tumor from the epithelium of the 
glands and mucous membranes covered with columnar epithelium. More 
often they can be found in the breast, thyroid gland, ovaries, prostate gland, 
uterus, and gastrointestinal tract. 
Grossly, adenoma is a soft whitish or pinkish node of different size. 
According to the histological structure adenoma may be tubular, trabecu-
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lar, papillary and alveolar. In tubular adenoma, there are glandular cavities 
resembling tubes in the connective tissue with vessels. In alveolar adenoma, 
numerous foci bedded with cylindrical or cubic epithelium are observed in 
the connective tissue with vessels. Trabecular adenoma consists of cellular 
cords, while papillary type of adenoma is composed of papillary structures. 
Sometimes papillary growth of epithelium, bedding glandular cavities, is 
observed. In some adenomas glandular cavities are widened and form large 
cavities, cysts filled with the serous fluid or mucus. These cyst-like adeno-
mas are called cystadenomas. In all these cases, the epithelium is separated 
from the surrounding tissue by its own membrane. Adenomas may trans-
form into malignant tumor.  
Immature or malignant epithelium tumor is called cancer. The popu-
larity of this term can be explained by the increase of the cancer incidence 
in the 20th century comparing with previous centuries. 
This fact can be explained by the increase of the life expectancy by 
20 years, that is the group of people of «cancer age» enlarged (due to in-
creased possibility to be exposed to carcinogenic factors, accumulation of 
the total number of precancerous processes and increased chance to develop 
latent cancer with long duration). Besides, increase of the tumors number  
can be associated with improvements in diagnosis. But the above does not 
exclude objective causes of cancer development, especially in the popula-
tion of the developed countries due to increase of the number of industrial 
tumors (cancer of lungs, skin, urinary bladder) associated with exposure to 
chemical carcinogens (at present there are about 300 of them, mainly poly-
cyclic aromatic hydrocarbon, azo- or aminocompounds). 
Carcinoma in situ is a frequent variant of cancer which is character-
ized by severe atypia, active cellular proliferation while infiltrative growth 
is absent, and basement membrane is not invaded. Noninvasive cancer is a 
step of cancer growth and it can transform into infiltrative malignant tumor. 
This tumor is well studied in many organs: cervix, mammary gland, skin, 
stomach, larynx, etc.  
Depending on the epithelium differentiated carcinomas histological-
ly are subdevided into following types: 
1. Squamous cell carcinoma may arise in any part of the skin or mu-
cous membranes lined by squamous epithelium (oral cavity, esophagus, lar-
ynx, vagina, uterus cervix, etc.). It can arise on glandular or transitional epi-
thelium too after preceding metaplasia. Grossly, this cancer is more com-
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monly an ulcerated poorly-circumscribed growth with elevated and indurat-
ed margin, less often, fungating or polypoid verrucous with necrotic and ul-
cerative lesions. Microscopically, squamous cancer is characterized by ir-
regular downward proliferation of epithelial cells into derma or underlying 
tissues with the formation of epithelial «nests». Masses of tumor cells show 
atypical features such as variation in cell size and shape, nuclear hyper-
chromatism, absence of intercellular bridges, atypical mitoses, individual 
cell keratinisation or whorled arrangement of malignant squamous cells 
forming horn pearls. 
2. Transitional cell carcinoma arises on  transitional epithelium 
of mucous membranes of urethra, urinary bladder, etc. Microscopically, it is 
characterized by irregular downward proliferation of epithelial cells into 
underlying tissues. Masses of tumor cells show all atypical features too. 
3. Adenocarcinoma arises appears on prismatic epithelium of 
mucous membranes or epithelium of glands. It has a structure similar to ad-
enoma but differs from it in presence of atypia, variation in cell and nucleus 
size and shape, nuclear hyperchromatism, atypical mitoses and infiltrative 
growth. There are acinar, tubular and papillary variants of adenocarcinoma. 
 
Undifferentiated carcinomas are classified into: 
1. Mucous (colloid) carcinoma. The tumor grows like masses having 
gelatinous appearance due to secretion of large quantities of mucus. Histo-
logically, mucoid carcinoma contains abundant pools of mucin in which are 
seen a small number of tumor cells. 
2. Signet-ring cell carcinoma carcinoma is a variant of mucous car-
cinoma when the mucous accumulates in cytoplasm of tumor cells. Sig-
netcells have abundant mucinous cytoplasm, which is positive for mucicar-
mine. 
3. Small cell carcinoma. Tumor cells are small, uniform, and lym-
phocyte-like with scanty cytoplasm. This carcinoma has rapid growth, fre-
quently undergoes the necrosis, gives early and multiple metastasis. 
4. Fibrous (scirrhus) carcinoma. If there is excessive connective tis-
sue stroma in the undifferentiated carcinoma, it is referred to as desmoplasia 
and the tumor is hard or scirrhous. Due to marked desmoplasia cancer cells 
may be difficult to find.  
5. Medullary carcinoma. If undifferentiated carcinoma is almost en-
tirely composed of parenchymal cells, it is called medullary. The loose con-
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nective tissue stroma is scanty and usually has a prominent lymphoid infil-
tration.  
6. Solid carcinoma is characterized by presence of solid layers of ma-
lignant epithelial cells separated by connective tissue which show marked 
cytologic atypia and frequent mitoses. 
 
ORGAN SPECIFIC EPITHELIAL TUMORS. 
TUMORS OF EXOCRINE GLANDS AND SKIN.  
Liver tumors. 
Metastatic tumors in the liver are more common than primary ones. 
Primary hepatic tumours may arise from hepatic cells and bile duct epitheli-
um. 
Benign hepatic epithelial tumours include hepatocellular adenoma 
and bile duct adenoma (cholangioma).  
Hepatocellular adenoma usually dvelops as asingle node, but about 
10% there are multiple nodes. It is partly or completely encapsulated and 
lighter in colour than adjacent liver tissue or may be bile-stained. Histologi-
cally, the tumor is composed of sheets and cords of hepatocytes. Hepatocel-
lular adenomas lack portal tracts and bile ducts but bile canaliculi contain-
ing bile-plugs may be present.  
Intrahepatic or extrahepatic bile duct adenoma is a rare benign tu-
mour. It may be small, composed of acini lined by biliary epithelium and 
separated by variable amount of connective tissue. And there are larger 
cystadenomas having locules lined by biliary epithelium.  
Malignant hepatic tumours are hepatocellular (liver cell) carcinoma 
and cholangiocarcinoma, and frequently mixed pattern is seen.  
Hepatocellular carcinoma (hepatoma) may develop as a single yel-
low-brown, large mass, with central necrosis, haemorrhage and occasional 
bile-staining (expanding or massive type). Less often, multifocal, multiple 
masses 3-5 cm in diameter, scattered throughout the liver (multifocal or 
nodular type) are seen. Rarely, the hepatocellular carcinoma forms diffusely 
infiltrating tumour mass (infiltrating of differentiation, ranging from well-
differentiated to highly anaplastic lesions).  
Cholangiocarcinoma is the designation used for carcinoma arising 
from bile duct epithelium within the liver and from the large hilar ducts. 
Grossly, the tumour is firm to hard and whitish. Microscopically, the tumour 
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has glandular structure. The tumour cells resemble biliary epithelium or dif-
fuse type. Microscopically, the tumour cells resemble hepatocytes but vary 
with the degree but are characterized by atypia and have no bile secretion.  
Tumors of kidney. 
Both benign and malignant tumours occur in the kidney. They may 
arise from renal tubules (adenoma, adenocarcinoma) and embryonic tissue 
(nephroblastoma or Wilms’ tumor). 
Adenoma of kidney. Histologically, there are basophilic, clear cell and 
acidophilic types of adenoma. Clear cell adenoma may form tiny nodules up 
to 3 cm in diameter. It is encapsulated and white or yellow. Microscopical-
ly, it is composed of tubular cords or papillary structures projecting into 
cystic space. The cells are usually uniform, cuboidal with no mitosis. How-
ever, size of the tumor rather than histologic criteria is considered more sig-
nificant parameter to predict the behavior of the tumor – those larger than 3 
cm in diameter are potentially malignant. Other types of adenoma have var-
iable size.  
Renal cell carcinoma (synonyms: adenocarcinoma of kidney, hyper-
nephroma, Grawitz tumour) is classified into clear cell, papillary, granular 
cell, chromophobe, sarcomatoid and collecting duct types. Grossly, renal 
cell carcinoma is a solitary and unilateral, generally large, golden yellow 
and circumscribed mass. Papillary tumours may be multifocal. Cut section 
of the tumor commonly shows large areas of ischaemic necrosis, cystic 
change and foci of haemorrhages. Another significant characteristic is the 
frequent presence of tumor thrombus in the renal vein which may extend 
into the vena cava.  
Nephroblastoma or Wilms’ tumor is an embryonic tumor derived 
from primitive renal epithelial and mesenchymal components. It is the most 
common abdominal malignant tumour of young children, seen most com-
monly between 1 to 6 years of age with equal sex incidence. Grossly, the 
tumor is usually quite large, spheroidal, replacing most of the kidney tissue. 
On cut section, the tumor shows variegated appearance – soft, fish flesh 
like, grey-white to cream-yellow tumor with foci of necrosis and haemor-
rhages. Microscopically, nephroblastoma shows mixture of primitive epi-
thelial and mesenchymal elements. Most of the tumor consists of small, 
round to spindled cells, abortive tubules and poorly-formed glomerular 
structures are present. Mesenchymal elements such as smooth and skeletal 
muscle, cartilage and bone, fat cells and fibrous tissue, may be seen.  
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Breast tumors. 
Fibroadenoma and intraductal papilloma are the most common be-
nign breast tumour.  
Fibroadenoma consists of fibrous and epithelial components. Grossly 
it is a small, solitary, well-encapsulated, spherical or discoid mass. The cut 
surface is firm, grey-white, slightly myxoid. Microscopically, there are in-
tracanalicular and pericanalicular patterns. 
Intraductal papilloma is a benign papillary tumor occurring most 
commonly in a lactiferous duct or lactiferous sinus near the breast nipple.  
Carcinoma of the breast is an important malignant tumor which oc-
curs as non-invasive (carcinoma in situ) and invasive cancer with its various 
morphologic varieties. Non-invasive carcinoma may be intraductal  and in-
tralobular. There are several types of invasive carcinoma: infiltrating ductal 
carcinoma, invasive lobular carcinoma, medullary carcinoma, colloid carci-
noma and etc. 
Non-invasive carcinoma (carcinoma in situ) is characterized histo-
logically by presence of tumour cells within the ducts or lobules without in-
vasion. 
Infiltrating ductal carcinoma is the common breast cancer. Macro-
scopically, it looks as irregular, 1-5 cm in diameter, hard cartilage-like 
mass. The cut surface of the tumour is gray-white to yellowish with chalky 
streaks and often extends irregularly into the surrounding fat. There are 3 
histological types of this carcinoma: 
• anaplastic tumour cells forming solid nests, cords, poorly-
formed glandular structures and some intraductal foci; 
• infiltration by these patterns of tumour cells into diffuse fibrous 
stroma and fat; 
• invasion into perivascular and perineural spaces as well as 
lymphatic and vascular invasion. 
Infiltrating (invasive) lobular carcinoma. Invasive cancers in being 
more frequently bilateral; and within the same breast, it may have multicen-
tric origin. Macroscopically, the appearance varies from a well-defined scir-
rhous mass to a poorly-defined area of induration that may remain undetect-
ed by inspection as well as palpation. 
Microscopically, there are 2 characteristics: 
1) Pattern – a characteristic single file (Indian file) linear arrangement 
of stromal infiltration by the tumour cells with very little tendency to gland 
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formation is seen. Infiltrating cells may be arranged concentrically around 
ducts in a target-like pattern; 
2) Tumour cytology – individual tumour cells resemble cells of in 
situ lobular carcinoma. They are round and regular with very little pleo-
morphism and infrequent mitoses. Some tumors may show signet-ring cells 
distended with cytoplasmic mucus. 
Medullary carcinoma has a significantly better prognosis than the 
usual infiltrating duct carcinoma, probably due to good host immune re-
sponse in the form of lymphoid infiltrate in the tumour stroma. Macroscopi-
cally, the tumour is characterized by a large, well-circumscribed, rounded 
mass that is typically soft and fleshy brain-like.  
Colloid (mucinous) carcinoma contains large amount of extracellular 
epithelial mucin and acini filled with mucin.  
Paget's disease of the nipple. The nipple bears a crusted, scaly ec-
zematoid lesion with a palpable subareolar mass in about half the cases. 
Macroscopically, the skin of the nipple and areola are crusted, fissured and 
ulcerated with oozing of serosanguineous fluid from the erosions. Micro-
scopically, the skin lesion is characterized by the presence of Paget's cells in 
the epidermis. These cells are larger than the epidermal cells. The underly-
ing breast contains invasive or non-invasive duct carcinoma which shows 
no obvious direct invasion of the skin of nipple. 
 
Skin tumors 
Tumours and tumour-like lesions may arise from different compo-
nents of the skin such as epidermis, epidermal appendages and dermal tis-
sues. Each of these tissues may give rise to benign and malignant tumours. 
The most important of epidermal appendages tumors are hydradenoma, 
spiradenoma, trichoepithelioma, and basal cell carcinoma.  
Hydroadenoma originates from the intradermal portion of the eccrine 
sweat duct. Histologically, it consists of solid masses and cords of tumour 
cells which may have an occasional duct-like structure containing mucin.  
Spiradenoma is found as solitary, painful, circumscribed nodule in 
the dermis. Histologically, it consists of lobules which are surrounded by a 
thin capsule. The tumor lobules contain 2 types of epithelial cells like in the 
secretory parts of the eccrine sweat gland.  
Trichoepithelioma is a tumor of hair follicle. The tumor may occur as 
solitary lesion or as multiple inherited lesions, predominantly on the face, 
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scalp and neck. It is often circumscribed. The most characteristic histologic 
feature is the presence of multiple horn cysts surrounded by basophilic 
cells. 
Basal cell carcinoma is a locally invasive, slow-growing tumor that 
rarely metastasizes (0.05% of all cases). Grossly, the most common pattern 
is a nodulo-ulcerative basal cell carcinoma in which a slow-growing small 
nodule undergoes central ulceration with pearly, rolled margins. Microscop-
ically, the most characteristic feature is the proliferation of basaloid cells 
(resembling basal layer of epidermis) having typical peripheral palisaded 
appearance of the nuclei.  
Most frequent malignant appendage tumors are are sweat gland car-
cinoma and sebaceous carcinoma.  
 
Uterus. 
Gestational trophoblastic diseases resulting from malignant over-
growth of trophoblast – invasive mole and choriocarcinoma should be dis-
cussed  as organ specific tumors of uterus. 
Invasive (destructive) mole (chorioadenoma destruens) shows inva-
sion of the molar tissue into the uterine wall which may be a source of 
haemorrhage. Rarely, molar tissue may invade the blood vessels and reach 
the lungs. Microscopically, the lesion is benign and identical to classic mole 
but has potential for haemorrhage. 
Choriocarcinoma is a highly malignant and widely metastasizing tu-
mour of trophoblast. Features: 1) absence of stroma, 2) invasion of the 
blood vessels, lymphatics, and myometrium, 3) widespread haematogenous 
metastases are early and frequent, found mainly in the lungs. Choriocarci-
noma is composed of masses and columns of highly anaplastic and bizarre 
cytotrophoblast and syncytiotrophoblast cells which are intermixed. The 
tumor is also characterized by invariable presence of haemorrhages and ne-
crosis. 
 
TUMORS OF ENDOCRINE GLANDS 
Ovarian tumors 
Ovarian tumors arise from normally-occurring cellular components 
of the ovary. There are five major groups: 
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1). Tumors of surface epithelium (serous tumors, mucinous tu-
mors, etc.), 
2). Germ cell tumours (teratomas, dysgerminoma, yolk sac tumor, 
etc.), 
3). Tumors of Sex Cord and Stromal Origin (granulosa cell tumour, 
thecoma, fibroma, etc.), 
4). Miscellaneous tumors, 
5). Metastatic tumors. 
Benign and malignant serous tumors are large unilocular or multiloc-
ulated cysts with intracystic papillary projections. Serous cystadenoma is 
characteristically lined by low columnar epithelium. Serous cystadenocar-
cinoma has multilayered malignant cells which show loss of polarity, pres-
ence of solid sheets of anaplastic epithelial cells and definite evidence of 
stromal invasion.  
Mucinous tumours are predominantly cystic tumours which contain 
mucin. Grossly, mucinous tumours are much larger than serous tumors. 
Mucinous cystadenoma has thin wall and septa dividing the loculi. It is 
lined by a single layer of columnar nonciliated epithelium. There is very lit-
tle tendency to papillary proliferation of epithelium. Mucinous cystadeno-
carcinoma usually has thickened areas and is characterized by piling up of 
malignant epithelium, at places forming solid sheets, papillary formation, 
adenomatous pattern and infiltration into stroma with or without pools of 
mucin. 
Dysgerminoma is an ovarian varient of the testes seminoma. All dys-
germinomas are malignant and are extremely radiosensitive. The tumor 
cells are arranged in diffuse sheets, islands and cords separated by scanty 
fibrous stroma which contains lymphocytic infiltrate. 
Granulosa cell tumor may occur at all ages. It invades locally but oc-
casionally may have more aggressive and malignant behavior. Most granu-
losa cell tumours secrete oestrogen. Cut section of tumor is yellowish-
brown. Microscopically, the granulosa cells are arranged in a variety of pat-
terns including micro- and macrofollicular, trabecular, bands and diffuse 
sheets.  
Thecoma is usually benign. It occurs more frequently in postmeno-
pausal women. Grossly, thecoma is a solid and firm mass, cut surface is yel-
lowish. Histologically, it consists of spindle-shaped theca cells of the ovary 




All testicular tumors are subdivided into 3 groups: germ cell tumours 
(seminoma, embryonal carcinoma, teratoma, yolk sac tumor, etc.), sex cord-
stromal tumours (Leydig`s cell tumor, Sertoli`s cell tumor, etc.) and mixed 
forms (gonadoblastoma).  
Seminoma is the commonest malignant tumour of the testis and cor-
responds to dysgerminoma in female. The tumor has a peak incidence in the 
4th decade of life. Grossly, the involved testis is enlarged up to 10 times its 
normal size. Cut section shows homogeneous, grey-white lobulated appear-
ance. Tumor cells generally lie in cords, sheets or columns forming lobules. 
Leydig`s (interstitial) cell tumors are quite uncommon. They may oc-
cur at any age but are more frequently at the age from 20 to 50 years. The 
tumor cells secrete androgen, or both androgen and oestrogen, and rarely 
corticosteroids. Crossly, the tumor appears as a small, well-demarcated and 
lobulated nodule. Cut surface is homogeneously yellowish or brown. The 
tumor is composed of sheets and cords of normal-looking Leydig`s cells.  
Sertoli`s cell tumors (androblastoma) may occur at all ages but more 
frequently in infants and children. The tumor may elaborate oestrogen or 
androgen and may account for gynaecomastia in an adult or precocious sex-
ual development of child. The tumour is fairly large, firm, round, and well 
circumscribed. Cut surface of the tumour is yellowish or yellow-grey.  
Gonadoblastoma is an example of combination of both germ cells 
and sex cord stromal components.  
 
Thyroid tumors 
Most tumors of the thyroid gland are of follicular epithelial origin; 
few arise from parafollicular C-cells.  
The most common benign thyroid neoplasm is a follicular adenoma. 
It is characterized by four features so as to distinguish it from a nodule of 
nodular goitre: 1. solitary nodule; 2. complete encapsulation; 3. clearly dis-
tinct architecture inside and outside the capsule; 4. and compression of the 
thyroid parenchyma outside the capsule. There are following 6 types of 
growth pattern: 1). Microfollicular adenoma; 2). Normofollicular adenoma; 
3). Macrofollicular (colloid) adenoma; 4). Trabecular adenoma; 5). Oxyphi-
lic adenoma; 6). Atypical adenoma. 
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Thyroid cancer. Carcinoma of the thyroid gland has 4 major morpho-
logic types with distinctly different clinical behavior and variable preva-
lence. These are papillary, follicular, medullary and undifferentiated (ana-
plastic) carcinoma.  
Papillary carcinoma is the most common type of thyroid carcinoma. 
Papillae are composed of fibrovascular stalk and covered by single layer of 
tumour cells which have characteristic nuclear features (optically clear ap-
pearance).  
Follicular thyroid carcinoma is composed of follicles of various sizes 
and may show trabecular or solid pattern. Vascular and adjacent structures 
invasion are significant features. 
Medullary thyroid carcinoma derived from parafollicular or C-cells. 
There are 3 distinctive features of this tumor: familial occurrence, secretion 
of calcitonin, and amyloid stroma.  
Anaplastic carcinoma is one of the most malignant tumors in hu-
mans. The tumour is generally composed of 3 types of cells occurring in 
varying proportions: small cells, spindle cells and giant cells.  
 
Parathyroid tumours. Parathyroid adenoma and carcinoma are the 
most freauent neoplasms found in parathyroid glands. Most of adenomas 
are characterized by the excessive secretion of parathyroid hormone causing 
features of hyperparathyroidism. These tumors are composed of chief-cells 
arranged in sheets or cords.  
 
Tumours of adrenal glands are uncommon and include distinct 
adrenocortical tumours and medullary tumors. There are 4 types of cortical 
adenoma: 1) clear cell cortical adenoma (produces aldosterone and results 
in Conn’s syndrome); 2) dark cell cortical adenoma (produces androgens 
and causes virilism or rarely Cushing’s syndrome); 3) mixed cortical ade-
noma (is characterized by hypercortisolism – Cushing’s syndrome); 4) glo-
merulosa cell adenoma (is characterized by increased secretion of mineral-
ocoticoids). Cortical carcinoma characterized by cellular atypia, local inva-
sion, and itdistant metastasis. 
Pheochromocytoma is a benign tumor arising from the chromaffin 
cells of the adrenal medulla. The most common feature of pheochromocy-
toma is hypertension, resulting from secretion of catecholamines. About 
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10% of pheochromocytomas may be malignant having tendency for osseous 
metastases.  
 
Thymoma is a tumor of epithelial origin. It may arise from cortical 
and medullar thymus cells. Clinically, it is asymptomatic, but sometimes it 
causes myasthenia, immunodeficiency and autoimmune diseases. There are 
4 types of thymoma: 1) cortical cell thymoma (characterized by invasive 
growth and cellular atypia); 2) medullar cell thymoma (generally benign); 
3) mixed cellular thymoma; 4) granulomatous thymoma (is composed of 
atypical multinuclear cells with the formation of granulomatous masses). 
 
Pituitary tumors. Tumors of the anterior pituitary are more common 
than those of the posterior one and hypothalamus. The most common of the 
anterior pituitary tumors are adenomas. They are conventionally classified ac-
cording to their H&E staining characteristics of granules into acidophil, baso-
phil and chromophobe adenomas. However, this morphologic classification is 
considered quite inadequate because of the significant functional characteris-
tics of each type of adenoma including the chromophobe adenoma, which on 
H&E staining doesn’t show visible granules. Modern classification of pituitary 
adenomas is based on functional features correlated with morphologic features 
of the older classification. Thus, the types of this classification are the follow-
ing: 1) lactotroph adenoma; 2) somatotroph adenoma; 3) mixed somatotroph-
lactotroph adenoma; 4) corticotroph adenoma; 5) gonadotroph adenoma; 6) 
thyrotroph adenoma; 7) oncocytoma; 8) plurihormonal adenoma.  
 
Epiphysis. Pinealoma is a benign tumor which is composed of glan-
dular epithelium and neuroglia. The tumor causes metabolic and hormonal 
disturbances. 
 
Endocrinal tumors of the pancreas (islet cell tumors) are rare as 
compared with tumors of the exocrine part of pancreas. Islet cell tumors are 
generally small and may be hormonally inactive or may cause hyperfunc-
tion. They may be benign or malignant, single or multiple. They are named 
according to their histogenesis such as:  
1. β-cell tumor – insulinoma. The tumor composed of cords and 
sheets of well-differentiated β-cells which do not differ from normal cells. 
The neoplastic cells secrete insulin into the blood stream which remains un-
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affected by normal regulatory mechanisms. This results in characteristic at-
tacks of hypoglycaemia and high plasma insulin level; 
2. G-cell tumor – gastrinoma, is characterized by hypergastrinae-
mia. Majority of gastrinomas occur in the wall of the duodenum. They may 
be benign or malignant. Gastrinomas are associated with the development 
of Zollinger-Ellison`s syndrome which is characterized by multiple peptic 
ulcers at usual sites such as the stomach and duodenum, or sometimes at 
unusual sites such as in the oesophagus and jejunum; 
3. A-cell tumor – glucagonoma. The tumor causes hyperglycemia 
and develop diabetes mellitus; 
4. D-cell tumor – somatostatinoma is characterized by hypoin-
sulinemia, hypoglucagonemia, steatorrhea and achlorhydria; 
5. D1 cell tumor – vipoma is characterized by hypopotassemia 
and dehydration; 
6. pancreatic polypeptide PP-secreting tumor; 
7. carcinoid tumor. 
However, except insulinoma and gastrinoma, all others are extremely 
rare. 
Carcinoid tumor is a generic term applied to tumors originating from 
endocrine cells of APUD-system and are therefore also called as apudomas. 
The endocrine cells are distributed throughout the mucosa of the gastroin-
testinal tract. Depending upon the embryologic derivation of the tissues 
where the tumour is located, these are classified as foregut (stomach, duo-
denum and oesophagus), midgut (terminal ileum and appendix), and hind-
gut (rectum and colon) carcinoids. Other uncommon locations are the bron-
chus, trachea, gallbladder, and Meckel’s diverticulum. Appendiceal, ileal 
and stomach carcinoids behave as malignant tumors. Tumor cells are mon-
omorphous, having uniform nuclei and are arranged in a variety of patterns 
– solid nests, sheets, cords, trabeculae and clusters. 
 
TUMORS OF MELANIN-PRODUCING TISSUE 
Melanin-producing cells (melanocytes) are of neurogenous origin. 
They may developas as well tumor-like formations (nevi) as melanomas.  
Nevi are defects of neuroectodermal pigment elements development. 
They look like brown spots of different sizes, and may be either flat or ele-
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vated over the surface or may be like warts. Sometimes their size is enor-
mous (giant pigmented nevus). 
There are the following types of nevi: 1) junctional nevus, 2) com-
pound nevus, 3) intradermal, 4) blue nevus, etc. 
Junctional nevus. Nests of nevus cells are found on the border of epi-
dermis and derma.  
Compound nevus. Nevus cells  are located as on the border of dermis 
and epidermis as in derma. 
Intradermal nevus. Nevus cells are located only in derma. Some of 
them can be found near the border between derma and epidermis. The nevus 
cells look like compact mass. In mature nevi cells may be multinuclear. 
Blue nevus. Macroscopically it looks like bluish or bluish-brown 
(bluish-gray) spot, of round or oval shape, it doesn`t elevate over the skin 
surface. Microscopic examination reveals spindle-shaped melanocytes 
which are situated deeply in the derma. 
 
Melanoma 
Melanoma is one of the most malignant tumors; it spreads through 
the lymphatic and hematogenous routes. 70% of melanomas develop in the 
skin of the face, body and extremities, pigment membrane of the eye, me-
ninges, medullar layer of adrenal glands, and rarely in mucous membranes. 
Depending upon the clinical course and prognosis there are of mela-
nomas: 1) Superficial spreading melanoma; 2) Nodular melanoma; 3) Len-
tigo malignant melanoma; 4) Acral lentigenous melanoma. 
Some melanomas don`t contain pigment. Tumor cells are pleo-
morphic, usually there are a lot of mitoses in melanoma. Nodular type of 
melanoma is characterized by hemorrhages and necroses. In the tumor de-
composition a great amount of melanin and promelanin enters the blood-
stream, which may be accompanied by melaninemia and melaninuria. 
 
TUMORS OF THE NERVOUS SYSTEM AND BRAIN COATS 
Tumors of nervous system develop from different elements of the nerv-
ous system: 1) central nervous system (CNS); 2) vegetative nervous syste; 3) 
peripheral nervous syste; 4) mesenchymal elements (blood vessels,etc.).  
According to the degree of maturity, brain tumors may be benign or malig-
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nant. But even being benign, with a slow growth tumor affects vitally im-
portant centers and causes their dysfunction. 
Neuroectodermal (neuroepithelial) tumors of the brain originating 
from neuroectoderm derivatives are dysontogenetic, i.e. develop from the 
cells which are known as precursors of mature CNS elements. Therefore, it 
may be difficult to determine their histological type. More often their cellu-
lar composition corresponds to definite stages of development of neuronal 
and glial elements. 
Brain tumors produce metastases within the skull, which spread 
through the liquor. 
Primary CNS tumours in the brain, or intracranial tumours, include: 
tumours arising from constituent cells of the brain (with the only exception 
of microglial cells) and from the supporting tissues. Childhood brain tumours 
arise from more primitive cells (e.g. neuroblastoma, medulloblastoma). 
WHO classification of intracranial tumours include: 




4. Choroid plexus papilloma 




ΙΙΙ. TUMOURS OF NEURONS AND NEUROGLIA  
Ganglioglioma 




3. PNET (primitive neuroectodermal tumor) 
V. TUMOURS OF MENINGES 
1. Meningioma 
2. Meningeal sarcoma 
VI. NERVE SHEATH TUMOURS 
1. Schwannoma (neurilemmoma) 
2. Neurofibroma 
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3. Malignant nerve sheath tumour 
Gliomas  
The term glioma is used for all tumours arising from neuroglia, or 
more precisely, from neuroectodermal epithelial tissue. They include tu-
mours arising from :  
- astrocytes (astrocytomas and glioblastoma multiforme); 
- oligodendrocytes (oligodendroglioma); 
- ependyma (ependymoma); 
- choroid plexus (choroid plexus papilloma). 
Gliomas may be well-differentiated or poorly-differentiated. Howev-
er, gliomas are never truly well-demarcated or encapsulated and thus all 
grades of gliomas infiltrate the adjacent brain tissue. 
Astrocytoma is the most common type of gliomas. It has a tendency 
to progress from low grade to higher grades of anaplasia. Low-grade astro-
cytomas evolve slowly, over several years, whereas higher grades (anaplas-
tic astrocytoma and glioblastoma multiforme) bring about rapid clinical de-
terioration of the patient. 
Morphologically, astrocytomas have been conventionally divided in-
to 3 progressive histologic grades: fibrillary (most common), hemistocytic 
and protoplasmic. WHO classification of astrocytomas includes 4 grades: 
Grade I (low grade) Astrocytoma: Juvenile pilocytic astrocytoma, 
pleomorphic xanthoastrocytoma; 
Grade II Astrocytoma: fibrillary, protoplastic, gemistocytic astrocy-
toma; 
Grade III Astrocytoma: anaplastic astrocytoma; 
Grade IV Astrocytoma: glioblastoma multiforme. 
Oligodendroglioma is an uncommon glioma of oligodendroglial 
origin and may develop in isolation or may be mixed with other glial cells. 
X-ray examination and CT scan reveal a well-defined mass with numerous 
small foci of calcification. The tumour is generally slow-growing. 
Ependymoma is a common tumour, derived from the layer of epithe-
lium in the brain ventricles or spinal cord central canal. It occurs mainly in 
children and young adults (upto 20 years). Typically, it is localized in the 
fourth ventricle (posterior fossa tumour). Other locations are the lateral ven-
tricles, third ventricle, and in the case of adults - the spinal cord in the re-




Ganglioneuroma is a rare mature tumor. More frequently it is local-
ized near the 3rd ventricle, less often in the hemispheres of the brain. It usu-
ally occurs in children and adolescents. The tumor consists of mature gan-
glionic cells separated with the bands of glial stroma. Macroscopically, 
ganglioneuroma looks like a circumscribed node. In the medulla oblongata 
it is diffuse, in the cerebellum it looks like hyperplastic folds. 
Cerebellum ganglioma is characterized by proliferation of  
Purkinjer's cells. 
Ganglioneuroblastoma is a malignant variant of ganglioneuroma 
(malignant gangliocytoma). It is an extremely rare tumor of CNS. It is char-
acterized by cellular polymorphism. 
Neuroblastoma is a rare highly malignant brain tumor. It occurs 
mainly in children. The tumor is formed from large cells with bubble-like 
nucleus. Mitoses are numerous. The cells grow like syncytium. 
 
Poorly-differentiated and embryonal tumours 
CNS tumours composed of primitive undifferentiated cells include 
medulloblastoma and glioblastoma. 
Medulloblastoma is the most common varient of primitive neu-
roectodermal tumour. It occurs in patients over the age of 20 years. The 
most common location is the cerebellum in the region of fourth ventricle 
roof, midline of cerebellum, vermis, or in the cerebellar hemispheres. 
Medulloblastoma is a highly malignant tumour and spreads to local as 
well as to distant sites. It invades locally and by the cerebrospinal fluid to me-
ninges, ventricles and subarachnoid space and has a tendency for widespread 
metastases to extraneural sites such as to lungs, liver, vertebrae and pelvis. 
 
Tumours of meninges 
The most common tumour arising from the pia-arachnoid is meningi-
oma (occurs in 20% cases of intracranial tumours). 
Meningiomas arise from the cap cell layer of the arachnoid. Their 
most common sites are in the front half of the head and include lateral cere-
bral convexities, midline along the falx cerebri adjacent to the major venous 
sinuses parasagittally, and olfactory groove. Less frequent sites are: within 
the cerebral ventricles, foramen magnum, cerebellopontine angle and the 
spinal cord. They are usually found in 2nd to 6th decades of life, with slight 
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female preponderance. Most meningiomas are benign and can be removed 
successfully. Rarely, a malignant meningioma may metastasise, mainly to 
the lungs. 
Grossly, meningioma is well-circumscribed, solid, spherical or hemi-
spherical mass of varying size (1-10 cm in diameter). The tumour is gener-
ally firmly attached to the dura and indents the surface of the brain but rare-
ly ever invades it.  
Microscopically, meningiomas are divided into 5 subtypes: menin-
gotheliomatous (syncytial), fibrous (fibroblastic), transitional (mixed), an-
gioblastic and anaplastic (malignant). 
 
Nerve sheath tumours 
Tumours of the peripheral nerves are commonly benign and include 
schwannoma (neurilemmoma) and neurofibroma. Both of them arise from 
Schwann`s cells but neurofibroma contains large amount of collagen. Rare-
ly, their malignant counterpart, malignant peripheral nerve sheath tumour, 
develops particularly in patients with von Recklinghausen's neurofibroma-
tosis. 
Microscopically, schwannoma is composed of fibrocellular bundles 
forming whorled pattern. There are areas of dense and compact cellularity 
alternating with loose acellular areas. Areas of pattern show palisaded nu-
clei called Verocay`s bodies. 
Neurofibromas may occur as solitary, fusiform cutaneous tumour of a 
single nerve, but more often are multiple associated with von Recklinghau-
sen's disease. Microscopically, a neurofibroma is composed of bundles and 
interlacing fascicles of delicate and elongated spindle-shaped cells having 
wavy nuclei.  
Malignant peripheral nerve sheath tumor is a poorly differentiated 
spindle cell sarcoma of the peripheral nerves occurring most often in adults. 
 
Tumors of vegetative nervous system originate from ganglionic cells 
of different degree of maturity (sympathogonias, sympathoblasts, gan-
glioneurocytes) in sympathetic ganglia as well as from the cells of non-
chromophinic paraganglia (glomes) genetically associated with sympathetic 
nervous system. Such benign tumors as ganglioneuroma, paraganglioma 
(glome tumor, chemodentoma) belong to this group. 
 
 239 
TUMOR DISEASES OF THE BLOOD AND LYMPHOID TISSUE 
LEUKAEMIAS 
Definition and classification. Leukaemias are a group of disorders 
characterized by malignant transformation of blood-forming cells. The pro-
liferation of leukaemic cells takes place primarily in the red bone marrow, 
and in certain forms, in the lymphoid tissue. Utimately, the abnormal cells 
appear in the peripheral blood raising the total white cell count to high lev-
el. In addition, features of bone marrow failure (e.g., anaemia, thrombocy-
topenia, neutropenia) and involvement of other organs (e.g., liver, spleen, 
lymph nodes, meninges, brain, skin etc) occur. 
In general, leukaemias are classified according to the cell types pre-
dominantly involved, into myeloid and lymphoid, and on the basis of  the 
disease evolution into acute (with the proliferation of blast, nondifferentiat-
ed  cells) and chronic (with the proliferation of differentiated cells, relative-
ly benign course). 
Depending on impairment in peripheral blood formula and the num-
ber of white blood cells there are following forms of leukaemias: 
1. Leukemic that are characterized by a significant increase in the 
number of WBC, including leukemia cells in peripheral blood (tens or hun-
dreds of thousands, sometimes millions in 1 /mcL of blood). This is the 
most common form. 
2. Subleukemic – the WBC count is slightly elevated - up to 30 000 
in 1 mcL of blood. 
3. Aleukemic – the number of WBC is whithin the normal range and 
tumor cells are not present in the blood. This type is rare, but it usually oc-
curs in the early stages of the disease.  
4. Leukopenic – the number of WBC is below normal. 
Hiatus leukemicus - A condition observed in acute myelogenous leu-
kemia in which there are numerous myeloblasts and a number of mature 
neutrophils in the peripheral blood, with few or no intermediate forms. The 
term "hiatus leukemicus" suggests a jump in cell development from an early 
stage to a late stage with nothing in between, analogous to changing from 
the appearance of a 10 year old to that of a 60 year old without any inter-
mediate stages. 
Leukaemias account for 4% of all cancer deaths. Generally, acute 
leukaemias have a rapidly progressing course, whereas chronic leukaemias 
 240 
tend to have more indolent behaviour. The incidence of both acute and 
chronic leukaemias is higher in men than in women. 
Etiology. The etiology of leukaemia is not known in most patients. 
However, a number of factors have been implicated. 
1. GENETIC FACTORS. There is high concordance rate among 
identical twins if acute leukaemia develops in the first year of life. Families 
with excessive incidence of leukaemia have been identified. Acute leukae-
mia occurs with increased frequency with a variety of congenital disorders 
such as Down's, Bloom's, Klinefelter's, Fanconi's and Wiskott-Aldrich's 
syndromes. 
2. ENVIRONMENTAL FACTORS. Certain environmental factors 
are known to play a role in the etiology of leukaemia. These include the fol-
lowing: 
i) Ionising radiation, e.g. in individuals exposed to occupational ra-
diation exposure, patients receiving radiation therapy, and Japanese survi-
vors of the atomic bomb explosions. Radiation exposure is related to the 
development of chronic myelocytic leukemia (CML), aqute myeloblastic 
leukemia (AML) and  aqute lymphloblastic leukemia (ALL) but not to 
chronic lymphocytic leukemia (CLL) or HCL. 
ii) Chemical carcinogens, e.g. benzene and other aromatic hydrocar-
bons are associated with the development of AML. 
iii) Certain drugs, e.g. treatment with alkylating agents and other 
chemotherapeutic agents is associated with increased incidence of AML. 
3. INFECTION. Induction of leukaemias in experimental animals by 
RNA viruses (retroviruses) has been studied for quite sometime but more 
recently viral etiology of adult T-cell leukaemia-lymphoma (ATLL) by a 
human retrovirus called human T-cell leukaemia-lymphoma virus I (HTLV-
I) and HTLV II for T cell variant of hairy cell leukaemia has been estab-
lished. 
Pathogenesis (Leukaemogenesis). The leukaemia arises following 
malignant transformation of a single clone of cells belonging to myeloid or 
lymphoid series, followed by proliferation of the transformed clone. The 
evolution of leukaemia is multi-step process, and in many cases, acute leu-
kaemia may develop after a pre-existing myelodysplastic or myeloprolifera-
tive disorder. 
The salient features in the pathogenesis of leukaemias are as under: 
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• In acute leukaemia, the single most prominent characteristic of the 
leukaemic cells is a defect in maturation beyond the myeloblast or promye-
locyte level in AML, and the lymphoblast level in ALL. However, it may be 
emphasised here that it is the maturation defect in leukaemic blasts rather 
than rapid proliferation of leukaemic cells responsible for causing acute 
leukaemia. In fact, the generation time of leukaemic blasts is somewhat pro-
longed rather than shortened. 
• The leukaemic cells proliferate primarily in the bone marrow, cir-
culate in the blood and infiltrate into other tissues such as lymph nodes, liv-
er, spleen, skin, viscera and the central nervous system. 
• The mechanism of leukaemic transformation is poorly understood. 
But, the basic defect lies in the DNA, conferring a heritable malignant char-
acteristic to the transformed cell and its progeny. A neoplastic pheno-type 
may be induced by RNA viruses (e.g. HTLV-I) and causes insertional mu-
tagenesis for which oncogenes may play a role as. A number of clonal cyto-
genetic abnormalities have been reported in association with the various 
forms of acute and chronic leukaemias. The most consistent chromosomal 
abnormality among these is Philadelphia (Ph) chromosome seen in 70-90% 
cases with CML, involving reciprocal translocation of parts of long arm of 
chromosome 22 to the long arm of chromosome 9 i.e. t (9;22). 
• As the leukaemic cells accumulate in the bone marrow, they sup-
press normal haematopoietic stem cells, partly by physically replacing the 
normal marrow precursors. However, some patients with acute leukaemia 
have a hypocellular marrow indicating that marrow failure is not simply due 
to overcrowding by leukaemic cells but may inhibit normal haematopoiesis 
via cell-mediated or humoral mechanisms. Nevertheless, some normal 
haematopoietic stem cells do remain in the marrow which are capable of 
proliferating and restoring normal haematopoiesis after effective anti-
leukaemic treatment. 
ACUTE LEUKAEMIAS 
Acute leukaemias are characterised by predominance of undifferenti-
ated leucocyte precursors or leukaemic blasts. Acute leukaemias may be de-
rived from the myeloid stem cells called acute myeloblastic leukaemia 
(AML), or from the lymphoid stem cells termed acute lymphoblastic leu-
kaemia (ALL). 
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Recently, more definite criteria for diagnosis and classification of 
acute leukaemias have been laid down by a group of French, American and 
British haematologists commonly called the FAB classification. According 
to this system, a leukaemia is acute if the bone marrow consists of more 
than 30% blasts. FAB classification divides AML into 8 subtypes (MO to 
M7) and ALL into 3 subtypes (LI to L3).  
Most frequenr types of acute leucemias are: 
1. Acute nondifferentiated, 
2. Acute myeloblastic, 
3. Acute lymphoblastic, 
4. Acute plasmoblastic, 
5. Acute monoblastic, 
6. Acute myelomonoblastic, 
7. Acute erythromyeloblastic, 
8.  Acute megakaryoblastic. 
More recently, another classification called revised European-
American classification of lymphoid neoplasms (REAL classification) has 
been formulated and includes acute and chronic lymphoid leukaemias and 
non-Hodgkin's lymphomas since they represent the counterparts neoplastic 
in the bone marrow and lymphoid tissue. 
Clinical Features 
AML and ALL share many clinical features. In approximately 25% 
of patients with AML, a preleukaemic syndrome with anaemia and other 
cytopenias is usually present for a few months to years prior to the devel-
opment of overt leukaemia. 
Clinical manifestations of acute leukaemias are divided into 2 groups: 
those due to bone marrow failure, and those due to organ  infiltration. 
 
I. DUE TO BONE MARROW FAILURE. These are some syn-
droms: 
1. Anaemia producing pallor, lethargy, dyspnoea. 
2. Bleeding manifestations due to thrombocytopenia: spontaneous 
bruises, petechuie, and other bleeding tendencies. 
3. Infections are quite common and include those of mouth, throat, 
skin, respiratory, perianal and other sites. 
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4. Fever is generally attributed to infections in acute leukaemia but 
sometimes no obvious source of infection can be found and may occur in 
the absence of infection. 
II. DUE TO ORGAN INFILTRATION. The clinical manifesta-
tions of acute leukaemia are more often due to replacement of the marrow 
and other tissues by leukaemic cells. These features are as under: 
1. Pain and tenderness of bones (e.g. sternal tenderness) are due to 
bone infarcts or subperiosteal infiltrates by leukaemic cells. These features 
are more frequent in children with ALL. 
2. Lymphadenopathy and enlargement of the tonsils are more com-
mon in ALL. 
3. Splenomegaly of moderate grade is common, especially in ALL. 
Splenic infarction, subcapsular haemorrhages, and rarely, splenic rupture 
may occur. 
4. Hepatomegaly is frequently present due to leukaemic infiltration 
but the infiltrates usually do not interfere with the function of the liver. 
5. Leukaemic infiltration of the kidney may be present and ordinarily 
does not interfere with its function unless secondary complications such as 
haemorrhage or blockage of ureter supervene. 
6. Gum hvpertrophy due to leukaemic infiltration of the gingivae is a 
frequent finding in myelomonocytic (M4) and monocytic (M5) leukaemias.  
7. Chloromas are localised tumour-forming masses occurring in the 
skin or orbit due to local infiltration of the tissues by leukaemic cells. They 
are greenish in appearance due to the presence of myeloperoxidase. 
8. Meningeal involvement manifested by raised intra-cranial pressure, 
headache, nausea and vomiting, blurring of vision and diplopia are seen 
more frequently in ALL during haematologic remission. Sudden death from 
massive intracranial haemorrhage as a result of leucostasis may occur. 
9. Other organ infiltrations include testicular swelling in ALL and 
mediastinal compression in T cell type ALL. 
Laboratory Findings 
The diagnosis of acute leukaemia is made by a combination of rou-
tine blood picture and bone marrow examination, coupled with cytochemi-
cal stains and certain biochemical investigations. 
I. BLOOD PICTURE. Findings of routine haematologic investigations are as under: 
1. Anaemia. Anaemia is almost always present in acute leukaemias. It is general-
ly severe, progressive and normo-chromic in type. A moderate reticulocytosis up to 5% 
and a few nucleated red cells may be present. 
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2. Thrombocytopenia. The platelet count is usually moderately to severely de-
creased (below 50,000/μl) but occasionally it may be normal. Bleeding tendencies in 
acute leukaemia are usually correlated with the level of thrombocytopenia but most seri-
ous spontaneous haemorrhagic episodes develop in patients with fewer than 20,000/μl 
platelets. Acute promyelocytic leukaemia (M3) may be associated with a serious coagu-
lation abnormality called disseminated intravascular coagulation (DIG). 
3. White blood cells. The total WBC count ranges from subnormal-to-markedly 
elevated values. In 25% of patients, the total WBC count at presentation is reduced to 
1,000-4,000 /μl. More often, however, there is progressive rise in white cell count which 
may exceed 100,000/μl in more advanced disease. The majority of leucocytes in the pe-
ripheral blood are blasts and there is often neutropenia due to marrow infiltration by leu-
kaemic cells. Some patients present with pancytopenia and have a few blasts (sub-
leukaemic leukaemia) or no blasts (aleukaemic leukaemia) in the blood. Both these con-
ditions are nowadays included under 'myelodysplastic syndrome'. In some instances, the 
identification of blast cells is greatly aided by the company they keep i.e. by more ma-
ture and easily identifiable leucocytes in the company of blastic cells of myeloid or lym-
phoid series. It is usual to find some 'smear cells' in the peripheral blood which represent 
degenerated leucocytes, particularly in the case of ALL. 
II. An examination of bone marrow reveals the s hypercellularity due to pan-
cytopenia. 
The diagnosis of the type of leukaemic cells, according to FAB classification, is 
generally possible with routine Romanowsky stains but cytochemical stains may be em-
ployed as an adjunct to Romanowsky staining for determining the type of leukaemia. 
The essential criteria for diagnosis of acute leukaemia, as per FAB classification, is the 
presence of at least 30% blasts in the bone marrow. 
Erythropoieric cells are reduced. Dyserythropoiesis, megaloblastic features and 
ring sideroblasts are commonly present. Megakaryocytes are usually reduced or absent. 
Chromosomal analysis of dividing leukaemic cells in the marrow shows karyo-
typic abnormalities in 75% of cases which may have a relationship to prognosis. Three 
of the common chromosomal abnormalities are as under: 
i) Aneuploidy is the most common finding in acute leukaemia. In ALL, aneu-
ploidy is almost always hyper-diploid while hypo- and hyper-diploid cell lines are found 
with approximately equal frequency in AML. Cases with hyper-diploidy between 50 to 
60 chromosomes are associated with good prognosis.  
ii) Ph chromosome, t (9; 22), though commonly found in CML, is found in 2-3% 
of children with ALL and 25-30% cases of adults with ALL. It is associated with poor 
prognosis in both these forms of acute leukaemia. 
iii) Mature form of B-ALL has characteristic t (8;14) trans-location which too is 
associated with worse prognosis. 
 
III. CYTOCHEMISTRY. Some of the commonly employed cytochemical stains, as 
an aid to classify the type of acute leukaemia: 
1. Myeloperoxidase: Positive in immature myeloid cells containing granules and 
Auer rods but negative in MO myeloblasts. 
2. Sudan Black: Positive in immature cells in AML. 
3. Periodic acid-Schiff (PAS): Positive in immature lymphoid cells and in 
erythroleukaemia (M6). 
4. Non-specific esterase (NSE): Positive in monocytic series (M4 and M5). 
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5. Acid phosphatase: Focal positivity in leukaemic blasts in ALL and diffuse re-
action in monocytic cells (M4 and M5). 
 
IV. OTHER INVESTIGATIONS. Other laboratory tests which may be of some help 
in classifying leukaemias are as under: 
1. Cell surface markers. These are of particular value in classifying various 
types of ALL. These include the following: 
i) For all types of ALL: Estimation of terminal deoxynucleotidyl transferase 
(TdT) by immunofluorescence in 95% cases of ALL. 
ii) For B cell ALL, positive lymphoid markers are CD19 (pan-B) and CD10 in 
most cases and CD20 in 50% cases. 
iii) For T cell ALL, lymphoid markers are CD3 and CD7. 
2. Serum muramidase. Serum levels of lysozyme (i.e. muramidase) are elevated 
in myelomonocytic (M4) and monocytic (M5) leukaemias. 
3. Serum uric acid. Because of rapidly growing number of leukaemic cells, se-
rum uric acid level is frequently increased. The levels are further raised after treatment 
with cytotoxic drugs because of increased cell breakdown. 
 
CHRONIC LEUKAEMIAS 
Chronic leukaemias are those haematologic malignancies in which 
the predominant leukaemic cells are initially well-differentiated and easily 
recognisable as regards their cell type. 
Chronic leukaemias are divided into 2 main types: chronic myeloid 
(granulocytic) leukaemia (CML or CGL), and chronic lymphocytic leukae-
mia (CLL).  
In general, chronic leukaemias have a better prognosis than the acute 
leukaemias. Currently CML has come to be classified alongwith other 
myeloproliferative syndromes due to common histogenesis from haemato-
poietic stem cells (described later). However, for the purpose of present dis-
cussion, CML is described here alongwith other chronic leukaemias. 
 
CHRONIC MYELOID LEUKAEMIAS (CML) 
Chronic myeloid (myelogenous, granulocytic) leukaemia comprises 
about 20% of all leukaemias and its peak incidence is seen in 3rd and 4th 
decades of life. A distinctive variant of CML seen in children under 3 years 
of age is called juvenile CML. Both the sexes are affected equally. The ex-
act etiology is not known but an increased incidence of both AML and 
CML was observed years later in Japanese atomic bomb survivors implicat-
ing radiation in their etiology. 
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Chronic leukaemias of myeloid origin fall into one of two WHO cat-
egories. The first, the myeloproliferative neoplasms (MPN), includes chron-
ic myelogenous leukaemia (CML), chronic neutrophilic leukaemia (CNL), 
chronic eosinophilic leukaemia (CEL) and mast cell leukaemia. These are 
clonal haematopoietic stem cell disorders with essentially normal morphol-
ogy of the endstage cell. The type of chronic leukaemia is defined by the 
lineage of the predominant proliferating cell. The second, the myelodysplas-
tic/myeloproliferative neoplasms, consists of chronic myelomonocytic leu-
kaemia (CMML), juvenile myelomonocytic leukaemia (JMML), and atypi-
cal chronic myeloid leukaemia (aCML). These all have dysplastic morphol-
ogy as well as proliferative features. 
Clinical Features 
The onset of CML is generally insidious. Some of the common pre-
senting manifestations are as under: 
1. Features of anaemia such as weakness, pallor, dyspnoea and tach-
ycardia. 
2. Symptoms due to hypermetabolism such as weight loss, lassitude, 
anorexia, night sweats. 
3. Splenomegaly is almost always present and is frequently massive. 
In some patients, it may be associated with acute pain due to splenic infarc-
tion. 
4. Bleeding tendencies such as easy bruising, epistaxis, menorrhagia 
and haematomas may occur. 
5. Less commonly, features such as gout, visual disturbance, neuro-
logic manifestations and priapism are present. 
6. Juvenile CML is more often associated with lymph node enlarge-
ment than splenomegaly. Other features are frequent infections, haemor-
rhagic manifestations and facial rash. 
The diagnosis of CML is generally possible on blood picture alone. 
However, bone marrow, cytochemical stains and other investigations are of 
help. 
The natural history of CML consists of 2 phases - chronic and blastic. 
• The chronic phase of CML begins as a myeloproliferative disorder 
and consists of excessive proliferation of myeloid cells of intermediate 
grade (i.e. myelocytes and metamyelocytes) and mature segmented neutro-
phils. Myeloblasts usually do not exceed 10% of cells in the peripheral 
blood and bone marrow. An increase in the proportion of basophils up to 
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10% is a characteristic feature of CML. A rising basophilia is indicative of 
impending blastic transformation. An accelerated phase of CML is also de-
scribed in which there is progressively rising leucocytosis associated with 
thrombocytosis or thrombocytopenia and splenomegaly. 
• The blastic phase or blast crisis in CML may be myeloid or lym-
phoid in origin. Myeloid blast crisis in CML is more common and resem-
bles AML. However, unlike AML, Auer rods are never seen in myeloblasts 
of CML in blast crisis. Lymphoid blast crisis in CML having the character-
istics of lymphoblasts such as presence of TdT is seen in one-third cases of 
blastic phase in CML. 
Generally, there is hypercellularity of marrow with total or partial re-
placement of fat spaces by proliferating myeloid cells. The myeloid cells pre-
dominate in the bone marrow with increased myeloid-erythroid ratio. Erythro-
poiesis is normoblastic but there is reduction in erythropoietic cells. Megakar-
yocytes are conspicuous but are usually smaller in size than normal. 
Cytogenetic studies on blood and bone marrow cells show the charac-
teristic chromosomal abnormality called Philadelphia (Ph) chromosome 
formed by reciprocal translocation between part of long arm of chromo-
some 22 and part of long arm of chromosome 9{(t(9;22)} seen in 70-90% 
cases with CML. 
The most common cause of death (in 80% cases) in CML is blastic 
transformation. 
 
CHRONIC LYMPHOCYTIC LEUKAEMIAS (CLL) 
Chronic lymphocytic leukaemia constitutes about 25% of all leu-
kamias and is predominantly a disease of the elderly (over 50 years of age) 
with a male preponderance (male-female ratio 2:1). 
CLL is the commonest leukaemia in the Western world and occurs in 
adults. It is characterized by monomorphic, small, round lymphocytes with 
clumped chromatin and minimal cytoplasm, together with a small number 
of prolymphocytes. The cells express B-cell antigens (CD19, weak CD20, 
and CD22), CD5, CD23, and weak IgM. Expression of ZAP70 and CD38, 




Chronic lymphocytic leukaemia (CLL)  
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Prolymphocytic leukaemia (PLL)  
Hairy cell leukaemia (HCL)  
Plasma cell (paraproteinaemic) leukaemia  
T-cell  
Large granular lymphocytic leukaemia 
T-cell prolymphocytic leukaemia (T-PLL)  
Adult T-cell leukaemia/ lymphoma 
Sézary syndrome 
 
Common Clinical Features 
The onset of disease is characteristically insidious. Common present-
ing manifestations are as under:  
1. Features of anaemia such as gradually increasing weakness, fa-
tigue and dyspnoea 
2. Enlargement of superficial lymph nodes is a very common 
finding. The lymph nodes are usually symmetrically enlarged, discrete and 
non-tender. 
3. Splenomegaly and hepatomegaly are usual. 
4. Haemorrhagic manifestations are found in case of CLL with 
thrombocytopenia. 
5. Infections, particularly of respiratory tract, are common in CLL. 
6. Less common are: mediastinal pressure, tonsillar enhrgement, dis-
turbed vision, and bone and joint pains. 
Laboratory Findings 
The diagnosis of CLL can usually be made on the basis of physical 
findings and blood smear examination. 
I. BLOOD PICTURE. The findings of routine blood picture are as under: 
1. Anaemia. Anaemia is usually mild to moderate and normocytic 
normochromic in type. Mild reticulocytosis may be present. About 20% 
cases develop a Coombs'-positive autoimmune haemolytic anaemia. 
2. White blood cells. Typically, there is marked leuco-cytosis but 
less than that seen in CML (50,000-200,000/μ1). Usually, more than 90% of 
leucocytes are mature small lymphocytes. Smear cells (degenerated forms) 
are present. The absolute neutrophil count is, however, generally within 
normal range. Granulocytopenia occurs in fairly advanced disease only. 
3. Platelets. The platelet count is normal or moderately reduced. 
II. BONE MARROW EXAMINATION. The typical findings are: 
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1. Increased lymphocyte count (25-95%). 
2. Reduced myeloid precursors. 
3. Reduced erythroid precursors. 
III. OTHER INVESTIGATIONS. These are: 
1. Erythrocyte rosette test with mouse red cells is positive in more 
than 95% of cases indicating that CLL is a monoclonal B cell neoplasm. 
2. Serum immunoglobulin levels are generally reduced. 
3. Coombs' test is positive in 20% cases. 
Prognosis is generally better than CML since blastic transformation 
of CLL seldom occurs. Rare T-cell variant of CLL, however, runs a more 
malignant course. Prognosis generally correlates with the stage of disease as 
under: 
Stage A: characterised by lymphocytosis alone, or with limited lym-
phadenopathy, has a good prognosis (median survival more than 10 years). 
Stage B: having lymphocytosis with associated significant lymphad-
enopathy and hepatosplenomegaly has intermediate prognosis (median sur-
vival about 5 years). 
Stage C: having lymphocytosis with associated anaemia and throm-
bocytopenia has a worse prognosis (median survival of less than 2 years). 
B-CELL PROLYMPHOCYTIC LEUKAEMIA 
B-cell prolymphocytic leukaemia (B-PLL) is rare in comparison with 
CLL. It presents in elderly patients, predominantly men, with marked sple-
nomegaly and minimal lymphadenopathy, and has a poor prognosis. The 
neoplastic cell is larger than in CLL and is round with a centrally placed 
nucleus, single prominent nucleolus, and basophilic cytoplasm. The cells 
strongly express surface IgM and B-cell antigens; CD5 is present in one-
third and CD23 is negative. 
HAIRY CELL LEUKAEMIA 
Hairy cell leukaemia (HCL) is a rare leukaemia that occurs primarily 
in middle-aged men, is indolent and potentially curable. It is typically asso-
ciated with pancytopenia, splenomegaly, and fibrotic marrow. The leukae-
mic cells are of intermediate size due to abundant irregular grey cytoplasm 
with ‘hairy’ projections. The nuclei are eccentrically located and have a ren-
iform shape. They have a characteristic phenotype with strong B-cell anti-
gens, and express CD11c, CD103, CD123 and CD25 antigens. They have 
cytochemical tartrate-resistant acid phosphatase positivity. 
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PARAPROTEINAEMIC LEUKEMIAS 
The paraproteinemic leukemias are characterised by abnormal prolif-
eration of immunoglobulin-producing cells and result in accumulation of 
monoclonal immunoglobulin in serum and urine. The group as a whole is 
known by various synonyms such as plasma cell dyscrasias, 
paraproteinaemias, dysproteinaemias and monoclonal gammopathies. The 
group comprises the following four disease entities: 
1. Multiple myeloma 
2. Waldenstrom's macroglobulinaemia 
3. Heavy chain disease 
4. Primary amyloidosis. 
The feature common to all plasma cell disorders is the neoplastic pro-
liferation of cells derived from B-lymphocyte lineage. Normally B lympho-
cytes have surface immunoglobulin molecules of both M and G heavy 
chains. Under normal circumstances, the B-cells are stimulated by exposure 
to surface immunoglobulin-specific antigen and mature to form IgG-
producing plasma cells. However, in the plasma cell disorders, the control 
over this process is lost and results in abnormal production of immuno-
globulin that appears in the blood and urine. These disorders differ from B-
cell lymphomas in having monoclonal synthesis, of immunoglobulins and 
lack of prominent lymphadeno-pathy. In addition to the rise in complete 
immunoglobulins, some plasma cell disorders synthesise excess of light 
chains (kappa or lambda), or heavy chains of a single class (alpha, gamma, 
or mu). Bence Jones proteins are free light chains present in blood and ex-
creted in urine of some cases with plasma cell disorders. After these brief 
general comments, we can now turn to the discussion of the specific plasma 
cell disorders. 
There is rise in the total serum protein concentration due to 
paraproteinaemia. Paraproteins are abnormal immunoglobulins or their 
parts circulating in plasma and excreted in urine. The most common 
paraprotein is IgG seen in two-third cases of myeloma, IgA in one-third, and 
rarely there may be IgM or IgD paraproteins, or various combinations. 
Though the commonest cause of paraproteinaemias is multiple myeloma, 
certain other conditions may also produce serum paraproteins such as: 
•   Waldenstrom's macroglobulinaemia; 
•   Benign monoclonal gammopathy; 
•   B-cell lymphomas; 
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•   CLL; 
•   Light chain disease; 
•   Heavy chain disease; and 
•   Cryoglobulinaemia. 
As a result of paraproteinaemia, normal serum immunoglobulins 
(IgG, IgA and IgM) and albumin are depressed. The paraprotein usually ap-
pears as a single narrow homogeneous M-band on the serum electro-
phoresis, most commonly in the region of y-globulin. About two-third cases 
of myeloma excrete Bence Jones (light chain) proteins in the urine, consist-
ing of either kappa or lambda light chains, alongwith presence of Bence 
Jones paraproteins in the serum. 
 
MULTIPLE MYELOMA 
Multiple myeloma is a multifocal malignant proliferation of plasma 
cells derived from a single clone of cells (i.e. monoclonal). The terms mul-
tiple myleoma and myeloma are used interchangeably. The tumour, its 
products (M component), and the host response result in the most important 
and most common syndrome in the group of plasma cell disorders that pro-
duces osseous as well as extraosseous manifestations. Multiple myeloma 
primarily affects the elderly (peak incidence in 5th-6th decades) and in-
creases in incidence with age. It is rare under the age of 40 and is slightly 
more common in males. 
Etiopathogenesis. Myeloma is a monoclonal proliferation of B-cells. 
But the exact pathogenesis how it occurs in certain individuals only is not 
known. Two hypotheses have been proposed: 
1. Antigenic stimulation: According to this hypothesis, chronic anti-
genic stimulation in a predisposed individual results in growth deregulation 
and eventual monoclonal proliferation of B-cell clones. 
2. Predisposition to myeloma: There is some evidence to suggest 
that chromosomal translocations and genetic predisposition to myeloma 
play roles in monoclonal proliferation of B-cell lineage. 
The current concept combines the features of both these hypotheses 
i.e. induction of myeloma requires prolonged exposure to foreign antigens 
in predisposed individuals. 
PATHOLOGIC CHANGES. Myeloma affects principally the bone marrow 
though in the course of the disease other organs are also involved. There-
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fore, the pathologic findings are described below under two headings–
osseous (bone marrow) lesions and extraosseous lesions. 
I. OSSEOUS (BONE MARROW) LESIONS. In more than 95% of 
cases, multiple myeloma begins in the bone marrow. In the majority of cas-
es, the disease involves multiple bones. By the time the diagnosis is made, 
most of the bone marrow is involved. Most commonly affected bones are 
those with red marrow i.e. skull, spine, ribs and pelvis, but later long bones 
of the limbs are also involved. The lesions of myeloma secrete osteoclast-
stimulating factor resulting in rarefaction of the bones. The lesions begin in 
the medullary cavity, erode the cancellous bone and ultimately cause de-
struction of the bony cortex. Radiographically, these lesions appear as 
punched out, rounded, 1-2 cm sized defects in the affected bone. 
Grossly, the normal bone marrow is replaced by soft, gelatinous, red-
dish-grey tumours. The affected bone usually shows focal or diffuse osteo-
porosis. 
Microscopically, the diagnosis of multiple myeloma can be usually 
established by examining bone marrow aspiration from an area of bony rar-
efaction. However, if the bone marrow aspiration yields dry tap or negative 
results, biopsy of radiologically abnormal or tender site is usually diagnos-
tic. The following features characterise a case of myeloma: 
i) Cellularity: There is usually hypercellularity of the bone marrow. 
ii) Myeloma cells: Myeloma cells constitute 15-30% of the marrow 
cellularity. These cells may form clumps or sheets, or may be scattered 
among the normal haematopoietic cells. Myeloma cells may vary in size 
from small, differentiated cells resembling normal plasma cells to large, 
immature and undifferentiated cells. Binucleate and multinucleate cells are 
sometimes present. The nucleus of myeloma cell is commonly eccentric 
similar to plasma cells but usually lacks the cart-wheel chromatin pattern 
seen in classical plasma cells. Nucleoli are frequently present. The cyto-
plasm of these cells is abundant and basophilic with perinuclear halo, vacu-
olisation and contains Russell bodies consisting of hyaline globules com-
posed of synthesised immunoglobulin  
In addition to multiple myeloma, plasmacytosis in the bone marrow 
can occur in some other disorders. These are: aplastic anaemia, rheumatoid 
arthritis, SLE, cirrhosis of liver, metastatic cancer and chronic inflamma-
tion. However, in all these conditions the plasma cells are mature and they 
do not exceed 10% of the total marrow cells. 
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II. EXTRAOSSEOUS LESIONS. Late in the course of disease, le-
sions at several extraosseous sites become evident. Some of the commonly 
involved sites are as under: 
1. Blood. Approximately 50% of patients with multiple myeloma 
have a few atypical plasma cells in the blood. Other changes in the blood in 
myeloma are the presence of anaemia (usually normocyric normochromic 
type), marked red cell rouleaux formation due to hyperviscosity of blood, 
and an elevated ESR. 
2. Myeloma kidney. Renal involvement in myeloma called myeloma 
nephrosis occurs in many cases. The main mechanism of myeloma kidney 
is by filtration of light chain proteins (Bence Jones proteins) which are pre-
cipitated in the distal convoluted tubules in combination with Tamm-
Horsfall proteins as tubular casts. The casts may be surrounded by some 
multinucleate giant-cells and a few inflammatory cells.  
3. Myeloma neuropathy. Infiltration of the nerve trunk roots by tu-
mour cells produces nonspecific polyneuropathy. Pathologic fractures, par-
ticularly of the vertebrae may occur causing neurologic complications. 
4. Systemic amyloidosis. Systemic primary generalised amyloidosis 
(AL amyloid) may occur in 10% cases of multiple myeloma and involve 
multiple organs and systems. 
5. Liver, spleen involvement. Involvement of the liver and spleen by 
myeloma cells sufficient to cause hepatomegaly, and splenomegaly occurs 
in a small percentage of cases. 
Clinical Features 
The clinical manifestations of myeloma result from the effects of in-
filtration of the bones and other organs by neoplastic plasma cells and from 
immunoglobulin synthesis. The principal clinical features are as under : 
1. Bone pain is the most common symptom. The pain usually in-
volves the back and ribs. Pathological fractures may occur causing persis-
tent localised pain. Bone pain results from the proliferation of tumour cells 
in the marrow. 
2. Susceptibility to infections is the next most common clinical fea-
ture. Particularly common are bacterial infections such as pneumonias and 
pyelonephritis. The increased susceptibility to infection is related mainly to 
decreased production and increased destruction of normal antibodies, and 
partly to granulocyte dysfunction and neutropenia. 
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3. Renal failure occurs in about 25% of patients, while renal patholo-
gy occurs in 50% of cases. Causes of renal failure in myeloma are hypercal-
caemia, glomerular deposits of amyloid, hyperuricaemia and infiltration of 
the kidney by myeloma cells. 
4.  Anaemia occurs in majority of patients of myeloma and is related 
to marrow replacement by the tumour cells and inhibition of haematopoie-
sis. 
5. Bleeding tendencies may appear in some patients due to thrombo-
cytopenia, deranged platelet function and interaction of the M component 
with coagulation factors. 
6. Neurologic symptoms occur in a minority of patients. 
7. Hyperviscosity syndrome may produce headache, fatigue, visual 
disturbances and haemorrhages. 
Diagnosis 
The diagnosis of myeloma is made by classic triad of features: 
1.   marrow plasmacytosis of more than 10%; 
2.   radiologic evidence of lytic bony lesions; and 
3.   demonstration of serum and/or urine M component. 
 
Two variants of myeloma which do not fulfil the criteria of classical 
triad are solitary bone plasmacytoma and extramedullary plasmacytoma. 
Both these are associated with M component in about a third of cases and 
occur in young individuals. Solitary bone plasmacytoma is a lytic bony le-
sion without marrow plasma-cytosis. Extramedullary plasmacytoma in-
volves most commonly the submucosal lymphoid tissue of nasopharynx or 
paranasal sinuses. Both variants have better prognosis than the classic mul-
tiple myeloma. Plasma cell granuloma, on the other hand, is an inflamma-
tory condition having admixture of other inflammatory cells with mature 
plasma cells. 
Prognosis 
Treatment of multiple myeloma consists of systemic chemotherapy in 
the form of alkylating agents and symptomatic supportive care. The median 
survival is 2 years after the diagnosis is made. The terminal phase is marked 
by the development of pancytopenia, severe anaemia and sepsis. 
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WALDENSTROM'S MACROGLOBULINAEMIA 
Waldenstrom's macroglobulinaemia is an uncommon malignant pro-
liferation of monoclonal B lymphocytes which secrete IgM paraproteins 
called macroglobulins as they have high molecular weight. The condition is 
more common in men over 50 years of age and behaves clinically like a 
slowly progressive lymphoma. 
Etiopathogenesis. Waldenstrom's macroglobulinaemia is a mono-
clonal proliferation of B-cells and is accompanied by IgM paraproteinae-
mia, but the exact etiology is not known. A possible relationship of IgM 
macroglobulin with myelin-associated glycoprotein which is lost in degen-
erating diseases has been suggested. The clinical evidence in favour is the 
appearance of peripheral neuropathy before the occurrence of macro-
globulinaemia in some patients. 
Pathologic changes. Pathologically, the disease can be regarded as 
the hybrid between myeloma and small lymphocytic lymphoma. 
• Like myeloma, the disease involves the bone marrow, but unlike 
myeloma it usually does not cause extensive bony lesions or hypercalcae-
mia. The bone marrow shows pleomorphic infiltration by lymphocytes, 
plasma cells, lymphocytoid plasma cells, mast cells and histiocytes. Like in 
myeloma, serum M component is present. • Unlike myeloma and more like 
small lymphocytk lymphoma, enlargement of lymph nodes, spleen and liver 
due to infiltration by similar type of cells is present more frequently. 
Clinical features. The clinical features of the disease are due to both 
infiltration by the disease and paraproteins in the blood. 
1.   Hyperviscosity syndrome is the major clinical manifestation. It re-
sults in visual disturbances, weakness, fatiguability, weight loss and nerv-
ous system symptoms. Raynaud's phenomenon may occur. 
2.   Moderate organomegaly in the form of lymphadenopathy, hepa-
tomegaly and splenomegaly are frequently seen. 
3.   Anaemia due to bone marrow failure may be present. 
4.   Bleeding tendencies may occur due to interaction of macroglobu-
lins with platelets and coagulation factors. 
Diagnosis Unlike myeloma, there are no characteristic radiologic 
findings. The diagnosis rests on laboratory data. These are: 
1. Pieomorphic bone marrow infiltration. 
2. Raised total serum protein concentration. 
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3. Raised serum monoclonal M component which is due to IgM 
paraprotein. 
4. Elevated ESR. 
5. Normocytic normochromic anaemia. 
Prognosis. The management of the patients is similar to that of myelo-
ma. Patients respond to chemotherapy with a median survival of 3-5 years. 
HEAVY CHAIN DISEASES 
Heavy chain diseases are rare malignant proliferations of B-cells ac-
companied by monoclonal excess of one of the heavy chains. Depending 
upon the type of excessive heavy chain, three types of heavy chain diseases 
are distinguished: γ, α and μ heavy chain diseases. 
GAMMA HEAVY CHAIN DISEASE: Also called Franklin's disease, it is 
characterised by excess of mostly γ1-paraprotein, both in the serum and 
urine and is demonstrated as M component. Clinically, the condition may 
develop at any age and present with lymphadenopathy, splenomegaly, hepa-
tomegaly, involvement of pharyngeal lymphoid tissue (Waldeyer's ring) and 
fever. 
Patients have rapidly downhill course due to severe and fatal infec-
tion. 
ALPHA HEAVY CHAIN DISEASE: This is the commonest of heavy 
chain diseases characterised by a-heavy chains in the plasma which are dif-
ficult- to demonstrate in electrophoresis due to rapid polymerisation. The 
patients present with bowel symptoms such as chronic diarrhoea, malab-
sorption and weight loss and may have enlargement of abdominal lymph 
nodes. Chemotherapy may induce long-term remissions. 
MUHEAVY CHAIN DISEASE: This is the rarest heavy chain disease. 
The neoplastic B-cells produce |i heavy chains as well as K light chains; the 
latter appear in the urine while the former do not. Another feature that dis-
tinguishes this type of heavy chain disease from the others is the presence of 
vacuoles in the malignant B lymphocytes. The course and prognosis are like 
those of leukaemia or lymphoma. 
 
HAIRY CELL LEUKAEMIA 
Hairy cell leukaemia (HCL) is an unusual and uncommon form of 
chronic leukaemia in which there is presence of abnormal mononuclear 
cells with hairy cytoplasmic projections in the bone marrow, peripheral 
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blood and spleen. These cells are best recognised under phase contrast mi-
croscopy but may also be visible in routine blood smears. These leukaemic 
'hairy cells' have characteristically positive cytochemical staining for tar-
trate-resistant acid phosphatase. The controversy on the origin of hairy 
cells whether these cells represent neoplastic T-cells, B-cells or monocytes, 
is settled with the molecular analysis of these cells which assigns them B-
cell origin expressing CD19 and CD20 antigen. 
Hairy cell leukaemia occurs in the older males. It is characterised 
clinically by the manifestations due to infiltration of reticuloendothelial or-
gans (bone marrow, liver and spleen) and, hence, its previous name as leu-
kaemic reticuloendotheliosis. Laboratory diagnosis is made by the presence 
of pancytopenia due to marrow failure and splenic sequestration, and identi-
fication of characteristic hairy cells positive for tartrate-resistant acid phos-
phatase. 
The disease often runs a chronic course requiring supportive care. 





Lymphomas are malignant tumours of lymphoreticular origin i.e. 
from lymphocytes and histiocytes and their precursor cells. Clinically and 
pathologically, lymphomas are quite heterogeneous. However, two distinct 
clinicopathologic groups are routinely distinguished: 
I. Hodgkin's lymphoma or Hodgkin's disease (HD) characterised by 
pathognomonic presence of Reed-Sternberg cells. This group comprises 
about 25% of all cases of malignant lymphoma. 
II. Non-Hodgkin's lymphomas (NHL) are more common and com-
prise the rest of cases. 
Both these groups have further histopathologic subtypes and are con-
sidered separately below. 
 
HODGKIN'S DISEASE 
Hodgkin's disease (HD) primarily arises within the lymph nodes and 
involves the extranodal sites secondarily. The incidence of the disease has 
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bimodal peaks - one in young adults between the age of 15 and 35 years and 
the other peak after 5th decade of life. The HD is more prevalent in young 
adult males than females. The classical diagnostic feature is the presence of 
Reed-Sternberg (RS) cell. 
Etiopathogenesis. The nature and origin of RS cells, which are the 
real neoplastic cells in HD, have been a matter of considerable debate. One 
main reason for this difficulty in their characterisation is that in HD, unlike 
most other malignancies, the number of neoplastic cells (i.e. RS cells) is 
very small (less than 5%) which are interspersed in the predominant reac-
tive cells. At different times, various haematopoietic cell lineages have been 
implicated in the origin of RS cells. These include: B-cells, T-cells, macro-
phages and follicular reticulum cells. But presently, there is general consen-
sus on monoclonal lymphoid cell origin of RS cell from B-cells in most 
subtypes of Hodgkin's disease. RS cells in all types of Hodgkin's diseases, 
except in lymphocyte predominance type, express immunoreactivity for 
CD15 and CD30. RS cells in lymphocyte predominance type, however, are 
negative for both CD15 and CD30, but positive for CD20. However, it is 
still not clear what stimulates these lymphoid cells to undergo transfor-
mation. The following possible hypotheses are suggested: 
1. Infectious etiology, possibly infection with an oncogenic virus such 
as Epstein-Barr virus, is implicated by some. Recently a few other viruses 
have been implicated e.g. human T lymphotropic viruses (HTLV-I and 
HTLV-II), HIV and herpesvirus-6. 
2. Genetic etiology is suggested by others on the basis of observation 
of occurrence of HD in families and with certain HLA type. HD is 99 times 
more common in identical twin of an affected case compared with general 
population, implicating genetic origin strongly. 
3. Presence of reactive inflammatory cells in the HD is due to secre-
tion of cytokines (e.g. interleukin-5) from the RS cells. 
Thus, the mystery surrounding the etiology of HD is not yet resolved. 
Classification. The diagnosis of HD requires accurate microscopic 
diagnosis by biopsy, usually from lymph node, and occasionally from other 
tissues. There are following 4 subtypes: of HD: 
1. Lymphocyte-predominance type. 
2. Nodular-sclerosis type. 
3. Mixed-cellularity type. 
4. Lymphocyte-depletion type. 
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Central to the diagnosis of HD is the essential identification of Reed-
Sternberg cell though this is not the sole criteria (see below). 
Reed-Sternberg Cell. The diagnosis of Hodgkin's disease rests on 
identification of RS cells, though uncommonly similar cells, can occur in 
infectious mononucleosis and other forms of lymphomas. Therefore, addi-
tional cellular and architectural features of the biopsy must be given due 
consideration for making the histologic diagnosis. 
There are several morphologic variants of RS cells which character-
ise different histologic subtypes of HD: 
1. Classic RS cell is a large cell which has characteristically a bi-
lobed nucleus appearing as mirror image of each other but occasionally the 
nucleus may be multi-lobed. Each lobe of the nucleus contains a prominent, 
eosinophilic, inclusion-like nucleolus with a clear halo around it, giving an 
owl-eye appearance. The cytoplasm of cell is abundant and amphophilic. 
2. Lacunar type RS cell is characteristically found in nodular sclero-
sis variety of HD. 
3. Polyploid type RS cells are seen in lymphocyte predominance 
type of HD. 
4. Pleomorphic RS cells are a feature of lymphocyte depletion type. 
It may be mentioned here that in general the number of RS cells is 
inversely proportional to the number of lymphocytes in a particular histo-
logic subtype of HD. 
RS cells are invariably accompanied by variable number of atypical 
Hodgkin cells which are believed to be precursor RS cells but are not con-
sidered diagnostic of HD. Hodgkin cells are large mononuclear cells but as re-
gards their nuclear, nucleolar and cytoplasmic features, they resemble RS cells. 
PATHOLOGIC CHANGES: Grossly, the affected lymph nodes ini-
tially remain discrete but later are matted together. The sectioned surface is 
homogeneous and fishflesh-like in lymphocyte predominance type, nodular 
due to scarring in'nodular sclerosis type, and abundance of necrosis in mixed 
cellularity and lymphocyte depletion types. Hodgkin's disease of liver, spleen 
and other organs forms spherical masses similar to metastatic carcinoma. 
Microscopically, the criteria for diagnosis of 4 histologic subtypes 
are as under: 
1. Lymphocyte-predominance type. The lymphocyte- predominance 
type of HD is characterised by proliferation of small lymphocytes admixed 
with a varying number of histiocytes forming nodular or diffuse pattern. 
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i) Nodular form is characterised by replacement of nodal architecture 
by numerous large neoplastic nodules. 
ii) Diffuse form does not have discernible nodules but instead there is 
diffuse proliferation of cells. 
Sometimes, both nodular and diffuse patterns may be seen in the in-
volved lymph node. 
For making the diagnosis definite demonstration of RS cells is essen-
tial which are few in number, requiring a thorough search. In addition to 
typical RS cells, polyploid variant having polyploid, and twisted nucleus 
(popcorn-like) may be found in some cases. This type of HD usually does 
not show other cells like plasma cells, eosinophils and neutrophils, nor are 
necrosis or fibrosis seen. 
2. Nodular-sclerosis type. Nodular sclerosis is the most frequent 
type of HD, seen more commonly in women than in men. It is characterised 
by two essential features: 
i) Bands of collagen: Variable amount of fibrous tissue is characteris-
tically present in the involved lymph nodes. Occasionally, the entire lymph 
node may be replaced by dense hyalinised collagen.  
ii) Lacunar type RS cells: Characteristic lacunar type of RS cells with 
distinctive pericellular halo are present. These cells appear lacunar due to 
the shrinkage of cytoplasm in formalin-fixed tissue. The pericellular halo is 
not seen if the tissue is fixed in inker's fluid. 
In addition to these 2 characteristics, the nodules between the fibrous 
septa consist predominantly of lymphocytes and macrophages, sometimes 
with foci of necrosis. 
3. Mixed-cellularity type. This form of HD generally replaces the en-
tire affected lymph nodes by heterogeneous mixture of various types of appar-
ently normal cells. These include proliferating lymphocytes, histiocytes, eo-
sinophils, neutrophils and plasma cells. Some amount of fibrosis and focal are-
as of necrosis are generally present. Typical RS cells are frequent. 
4. Lymphocyte-depletion type. In this type of HD, the lymph node is 
depleted of lymphocytes. There are two variants of lymphocyte-depletion HD: 
i) Diffuse fibrotic variant is hypocellular and the entire lymph node is 
replaced by diffuse fibrosis, appearing as homogeneous, fibrillar hyaline mate-
rial. The area of hyalinosis contains some lymphocytes, atypical histiocytes 
(Hodgkin cells), and numerous typical and atypical (pleomorphic) RS cells.  
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ii) Reticular variant is much more cellular and consists of large num-
ber of atypical pleomorphic histiocytes, scanty lymphocytes and a few typi-
cal RS cells. 
Clinical Features. Hodgkin's disease is particularly frequent among 
young and middle-aged adults. All histologic subtypes of HD, except the 
nodular sclerosis variety, are more common in males. The disease usually 
begins with superficial lymph node enlargement and subsequently spreads 
to other lymphoid and non-lymphoid structures. 
1. Most commonly, patients present with painless, movable and firm 
lymphadenopathy. The cervical and mediastinal lymph nodes are involved 
most frequently. Other lymph node groups like axillary, inguinal and ab-
dominal are involved sometimes. 
2. Approximately half the patients develop splenomegaly during the 
course of the disease. Liver enlargement too may occur. 
3. Constitutional symptoms (type B symptoms) are present in 25-40% 
of patients. The most common is low-grade fever with night sweats and 
weight loss. Other symptoms include fatigue, malaise, weakness and pruritus.  
Haematologic abnormalities: 
1. A moderate, normocytic and normochromic anaemia is often present. 
2. Serum iron and TIBC are low but marrow iron stores are normal or 
increased. 
3. Marrow infiltration by the disease may produce marrow failure 
with leucoerythroblastic reaction. 
4. Routine blood counts reveal moderate leukaemoid reaction. Cases 
with pruritus frequently show peripheral eosinophilia. Advanced disease is 
associated with absolute lymphopenia. 
5. Platelet count is normal or increased. 
6. ESR is invariably elevated. 
Immunologic abnormalities: 
1. There is progressive fall in immunocompetent T-cells with defec-
tive cellular immunity. There is reversal of CD4: CDS ratio and anergy to 
routine skin tests. 
2. Humoral antibody production is normal in untreated patients until 
late in the disease. 
Staging 
Following biopsy and histopathologic classification of HD, the extent 
of involvement of the disease (i.e. staging) is studied so as to select the 
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proper treatment and assess the prognosis. The Ann Arbor staging classifi-
cation takes into account both clinical and pathologic stage of the disease. 
The suffix A or B are added to the above stages depending upon 
whether the three constitutional symptoms (fever, night sweats and unex-
plained weight loss exceeding 10% of normal) are absent (A) or present (B). 
The suffix E or S are used for extranodal involvement and splenomegaly re-
spectively. 
For complete staging, a number of other essential diagnostic studies 
are recommended. These are as under: 
1. Detailed physical examination including sites of nodal involvement 
and splenomegaly. 
2. Chest radiograph to exclude mediastinal, pleural and lung parenchy-
mal involvement. 
3. CT scan of abdomen and pelvis. 
4. Documentation of constitutional symptoms (B symptoms). 
5. Laboratory evaluation of complete blood counts, liver and kidney 
function tests. 
6. Bilateral bone marrow biopsy. 
7. Finally, histopathologic documentation of the type of Hodgkin`s dis-
ease. 
More invasive investigations include lymphangiography of lower ex-
tremities and staging laparotomy. Staging laparotomy includes biopsy of 
selected lymph nodes in the retroperitoneum, splenectomy and wedge biop-
sy of the liver.  
Prognosis 
With use of aggressive radiotherapy and chemotherapy, the outlook 
for Hodgkin's disease has improved significantly. Although several factors 
affect the prognosis, two important considerations in evaluating its outcome 
are the extent of involvement by the disease (i.e. staging) and the histologic 
subtype. 
• With appropriate treatment, the overall 5 year survival rate for stage 
I and II A is as high as about 100%, while the advanced stage of the disease 
may have upto 50% 5-year survival rate. 
• Patients with lymphocyte-predominance type of HD tend to have lo-
calised form of the disease and have excellent prognosis. 
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• The nodular sclerosis variety too has very good prognosis but those 
patients with larger mediastinal mass respond poorly to both chemotherapy 
and radiotherapy. 
• The mixed cellularity type occupies intermediate clinical position be-
tween the lymphocyte predominance and the lymphocyte-depletion type, but 
patients with disseminated disease and systemic manifestations do poorly. 
• The lymphocyte-depletion type is usually disseminated at the time 
of diagnosis and is associated with constitutional symptoms. These patients 
usually have the most aggressive form of the disease. 
 
NON-HODGKIN'S LYMPHOMAS 
Non-Hodgkin's lymphomas (NHL) are the malignant neoplasms of 
the immune system of the body and are more common than Hodgkin's lym-
phoma. The biologic and clinical behaviour of NHL are quite distinct from 
HD and thus the two are quite different diseases. NHL is most frequent in 
young adults (20-40 years). Its incidence is showing an upward trend due to 
increasing incidence of AIDS. 
Majority of NHL arise in lymph nodes (65%) while the remaining 
35% take origin in extranodal lymphoid tissues. However, all forms of NHL 
have potential to spread to other lymph nodes, liver, spleen and bone mar-
row. The involvement of bone marrow may be followed by spill over of 
NHL into the peripheral blood, and vice versa when lymphoid leukaemia 
originating in the bone marrow may spread to lymph nodes, creating an over-
lapping picture of lymphoid leukaemia and NHL. In such situations, it may 
become difficult to determine which appeared first in the affected patient. 
Etiopathogenesis 
Malignant lymphomas are considered as the clonal proliferation of 
immune cells. About 65% of NHL are of B-lymphocyte origin, 35% of T-
lymphocytes, and less than 2% are histiocytic derivatives. The agents in-
volved in inducing neoplastic transformation of these cells are poorly un-
derstood, but the following etiologic factors have been shown to have 
strong association with the development of NHL. 
1. Viral association. There is evidence to suggest that Epstein-Barr 
virus (EBV) is involved in endemic variety of Burkitt's lymphoma, while 
human-T-cell leukaemia virus type I (HTLV-I) has strong association with 
adult T-cell lymphoma. 
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2. Genetic association. A number of cytogenetic abnormalities have 
been detected in cases of NHL, most important of which are chromosomal 
translocations. 
3. Immunodeficiency diseases. Various inherited and acquired im-
munodeficiency diseases including AIDS are associated with subsequent 
development of lymphomatous transformation. 
4. Immunosuppression. latrogenic immunosuppres-sion induced by 
chemotherapy or radiation is associated with induction of NHL. 
5. Autoimmune disease association. A few autoimmune diseases 
such as Sjogren's syndrome, non-tropical sprue, rheumatoid arthritis and 
SLE are associated with higher incidence of NHL. 
Classification 
Unlike Hodgkin's disease in which Rye classification is the only uni-
versally accepted classification since 1966, the pathologic classification of 
NHL has been difficult for both pathologists and clinicians. Several classi-
fications have been described at different times adding further confusion. 
The widely used classification systems of NHL (in chronologic order) are: 
Rappaport (1966), Lukes-Collins (1974), Working Formulations for clinical 
usage (1982), and R.E.A.L. (1994). 
 
R.E.A.L. CLASSIFICATION. International Lymphoma Study 
Group in 1994 has proposed another classification called revised European-
American classification of lymphoid neoplasms abbreviated as R.E.A.L. 
classification. This classification is based on the hypothesis that all forms of 
lymphoid malignancies (NHLs as well as lymphoblastic leukaemias) repre-
sent malignant counterparts of normal population of immune cells (B-cells, 
T-cells and histiocytes) present in the lymph node and bone marrow. It is 
believed that lymphoid malignancies arise due to arrest at the various dif-
ferentiation stages of B and T-cells since tumours of histio-cytic origin are 
quite uncommon. Accordingly, it is considered essential to understand and 
correlate the differentiation stages of B and T-cells with various lymphoid 
malignancies. R.E.A.L. classification divides all lymphoid malignancies in-
to two broad groups, each having further subtypes: 
• Leukaemias and lymphomas of B-cell origin: B-cell derivation 
comprises 80% cases of lymphoid leukaemias and 90% cases of NHLs. 
Based upon these phenotypic and genotypic features, B-cell neoplasms are 
of pre-B and mature B-cell origin. Based on their biologic behaviour, B-cell 
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malignancies are further subclassified into indolent and aggressive. All the-
se tumours express Pan-B (CD19) antigen besides other markers. 
• Leukaemias and lymphomas of T-cell origin: T-cell malignancies 
comprise the remainder 20% cases of lymphoid leukaemia and 10% cases 
of NHLs. T-cell malignancies reflect the stages of T-cell ontogeny. Like B-
cell malignancies, T-cell derivatives too are further categorised into indo-
lent and aggressive T-cell malignancies. The most widely expressed T-cell 
antigens are CD2 and CD7. 
PATHOLOGIC CHANGES. The histologic diagnosis of NHL can only 
be reliably made on examination of lymph node biopsy. However, salient 
features of morphologic subtypes are considered below. 
Grossly, the affected groups of lymph nodes are enlarged in majority 
of cases of NHL. Any lymph node group may be involved but most com-
monly affected are the cervical, supraclavicular and axillary groups. Less 
commonly at the time of diagnosis, there may be enlargement of lymphoids 
tissue elsewhere such as in the tonsils, spleen, stomach, bone etc. Initially, 
the lymph nodes are discrete and separate from one another but later the 
lymph nodes form a large matted mass due to infiltration into the surround-
ing connective tissue. Extranodal involvements produce either a discrete 
tumour or diffuse enlargement of the affected organ. The sectioned surface 
of the involved lymph nodes or extranodular organ involved appears grey-
white and fishflesh-like. Thus, the gross appearance of Hodgkin`s and non-
Hodgkin`s lymphoma is much the same. 
Histologicalty, the features of various prognostic groups in the Work-
ing Formulation for Clinical Usage are given below. The synonyms in 
brackets in each subgroup of NHL described below correspond to the Rap-
paport and Lukes-Collins classification respectively. 
1. LOW-GRADE NHL. This group includes the following three 
subgroups: 
A. Small lymphocytic lymphoma SLL. (Diffuse, well-differentiated 
lymphocytic; B-small lymphocytic and plasmacytoid lymphoma). This low-
grade lymphoma of B-cell origin constitutes about 4% of all NHLs. The 
lymph node is replaced by diffuse proliferation of well-differentiated, ma-
ture, small and uniform lymphocytes without any cytologic atypia or signif-
icant mitoses. 
SLL involves bone marrow frequently and produces CLL-like pic-
ture. If this occurs, then it may not be possible to distinguish between CLL 
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and SLL on the basis of lymph node biopsy. Both conditions occur more 
commonly in middle and older age groups. SLL may be associated with oc-
currence of an IgM monoclonal gammopathy called Waldenstrom's macro-
globuli-naemia. 
B.  Follicular, predominantly small cleaved cell lymphoma (Nodu-
lar, poorly-differentiated lymphocytic; Follicular centre cell, small cleaved 
lymphoma). Follicular lymphomas comprise approximately 50% of all 
NHLs. Small cleaved cell variety is the most common subtype. Morpholog-
ically, as the name suggests, this form of follicular lymphoma is character-
ised by follicular or nodular pattern of growth in which are present predom-
inantly small, normal lymphocytes having irregular, cleaved (indented) nu-
clei and a few large cleaved or non-cleaved cells. Mitoses are infrequent. 
The small cleaved follicular lymphoma occurs in older individuals, 
most frequently presenting with painless peripheral lymphadenopathy 
which is usually waxing and waning type. Bone marrow infiltration is typi-
cally paratrabecular. Peripheral blood involvement as occurs in SLL is un-
common in this variety. In contrast to diffuse lymphomas, extranodal in-
volvement is also infrequent. Conversion to higher grades of lymphoma 
may, however, occur. Median survival for patients with this group of NHL 
is 7-9 years. 
C. Follicular, mixed small and large cleaved cell lymphoma (Nod-
ular mixed; Follicular centre cell, small and large cleaved lymphoma). This 
type of follicular lymphoma has features of both follicular small cleaved 
lymphoma and follicular large cell lymphoma. 
It presents commonly with large abdominal masses. Bone marrow in-
filtration is infrequent. This form of NHL has a less favourable prognosis 
than the former. 
II. INTERMEDIATE GRADE NHL. This prognostic group in-
cludes four subtypes: a follicular lymphoma, and three diffuse lymphomas. 
D. Follicular, predominantly large cell lymphoma(Nodular histio-
cytic; Follicular centre cell, large cleaved or non-cleaved lymphoma). This 
is an uncommon follicular lymphoma in which the follicular morphology is 
preserved, but the type of cells in the follicle are large with cleaved or non-
cleaved nuclei and numerous mitoses. In contrast to other follicular lym-
phomas, this form involves the bone marrow and liver less frequently. Usu-
ally, the disease presents with large masses and behaves like a diffuse large 
cell lymphoma. 
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E. Diffuse, small cleaved cell lymphoma (Diffuse poorly-
differentiated lymphocytic; Follicular centre cell, small cleaved diffuse 
lymphoma). This variety is the diffuse counterpart of follicular small 
cleaved cell lymphoma i.e. it is composed of small cleaved cells spread in a 
diffuse pattern. 
Infiltrations of the bone marrow, liver and spleen are frequent at the 
time of presentation. The survival of this subgroup is much shorter than in 
the patients with low-grade lymphomas. 
F. Diffuse, mixed small and large cell lymphoma(Diffuse mixed 
lymphocytic-histiocytic; Follicular centre cell, small or large cleaved or 
non-cleaved lymphoma). This subgroup of diffuse NHL is composed of 
small and large cells which may be cleaved or noncleaved and contains nu-
merous mitoses. Diffuse mixed lymphoma is more common in women and 
is generally regarded as a waste- basket diagnosis. Majority of cases behave 
like diffuse large cell lymphoma. 
G. Diffuse large cell lymphoma (Diffuse histiocytic; Follicular cen-
tre cell, large cleaved or non-cleaved lymphoma). Morphologically, this 
subtype contains large cleaved or noncleaved cells in a diffuse pattern. 
The patients may have nodal or extranodal disease in the form of 
large masses. The tumour is highly invasive and may disseminate to other 
organs, especially to the CNS. The patients with diffuse large cell lympho-
ma have a poor prognosis. 
III. HIGH-GRADE NHL. High-grade group of NHL consists of 
three subgroups: 
H. Large cell immunoblastic lymphoma (Diffuse histiocytic; Im-
munoblastic B or T-cell lymphoma). This variant is characterised by re-
placement of the lymph node by distinctive large tumour cells (4 to 5 times 
the size of small lymphocytes) and having plasrna-cytoid features. The nu-
cleus is round to oval with vesicular nuclear chromatin and 1-2 prominent 
nucleoli. The cytoplasm is abundant and deeply amphophilic or basophilic 
and pyroninophilic because of proliferation of the rough endoplasmic re-
ticulum in the cell. These tumour cells are most commonly B-cells, some-
times T-cells, but the distinction is possible by immunophenotyping only. 
This disease occurs in adults over 50 years of age and has frequent 
association with prior immunologic disorders such as coeliac disease, Hash-
imoto's thyroiditis, Sjogren's syndrome, immunosuppressive therapy and in 
AIDS. Constitutional symptoms (B symptoms) are frequent in advanced 
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disease. Extranodal involvement and invasion of the bone marrow and CNS 
are common. 
I. Lymphoblastic lymphoma (Diffuse lymphoblastic; Convoluted T-
cell lymphoma). In this type, the tumour cells resemble lymphoblasts of 
ALL. They are generally uniform in size with scanty cytoplasm and have 
numerous mitoses. 
Lymphoblastic lymphoma occurs more commonly in children and is 
more frequent in males. At presentation, there is either peripheral adenopa-
thy in the neck and axilla, or an anterior mediastinal mass. Bone marrow 
infiltration is present in more than half the cases and develop subsequently 
into leukaemia that is indistinguishable from T-cell ALL. These patients 
have very high incidence of CNS involvement. 
J. Small non-cleaved cell lymphoma (Diffuse undifferentiated Bur-
kitt's and Non-Burkitt's; Follicular centre cell, small non-cleaved cell lym-
phoma). This subgroup includes African endemic form of Burkitt's lym-
phoma and non-endemic form of related tumour seen outside Africa. 
• Burkitt's lymphoma was first described in African children, pre-
dominantly presenting as jaw tumour that spreads to extranodal sites such 
as the bone marrow and meninges. The relationship of this tumour with on-
cogenic virus, Epstein-Barr virus (EBV).Morphologically, the involved 
lymph nodes and other tissues are replaced by closely packed, uniform 
looking tumour cell of the size of macrophages. These cells have a narrow 
rim of amphophilic or basophilic cytoplasm, round to oval nuclei, promi-
nent nucleoli and high mitotic activity. The tumour cells have moderate 
amount of basophilic vacuolated cytoplasm. Scattered among the tumour 
cells are non-neoplastic benign macrophages often surrounded by a clear 
space, producing what is called a 'starry sky' pattern.' 
• Non-endemic Burkitt's lymphoma is a related tumour in which 
the tumour cells are similar to those of Burkitt's lymphoma but are more 
pleomorphic and may sometimes be multinucleated. Non-Burkitt's small 
cell lymphoma is seen outside Africa and is sporadic and more aggressive 
than true Burkitt's lymphoma, 
IV. MISCELLANEOUS LYMPHOMAS. Besides the three prog-
nostic groups of NHL described above, the Working Formulations include 
the following histologic subtypes: 
1. Adult T-cell leukaemia/lymphoma. This is an uncommon T-cell 
malignancy but has gained much prominence due to association with human 
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T-cell lymphotropic virus-1 (HTLV-1). This entity is observed in Japan, the 
Caribbean and parts of the US but is rare in rest of the world. The patients 
have usually widespread lymphadenopathy with leukaemia, hepatospleno-
megaly and involvement of skin and leptomeninges. The involved lymph 
nodes have proliferation of large atypical T-cells, most prominent in the 
paracortical zone. The blood also shows large pleomorphic T-cell leukae-
mia. This disease has a fulminant course. 
2. Cutaneous T-cell lymphoma. Its major variants include mycosis 
fungoides and Sezary's syndrome, both of which are T-cell derived ru-
mours. Advanced cases have infiltration of the bone marrow and leukaemia. 
3. Histiocytic lymphoma. Histiocytic lymphoma or histiocytic me-
dullary reticulosis is a rare type of lymphoma affecting older people and in-




Features pertaining to specific types of NHL have been given along-
with their morphologic description above. Some general clinical features 
common to most cases of NHL are as under: 
1. Superficial lymphadenopathy. At presentation, there is painless, 
asymmetric enlargement of one or more groups of peripheral lymph nodes. 
2. Constitutional symptoms. Fever, night sweats and more than 10% 
weight loss comprise the constitutional symptoms (type B symptoms) simi-
lar to those found in Hodgkin's disease. 
3. Oropharyngeal involvement. Involvement of Waldeyer's ring is 
present in 5-10% of patients. 
4. Abdominal disease. Enlargement of liver, spleen and mesenteric 
and retroperitoneal lymph nodes are found in some cases. Lymphomatous 
involvement of the GIT is the most common extranodal involvement after 
the bone marrow. 
5. Other organs. Involvement of the skin or brain occurs in certain 
subtypes of NHL. 
 
Other Laboratory Findings 
In addition to clinical and histopathological findings, certain abnor-
mal haematologic and immunologic findings are found in NHL. 
Haematologic abnormalities: 
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1. Anaemia of normocytic normochromic type. 
2. Advanced disease with marrow infiltration may show neutropenia, 
thrombocytopenia and leucoerythro-blastic reaction. 
3. Lymphosarcoma cell  leukaemia  (leukaemic conversion of NHL) 
occurs in some patients. 
4. Marrow involvement by NHL is seen in 20% of cases. 
5. Hyperuricaemia and hypercalcaemia occur late in the disease. 
 
Immunologic abnormalities: 
Immunologic studies reveal that majority of NHLs are of B lympho-
cyte origin. There may be associated monoclonal excess of immunoglobu-
lins, usually IgG or IgM. Plasmacytoid lymphoma may produce excess of a 
heavy chain or a light chain. 
Staging 
The Ann Arbor staging system developed for Hodgkin's disease is 
used for staging NHL too. This staging system depends upon the number 
and location of nodal and extranodal sites involved, and presence or ab-
sence of constitutional (B) symptoms. But the concept of staging is much 
less helpful in NHL than in Hodgkin's disease because the prognosis is not 
correlated with the anatomic site of involvement of the disease. 
Prognosis 
Low-grade lymphomas usually progress slowly and local radiothera-
py brings about remission lasting for up to 10 years in 75% cases. More ex-
tensive disease is treated with combination chemotherapy and local radio-
therapy. Children with lymphoblastic lymphoma and Burkitt's lymphoma 
respond extremely well to chemotherapy. Meningeal involvement is treated 
with irradiation of the brain. Patients with histiocytic lymphoma and T-cell 
leukaemia/lymphoma have an extremely poor prognosis. 
 
LYMPH NODE METASTATIC TUMOURS 
The regional lymph nodes draining the site of a primary malignant 
tumour are commonly enlarged. This enlargement may be due to benign re-
active hyperplasia or metastatic tumour deposits. 
1. Benign reactive hyperplasia, is due to immunologic reaction by 
the lymph node in response to tumour-associated antigens. It may be ex-
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pressed as sinus histiocytosis, follicular hyperplasia, plasmacvtosis and oc-
casionally may show non- caseating granulomas. 
2. Metastatic deposits in regional lymph nodes occurs most com-
monly from carcinomas and malignant melanoma. Sarcomas generally dis-
seminate by the haematogenous route but uncommonly may metastasise to 
the regional lymph nodes. Metastatic tumour cells from the primary malig-
nant tumour are drained via lymphatics into the subcapsular sinuses initially 
but subsequently the lymph node stroma is also invaded. The pushing mar-
gins of advancing metastatic tumour in stroma of lymph node is characteris-
tically well demarcated. Areas of necrosis are frequent in metastatic carci-
nomas. The morphologic features of primary malignant tumour are reca-
pitulated in metastatic tumour in lymph nodes. 
 
LANGERHANS' CELL HISTIOCYTOSIS 
Langerhans' cell histiocytosis is a group of malignant proliferations 
of histiocytes and macrophages. Earlier, this group was referred to as histio-
cytosis-X and included three conditions: eosinophilic granuloma, Hand-
Schuller-Christian disease and Letterer-Siwe syndrome. Now, it is known 
that: 
• Firstly, histiocytosis-X are not proliferations of unknown origin (X-
for unknown) but proliferating cells are in fact Langerhans' cells of marrow 
origin. Langerhans' cells are normally present mainly in the epidermis but 
also in some other organs. 
• Secondly, the three conditions included under histiocytosis-X are 
actually different expression of the same basic disorder. This has been made 
possible by demonstration of common antigens on these cells (positive for 
S-100 protein, CD1, CD 74 and HLA-DR) as well as by ultrastructural fea-
tures of Langerhans' cell or Birbeck granules in the cytoplasm. 




Unifocal eosinophilic granuloma is more common (60%) than the 
multifocal variety which is often a component of Hand-Schuller-Christian 
disease. Most of the patients are children and young adults, predominantly 
males. The condition commonly presents as a solitary osteolytic lesion in 
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the femur, skull, vertebrae, ribs and pelvis. The diagnosis requires biopsy of 
the lytic bone lesion. 
Microscopically, the lesion consists largely of closely-packed aggre-
gates of macrophages admixed with variable number of eosinophils. The 
macrophages contain droplets of fat or a few granules of brown pigment in-
dicative of phagocytic activity. A few multinucleate macrophages may also 
be seen. The cytoplasm of a few macrophages may contain rod-shaped in-
clusions called histiocytosis-X bodies. 
Clinically, unifocal eosinophilic granuloma is a benign disorder. The 
bony lesion remains asymptomatic until the erosion of the bone causes pain 
or fracture. Spontaneous fibrosis or healing may occur in some cases, while 
others may require curettage or radiotherapy. 
 
HAND-SCHULLER-CHRISTIAN DISEASE 
A triad of features consisting of multifocal bony defects, diabetes in-
sipidus and exophthalmos is termed Hand-Schiiller-Christian disease. The 
disease develops in children under 5 years of age. The multifocal lytic bony 
lesions may develop at any site. Orbital lesion causes exophthalmos, while 
involvement of the hypothalamus causes diabetes insipidus. Multiple spher-
ical lesions in the lungs are frequently present. Half the patients have in-
volvement of the liver, spleen and lymph nodes.  
Microscopically, the lesions are indistinguishable from those of 
unifocal eosinophilic granuloma. 
Clinically, the affected children frequently have fever, skin lesions, 
recurrent pneumonitis and other infections. Though the condition is benign, 
it is more disabling than the unifocal eosinophilic granuloma. The lesions 
may resolve spontaneously or may require chemotherapy or radiation. 
 
LETTERER-SIWE DISEASE 
Letterer-Siwe disease is an acute clinical syndrome of unknown eti-
ology occurring in infants and children under three years of age. The dis-
ease is characterised by hepatosplenomegaly, lymphadenopathy, thrombo-
cytopenia, anaemia and leucopenia. There is generalised hyperplasia of tis-
sue macrophages in various organs. 
Microscopically, the involved organs contain aggregates of macro-
phages which are pleomorphic and show nuclear atypia. The cytoplasm of 
these cells contains vacuoles and rod-shaped histiocytosis-X bodies. 
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Clinically, the child has acute symptoms of fever, skin rash, loss of 
weight, anaemia, bleeding disorders and enlargement of lymph nodes, liver 
and spleen. Cystic bony lesions may be apparent in the skull, pelvis and 
long bones. Intense chemotherapy helps to control Letterer-Siwe disease but 
intercurrent infections result in fatal outcome in many cases. The condition 
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